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 The aim of this work was to understand the bioconcentration potential of 
pharmaceuticals in a freshwater invertebrate. The novelty of this work lies in 
several parts of which the most important was that a computational model was 
developed to successfully predict bioconcentration in invertebrates, which has 
not been achieved previously. For the first time, a developed analytical method 
using liquid chromatography tandem mass spectrometry (LC-MS/MS) was used 
to determine the occurrence of pharmaceuticals in Gammarus pulex across 
several tributaries of the River Thames (London, UK). The occurrence reached 
low level ng g-1 concentrations and indicated that further experiments were 
needed to determine the accumulation potential.  
Toxicokinetic exposures were performed to characterise the 
bioconcentration potential of 16 pharmaceuticals. The determined 
bioconcentration factors (BCFs) remained below regulatory thresholds indicative 
of bioaccumulation, which contrasted field-derived bioaccumulation factors that 
would have triggered regulatory guidelines. However, the standardised models 
employed for kinetic BCF estimation were evaluated and it was found that model 
assumptions concerning the uptake rate constant were not reliable, leading to 
extremely important implications for regulatory bodies. In addition, the developed 
LC-MS/MS method determined phase I and phase II metabolites in G. pulex, 
indicating that these organisms are capable of extensive biotransformation of 
pharmaceuticals.  
 To further understand uptake mechanisms such as passive diffusion, a 
modelling approach using artificial neural networks were developed to 
characterise the uptake of pharmaceuticals onto passive sampling devices. No 
previous investigations have aimed to predict uptake onto polar organic chemical 
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integrative sampler devices and this work represented the first of its kind. The 
passive sampling models demonstrated good predictive accuracy at a fraction of 
the cost and time required by experimental measurements. Furthermore, the 
modelling gave mechanistic insight into molecular descriptors that were related 
to uptake onto passive samplers. The modelling approach was extended to 
predict bioconcentration of pharmaceuticals in fish and G. pulex using data from 
the literature and data determined from the toxicokinetic experiments presented 
here. Interestingly, the fish-based model could not be used to predict the 
invertebrate data. This indicated that either the class of compounds 
(pharmaceuticals) or the fish-to-invertebrate bioconcentration data could not be 
cross predicted. Thus, a standalone model was developed for the invertebrates 
and showed good predictive accuracy for this species. Overall, the work 
presented herein has achieved novel impact to address the lack of knowledge 
concerning bioconcentration in invertebrates.  
 












Chapter 1 Review of literature concerning pharmaceuticals in the aquatic 
environment. 
1.1 Overview of xenobiotics in the environment  
Continued anthropogenic activities that introduce millions of tonnes of 
chemicals into the environment are a growing cause for concern [1]. Research 
into the field of ecotoxicology has become a priority among various scientific and 
governmental bodies, in which their main efforts have been to investigate the 
occurrence and fate of xenobiotics from a variety of sources including industry, 
hospital/veterinary waste, domestic waste, agricultural and livestock farms thus 
far. The potential risk of these chemicals is characterised by hazard criteria which 
can be used to classify priority pollutants, such as persistence, bioaccumulation 
and toxicity (PBT). Compounds may persist in the environment for days to years 
before they are degraded and they have the ability to accumulate in an organism 
even across trophic levels. Therefore, they may have an associated toxicity to 
exposed biota. The aquatic environment is exposed via several sources including 
the continual contribution of contaminants from waste water effluents as well as 
the input from the terrestrial environment where contaminants are cycled into 
aquatic environments (i.e. surface run-off). Therefore, these contaminants can be 
termed ‘pseudo-persistent’ due to their continual input which leads to chronic 
exposures of biota over their entire life cycle which may have further implications 
for toxicity and transfer between trophic levels [2].  
 Contaminants are subject to a complex pathway of interactions when 
exposed in the environment, which will be discussed in later sections. This 
creates difficulty in fully understanding the resultant risk to the environment. This 
highlights the importance of research into their fate and occurrence, but also the 
acute and chronic toxicity as single compounds and mixtures. The strategies to 
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deal with pollutants in environmental matrices can be broadly characterised into 
environmental risk assessment and environmental risk management, which allow 
the mapping of fate and effects with monitoring and control for those compounds 
deemed the most hazardous. This topic has not only gained attention from 
researchers but also from governmental agencies that have published legislation 
and guidelines for controlling the mass of pollutants that are introduced into the 
environment. Among the numerous classes of compounds that exist today there 
is one particular set that have been termed pharmaceutically active compounds 
(PhAC) which can be defined as compounds which are used for health or 
cosmetic purposes and are not limited to human application [2]. These 
compounds have been described as emerging contaminants and thus research 
efforts are required to understand the potential environmental risks posed by this 
class of compounds.  
1.2 Sources of PhACs in the environment  
As mentioned above there are many routes that can lead to the entry of 
PPCPs into the environment. The largest identified route of contamination is 
currently via consumption and excretion or topical use of PhACs by the general 
population. Figure 1.1 summarises the various routes of entry of PhACs into the 









1.2.1 PhAC manufacturers 
Industry waste could be considered a source contributing to contamination 
but due to various legislation and guidelines from environmental protection 
agencies as well as the good management practice, it is considered to have a 
relative minor contribution [4]. This may be true for Europe and North America 
but recent studies in Asian regions have revealed that production plants in India 
had effluents containing up to 31 mg L-1 of ciprofloxacin, a synthetic 
fluoroquinolone antibiotic [5]. This is a cause for concern as many PhACs are 
found at much lower concentrations, often in the ng L-1 range. It should also be 
noted that compounds in the mg L-1 range are often used in acute toxicity assays 
to determine lethal concentrations to 50% of the population (LC50). A production 
plant from China that manufactured contraceptives was found to contain up to 51 
ng L-1 of ethinylestradiol (EE2) in effluents which is high enough to cause 
Figure 1.1: Schematic overview of the major routes of PhACs into terrestrial and 




detrimental effects to aquatic organisms [6, 7]. The reason for such high 
concentrations could be due to lower enforcement of legislation and regulations 
when compared with more developed countries. For example, it was reported 
that a local authority, in the Indian region referred to above, identified 40 dumping 
sites of industrial waste [8]. 
1.2.2 Hospitals 
The use of antibiotics among other pharmaceuticals at hospitals could be 
a significant point source of PhAC contamination in the environment. Wastewater 
effluents from hospitals  often have no preliminary treatment and is directly fed 
into municipal sewerage systems, which may lead to a high input of antibiotics. A 
study of five hospitals in New Mexico revealed untreated effluents contained six 
antibiotics ranging from 0.3 – 35 µg L-1, this value is generally the range that other 
classes of antibiotics are found within hospital effluents from different countries 
[8-11]. It is not only antibiotics that are input from hospitals, many different classes 
of PhACs such as cytostatics, anti-epileptic drugs (AEDs), analgesics, beta-
blockers, lipid regulators and barbiturates have been quantified in hospital 
wastewater effluents, ranging from ng - µg L-1 [12, 13]. 
1.2.3 Veterinary practices & agriculture 
Veterinary practices lead to antibiotics and other pharmaceuticals 
excreted from animals which are can be leached into soilaffecting terrestrial 
environments and also lead to the contamination of groundwater sources or 
alternatively may be washed into surface waters via surface run-off affecting 
aquatic environments [14]. Manure and bio-solid sludge are often used in 
agriculture to fertilise fields for crop growth, these solids may be contaminated 
with PhACs and thus can enter aquatic and terrestrial environments as mentioned 
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above [15]. These compounds can often reach up to mg kg-1 concentrations [16, 
17]. Prophylactic antibiotics are commonly used in animal husbandry to prevent 
disease due to often poor housing conditions, they are given to both healthy and 
unhealthy animals,thus accounting for another source of PPCP contamination in 
the environment. In addition to terrestrial agriculture that is a source of 
contamination, aquatic farming (aquaculture) use antibiotics which leads to the 
direct emission of PPCPs into surface waters and sediments, which can also lead 
to ground water contamination [18].  
1.2.4 Unused Medication 
PhACs may be produced in quantities that reach several thousand tonnes 
per annum, which are distributed to hospitals, pharmacies and veterinary 
practices. Often these compounds that are prescribed or bought over the counter 
will be taken by an individual at home, and is the reason that domestic use of 
PhACs  account for the largest contributor of environmental contamination. The 
disposal of expired or unused PhACs also contributes to the contamination of the 
environment; a survey in the United States (US) reported that 35.4% of people 
flushed medication down the toilet/sink [19]. A more recent survey in the United 
Kingdom (UK) reported only 11.5% are disposed of down the toilet/sink [20], this 
could be due to better awareness of disposal methods but as the sample sizes 
were small in the surveys (n = <500) it may not represent true disposal patterns. 
Whilst, PhACs may not necessarily be flushed down the drain in the majority of 
cases, other responses showed that the main route of disposal is the bin. This 
does not avert the problem as waste will most likely be transported to landfill sites 
where they can enter the environment directly through either leaching or surface 
run-off.   
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1.2.5 Combined sewer overflows (CSOs) 
During periods of heavy precipitation the capacity of sewers can often be 
exceeded, to alleviate this overload many sewerage systems have CSOs. These 
systems therefore allow the overflow of rainwater and municipal wastewaters 
leading to direct emission into surface waters without any treatment. Thus, 
leading to potentially a great source of contamination in aquatic environments. It 
is considerably difficult to quantify the input of CSO related PPCPs, but a recent 
study correlated that increased rainfall lead to an increased input of caffeine into 
a lake in Switzerland [21]. Caffeine was suitable as a CSO marker due to the high 
removal efficiency of the compound from sewage at wastewater treatment plants, 
which allowed accurate determination of caffeine input from  CSOs [21]. 
1.2.6 Wastewater treatment plants (WWTPs)  
The implication that a pharmaceutical that is used may end up in sewage, 
provides a significant route of entry for PhACs into the environment. Urban areas 
will generally not discharge wastewater directly to the environment, and most are 
subject to sewage treatment at WWTPs. These plants will receive influent from 
the area they service known as a catchment area. The incoming water may be 
contaminated with PPCP residues which will undergo treatment before they are 
input into surface waters. However, the efficiency treatment process is variable 







1.3 WWTP Removal efficiency  
Removal of contaminants is often incomplete by WWTPs and the 
efficiency of the removal process is dependent on several factors, the first of 
which is the type of treatment stages used. Primary treatment involves the 
removal of suspended solids by sedimentation/flocculation units but does not 
remove dissolved solids. Secondary treatment can involve a biological process 
which is dependent on the use of microbial populations to remove organic matter. 
These biological treatments can be separated into eitherof suspended growth 
processes (activated sludge/oxidation ditches) or attached growth processes 
(trickling filters/biotowers). Tertiary treatments can involve ozonation, membrane 
filtration or the addition of ferric/aluminium salts [22]. Outcomes of tertiary 
treatment depend on the type of treatment in place; suspended solids are 
removed from the activated sludge stage (membrane filtration, ferric/aluminium 
salts), remaining PhACs from the secondary treatment are oxidised (ozonation) 
or further biological treatment is used for nutrient removal (ammonia and 
phosphorus). After the secondary treatment and if there is no tertiary treatment 
the effluent may undergo a disinfection stage to reduce microbial populations by 
chlorination or ultraviolet (UV) radiation before discharge into surface waters [23]. 
There are many factors that influence the removal of PPCPs such as the 
type treatment stages a WWTP uses, biochemical oxygen demand (BOD), total 
suspended solids (SS), solids retention time (SRT), pH, temperature and the type 
of compounds present in the influent. Due to the variety of classes that 
encompass PhACs there is a great range in physicochemical properties 
exhibited. Properties such as hydrophobicity that are quantified via the partition 
coefficient (logP) and distribution coefficient (logD) influence the sorption 
mechanisms. As mentioned in the previous section, the primary and secondary 
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WWTP stages will have suspended solids present that may sorb PPCPs via 
hydrophobic interactions, this sorption will effectively remove certain PPCPs from 
the aqueous phase of the influent. However, sorption to suspended solids can 
result from more than a single type of interaction and can be the result of a mixture 
of interactions such as ionic exchange, cation bridging, complexation, Van der 
Waals and hydrophilic interaction [24].  
Another important consideration of influent in WWTPs is the dissolved 
organic matter (DOM) which is primarily acidic in nature but will vary from plant 
to plant [25]. It may be expected that hydrophobic compounds would sorb to the 
sludge and be removed during primary/secondary treatment but DOM provides 
an alternate pathway for hydrophobic compounds to remain in the aqueous 
phase, thus lowering their removal efficiency and allowing for input to aquatic 
environments [26]. The microbial populations in the activated sludge treatment 
may remove PPCPs by biodegradation of the compound, one study showed that 
biodegradation of PPCPs can account for up to 80% removal from WWTP 
influents [27]. However, studies often measure only the reduction of the parent 
compound which does not necessarily indicate that the compound has 
undergone biodegradation, it may be present as a metabolite or biotransformed 
product which is not often determined.  
SRT is a very important variable during wastewater treatment, it is defined 
as the length of time in days that the activated sludge is in contact with the 
wastewater. A high SRT means that microbial populations will be well established 
and consist of range of microorganisms which may allow for a higher removal 
efficiency. Generally, a higher removal efficiency has been observed with SRTs 
of at least 10 days (approximately 95% or above), but is not always true for some 
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pharmaceuticals such as diclofenac and carbamazepine which have 
demonstrated low removal [28]. 
 
1.4 Occurrence of PhACs in the aquatic environment  
The occurrence of PhACs in the environment and their concentrations 
within organisms depend on a broad range of factors such as temperature, pH, 
season, removal efficiency at WWTPs, usage patterns, physicochemical 
properties of the compounds and the physiological characteristics of organisms 
(discussed in later sections). As mentioned above, removal efficiency is a 
predominant factor that will affect occurrence of contaminants in surface waters. 
Therefore, a high removal efficiency is often desirable but a high rate of removal 
may not be sufficient to reduce the input of contaminants into the environment.  
This has been observed, with the non-steroidal anti-inflammatory drugs 
(NSAIDs) that are often detected at high concentrations relative to other PhACs 
in influent. This class of pharmaceuticals are usually over-the-counter and can be 
sold in amounts reaching up to 1,000 tonnes per annum [29]. Removal is often 
>90%, but they are still released at relatively high concentrations from WWTPs 
due to the daily loads in wastewater resulting from high usage rates. Usage 
patterns are important as they can explain trends for occurrence of PhACs, such 
as seasonal trends associated with macrolide antibiotic use [30]. One study 
showed that the daily usage of macrolides, sulphonamides and trimethoprim was 
correlated with daily variations from composite samples within a WWTP [31].  
Furthermore, removal does not indicate that the compound has been mineralised. 
The compound may exist as a biotransformed product, which are often not 
determined during environmental monitoring campaigns.  
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1.4.1 Occurrence in surface waters 
The occurrence is surface waters will be predominantly a result of the input 
through wastewater. However, abiotic and biotic degradation will also influence 
the concentration of contaminants in surface waters. In addition to degradative 
processes, the removal of contaminants in the water phase due to their sorption 
to sediments will also have a role in the concentrations of contaminants that are 
quantified. Monitoring of surface waters will often involve composite sampling 
where a set volume of water is collected over a specified time period or point 
sampling where samples are taken at a single point in time. Whilst composite 
sampling mitigates the limitation of temporal fluctuations in contaminant 
concentrations both sampling techniques are still limited by this and thus may not 
accurately reflect surface water concentrations [32]. Furthermore, these 
techniques are also limited as they require high-volume sampling frequency. An 
alternative sampling technique is the use of passive sampler devices (PSDs). 
These samplers contain a sorbent material which acts as a ‘sink’ for the 
accumulation of contaminants in surface waters [32]. PSDs enable the integration 
of temporal fluctuations of contaminant concentrations. Thus, they can be used 








                  
  Mean Concentration (µg L
-1) Mean Maximum Concentration (µg L-1) 




(%) Influent Effluent 
Surface 
Water 
Diclofenac NSAID 1.854 1.028 0.185 45 181.000 24.256 18.740 
Carbamazepine TCA 0.637 0.498 0.409 22 2.600 67.715 11.561 
Ibuprofen NSAID 12.005 1.363 0.240 89 373.110 95.000 303.000 
Sulfamethoxazole Sulfonamide 2.333 0.238 0.120 90 309.000 24.800 29.000 
Naproxen NSAID 3.380 0.514 0.119 85 551.960 39.300 12.300 
Estrone Estrogens 0.219 0.073 0.039 67 129.000 32.980 5.000 
Estradiol Estrogen  0.359 0.019 0.005 95 3.000 0.082 0.012 
Ethinylestradiol Estrogen  0.032 0.027 0.143 16 140.000 5.040 5.900 
Estriol Estrogen  0.226 0.226 0.010 0 110.700 83.430 0.480 
Trimethoprim Antibiotic  0.768 0.879 0.071 - 162.000 95.100 13.600 
Paracetamol NSAID 35.902 3.492 0.331 90 1200.000 280.000 37.000 
Clofibric acid 
Lipid 
regulator 0.568 0.049 0.068 91 61.000 3.290 7.910 
Ciprofloxacin Quinolone 1.784 185.855 20.509 - 160.000 31000.000 2500.000 
Ofloxacin Quinolone 0.201 0.406 0.208 - 20.200 160.000 10.000 
Norfloxacin Quinolone 0.458 7.487 0.061 - 16.500 420.000 4.700 
Aspirin NSAID 88.385 8.863 1.773 90 1731.000 193.000 20.960 
Table 1.1: Example of occurrence data for pharmaceuticals determined in surface waters. 
 




Example occurrence data of PPCPs around the world is presented in 
Table 1.1, these 16 compounds are the only PhACs that have been detected in 
all 5 UN regions [34-41]. Depending on the location, surface concentrations of 
PPCPs ranged from up to 2500 µg L-1 for the antibioitc ciprofloxacin. It might be 
expected that over-the-counter pharmaceuticals, like the non-steroidal anti-
inflammatory drugs (NSAIDs), reach higher concentrations in surface water due 
to their high usage consumptions [29]. However, the quantification of these 
pharmaceuticals can also be influenced by the proximity to WWTPs. Other 
antibiotics such as amoxicillin has been detected at relatively high concentrations 
reaching up to 622 ng L-1 in the River Taff, U.K. The authors of this study, noted 
that the high concentration of amoxicillin was due to the close proximity of a 
WWTP. Further downstream the concentration had decreased below the limit of 
detection (LOD) [35]. Similarly, from Table 1.1 effluent concentrations of PhACs 
are usually much higher than surface water concentrations. Thus, suggesting that 
high risk areas for adverse effects could be areas that surround WWTP outfalls 
[23].  
The reduction in concentration downstream is likely to be a result of 
dilution, sorption, biodegradation, photodegradation and bioaccumulation [42, 
43]. Photodegradation can be direct or indirect where half-lives can vary 
depending on the presence of other substances such as humic acids, nitrate and 
Fe(III) [44]. In addition, ionic speciation of the compound can increase 
photodegradation, where deprotonation can increase electron densities favouring 
electrophilic attack by reactive oxygen species [44, 45]. Biodegradation is also 
variable and is a result of the degradation by microbial populations in the WWTP 
and surface waters. A major limitation of monitoring occurrence is that methods 
do not often target transformation products. Therefore, the reduction of the 
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precursor compound may not indicate removal and these transformation products 
might potentially be more toxic [46]. As mentioned previously, compounds can 
also vary in line with seasonal trends thus the sampling times of monitoring 
studies may also influence reported concentrations. Interestingly, diclofenac was 
reported to reach high concentrations (700 - 4400 ng L-1) in Pakistan. This region 
has had severe ongoing socioeconomic consequences due to the collapse of 
several vulture species through the use of diclofenac by livestock farmers [47]. 
This may suggest that surface run-off and leaching is leading to high input into 
surface waters, among other potential sources. Furthermore, the compound 
diclofenac has also been observed to have low removal rates in WWTPs, often 
<40 % [48]. As summarised, the occurrence of PhACs in surface waters is a 
mixture of complex interactions that requires the determination by monitoring 
campaigns to assess the potential risk posed by these emerging contaminants.  
1.4.2 Occurrence in aquatic biota  
Currently, the occurrence of PhACs in biota is under reported with most 
focus on the occurrence in fish in contrast to invertebrates. To the authors’ 
knowledge, a total of 43 publications have reported PhAC (with the exception of 
endocrine disruptors) occurrence data in aquatic biota. This is of critical 
importance as surface water concentrations may not translate well into biota 
concentrations due to the number of interactions in the environment (temporal 




Table 1.2: Occurrence data of pharmaceuticals determined in fish and 
invertebrates. Concentration for solid samples is ng g-1 and for liquid 
samples is ng mL-1. 
 Compound Concentration Sample Type Organism Location
diclofenac 6.0-95.0 Bile Bream Finland [49]
44.0-148.0 Bile Roach Finland [49]
2.2-20.0 Plasma Trout Sweden [52]
<LOD-16.1 Whole-body Mussel Italy [60]
<LOD-12.4 Whole-body Invert Spain [50]
4.1-8.8 Homogenate Fish Spain [51]
naproxen 6.0-32.0 Bile Bream Finland [49]
11.0-103.0 Bile Roach Finland [49]
33.0-46.0 Plasma Trout Sweden [52]
ibuprofen 16.0-34.0 Bile Bream Finland [49]
15.0-26.0 Bile Roach Finland [49]
5.5-102.0 Plasma Trout Sweden [52]
<LOD-9.4 Whole-body Mussel Italy [60]
<LOD-183.0 Whole-body Invert Spain [50]
carbamazepine 0.3-1.0 Plasma Trout Sweden [52]
1.3-5.3 Whole-body Mussel USA [53, 56]
17.9 Liver Fish Spain [51]
cilazapril <LOQ-0.7 Plasma Trout Sweden [52]
diltiazem <LOQ-0.9 Plasma Trout Sweden [52]
<LOD-0.1 Whole-body Mussel USA [53, 56]
haloperdiol <LOQ-1.2 Plasma Trout Sweden [52]
ketoprofen 15.0-107 Plasma Trout Sweden [52]
levonorgesterol <LOQ-12.0 Plasma Trout Sweden [52]
meclozine <LOQ-0.7 Plasma Trout Sweden [52]
memantine <LOQ-2.3 Plasma Trout Sweden [52]
oxazepam 0.4-0.7 Plasma Trout Sweden [52]
risperidone 0.4-2.4 Plasma Trout Sweden [52]
sertraline <LOQ-1.2 Plasma Trout Sweden [52]
<LOD-5.5 Whole-body Mussel USA [53, 56]
<LOQ-4.2 Brain Fish USA [58]
tramadol 1.1-1.9 Plasma Trout Sweden [52]
verpamil <LOQ-0.7 Plasma Trout Sweden [52]
trimethoprim <LOQ-9.2 Whole-body Mussel Ireland [54]
fluoxetine <LOQ-79.1 Whole-body Mussel USA [55]
<LOQ-1.6 Brain Fish USA [58]
norfluoxtine <LOQ-3.6 Brain Fish USA [58]
sulfamethazine <LOD-430.0 Whole-body Mussel USA [53, 56]
caffeine <LOD-140.0 Whole-body Mussel USA [53, 56]
diphenhydraine <LOD-11.0 Whole-body Mussel USA [53, 56]
0.04-0.07 Muscle Bream Germany [57]
methylprednisolone <LOD-210.0 Whole-body Mussel USA [53, 56]
amitriptyline <LOD-6.2 Whole-body Mussel USA [53, 56]
enrofloxacin <LOD-12.0 Whole-body Mussel USA [53, 56]
atenolol <LOD-13.0 Whole-body Mussel USA [53, 56]
norsertraline 1.7-3.3 Muscle Bream Germany [57]
0.2-6.1 Brain Fish USA [58]
diazepam 23.0-110.0 Liver Flatfish USA [59]
nimesulide 3.0-6.0 Whole-body Mussel Italy [60]
citalopram 0.8 Homogenate Fish Spain [51]
venlafaxine 0.6 Homogenate Fish Spain [51]
carazolol 3.8 Homogenate Fish Spain [51]
propranolol 4.2 Homogenate Fish Spain [51]
salbutamol 2.6 Homogenate Fish Spain [51]
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Example data on occurrence in both fish and invertebrates is presented in 
Table 1.2 [49-60]. The concentration of PPCPs ranged from <LOD-430 ng g-1 
(sulfamethazine) for tissue analysis and <LOQ-148 ng mL-1 (diclofenac) for 
plasma/bile measurements. A majority of the PPCPs were detected below three 
figure concentrations (0-100 ng mL-1 or ng g-1) with higher concentrations 
generally occurring with high consumption compounds such as ibuprofen (183 ng 
g-1), diclofenac (148 ng mL-1) and caffeine (140 ng g-1). Factors that affect the 
occurrence of PPCPs in biota are further discussed in Section 1.6 that details 
uptake and elimination processes in bioaccumulation.  
As pharmaceuticals undergo significant metabolism, it is possible that 
biotransformed products might be present at higher concentrations. This is a key 
consideration as transformation products might be more toxic than precursors, 
such as prodrugs where the metabolite is the biologically active compound. As 
mentioned previously with surface water measurements, current analytical 
methods often do not target biotransformation products. This can be explained in 
part by the lower availability of reference standards for confirmation and 
quantification of these types of compounds. Furthermore, the complexity of 
biological matrices to determine both precursor and biotransformed compounds 
is very analytically challenging [61]. Thus, this is likely to account for the low 
number of studies focussed on PPCP occurrence in biota. As the occurrence of 
PPCPs is understudied it is essential that methods are developed to analyse 
these compounds in biota. Furthermore, future studies are needed to address the 
uptake, metabolism and elimination of pharmaceuticals in biota to ensure that risk 





1.5 Instrumental techniques for analysis of environmental samples 
The determination of trace PPCP residues in complex media, such as 
sewage influent or a biological matrix requires instrumental techniques and 
methodologies that are accurate, selective, sensitive and precise. Occurrence, 
especially for PPCPs, is most commonly determined by liquid chromatography 
coupled to mass spectrometry (LC-MS) which enables the determination of 
compounds at trace levels (ng - µg) without required chemical derivitisation. 
Other techniques used to measure occurrence can also involve gas 
chromatography coupled to MS. However, this type of technique is usually used 
with more volatile hydrophobic organic contaminants such as phthalates [62]. 
Polar compounds such as pharmaceuticals will usually require derivitisation 
before they can be analysed by GC-MS [63]. Therefore, LC-MS is the technique 
of choice for more polar compounds.  
As the complexity of environmental samples can hinder the performance 
of these techniques, a sample preparation methodology can be used to pre-
concentrate the analytes and clean-up interfering matrix components. Sample 
preparation methods can involve techniques such as protein precipitation, solid-
phase extraction (SPE) and liquid-liquid extraction (LLE). In addition to 
occurrence studies, these methods and techniques can also be used to study the 
bioaccumulation and effects of environmental contaminants. Furthermore, 
bioaccumulation studies can also involve the use of liquid scintillation counting 
(LSC) to measure activity of radiolabelled compounds to determine the 






1.5.1 Liquid scintillation counting (LSC) 
Liquid scintillation counting is a technique that is used to detect the 
radioactivity of a sample and can be used to quantify the amount of radionuclide 
for alpha and beta particle emitters. Typically, a sample that contains 
radionuclides is dissolved in a solution known as a liquid scintillation cocktail. This 
cocktail contains a scintillator (fluor) and solvent. The fluor will exhibit scintillation 
(re-emission of energy as photons) when it is excited which will then be detected 
by a photomultiplier tube and counted as disintegrations per minute (DPM) [64]. 
In a sample, a radionuclide will typically decay through the emission of either beta 
or alpha particles due to nuclear instability. These particles will transfer energy to 
the solvent molecules through excitation of the π-cloud in aromatic solvent 
molecules leading to singlet states. The solvent molecules serve to transfer this 
energy to the fluor, which once excited will emit the absorbed energy through the 
emission of photons. The solvent molecules have a low quantum efficiency 
resulting in a low probability to release energy as photons. Therefore, they are 
efficient at transferring energy to other solvent molecules and eventually the fluor. 
The transfer between solvent molecules has two proposed mechanisms. First the 
energy is transferred by a non-radiative process such as seen with Forster 
resonance energy transfer (FRET) [65]. The second is that solvent molecules 
form an excimer and then dissociate so that the previously unexcited molecule 
becomes excited [66, 67]. The flour will trap the energy transfer so that solute-
solvent excitation does not occur. In most cases an additional fluor is used which 





1.5.2 High performance liquid chromatography (HPLC)   
Chromatography, a technique for analysis has existed since the beginning 
of the 20th century [68]. In chromatography, two important components referred 
to as the mobile phase and stationary phase are used to separate a mixture of 
compounds. The mobile phase can either be a liquid or gas. The stationary 
phase, depending of the physicochemical properties of the compound, will hinder 
the movement of the analyte in the mobile phase. It was not until the 1960s that 
HPLC was developed; revolutionising the field of separation science [69]. This 
technique, as the name suggests, involves the use of a high pressure to pump 
mobile phase (liquid) through a column containing the stationary phase leading 
to greater efficiency and hence improved separations. The efficiency seen in 
chromatographic separation can be represented by theoretical plates. These 
plates can also be described by the van Deemter equation [70] which relates 
column efficiency to flow rate and mass transfer kinetics (Equation 1.1). 
𝐻 = 𝐴 +  
𝐵
𝜇
+ 𝐶. 𝜇 
Where, A is eddy diffusion, B is longitudinal diffusion, C is the resistance 
to mass transfer and µ is the flow rate. The resistance to mass transfer is the 
reciprocal of mass transfer coefficient, thus larger mass transfer coefficients will 
lead to smaller C terms and improve efficiency. The A term in the equation 
describes the eddy diffusion, also referred to as the multiple flow path, which 
arises from the particles that are used in the stationary phase. This process is 
independent of flow rate and is proportional to particle size and packing factor  
The longitudinal diffusion term describes the molecular diffusion at the 
front and the end of the eluting band of molecules, as the molecules become 




This term is inversely proportional to the mean flow rate, therefore by increasing 
the flow rate the effect of molecular diffusion is reduced [71]. Expansion of the 
van Deemter equation into its explicit form is given in Equation 1.2 [72].   
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Where, f1(k’) is a constant, Dm is the diffusion coefficient in the mobile 
phase, Ds is the diffusion coefficient in the stationary phase, Df is the film 
thickness, γ is an obstruction factor, λ is a packing factor and Dp is the particle 
size. The expanded resistance to mass transfer term is separated into the mass 
transfer concerning the stationary and mobile phase. As expected larger diffusion 
coefficients will lead to a smaller C term, thus improving efficiency. Larger particle 
diameters will increase the C term leading to decreased efficiency. The 
decreased efficiency is a result of stagnant mobile phase in the pores of the 
particle where large particle sizes will result in increased diffusion distance. The 
same explanation can also be attributed to film thickness of the stationary phase.  
1.5.3 Mass spectrometry (MS) 
Mass spectrometry is a technique that measures the mass-to-charge ratio 
(m/z) of an ion. The measurement of the ion is achieved through either the use 
of a magnetic field (magnetic sector instruments) or electric field (time-of-flight, 
quadrupole, orbitrap, ion trap, electric sector instruments) or a combination of 
both (sector and fourier transform ion cyclotron resonance instruments). In basic 
mass spectrometers (sector instruments) the sample containing the analyte to be 
ionised will be accelerated by an electric field where the ions will enter a magnetic 




field a full spectrum of the analytes in a sample will be produced. The kinetic 
energy of an ion can be explained by Equation 1.3 below.  




Where, e.E is the kinetic energy (e, charge on the ion, E, electric field 
potential), m is the mass of the ion and v is the velocity of the ion. This equation 
can be rearranged to show that both the magnetic field and electric field can be 







Where, H is the applied magnetic field and r is the radius. Thus, by 
increasing or decreasing either the magnetic of electric field the m/z detected is 
different. Heavier ions or ions with low charges will move in a wider radius 
whereas lighter or more highly charged particles will move in a smaller radius, the 
motion of these ions will thus determine whether they reach the detector or collide 
with the walls of the mass analyser. This equation also shows that if a particle 
had a +2 charge the mass that is detected would be half of its true value [73]. 
1.5.3.1 Quadrupole mass spectrometry 
As mentioned above the electric or magnetic field can be manipulated to 
detect ions of specific m/z values. The quadrupole mass analyser consists of four 
rods that have an applied direct current (DC) voltage and alternating current (AC) 
voltage of a radiofrequency (RF) range. The rods are placed parallel to each other 
in the X and Y plane, where the ions will travel along the Z-axis. By varying the 
applied voltage only specific ions of a single m/z value may pass along the 





poles. The applied voltages are described by two equations of which one applies 
to the rods on the X axis and one to the rods on the Y axis (Equation 1.5 and 1.6) 
[74].  
𝑥 = ∪ +𝑉𝑜 cos(𝜔𝑡) 
𝑦 =  − ∪ −𝑉𝑜 cos(𝜔𝑡) 
Where, ∪ is the DC potential, V is the AC potential, ω is the angular 
frequency of the AC potential and t is time. As shown the rods on the X plane 
have a positive DC potential with a varying AC potential and the Y rods have a 
negative DC potential with an applied AC potential (Figure 1.2).  
 
 
These rods have a bias so that simply the X rods are more positive and 
the Y rods are more negative until the potential of the AC voltage is high enough 
to reverse the charge on the rods. If the individual pairs of rods are taken into 
account separately, then once the potentials are applied the ions will be focused 
along the Z plane by the positive DC and will be focused and defocused by the 
changing AC potential. The effect is also time dependent so that if the AC 
potential has a high frequency then the ions will tend to only ‘feel’ an average 
potential or if the ion is heavy as described previously, the radius of motion will 
be larger so that the smaller amount of time the rods are negative will have little 








Figure 1.2: Configuration of the rods in a quadrupole mass 
analyser. The flight path of the gas phase ions is along the z-axis. 
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is light the force exerted by the varying AC potential when it is negative may be 
sufficient to cause the ion to follow an unstable trajectory and collide with the 
rods, thus the X rods are known as a high pass mass filter. The Y rods will have 
an equal potential to the X rods but will be the opposite sign, so the waveforms 
are 180o out of phase. As the larger ions only feel an average of the applied 
potential and these rods are negatively bias, they will follow an unstable 
trajectory. However, a light ion will be focused and defocused continually so that 
overall the path is stable and the ions are detected. There is a critical point at a 
specific DC and AC potential in each X-Z and Y-Z plane that will determine if an 
ion will pass through or be removed as a neutral upon collision with the rod. For 
an ion to reach the detector in a quadrupole mass analyser, the ion must be of a 
specific m/z so that it is not too light to go below the critical point in the high pass 
mass filter and not to heavy that it is above the critical point in the low pass mass 
filter. Thus, if an AC:DC ratio of potentials is optimised, a point at which only one 
atomic mass unit can pass through the rods is obtained.  
Mass analysers can be coupled to together to form what is known as 
tandem mass spectrometry (MSn). Tandem mass spectrometry is a very selective 
and sensitive technique enabling both accurate and reliable determination of 
trace concentrations of analytes. In quadrupole analysis the most common type 
of mass spectrometer is a triple quadrupole, where the sample will be ionised and 
enter the first quadrupole. Here in the first mass analyser usually parent ions are 
detected which are then accelerated to the second mass analyser which acts a 
collision cell, this causes collision induced dissociation (CID) of the parent 
molecules so that fragmented ions or product ions are produced. These product 
ions are then detected by the third quadrupole. The fragmentations are known as 
transitions, a specific parent ion will fragment to a specific product ion, so the 
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operator can perform single or multiple reaction monitoring (SRM/MRM). This 
allows the monitoring of single or multiple transitions which in turn allows 
quantification and confirmatory determination of selected analytes.  
 
1.5.4 Liquid chromatography-mass spectrometry 
The coupling of liquid chromatography to mass spectrometry is perhaps 
one of the most powerful instrumental techniques for target/non-target analysis, 
structure elucidation and confirmation. As described previously, it allows the 
separation of complex mixtures which can subsequently be analysed for 
identification of the analytes in the sample. The coupling of LC to MS was 
particularly difficult as the flow rate from the HPLC translated into gas flow rates 
that were far too high to be able to maintain the high vacuum required for mass 
analysers. Many different types of interfaces were produced to overcome this 
problem such as direct liquid introduction (DLI), moving belt interface and 
thermospray which had moderate success in laboratory application. The major 
revolutionary interface in LC-MS that overcame the previous problems 
encountered with other interfaces was known as electrospray ionisation (ESI) 
developed by Fenn et al., [75]. This ion source was a soft ionisation technique 
meaning that there was less fragmentation in source so parent ions would be 
detected, molecular ions could also be produced that would be beyond the 
operating mass range associated with a particular mass analyser (multiple 
charged ions). These sources could only be used with low flow rates at first but 
were then modified to include a nebuliser gas which aided with desolvation of the 
effluent allowing flow rates from the LC of up to 1 mL min-1.  
The ESI source directly introduces the LC eluate via a capillary that has a 
very high potential applied to the tip. As the liquid passes this tip it is sprayed into 
52 
 
a mist where small droplets become charged [76]. Droplets are emitted from the 
capillary tip due to the formation of a Taylor cone by the balance of the 
electrostatic potential and the surface tension of the effluent. The potential acts 
to ‘pull’ the liquid from the capillary tip to the ground plate, counter to this force is 
the surface tension which acts to minimise the surface area of the liquid by 
opposing the pull of the electrostatic force. Upon the applied potential a point is 
reached where the electrostatic force and the surface tension are equal to one 
another and thus a Taylor cone is formed. If the threshold potential of the capillary 
is exceeded the balance between the forces is disrupted and thus droplets are 
ejected from the Taylor cone [77].  
Two models exist that explain the formation of charged analytes from the 
charged droplet which are known as the ion evaporation model (IEM) and the 
charge residue model (CRM) [78]. In the first model after the formation of the 
Taylor cone and emission of charged droplets, as the droplet size decreased the 
charge density on its surface would become sufficiently high to overcome the 
surface tension forces of the droplet so that an ion would be ejected from the 
droplet and into a gaseous phase ion. The CRM proposed that as the droplet 
decreases in size due to evaporation the charge density on the droplet increases 
until a point is reached known as the Rayleigh limit whereby the ions on the 
surface of the droplet become so close their repulsion causes a process known 
as coloumbic explosion [79]. This process repeats constantly until a droplet 
contains a single analyte ion. The coloumbic explosion occurs in both models but 
the difference is that the IEM describes that before a droplet can become so small 
to only contain one analyte, desorption of a single analyte will occur from a larger 
droplet. Much debate has occurred over which mechanism is responsible for ion 
formation in ESI-MS and there is evidence for both mechanisms occurring. It was 
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suggested that IEM occurs for lower molecular weight analytes whereas CRM ion 
formation occurs with large molecular mass compounds [80]. This is perhaps due 
to the fact that a molecule increases in size, the energy required for the ion to 
desorb from the droplet is not reached. 
1.5.5 Sample preparation  
One key aspect to the development of analytical workflows to determine 
the impact of environmental contaminants is sample preparation. As 
environmental samples are complex matrices which include biological tissues, 
soil, surface water and biosolids, it is essential to sample preparation that allows 
the clean-up of the sample and pre-concentration of the analytes. There are 
numerous sample preparation techniques with the most common employing 
protein precipitation, solvent extraction and solid-phase extraction (SPE) [81]. 
Protein precipitation usually involves the uses of organic solvents such as 
acetonitrile which precipitate proteins out of solution due to the low solubility of 
the proteins in these hydrophobic solvents. Weak acids such as acetic acid can 
also be added to a biological sample which disrupts protein binding to analytes 
such as pharmaceuticals.  
Liquid extractions also involve the use of organic solvents due to the high 
solubility of organic compounds. Liquid extractions can involve liquid-liquid 
extractions (LLE) where two immiscible solvents are used to extract analytes into 
one of the phases. Microwave-assisted extraction (MAE) is the use of microwave 
radiation to heat a solvent and improve extraction efficiency of a sample. Another 
comparable technique is pressurised liquid extraction (PLE) or also known as 
accelerated solvent extraction (ASE) which uses high pressure to alter the boiling 
point (increases) of a solvent so that higher temperatures can be used during 
extraction. The increase of temperature and pressure raises the solvent to near 
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their supercritical region leading to improved extraction efficiencies. The 
increased temperature of both MAE and PLE enables greater extraction 
efficiencies as penetration of the sample with the solvent and diffusion of the 
analyte out of the sample is increased [82]. Several factors can affect solvent 
extractions but of greater importance is the choice of solvent [83] and the 
temperature [84]. A solvent or mixture of solvents can be used to take advantage 
of the physicochemical properties of the analyte. Temperature is critical for 
compounds that may be thermolabile and degrade during extraction.  
One of the most used sample clean-up and pre-concentration techniques 
is SPE. This technique allows clean-up by removing interfering matrix 
components whilst retaining analytes [85]. SPE also pre-concentrates analytes 
as it is possible to use very large samples volumes (up to 20 L). However, sample 
volumes used are typically < 1 L. SPE involves a cartridge that contains a sorbent 
material such as C8. The sample solution is passed through a conditioned 
cartridge in a loading phase where the sorbent retains the analyte whilst matrix 
components pass through and go to waste. However, the sorbent may also retain 
some undesirable matrix components that can interfere with the instrumental 
analysis. Thus, a wash phase is used that uses a ‘weak’ solvent to remove the 
interferences whilst not affecting the retention of the analytes. After the wash 
step, the analytes are eluted with an organic solvent and then dried down under 
nitrogen and reconstituted in a small volume (e.g. 50 to 1000 µL) for analysis. 
The main factor to influence the extraction and recovery in SPE will be the sorbent 
material. Many environmental applications use a dual mode copolymer known as 
hydrophilic-lipophilic balance (HLB) which can retain both polar and non-polar 
compounds through Van der Waals forces, π-π interactions and hydrogen 
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bonding. Retention can also be through ionic interactions in ion exchange 
sorbents, which can be useful for compounds that are ionised.  
Another factor that can affect SPE efficiency is the sample volume, where 
larger volumes lead to breakthrough, where recovery is low and not reproducible 
[86]. The wash and elution solvents are also important as it can lead to the loss 
of analyte and increase the remaining matrix components after the procedure. As 
a final point, the pH of the sample when loading can be important for retention on 
ion exchange cartridges or for compounds that are ionisable such as 
pharmaceuticals. Whilst sample preparation is important for environmental 
applications, due to the complexity of samples interfering components will 
inevitably remain and can affect the instrumental analysis. Therefore, it is 
important to characterise the extraction efficiency and any matrix effects to 
ensure reliable analysis.   
1.6 Accumulation of PPCPs in aquatic biota 
The uptake and elimination of contaminants in biota can be quantified 
using a ratio that represents either the bioconcentration, bioaccumulation or 
biomagnification of a selected compound. Bioconcentration has been defined as 
the uptake of contaminants from only the exposure medium 
(freshwater/sediment) and is represented by the bioconcentration factor (BCF). 
Bioaccumulation and biomagnification relate to the accumulation through both 
the exposure medium and the diet of organism. Where, biomagnification 
quantifies the accumulation across trophic levels in contrast to a single organism. 
These two processes are quantified by the bioaccumulation factor (BAF) and 
biomagnification factor (BMF). These factors thus provide a quantitative measure 
of the accumulation potential useful in a regulatory context. However, these 
factors can be influenced by several variables that will be discussed further.   
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1.6.1 Uptake pathways  
The uptake pathways are depicted simplistically in Figure 1.3 [87, 88]. 
Membranes that are specialised for transport such as those found in the gills and 
digestive tracts of aquatic organisms are constantly exposed to contaminated 
surface waters which leads to the possibility that PPCPs will be transported into 
the organisms by a process such as diffusion or carrier-mediated transport. 
Specialised sensory organs such as lateral lines in fish or olfactory/optic cells can 
also affect accumulation of pollutants of contaminants leading to localised areas 
of within organisms containing high concentrations of xenobiotics [89].  
1.6.1.1 Accumulation through gill uptake 
Gill transport is likely to be a major mechanism of PPCP accumulation. 
Early work with gill tissue investigated logP with uptake rate, and it was 
determined that over a defined logP range the uptake increased. However, after 
a specific point was met, the uptake began to decrease. It was found that when 
logP when plotted against uptake rate a sigmoid curve was fitted. Based on 
passive diffusion, the reason for such an observation is that compounds with a 
low logP would be insoluble in lipid thus not able to penetrate biological 
Figure 1.3: Accumulation pathways in fish, (a) the uptake and elimination routes (b) 
the uptake pathways across epithelia tissue (i.e. gill) (c) transport through vesicles 
into the cell (endocytosis). 
(a) (b) (c) 
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membranes. Compounds with high logP would essentially become ‘stuck’ in the 
lipid layer and would not be released into the blood or other compartments [90]. 
As PPCPs usually have a moderate range of logP (e.g. 0-5), they will most likely 
accumulate through passive diffusion. However, as many exist in an ionisable 
form it is possible that carrier-mediated transport, in the form of either facilitated 
diffusion or active transport could also account for uptake.  
Mechanisms of drug absorption is usually based on lipophilicity and is 
thought to be the dominant mechanism of transport across memebranes. 
However, carrier-mediated transport may play a more important role than 
previously thought [91]. Xenobiotics may act a substrate for various families of 
transporters such as the solute carrier family (SLCs). These SLCs have been 
isolated in fish gill cells which are considered the primary organ for contaminant 
uptake in aquatic organisms [92-94]. Furthermore, SLCs can recognise multiple 
substrates such as ionic and non-ionic organic compounds and thus provide a 
pathway for non-specific substrate transport [91]. Characterisation of transporters 
is limited with perhaps the greatest coverage in humans. However, conservation 
of transporters across taxonomic groups may underpin identification from well-
studied model organisms. For example the SLC22 family of transporters (organic 
anionic/zwitterionic/cationic transporters) which is involved with the transport of 
many pharmaceuticals has homologs found in Drosophila and C. elegans [95].  
Localised accumulation of tributyltin in the brain of fish suggested specific 
tissue accumulated this organometal. This data may indicate that that passive 
diffusion may not account for the uptake [89, 91]. A study on the concentration of 
the β-blocker propranolol in fish plasma showed that at a relatively high exposure 
concentration (10 mg L-1) the concentration in the fish plasma exceeded that of 
the exposure media that may also indicate active transport of this pharmaceutical 
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[96]. The epithelial tissues that make up the gills are involved heavily in ion 
transport systems for ion regulation and osmoregulation in aquatic organisms, 
and have been noted to accumulate toxic heavy metal ions via these transport 
mechanisms [97].  
The uptake of acidic organic chemicals was shown to decrease as the pH 
of the environment increased indicating that the ionised form was accumulated 
at a lower rate to the neutral form. This data demonstrates the idea that crossing 
hydrophobic membranes is unlikely for ionised compounds. However, authors 
noted that the change in the fraction of the ionised species compared with the 
increase in the pH did not decrease the uptake rates proportionately, thus 
indicating that even in a compounds ionised form it still accumulates [98]. Release 
of ammonia and carbon dioxide across the gill structures will affect the pH of the 
interphase layer compared with that of the bulk solution, thus an underestimate 
of uptake is likely as the compounds that would be expected to be ionised may 
remain neutral. It is also a possibility that organic ions such as pharmaceuticals 
may be able to partition directly into across the membrane depending on their 
lipophilicity or accumulate into tissue by paracellular transport at cell junctions 
[98].  
The equilibrium of a predominantly ionised compound outside the gill will 
shift towards the formation of neutral species as the neutral fraction diffuses 
across the membrane [98]. Therefore, this equilibrium process suggests another 
mechanism for uptake of ionisable compounds. The potential across the 
membrane may also have an effect on the efficiency of uptake. Diffusion is 
dictated by electrochemical gradients where the PPCP will move down the 
gradient into the epithelial tissue. However, the potential of the membrane may 
setup a gradient that will oppose or enhance the chemical gradient depending on 
59 
 
the ions involved, thus known as the Nernst potential [99]. Transepithelial electric 
potentials (TEP) have been demonstrated to vary on a species basis and are 
found to be positive to negative thus affecting uptake and extrusion of various 
ions [97]. These potentials are also varied depending on the aquatic environment 
(salt-water or freshwater) as salt-water will have increased ionic strength, thus 
affecting ionic transporters. 
1.6.1.2 Dermal and digestive tract accumulation  
Trophic transfer and feeding (biomagnification/bioaccumulation) is 
another route for uptake as the digestive tract will contain assimilated food that 
may be contaminated with PPCPs (or other contaminants). Thus, accumulation 
of PPCPs through the diet and trophic levels can occur. Sorption of contaminants 
to sediment may also enter digestive tracts of some aquatic organisms through 
feeding. Sorption is an important consideration when studying the effects of 
uptake, as PPCPs have the potential to adsorb to exoskeletons and scales which 
could then diffuse through and accumulate in tissues. Studies have estimated 
between 10-50 % of absorption of contaminants is by dermal absorption in fish 
[100, 101]. To understand this potential the structure of both fish dermal layers 
as with invertebrate exoskeleton must be considered.  
Teleost fish scales consist of a mineral layer known as hydroxyapatite 
containing ionic groups such as phosphate, which is interwoven with type 1 
collagen fibres, containing alkylated amino groups, carbonyl and carboxylic acid 
groups [102-104]. The phosphate groups have been noted to complex with metal 
ions in the aqueous phase and that the amino groups play an important part of 
sorption [102]. The hydroxyapatite layer in fish scales has been determined to 
have a porous structure therefore the possibility for molecules to penetrate and 
absorb into epithelial tissue exists. However, this will be limited by the diffusivity 
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of the compounds in these pores which may account for the lower estimate of 
dermal absorption reported [103]. Estimates were reported for different sizes of 
fish and the variability could also be the result of surface area to volume of the 
organism. Furthermore, some estimates were based on models developed on 
mammals which may not be suitable to assess dermal absorption in fish [100, 
105]. A subcutaneous layer of fat in fish also exists which could have storage 
capacity for organic contaminants [100].  
Invertebrate organisms have an exoskeleton which consists of chitin, or 
more specifically N-acetyl-glucosamine [106]. Early work with chitin involved 
dichlordiphenyltrichloroethane (DDT) sorption capacity, the authors noted that 
when compared with cellulose, which is structurally similar to chitin, there was no 
sorption of DDT. Thus, the authors concluded that the amino groups in chitin 
would be responsible for the sorption of DDT [107]. Later experiments determined 
that sorption of lindane to chitin was through hydrophobic and electrostatic 
interactions and decreased with increasing temperature owing to an increase in 
energy of the solute to overcome intermolecular forces. The authors also noted 
that sorption was split into two categories; one that was reversible (i.e. sorption-
desorption) and a second that was resistant to desorption. The effect of salinity 
on this desorption resistance showed that as the ionic strength increased the 
resistant mode became more favourable. This could be due two reasons, firstly 
that ions will effectively reduce the hydration of sorbent surface making sorption 
more favourable. Secondly, an increase in adsorbed cations from the seawater 
will allow more specific electrostatic interactions to occur. It is also possible that 
inorganic salt concentration could effectively begin to ‘salt-out’ hydrophobic 
molecules causing them to aggregate with chitin molecules [106, 108]. 
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Although these studies described above have not been conducted with 
PPCPs, pharmaceuticals that contain multiple ionisable sites and varying 
degrees of hydrophobicity may undergo biosorption, particularly as electrostatic 
interactions might be more important in determining sorption than hydrophobicity 
[109]. Sorption to animals is not often a considered aspect in bioconcentration 
studies. If the compound is adsorbed to the animal then it may be prevented from 
accumulating in the organism internally. However, sorption is important in 
bioaccumulation where bound contaminants may enter into the digestive tract of 
higher trophic level organisms.  
1.6.2 Models of accumulation 
To determine the accumulation of a xenobiotic in the aquatic environment, 
models were developed that described the uptake of compound into an organism. 
These model described variables such as chemical fugacity, metabolism, 
respiration, fish weight, gill flow rate, diffusion resistance and permeation 
resistance among others [110-112]. Early models were used to determine 
hydrophobic organic contaminants and organometals in fish [113]. Other models 
have tried to predict bioconcentration from using physicochemical properties 
such as logP and logS based off of linear regressions estimates using a training 
set of compounds [114, 115].  
The importance of determining the potential of a compound to accumulate 
in an organism is crucial to assess the risk in the environment. Therefore, several 
technical guidance documents have been released including the American 
Society for Testing and Materials (ASTM) 1993, European Centre for 
Ecotoxicology and Toxicology of Chemicals (ECETOC) 1996 and Organisation 
for Economic Co-operation and Development (OECD) 1996 to experimentally 
determine bioconcentration/bioaccumulation [116]. However, the most generally 
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applied guidance document to determine BCF/BAF is the OECD 305 
bioaccumulation in fish: aqueous and dietary exposure [117]. The determination 
of BCF using this document can involve kinetic estimation where the ratio of the 
uptake rate constant (k1) and the elimination rate constant (k2) are used to 
estimate the BCF. Alternatively, steady-state measurement (concentration no 
longer increases in the animal) can be used to estimate the BCF where the 
concentration of compound in the organism is divided by the concentration in the 
water.  
The advantage of steady-state measurements is the simplicity in 
determining BCFs. However, the time to reach steady-state can be considerable, 
thus if steady state is not reached a BCF cannot be determined. Extension of the 
experiment length is also undesirable as they are resource intensive (cost, time 
and labour). Therefore, the kinetic measurements offer a solution to this limitation 
but as they use iterative algorithms (Levenberg-Marquardt) another source of 
error is introduced in the estimation of BCFs.  Currently, the models that have 
been developed describe only the accumulation potential of a contaminants in 
fish. Models that describe accumulation in invertebrates do not exist. Therefore, 
the application of fish uptake models to the invertebrate phyla remains 
understudied. In addition, contaminants used to develop models have 
predominantly been neutral hydrophobic contaminants. Thus, whether these 
models are suitable to describe the accumulation of amphoteric and ionisable 
PPCPs is a current knowledge gap.   
1.6.3 Factors influencing bioaccumulation  
The accumulation of contaminants can be affected by numerous factors 
including bioavailability, metabolism, water chemistry, growth and excretion. 
Sorption is important in understanding the bioavailability of the PPCPs to 
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organisms, and the idea of non-reversible desorption is also a factor for 
consideration. If a compound is adsorbed to sediment particle, particularly the 
desorption-resistant fraction will be unavailable to accumulate in organisms which 
is more likely to be advantageous in benthic organisms. As demonstrated with 
the hydrophobic organic compound phenanthrene, there was desorption-
resistant fraction and the sediment bioaccumulation factor for the resistant 
fraction of phenanthrene was two times lower than the reversible fraction [118]. 
Furthermore, the association of contaminants to DOM such as humic acids may 
also reduce the bioavailability of the compound to accumulate in biota [119].  
We must also consider the efflux and removal of PPCPs from organisms 
to understand the accumulation potential. As mentioned above gradients of 
electric potential and chemical concentration can oppose each other increasing 
the extrusion of organic ions that are accumulated in the cell and may also 
prevent further uptake from the outside environment. Proteins known as the 
multidrug resistance (MDR) transporters consisting of the proteins from the ATP 
binding cassette (ABC) superfamily can also affect accumulation. This 
superfamily of proteins are found in aquatic species and are termed multi-
xenobiotic resistant MXR transporters, these proteins have a very wide spectrum 
of substrate affinities which is very advantageous for removing toxic xenobiotics 
and as these are driven by active transport it counters passive diffusion [120].  
Accumulation of compounds is also affected by numerous biotic factors. 
Studies suggest that strategies and traits specific to different taxonomic groups, 
for example life cycle and reproduction, will affect the sensitivity of the organism 
to the pollutant [121]. The habitat choice will determine the accumulation as 
benthic organisms will come into contact with sediment which could contain more 
hydrophobic compounds associated with high uptake potentials. There is the 
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metabolic rate which determines the nutrient requirement indicating that 
organisms that feed frequently might have a higher exposure to pollutants. The 
type of integument of the organisms whether the species is soft bodied or 
hardened with heavily deposited inorganic salts will influence the permeability of 
the compound and whether the compound is lost to moulting cycles [122]. The 
type of lipid and the lipid content will affect accumulation predominantly through 
hydrophobic effects, in combination with the variety of physico-chemical 
properties it is apparent that there is a complex network of interactions that 
influence the occurrence of PPCPs in biota [123]. The biochemical activity inside 
the organism (xenometabolism) may also have a profound effect on accumulation 
as one species may be able to efficiently remove the compound in comparison to 
another [124]. This will be determined by conservation of Phase 1 and Phase 2 
metabolic enzymes such as cytochrome P450 (CYP). Currently, xenometabolism 
is understudied in assessing the accumulation potential. Models to determine 
bioconcentration do not often take biotransformation into account. Thus, the 
potential of non-target organisms to biotransform PPCPs is not well known. This 
is especially so for invertebrates where conservation of metabolic enzymes is not 
well characterised.  
In an exposure study, five pharmaceuticals were measured across two test 
species which had very similar order of accumulation but at very different 
concentrations [125]. In G. pulex fluoxetine was shown to have a BCF value of 
185,900 in comparison to N. Glauca which was measured at 1.387. The reason 
for such a difference was explained in part by the different exposure pH values, 
as fluoxetine would have been more ionised in the N. glauca exposure than in 
the G. pulex exposure. However, three other compounds had higher BCFs in G. 
pulex although the influence of pH would have been minimal. This further 
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demonstrates species differences in uptake and depuration rates and may have 
been further explained by biotransformation [125]. The authors of this paper also 
noted that they found no relationship between lipid content and BCF which was 
also indicated in two other studies where uptake was unrelated to lipid content, 
although it was shown in one of the investigations that chlorpyrifos uptake 
correlated well with the water permeability of the organism [125-127]. Fluoxetine 
has also been studied in Oryzias latipes with reported BCF values ranging from 
74 – 260 depending on the pH, in which it is shown to increase as the compound 
becomes less ionised. In both investigation the authors also noted that the 
metabolite of fluoxetine, norfluoxetine, was measured at a higher concentration 
than the parent compound and it was noted that a longer exposure study may in 
turn reduce the apparent uptake rate of the parent as it is metabolised into 
norfluoxetine. [128, 129]. The pH influence on BCFs indicates the potential for 
water chemistry to affect accumulation.  
Other abiotic factors may also affect accumulation such as temperature 
which was demonstrated to increase determined BCFs [130]. Seasonal variation 
in BCFs can also occur where a mixture of factors can have influence such as 
dilution of contaminant levels in surface waters and temperature of the water 
[131]. Furthermore, the physico-chemical properties of the compound itself can 
affect accumulation through its ionisability, hydrophobicity, molecular size and 
solubility among other factors. It is also important to note that these influences do 
not occur individually and thus it is a complex interaction between numerous 
biotic and abiotic factors that determine the accumulation potential of a 
compound. Therefore, accurate modelling and prediction of accumulation such 




1.7 Ecotoxicological importance of invertebrates  
Invertebrates are critical to understand the impact of environmental 
contaminants. This phylum is the largest and most diverse to exist with many 
species not yet identified [132]. They are of crucial importance to ecosystem 
services, the most well-known of which is insect pollination [133]. These 
organisms also constitute important roles in food webs where adverse effects to 
this group of animals could have detrimental effects to ecosystem function [134]. 
These organisms can be used to understand the impact of environmental 
contaminants through bioaccumulation and toxicity studies where they serve as 
useful indicators of adverse effects.  
The relative sensitivity of aquatic invertebrates and vertebrates to 
environmental stressors can vary widely. For example, invertebrates have been 
shown to be more tolerant to ammonia than fish [135], fish were shown to be 
relatively less sensitive to metal contaminated sediments than invertebrates [136] 
and there were varying sensitivities between invertebrates and vertebrates when 
exposed to thirteen different chemicals [137]. However, even with differing 
sensitivities, a majority of ecotoxicological assessments are performed with fish 
where invertebrates are understudied. Thus, it is crucial that we extend studies 
to the invertebrate phyla to address the current paucity of research in this 
taxanomic group [138]. Furthermore, responses of invertebrates to environmental 
pollutants can be used to understand read-across to other vertebrate animals 
[139]. This is especially important for the replacement of fish species as defined 
by the policy of replacement, reduction and refinement (3Rs) in animal testing. 
The use of invertebrates as environmental indicators has involved assessment of 
endpoints including mortality and sub-lethal endpoints such as the inhibition of 
feeding among other behavioural and physiological responses [140-143]. 
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The majority of invertebrate regulatory testing involves Daphnia magna 
and Ceriodaphnia dubia where they are involved in acute toxicity assays [144]. 
However, acute toxicity assays are limited in their environmental relevance where 
exposures are often several orders of magnitude lower. Thus, the focus of 
research into toxicity should involve sub-lethal chronic exposures to assess the 
subtle effects of environmental contaminants such as PPCPs. For example, a 
bioassay used as a stress indicator for both natural and anthropogenic activity is 
known as the “Scope for Growth” bioassay which measures the difference 
between energy intake and metabolic output. This assay had been successfully 
used for the marine mussel (Mytilus edulis) and was also determined as a 
sensitive bioassay when used with the freshwater amphipod Gammarus pulex 
















1.7.1 Gammarus pulex 
G. pulex is a freshwater benthic detritivore that feed on decaying organic
matter and occupy the bottom most layer of a freshwater habitat, i.e. the interface 
between the sediment and water. Thus, these species provide an important 
ecosystem service known as nutrient cycling. This species belong to the 
arthropoda phyla and are sub-classified as crustacea, these organisms are 
segmented and have a cuticle known as an exoskeleton which is formed of 
calcified chitin, a polymer formed of N-acetylguclosamine.  
These organisms breed throughout the year and will reach sexual maturity 
within 3-4 months, the juveniles are also found to be much more sensitive to 
pollutants than the oldest life stage group which further demonstrates that these 
organisms can be used as very sensitive bioassays for polluted waters [147, 148]. 
Lipid content of G. pulex can vary from ~300-400 µg with males containing a 
higher lipid content except in cases where gravid females were measured and 
contained ~550 µg of lipid [149]. The cuticle of G. pulex consists of three layers 
Figure 1.4: (a) Gammarus pulex showing (1) the cephalon, (2) pereon, (3) the 
pleon, (4) the gnathopods, (5) location of the gills and (6) pereopods, pleopods 
and uropods. (b) Scanning electron micrograph of an arthropod cuticle cross 
section. Ep is the epicuticle, Ex is the exocuticle, En is the endocuticle and PC 
shows a pore channel. Figure taken from [150]. 
(a) (b) 
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the epicuticle (outermost), exocuticle (middle) and endocuticle (innermost) below 
which is the epidermis (Figure 1.4) [150]. The cuticle contains numerous pore 
channels that contain chitin fibres and cytoplasmic extensions which terminate 
below the epictuicle layer or at the surface of the epicuticle [151]. The epicuticle 
layer can be further subdivided into additional layers such as the cement layer, 
wax layer and cuticulin layer [152]. However, the exact composition of these 
layers has not been characterised. It is proposed that the cuticulin layer is a 
formed of an unknown lipoprotein [153]. The epicuticle is also perforated with 
pore canals which allow secretions when modifying the exoskeleton during moult 
cycles [150]. The exoskeleton of arthropods must be shed after periods of growth  
which consists of five stage (A-E) which are further subdivided into A1, A2, B2, 
B1, C1, C2 and C3 (post-molt stage); C4 (intermolt stage) D0, D1’, D1’’, D1’’’, D2, 
D3, and D4 (pre-molt stage); finally the ecdysis of the cuticle, E [151]. The moult 
cycle is important when considering ecotoxicological effects as the uptake and 
depuration may change as certain physiological characteristics of the 
crustaceans will change such as the calcium concentration and pH value of the 
haemolymph [151]. In addition to pH alterations, it has also been suggested that 
CYP expression is increased during post-moult stages where the high levels of 
the hormone ecdysone (responsible for moulting) is required to be reduced 
through metabolism [154]. These organisms have been used by several 
researchers to investigate mortality, sub-lethal effects, bioaccumulation and more 
recently metabolism of environmental contaminants including PPCPs [140-143, 
155-157]. Demonstrating the suitability of these organisms for use in 





1.8 Regulation and legislation 
To mitigate the risks posed by environmental contaminants a number of 
governmental bodies have released regulatory and legislative guidance 
documents. Of this legislation, the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) is the main document to assess environmental 
risk across the European Union (EU) [158]. A stipulation of REACH is that any 
chemical that is manufactured in excess of 10 tonnes per annum requires a 
chemical safety assessment (CSA). These CSAs involves the persistent, 
bioaccumulative and toxicity (PBT) testing. As the name suggests chemicals are 
tested to determine if a chemical; persists in the environment usually determined 
by a half-life, bioaccumulates in an organism determined by a BCF or BAF and 
whether it is toxic to organisms that are exposed to it determined by effect 
concentrations such as the EC50 or LC50.  
During the assessment a compound may be classed persistent and 
bioaccumulative (P/B) or very persistent and bioaccumulative (vPvB). If a 
manufacturer determines that their chemical fulfils the criteria of PBT testing then 
they must perform an emission characterisation and minimise exposures 
through-out the lifecycle of the chemical. The emission characterisation aims to 
identify and estimate the emission of a chemical into the environment. Secondly, 
it aims to identify routes of exposure to humans and the environment. The 
emission characterisation forms the basis of the risk characterisation and 
management measures. This involves minimising the emissions from a specific 
use, communicate safety data sheets (SDS) to end-users, containment of the 
substance, trained personnel to handle the chemical, control technologies and 
characterising direct exposure risk by establishing exposure thresholds. 
Substances identified as B/P or vPvB are also prioritised to be phased out of 
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manufacture where technically and economically viable substitutions are 
available. Additionally, if a substance has fulfilled the PBT criteria it can be subject 
to being placed on the candidate list for substances of very high concern (SVHC) 
by the European Chemicals Agency (ECHA).  
Substances defined as SVHC are subject to authorisation so that the risks 
posed are controlled and prioritised for replacement. Alternatively, the substance 
can be placed under restriction where the manufacture, placing on the market or 
use is restricted or banned completely. Substances fulfilling the PBT assessment 
may also overlap with substances identified by the United Nations Economic 
Commission for Europe (ENCE) Protocol for Persistent Organic Pollutants 
(POPs) [159]. This protocol bans the production and use of selected substances 
where others are scheduled for bans at a later date. The protocol addresses the 
control and reduction of emissions POPs including waste from banned 
substances.  
The Convention for the Protection of the Marine Environment of the North-
East Atlantic (OSPAR) is a legislative body  that regulates international 
environmental protection [160]. This body regulates the emission of hazardous 
or radioactive substances and the emission of off-shore industrial chemicals and 
oil from the oil and gas industry. The body aims to achieve this by monitoring 
environmental emissions, phase out use of hazardous substances, develop best 
available techniques (BAT) and best environmental practice (BAP).  This body 
also has a List of Chemicals for Priority Action which was the first to include a 
pharmaceutical among legislative bodies that was clotrimazole in 2002 [161]. 
This substance only fulfils the P and T assessment set by REACH but fulfils all 
the PBT criteria set by OSPAR itself.  
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In addition to OSPAR for the protection of aquatic environments is the EU 
Water Framework Directive (WFD) [162]. The directive aims to assess the 
ecological and chemical status of surface waters and groundwater. The 
framework sets out environmental thresholds for specific pollutants named on the 
list of Priority Substances. This required EU member states to take action to meet 
standards set out by Environmental Quality Standards Directive (EQSD). In 
addition to the Priority Substances List, the WFD also has a Watch List where 
compounds are required to be monitored across a range of surface waters to 
assess the potential impact on the environment. The Watch List included three 
pharmaceutical compounds, a NSAID and two hormones; diclofenac, 17-Beta-
estradiol (E2), and 17-Alpha-ethinylestradiol (EE2) [163]. Pharmaceuticals are a 
unique case for legislation and assessment of environmental risks.  
REACH does not cover pharmaceutical compounds. Instead they are 
covered by the European Medicines Agency (EMA) [164]. The EMA requires ERA 
for pharmaceutical products which Phase I and Phase II testing. Phase I involves 
the estimation of exposure through standard testing approaches such as PBT. 
Phase II involves the fate and effects of pharmaceuticals which are often 
characterised by OECD technical guidance documents. However, 
pharmaceuticals intended for veterinary use do not require PBT testing until 
Phase II. The outcome of the ERA will involve standard approaches such as 
minimising emissions to the environment, appropriate labelling for disposal 
methods and other appropriate risk mitigation measures. The ERA involves 
criteria that will trigger the next level of assessment, but if they are not fulfilled the 
ERA stops. Thus, for example if Phase I testing concludes a substance is not 
PBT no further assessments are carried out. However, as these tests are 
preliminary they do not fully investigate routes of exposures, metabolite products 
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or chronic toxicity. This presents a problem as the risk posed by pharmaceuticals 
may not properly be characterised due to poor quality ERAs. In addition to this, 
pharmaceuticals intended for human use cannot be rejected for market 
placement regardless of the outcome of an ERA. Thus, it is essential that 
pharmaceutical risk to the environment requires a focus of research effort to 
understand the potential for adverse outcomes.   
1.9 Quantitative structure activity relationship (QSAR) models  
Modelling has become an important aspect in environmental science due 
to the complexity of the environment and the number of factors that may affect 
one aspect, for example bioaccumulation [165]. Modelling approaches can 
involve the linear or non-linear prediction or classification of a desired output 
function such as toxicity. QSAR models involve the use of multiple input variables 
which are often molecular descriptors covering a range of chemical compounds. 
These inputs can cover physico-chemical properties, constitutional, topological 
(2-D) and geometrical descriptors (3-D). Where selection of descriptors involves 
some form of pre-processing which can include normalisation (zero/near zero 
variance), transformation, centering and scaling to reduce descriptor redundancy 
and improve modelling. Input pre-treatment can also include feature selection 
such as stepwise or genetic algorithms to identify important descriptors in the 
modelling approach.  
The modelling makes use of either linear or non-linear regression 
algorithms where non-linear methods are usually accomplished in silico [166]. 
These non-linear algorithms can include artificial neural networks (ANN) [167], 
support vector machines (SVM) [168], partial least squares (PLS) [169] and tree-
based models [170]. Many QSAR models will use two data subsets referred to 
as the training and validation data. The training data is used to build and develop 
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the models whilst the validation data is used to test and validate the model. 
QSARs can be used in categorical classifications or in quantitative predictions 
depending on the application required. In addition to predictive and categorical 
applications, developed QSARs can also be used to mechanistically interpret the 
descriptor-output relationship. Thus, QSARs are both useful and important in 
understanding complex processes [171].  
1.9.1 Artificial neural networks (ANNs)   
One computational model that has been established is ANNs. These 
models map input data to an output or to multiple outputs. The mapping of the 
input-output relationship is achieved through means of a hidden layer. This layer 
contains hidden nodes which are connected to both input and output variables 
(Figure 1.5).  
 
 
Figure 1.5: Schematic representation of an ANN 
with 3 inputs, a single hidden layer (3 nodes) and 
a single output.  
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The connections between the layers are referred to as neurons which have 
an individual weight applied. The weight on a neuron can change over time as 
the model learns. The weight associated with an input neuron will then be 
converted into an output by means of an activation function on the hidden node. 
The output activation will be a function of the input neuron weights and bias that 
is applied. The learning process used to model the data will depend on the type 
of ANN used such as multi-layer perceptrons (MLP) [172], probabilistic neural 
networks (PNN) [173] and radial basis function (RBF) networks [174].  
MLPs are perhaps the most well-known and are trained using gradient 
descent algorithms. Gradient descent can be visualised by a plot of an error 
surface of two or more variables against a loss function [175]. The gradient 
descent aims to descend down the gradient of the error surface to reach the 
global minimum, analogous to a ball rolling down a valley. The most popular 
gradient descent method in MLPs is backpropagation (BP) where the training is 
recursive [176]. Backpropagation similar to other methods of gradient descent 
operates by minimising the loss function (usually a quadratic loss function, i.e. 
mean squared error) using a gradient vector [177]. The gradient vector is 
calculated and the variables are changed (weights and bias) to decrease the loss 
function. The change in the variables can be controlled by other variables known 
as hyper parameters which include the epoch number, learning rate, and 
momentum [178]. The epoch number is related to the number of iterations the 
backpropagation uses to reduce the cost function of the network. Learning rates 
can be small indicating that small changes in weights and bias will take place, 
thus learning can be slow but more accurate and vice versa. Momentum indicates 
that if the direction of the gradient descent continues to decrease the loss function 
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the algorithm will start to ‘jump’ further in the same direction thus reducing the 
time that learning will take.  
Backpropagation as a form of gradient descent is powerful for error 
minimisation but does have limitations. Firstly, the initial weights and biases on 
the neurons may start a great distance from the global minima, thus training can 
be slower and shower poorer performance. Secondly, the gradient descent can 
get stuck in local minima as the error surface of the cost function can be quite 
complex [176]. Whilst, ANNs offer a very powerful modelling approach to complex 
processes the main limitation that are associated with ANNs is that they are quite 
susceptible to overfitting/overtraining [179]. Thus, the model will lose 
generalisability and predictive power. To avoid this, the training data should be 
as large reasonably possible, the network architecture (hidden layers and nodes) 
should be kept as small as possible and test data should also be large to validate 
the generalisability of the model. A final step to prevent overfitting is a method 
known as regularisation. Regularisation can include a weight decay which applies 
a bias to the cost function so that small weight changes or reducing the cost 
function is favoured during the learning process (depending on the value of the 
bias) [180]. The smaller weights on the neurons means that changes in a minority 
of the inputs will not alter the output significantly. Thus, a regularised model does 
not learn the noise in the data. In contrast, large weights on neurons may change 
considerably between input data, thus the output will also vary significantly.  
In summation, the model will learn general trends across all the data whilst 
reducing the impact of individual irregular data points thus enabling better 
generalisation of the actual underlying process that is modelled. Furthermore, this 
form of regularisation also prevents the algorithm getting stuck in local minima 
and thus models become more repeatable. The most common and simple form 
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of regularisation is known as early stopping [181]. As mentioned previously, for 
QSARs models are split into two subsets (training and validation). However, in 
the case of ANNs it is often split into three subsets which are the training, 
verification and test subsets. The verification subset is supervised and used to 
select the hyper parameters to develop the model but is also used in early 
stopping. The training of the network is continued across a number of epochs. As 
the model learns the verification and training error should gradually decrease. 
However, as training is continued the verification subset error will suddenly 
increase whilst the training error continues to decrease thus indicating 
overtraining. Therefore, the training is stopped as this point is reached to prevent 
overfitting. Whilst ANNs are susceptible overfitting they are an extremely powerful 
tool in classification and regression of very complex processes as shown in 
Section 1.9.2.    
1.9.2 Applications of QSARs in the environment 
As mentioned previously, QSAR modelling approaches are very powerful 
for understanding complex processes and have a predictive capability that makes 
their use in environmental sciences suitable. QSARs in environmental sciences 
have seen application in aquatic toxicity (acute) [182], sorption in soil [183], 
chromatographic retention behaviour [184], persistence [185], logP estimations 
[186], WWTP performance [187] and bioaccumulation [188]. The applications are 
wide ranging and have become increasingly popular due to the number of 
advantages they offer in environmental sciences. They can interpret complex 
processes to give a mechanistic understanding. They are less resource intensive 
than using experimental determinations and also reduce the need for testing 
which is ethically important for experiments that involve animal use. Under 
REACH alone it has been suggested that 54 million vertebrate animals will be 
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tested costing an estimated €9.5 billion [189]. Furthermore, the number of 
chemicals on the market that require ERAs are likely to reach into the hundreds 
of thousands. Therefore, with the number of chemicals to be tested, animals used 
and the cost of ERAs, it is possible that QSARs are potentially the only feasible 
route to prioritise and assess chemical risks in the environment. Furthermore, the 
predictive ability of models is also valuable to regulators. For example, the use of 
QSARs have been supported by regulatory bodies such as REACH [190] and the 
US EPA [191].  
QSARs in certain cases have been used to substitute experimental data 
when it has not been technically possible to perform tests [192]. However, in the 
majority of cases experimental data is used whilst QSARs supplement 
experimental measurements in a weight-of-evidence approach. The preference 
of regulators to use experimental data stems from the reliability of QSARs. The 
reason is that QSARs are often built on a relatively small number of cases, thus 
the applicability domain of the model will be relatively narrow. Extrapolations 
outside of this domain leads to greater uncertainty when a model is used to 
predict for a compound with no previously available data. Whilst this limitation is 
critical for ERA, there are technical guidance documents (OECD) available that 
can be used to ensure models are reliable and validated. The use of ANNs for 
QSAR applications in environmental toxicology is extremely limited with few 
studies that have used ANNs to predict toxicity [193-195] and bioconcentration 
factors [196]. However, these studies have all been limited in the number of 
training and test cases used. With QSARs becoming more popular in 
environmental toxicology, the use of ANNs holds great potential as they have 
been recognised as more powerful tools when compared to classical regression 
models [193].   
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1.10 Aims and Objectives 
The previously described sections have identified several knowledge gaps in 
environmental toxicology. Currently understanding is limited with regards to 
whether pharmaceuticals are accumulative within aquatic biota and this 
accumulation potential is particularly limited with regards to invertebrates.  
The aim of this work is to further the understanding of the extent of 
pharmaceutical bioconcentration in a freshwater invertebrate, G. pulex, with the 
view towards modelling this in silico. To this end, the objectives of the work are: 
(a) To develop a reliable analytical method for the determination of PhAC 
occurrence in whole invertebrate specimens and surrounding surface 
waters; 
(b) To characterise the uptake and depuration kinetics for a selection of 
PhACs and to determine their bioconcentration factors in G. pulex; 
(c) To characterise and determine the pathways and extent of metabolism for 
selected PhACs 
(d) To model and predict the uptake of PhACs and other emerging 
environmental contaminants in fish, invertebrates and moderate 
hydrophilicity passive sampler sorbent chemistries using ANNs (to be 
potentially used as a surrogate for G. pulex);  
The work presented herein, addresses several knowledge gaps related to the 
occurrence, toxicokinetics and bioaccumulation of PhACs in aquatic 
invertebrates that has allowed further assessment of the potential of PhACs to 
pose a risk in the environment. Specifically, the development and use of an 
analytical method to determine the occurrence of pharmaceuticals in a freshwater 
invertebrate within the UK has not been previously reported. Furthermore, critical 
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assessment of models currently used to determine pharmaceutical toxicokinetics 
and bioconcentration were shown to be unreliable due to non-observance of 
model assumptions. Finally, the work presents novel in silico modelling of 
accumulation for pharmaceuticals and other organic micropollutants in passive 




















1. Schwarzenbach, R.P., T. Egli, T.B. Hofstetter, U. Von Gunten, and B. 
Wehrli, Global water pollution and human health. Annual Review of 
Environment and Resources, 2010. 35: p. 109-136. 
2. Daughton, C.G. and T.A. Ternes, Pharmaceuticals and personal care 
products in the environment: agents of subtle change? Environmental 
health perspectives, 1999. 107(Suppl 6): p. 907. 
3. Boxall, A.B., The environmental side effects of medication. EMBO reports, 
2004. 5(12): p. 1110-1116. 
4. Kümmerer, K., Pharmaceuticals in the environment: sources, fate, effects 
and risks. 2008: Springer Science & Business Media. 
5. Larsson, D.J., C. de Pedro, and N. Paxeus, Effluent from drug 
manufactures contains extremely high levels of pharmaceuticals. Journal 
of hazardous materials, 2007. 148(3): p. 751-755. 
6. Cui, C., S. Ji, and H. Ren, Determination of steroid estrogens in 
wastewater treatment plant of a controceptives producing factory. 
Environmental monitoring and assessment, 2006. 121(1-3): p. 409-419. 
7. Kime, D. and J. Nash, Gamete viability as an indicator of reproductive 
endocrine disruption in fish. Science of the Total Environment, 1999. 
233(1): p. 123-129. 
8. Larsson, D.J. and J. Fick, Transparency throughout the production chain—
a way to reduce pollution from the manufacturing of pharmaceuticals? 
Regulatory Toxicology and Pharmacology, 2009. 53(3): p. 161-163. 
9. Gómez, M.J., M. Petrović, A.R. Fernández-Alba, and D. Barceló, 
Determination of pharmaceuticals of various therapeutic classes by solid-
phase extraction and liquid chromatography–tandem mass spectrometry 
82 
 
analysis in hospital effluent wastewaters. Journal of Chromatography A, 
2006. 1114(2): p. 224-233. 
10. Martins, A.F., T.G. Vasconcelos, D.M. Henriques, C.d.S. Frank, A. König, 
and K. Kümmerer, Concentration of ciprofloxacin in Brazilian hospital 
effluent and preliminary risk assessment: a case study. Clean–Soil, Air, 
Water, 2008. 36(3): p. 264-269. 
11. Kosma, C.I., D.A. Lambropoulou, and T.A. Albanis, Investigation of 
PPCPs in wastewater treatment plants in Greece: occurrence, removal 
and environmental risk assessment. Science of the Total Environment, 
2014. 466: p. 421-438. 
12. Lenz, K., S. Mahnik, N. Weissenbacher, R. Mader, P. Krenn, S. Hann, G. 
Koellensperger, M. Uhl, S. Knasmüller, and F. Ferk, Monitoring, removal 
and risk assessment of cytostatic drugs in hospital wastewater. Water 
Science and Technology, 2007. 56(12): p. 141-149. 
13. Verlicchi, P., M. Al Aukidy, A. Galletti, M. Petrovic, and D. Barceló, Hospital 
effluent: investigation of the concentrations and distribution of 
pharmaceuticals and environmental risk assessment. Science of the total 
environment, 2012. 430: p. 109-118. 
14. Kemper, N., Veterinary antibiotics in the aquatic and terrestrial 
environment. Ecological indicators, 2008. 8(1): p. 1-13. 
15. Sabourin, L., A. Beck, P.W. Duenk, S. Kleywegt, D.R. Lapen, H. Li, C.D. 
Metcalfe, M. Payne, and E. Topp, Runoff of pharmaceuticals and personal 
care products following application of dewatered municipal biosolids to an 




16. McClellan, K. and R.U. Halden, Pharmaceuticals and personal care 
products in archived U.S. biosolids from the 2001 EPA national sewage 
sludge survey. Water Research, 2010. 44(2): p. 658-668. 
17. Walters, E., K. McClellan, and R.U. Halden, Occurrence and loss over 
three years of 72 pharmaceuticals and personal care products from 
biosolids–soil mixtures in outdoor mesocosms. Water Research, 2010. 
44(20): p. 6011-6020. 
18. Björklund, H., C. Råbergh, and G. Bylund, Residues of oxolinic acid and 
oxytetracycline in fish and sediments from fish farms. Aquaculture, 1991. 
97(1): p. 85-96. 
19. Kuspis, D. and E. Krenzelok, What happens to expired medications? A 
survey of community medication disposal. Veterinary and human 
toxicology, 1996. 38(1): p. 48-49. 
20. Bound, J.P., K. Kitsou, and N. Voulvoulis, Household disposal of 
pharmaceuticals and perception of risk to the environment. Environmental 
toxicology and pharmacology, 2006. 21(3): p. 301-307. 
21. Buerge, I.J., T. Poiger, M.D. Müller, and H.-R. Buser, Combined sewer 
overflows to surface waters detected by the anthropogenic marker 
caffeine. Environmental science & technology, 2006. 40(13): p. 4096-
4102. 
22. Suárez, S., M. Carballa, F. Omil, and J.M. Lema, How are pharmaceutical 
and personal care products (PPCPs) removed from urban wastewaters? 




23. Batt, A.L., I.B. Bruce, and D.S. Aga, Evaluating the vulnerability of surface 
waters to antibiotic contamination from varying wastewater treatment plant 
discharges. Environmental pollution, 2006. 142(2): p. 295-302. 
24. Tolls, J., Sorption of veterinary pharmaceuticals in soils: a review. 
Environmental science & technology, 2001. 35(17): p. 3397-3406. 
25. Imai, A., T. Fukushima, K. Matsushige, Y.-H. Kim, and K. Choi, 
Characterization of dissolved organic matter in effluents from wastewater 
treatment plants. Water Research, 2002. 36(4): p. 859-870. 
26. Katsoyiannis, A. and C. Samara, The fate of dissolved organic carbon 
(DOC) in the wastewater treatment process and its importance in the 
removal of wastewater contaminants. Environmental Science and 
Pollution Research-International, 2007. 14(5): p. 284-292. 
27. Jim, T.Y., E.J. Bouwer, and M. Coelhan, Occurrence and biodegradability 
studies of selected pharmaceuticals and personal care products in sewage 
effluent. Agricultural water management, 2006. 86(1): p. 72-80. 
28. Clara, M., N. Kreuzinger, B. Strenn, O. Gans, and H. Kroiss, The solids 
retention time—a suitable design parameter to evaluate the capacity of 
wastewater treatment plants to remove micropollutants. Water research, 
2005. 39(1): p. 97-106. 
29. Dietrich, D.R., S. Webb, and T. Petry, Hot spot pollutants: Pharmaceuticals 
in the environment. 2005: Academic press. 
30. McArdell, C.S., E. Molnar, M.J.-F. Suter, and W. Giger, Occurrence and 
fate of macrolide antibiotics in wastewater treatment plants and in the Glatt 
Valley Watershed, Switzerland. Environmental Science & Technology, 
2003. 37(24): p. 5479-5486. 
85 
 
31. Göbel, A., A. Thomsen, C.S. McArdell, A. Joss, and W. Giger, Occurrence 
and sorption behavior of sulfonamides, macrolides, and trimethoprim in 
activated sludge treatment. Environmental science & technology, 2005. 
39(11): p. 3981-3989. 
32. Vrana, B., I.J. Allan, R. Greenwood, G.A. Mills, E. Dominiak, K. Svensson, 
J. Knutsson, and G. Morrison, Passive sampling techniques for monitoring 
pollutants in water. TrAC Trends in Analytical Chemistry, 2005. 24(10): p. 
845-868. 
33. Lohmann, R., K. Booij, F. Smedes, and B. Vrana, Use of passive sampling 
devices for monitoring and compliance checking of POP concentrations in 
water. Environmental Science and Pollution Research, 2012. 19(6): p. 
1885-1895. 
34. aus der Beek, T., F.-A. Weber, A. Bergmann, S. Hickmann, I. Ebert, A. 
Hein, and A. Küster, Pharmaceuticals in the environment—Global 
occurrences and perspectives. Environmental Toxicology and Chemistry, 
2016. 35(4): p. 823-835. 
35. Kasprzyk-Hordern, B., R.M. Dinsdale, and A.J. Guwy, The occurrence of 
pharmaceuticals, personal care products, endocrine disruptors and illicit 
drugs in surface water in South Wales, UK. Water Research, 2008. 42(13): 
p. 3498-3518. 
36. Kim, J.-W., H.-S. Jang, J.-G. Kim, H. Ishibashi, M. Hirano, K. Nasu, N. 
Ichikawa, Y. Takao, R. Shinohara, and K. Arizono, Occurrence of 
pharmaceutical and personal care products (PPCPs) in surface water from 




37. da Silva, B.F., A. Jelic, R. López-Serna, A.A. Mozeto, M. Petrovic, and D. 
Barceló, Occurrence and distribution of pharmaceuticals in surface water, 
suspended solids and sediments of the Ebro river basin, Spain. 
Chemosphere, 2011. 85(8): p. 1331-1339. 
38. Yoon, Y., J. Ryu, J. Oh, B.-G. Choi, and S.A. Snyder, Occurrence of 
endocrine disrupting compounds, pharmaceuticals, and personal care 
products in the Han River (Seoul, South Korea). Science of the Total 
Environment, 2010. 408(3): p. 636-643. 
39. Feitosa-Felizzola, J. and S. Chiron, Occurrence and distribution of 
selected antibiotics in a small Mediterranean stream (Arc River, Southern 
France). Journal of Hydrology, 2009. 364(1): p. 50-57. 
40. Scheurell, M., S. Franke, R. Shah, and H. Hühnerfuss, Occurrence of 
diclofenac and its metabolites in surface water and effluent samples from 
Karachi, Pakistan. Chemosphere, 2009. 77(6): p. 870-876. 
41. Peng, X., Y. Yu, C. Tang, J. Tan, Q. Huang, and Z. Wang, Occurrence of 
steroid estrogens, endocrine-disrupting phenols, and acid pharmaceutical 
residues in urban riverine water of the Pearl River Delta, South China. 
Science of the total environment, 2008. 397(1): p. 158-166. 
42. Fick, J., H. Söderström, R.H. Lindberg, C. Phan, M. Tysklind, and D. 
Larsson, Contamination of surface, ground, and drinking water from 
pharmaceutical production. Environmental Toxicology and Chemistry, 
2009. 28(12): p. 2522-2527. 
43. Watkinson, A., E. Murby, D. Kolpin, and S. Costanzo, The occurrence of 
antibiotics in an urban watershed: from wastewater to drinking water. 
Science of the total environment, 2009. 407(8): p. 2711-2723. 
87 
 
44. Chen, Y., K. Zhang, and Y. Zuo, Direct and indirect photodegradation of 
estriol in the presence of humic acid, nitrate and iron complexes in water 
solutions. Science of the Total Environment, 2013. 463: p. 802-809. 
45. Vasconcelos, T.G., D.M. Henriques, A. König, A.F. Martins, and K. 
Kümmerer, Photo-degradation of the antimicrobial ciprofloxacin at high 
pH: identification and biodegradability assessment of the primary by-
products. Chemosphere, 2009. 76(4): p. 487-493. 
46. Dodard, S.G., A.Y. Renoux, J. Hawari, G. Ampleman, S. Thiboutot, and 
G.I. Sunahara, Ecotoxicity characterization of dinitrotoluenes and some of 
their reduced metabolites. Chemosphere, 1999. 38(9): p. 2071-2079. 
47. Markandya, A., T. Taylor, A. Longo, M. Murty, S. Murty, and K. Dhavala, 
Counting the cost of vulture decline—an appraisal of the human health 
and other benefits of vultures in India. Ecological economics, 2008. 67(2): 
p. 194-204. 
48. Heberer, T., Occurrence, fate, and removal of pharmaceutical residues in 
the aquatic environment: a review of recent research data. Toxicology 
letters, 2002. 131(1): p. 5-17. 
49. Brozinski, J.-M., M. Lahti, A. Meierjohann, A. Oikari, and L. Kronberg, The 
anti-inflammatory drugs diclofenac, naproxen and ibuprofen are found in 
the bile of wild fish caught downstream of a wastewater treatment plant. 
Environmental science & technology, 2012. 47(1): p. 342-348. 
50. Huerta, B., A. Jakimska, M. Llorca, A. Ruhí, G. Margoutidis, V. Acuña, S. 
Sabater, S. Rodriguez-Mozaz, and D. Barcelò, Development of an 
extraction and purification method for the determination of multi-class 
pharmaceuticals and endocrine disruptors in freshwater invertebrates. 
Talanta, 2015. 132: p. 373-381. 
88 
 
51. Huerta, B., A. Jakimska, M. Gros, S. Rodríguez-Mozaz, and D. Barceló, 
Analysis of multi-class pharmaceuticals in fish tissues by ultra-high-
performance liquid chromatography tandem mass spectrometry. Journal 
of Chromatography A, 2013. 1288: p. 63-72. 
52. Fick, J., R.H. Lindberg, J. Parkkonen, B.r. Arvidsson, M. Tysklind, and D.J. 
Larsson, Therapeutic levels of levonorgestrel detected in blood plasma of 
fish: results from screening rainbow trout exposed to treated sewage 
effluents. Environmental science & technology, 2010. 44(7): p. 2661-2666. 
53. Klosterhaus, S.L., R. Grace, M.C. Hamilton, and D. Yee, Method validation 
and reconnaissance of pharmaceuticals, personal care products, and 
alkylphenols in surface waters, sediments, and mussels in an urban 
estuary. Environment international, 2013. 54: p. 92-99. 
54. McEneff, G., L. Barron, B. Kelleher, B. Paull, and B. Quinn, A year-long 
study of the spatial occurrence and relative distribution of pharmaceutical 
residues in sewage effluent, receiving marine waters and marine bivalves. 
Science of the Total Environment, 2014. 476: p. 317-326. 
55. Bringolf, R.B., R.M. Heltsley, T.J. Newton, C.B. Eads, S.J. Fraley, D. Shea, 
and W.G. Cope, Environmental occurrence and reproductive effects of the 
pharmaceutical fluoxetine in native freshwater mussels. Environmental 
Toxicology and Chemistry, 2010. 29(6): p. 1311-1318. 
56. Dodder, N.G., K.A. Maruya, P.L. Ferguson, R. Grace, S. Klosterhaus, M.J. 
La Guardia, G.G. Lauenstein, and J. Ramirez, Occurrence of 
contaminants of emerging concern in mussels (Mytilus spp.) along the 
California coast and the influence of land use, storm water discharge, and 




57. Subedi, B., B. Du, C.K. Chambliss, J. Koschorreck, H. Rüdel, M. Quack, 
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Chapter  2. The development of a multi-residue LC-MS method for 
the determination of pharmaceutical residues in Gammarus pulex 
 
2.1 Introduction 
Research into the field of ecotoxicology arguably began with Rachel 
Carson in the early 1960’s [1]. Research efforts have gained momentum within 
environmental toxicology to study the effects of a number of anthropogenic 
contaminants. These contaminants cover several different classes of compounds 
including synthetic hormones, polychlorinated biphenyls (PCBs), polyaromatic 
hydrocarbons (PAHs), pharmaceuticals and personal care products (PPCPs) [2-
5]. Monitoring studies across the globe have determined the concentrations of 
these contaminants ranging from low ng L-1 to mg L-1 depending on the region 
and legislation in place to reduce contamination and pollution [6-8]. The class of 
compounds known as PPCPs have been designated as emerging contaminants 
due to their occurrence and with little understanding of the risk they pose to the 
environment [9].  
Until recently, the only body that recognised the concern of PPCPs was 
the Oslo-Paris Convention for the Protection of the Marine Environment of the 
North-East Atlantic (OPSAR). However, due to potential adverse effects in the 
environment, two PPCPs were added to the ‘watch list’ of the EU Water 
Framework Directive which aims to regulate emissions of 
contaminants/pollutants into bodies of water. The ‘watch list,’ has no formal 
regulation for compounds designated under this list. However, they are monitored 
in surface water so that they may be added to the ‘priority list,’ if required. The 
number of compounds in this class is over several thousand and cover a diverse 
range of physicochemical properties, thus efforts to identify the potential risks 
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presents a challenge in the field. Furthermore, environmental factors such as 
temporal flow, dissolved organic matter (DOM) and pH in aquatic matrices may 
lead to complex interactions between cause and effects [10]. 
Many investigations to date have only considered surface water 
concentrations with less attention given to internal concentrations in biota. The 
measurement of these internal concentrations is now considered key to the 
understanding and prediction of risk [11]. Few methods have been reported that 
can determine internal concentrations of pharmaceuticals in biota, with most 
methods focused on fish tissue and mussels [12]. A study by McEneff et al. [13], 
determined concentrations of trimethoprim reaching up to 9 ng g-1 in marine 
mussels off the coast of Ireland. Researchers focussing on marine mussels in 
San Francisco, reported the occurrence of compounds such as carbamazepine 
(5.3 ng g-1), sertraline (1.4 ng g-1), atenolol (0.3 ng g-1) amitriptyline (0.2 ng g-1) 
[14]. A report of a similar study along the coast of California showed mean 
concentrations of pharmaceuticals reaching up to 29 ng g-1 dry weight (dw) [15]. 
Venlafaxine was measured in marine mussels at 2.7 ng g-1 dw [16].  Freshwater 
mussels were observed to accumulate fluoxetine from an effluent channel, 
reaching a mean measured concentration of 79.1 ng g-1 wet weight (ww) [17]. A 
reason for the small number of investigations into occurrence of pharmaceuticals 
in biota is that complex biological matrices present a significant analytical 
challenge for the reliable measurement of trace pharmaceutical residues that 
may be found in these organisms.  
Models that are concerned with uptake and accumulation are often based 
on hydrophobicity (logP) such as early studies involving with non-polar organic 
chemicals where passive diffusion across membranes was predominant [18-20]. 
However, these models may fail to prioritise pharmaceuticals based on their 
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physicochemical properties (polarity, ionisation etc.). Mounting evidence has also 
suggested that carrier-mediated uptake is also important in accumulation for 
bioactive compounds such as pharmaceuticals [21, 22]. Thus, occurrence of 
PhACs in biota may also indicate compounds that have a potential to accumulate 
and that should be focused on in future investigations [23].  
As mentioned above, reported biota occurrence is sparse with a small 
focus on fish, and to a lesser extent invertebrates. Furthermore, many of the 
selected invertebrates in monitoring campaigns are collected from estuarine or 
marine environments with fewer studies focusing on freshwater species [12]. This 
is important as many sources of PhAC contamination (WWTP, CSOs, agriculture 
etc.) will primarily enter freshwater environments. In addition, invertebrates are 
the largest and most diverse group within the Animalia kingdom and therefore are 
of significant importance to prioritise for environmental risk factors that may affect 
ecosystem services [24]. One particular species that is useful in monitoring 
campaigns of freshwater habitats is the amphipod G. pulex, which is common 
throughout Europe. This organism is a detritivore that is important for detritus 
processing in freshwater ecosystems and also serves as an important food 
source for fish and birds [25, 26].  Therefore, potential adverse effects would be 
important to identify within this animal. G. pulex has already been demonstrated 
to be a sensitive indicator of pollutants and contaminants in aquatic environments 
by using behavioural endpoints [27-30]. Pharmaceutical uptake in G. pulex has 
also been observed by Meredith-Williams et al. [31], which examined the kinetics 
of five pharmaceuticals with the largest BCF observed for the selective serotonin 
reuptake inhibitor (SSRI), fluoxetine (~185,000). However, multi-residue methods 
to determine internal concentrations in G. pulex are still lacking.  
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The aim of this chapter was to develop and optimise an analytical LC-
MS/MS methodology for the detection and quantification of several 
pharmaceutical compounds in the selected aquatic invertebrate G. pulex using a 
combination of extraction techniques. Thus, enabling the confirmatory 
determination of trace pharmaceutical contamination in a freshwater invertebrate. 
Then the developed method was assessed for application to specimens sampled 
from several field sites (tributaries of the River Thames) to determine the 
occurrence of the selected pharmaceutical across the Greater London catchment 
area. The work herein represents the first study to report the environmental 
occurrence of pharmaceuticals in a freshwater invertebrate.  
 
2.2 Materials & methods 
2.2.1 Reagents, chemicals and consumables  
HPLC grade methanol, acetonitrile, acetone, ethyl acetate, 
dichloromethane and dimethyldichlorosiloxane were purchased from Fischer 
Scientific (Loughborough, UK). Analytical grade ammonium acetate was sourced 
from Sigma-Aldrich (Dorset, UK). Propranolol hydrochloride, ketoprofen, 
diclofenac sodium salt, bezafibrate, warfarin, flurbiprofen, indomethacin, 
ibuprofen sodium salt, meclofenamic acid sodium salt, gemfibrozil, atenolol, 
sulfamethoxazole, sulfamethazine sodium salt, furosemide, carbamazepine, 
nimesulide, (±)-metoprolol (+)-tartrate salt, triclocarban,  cimetidine, ranitidine, 
antipyrin, temazepam, diazepam, fluoxetine, nifedipine and mefenamic acid were 
all obtained from Sigma-Aldrich (Steinheim, Germany). Trimethoprim, caffeine, 
and naproxen were ordered from Fluka (Buchs, Switzerland). Stable isotope-
labelled standards including carbamazepine-d10, propranolol-d7, temazepam-d5 
and diazepam-d5 were ordered from Sigma-Aldrich. Trimethoprim-d3 and 
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warfarin-d5 were ordered from QMX Laboratories (Essex, UK). All 
pharmaceuticals were of a purity of ≥97 %. Ultra-pure water was obtained from a 
Millipore Milli-Q water purification system with a specific resistance of 18.2 
MΩ.cm or greater (Millipore, Bedford, MA, USA). Stock solutions (1 mg mL-1) 
were prepared in methanol and stored in silanised amber vials (40 mL). Working 
solutions were prepared daily in ultra-pure water, as required. All solutions were 
stored at 4oC and in the dark for optimum stability. 
2.2.2 Sample collection and preparation 
Gammarid and surface water samples were sourced from eight tributaries 
of the River Thames, UK. Surface water chemistry (i.e. pH, DO and temperature) 
was not measured. These were spread across the greater London catchment 
area and included the River Wandle (Sites 1 and 2), the River Quaggy (Site 3), 
the River Ravenstone (Site 4), the River Cray (Sites 5 and 6), the River Darent 
(Site 7) and Beverley Brook (Site 8). The specific locations of the selected sites 
are shown in Figure 2.1. Adult specimens were collected in September 2012 via 
the kick sampling netting method and weighed >5 mg ww. Samples were 
transported back to the laboratory in NalgeneTM flasks containing 500 mL of 
freshwater obtained from each corresponding sampling site. A bulk sample of G. 
pulex (~ 25 g dw) from Site 1 was used in all analytical method optimisation 
experiments and was taken six months prior to samples from the same site used 
for analyte determination. G. pulex were wiped free of debris, rinsed immediately 
with ultra-pure water (n=3) and gently blotted dry before freezing at -20 oC. A 
separate 1 L grab sample of surface water at each site was also collected and 
transported back to the laboratory in 500 mL NalgeneTM flasks. Water samples 
were also frozen at -20 oC until analysis. All glassware and glass beads used for 
extraction were silanised prior to use and on a recurring monthly basis by washing 
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each vessel with 10 % (v/v) dichlorodimethylsilane solution in dichloromethane 
(n=3) and followed by a sequence of triplicate rinses with each of 
dichloromethane, methanol and ultrapure water respectively. 
 
 
2.2.3 Sample extraction and clean-up 
Prior to extraction, frozen G. pulex samples were lyophilised at -50 oC 
under vacuum for 24 hours and ground to a fine powder. Pulverised liquid 
extraction (PuLE) was performed on an Ultra-Turrax® tube driver (IKA, Staufen, 
Germany). The tube driver was used with an extraction vessel for sample 
homogenisation and extraction. The contents of the extraction tube were agitated 
at a set rate by means of a rotor located inside the tube. For each analysis, freeze-
dried composite sample material from each sampling site (0.1 g, ~ 40 animals) 
was transferred to a 20 mL extraction tube (IKA) with any necessary spiking 
carried out directly onto the solid matrix using a 100 μL volume of an appropriate 








Figure 2.1: Location of the field sites were G. pulex were sampled from; site 1 & 2 – 
River Wandle, site 3 – River Quaggy, site 4 – River Ravensbourne, site 5 & 6 – River 
Cray, site 7 – River Darent and site 8 – Beverley Brook. Picture inset is the River Cray 




was allowed to evaporate before the addition of the extraction solvent. Two glass 
beads (diameter 5 mm) were then added to the extraction tube to enable 
pulverisation of the sample and the tube agitated at 2,500 rotations per minute 
(rpm) for 5 minutes (optimised). Following extraction and settling, an aliquot of 
the supernatant (4.5 mL) was diluted to 100 mL with 10 mM ammonium acetate 
in ultra-pure water (pH 6.5). Solid phase extraction (SPE) was then carried out 
as in previously published work on a similar selection of compounds [32] on the 
diluted extract using Oasis HLB cartridges (6 mL, 200 mg, Waters Corp., 
Hertfordshire, UK). Before loading of the sample, SPE cartridges were first 
conditioned with 6 mL of methanol and 6 mL of ultra-pure water. After sample 
extraction, cartridges were then washed with 1 mL ultra-pure water and dried for 
~30 min under vacuum. Sample extracts were eluted with 10 mL of 50:50 (v/v) 
ethyl acetate:acetone and dried under pure nitrogen (1.0 bar) and heated at 30 
oC using a TurboVap (Biotage, Uppsala, Sweden). Extract residues were 
reconstituted in 0.5 mL 90:10 (v/v) 10 mM ammonium acetate in 
water:acetonitrile. Surface water samples (100 mL) were adjusted to pH 6.5 with 
ammonium acetate (1 mL of a 1 M solution). Water samples then underwent SPE 
and reconstitution as described above. Any necessary spiking or liquid volume 
measurements were carried out using positive displacement pipettes (Gilson 
Microman, Villiers-le-Bel, France). 
2.2.4 Instrumental conditions 
A previously published chromatographic method for the analysis of PPCPs 
in soil and sludge was adapted and applied here [32]. Liquid chromatography 
(LC) was performed on an Agilent 1100 series LC system (Agilent Technologies, 
Cheshire, UK) using a Waters SunFire C18 column (3.5 μm, 2.1 mm x 150 mm, 
Waters Corp., Milford, MA, USA) with a KrudKatcherTM Ultra guard column (0.1 
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mm ID, 0.5 μm filter, Phenomenex, Macclesfield, UK) at a flow rate of 0.2 mL min-
1 and an injection volume of 20 μL. Mobile phases were 90:10 (v/v) 10 mM 
ammonium acetate in water:acetonitrile (A) and 20:80 (v/v) 10 mM ammonium 
acetate in water:acetonitrile (B). The profile followed a linear gradient ramp of 
mobile phase B which increased to 10 % at 5 min, 35 % at 28 min, 40 % at 35 
min, 50 % at 40 min and 100 % at 55 min and was held for a further 7.5 min 
before returning to initial conditions. Re-equilibration time was 12.5 min resulting 
in an overall run time of 75 min. Gradient elution temperature was maintained at 
45oC. Detection and quantification was carried out with a Waters Quattro triple 
quadrupole mass spectrometer (Waters Corp., Milford, MA, USA) equipped with 
an atmospheric pressure interface-electrospray ionisation (API-ESI) source or a 
photodiode array detector (DAD) G1315B DAD (Agilent) monitoring three UV 
wavelengths of 220 nm, 254 nm and 270 nm. DAD setting were as follows; a 
bandwidth of 8 nm, slit width of 4 nm and a response time of 0.4 s. Mass 
spectrometric (MS) analysis was carried out in selected reaction monitoring 
(SRM) mode using positive-negative ionisation mode polarity switching. A scan 
rate of 0.03 min was utilised with a minimum of 15 points per peak measuring 
±0.5 mass units for all transitions monitored. Confirmation of the selected 
compounds was achieved using both retention time and two transitions (MS2) 
with the most intense fragment ion transition signal selected for analyte 
quantification (Table 2.1). MS conditions as well as all SRM transitions are 
summarised in Tables 2.1 and 2.3 were determined by direct infusion using a 
syringe pump which delivered 300 μL h-1 of analyte solution at a concentration of 





          Table 2.1: ESI-MS conditions used during analysis 
Electrospray ionisation conditions 
Desolvation temperature (oC) 300 
Source temperature (oC) 100 
Desolvation flow (L h-1) 450 
Nebuliser flow (L h-1) 90 
Mass spectrometric conditions  
Positive ion mode Negative ion mode 
Capillary (kV) 3.00 3.00 
Extractor (V)  3.0 3.0 
Cone (V) 35.0 30.0 
RF Lens (V) 0.30 0.40 
 
2.2.5 Method performance characteristics and quality control 
Matrix matching was performed for biota to assess method performance. 
Linearity was determined by measuring the peak area at concentrations from 0.01 
to 10 µg g-1 for the G. pulex (n≥5). Limits of detection (LODs) were estimated as 
the lowest concentration of analyte which produced a signal-to-noise (S/N) ratio 
of 3:1. Limits of quantification (LOQs) were estimated as that analyte 
concentration to give an S/N ratio of 10:1. Both LOD and LOQ were calculated 
using the S/N ratios of low-level spiked samples (n=6). Instrumental retention 
time and method precision was carried out for n=6 replicate injections of a biotic 
sample spiked at 1 µg g-1. Recovery was determined by comparing spiked sample 
extracts (1 µg g-1 for G. pulex, n=3) to sample extracts spiked post-extraction 
(n=3) at the expected final concentration. Control samples were also analysed for 
background correction purposes, where necessary. The measurement of ion 
suppression or enhancement in ESI-MS involved the comparison of sample 
extracts spiked post-extraction to a 100 ng g-1 working solution mixture in starting 
mobile phase A (n=3). The target analytes in both surface waters and biota were 
quantified based on their peak areas relative to that of an isotopically-labelled 
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internal standard (100 ng g-1) or, where unavailable, by an external matrix 
matched calibration curve (n=3). Relative recovery in G. pulex was measured 
following the analysis of spiked biotic samples (analytes and the internal standard 
at 100 ng g-1 each) by comparing the analyte peak areas to that of the internal 
standard (n=12). Standard and internal standard solutions were prepared daily.  
Mobile phase A was injected between samples from each site as well as 
between matrix-matched standards and controls to minimise the possibility of 
carry over. Direct infusion of a propranolol standard (1 μg mL-1) was carried out 
before each batch analysis to ensure that the MS was operating satisfactorily. 
None of the targeted analytes were detected in any solvents, reagents or ultra-
pure water used in this study. 
 
2.3 Results & discussion 
2.3.1 Method development  
To understand how PhACs may bioconcentrate in biota, a multi-residue 
method was developed that allowed the trace determination of selected 
pharmaceuticals in the invertebrate G. pulex. A previously published method that 
allowed multi-residue analysis in biosolids was used as a starting point [33]. The 
method was applied to a mixture of 41 pharmaceuticals which resulted in an 
adequate separation of 25 of the compounds (Figure 2.2). However, the 
remaining compounds were not resolved and co-eluted. As shown in Figure 2.2 
three sets of critical peaks from 20 – 35 min were observed to co-elute with each 







2.3.2 Chromatographic gradient and chemical composition 
As the base method initially gave a fair separation, only the percentage of 
the two phases were changed at the time points specified (Materials and 
Methods). The previous method used a linear ramp between 28 - 35 min of MeCN 
to 85 %. The decrease in the polarity of the mobile phase would result in more 
non-polar compounds eluting earlier by reducing hydrophobic interaction with the 
alkyl chains in the stationary phase.  
The percentage of MeCN was lowered at the 28 minute and 35 minute 
points to improve separation of the later eluting compounds. Method 3 (Figure 
2.3c) had the best separation of the compounds eluting after 30 min, in 
comparison to method 1 which had a slightly higher percentage of MeCN at the 
28 and 35 min time intervals (Figure 2.3). The mobile phase of method 1 was less 
polar between 28 – 35 min, thus more hydrophobic compounds would elute more 
















































Figure 2.2: Gradient separation of 41 pharmaceuticals from a previously published 
method used in the analysis of solids (soil and sludge).The dashed line represents 
the gradient profile of Mobile Phase B (80 : 20 (v/v) of MeCN:10 mM ammonium 
acetate in H2O. Dashed line boxes indicate several co-eluting peaks. 
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methods had very similar separations, thus based on the better separation of the 
late eluting compounds in method 3, this method was taking forward for further 
development. As shown in Figure 2.3, peak separation in the highlighted box was 
of importance as several compounds co-eluted thus further methods were 
focused to separate these compounds.  
The decrease in the percentage of MeCN gave the late eluting compounds 
a better separation at the 35 minute time point. Increasing the polarity of the 
mobile gradient would increase the retention of these more non-polar (late 
eluting) compounds through hydrophobic interaction with the C18 stationary 
phase. Therefore, development of method 3 involved further decreasing MeCN 
to improve the resolution of the late eluting peaks. Method 4 showed an improved 
separation, which gave a good overall separation with a better resolution of 
compounds eluting between 30 – 40 min. There were also spurious peaks visible 
in the chromatogram that did not relate to any retention time observed for the 
pharmaceuticals in the method. These peaks were found to originate from the 
lansoprazole and ketotifen fumarate standards, which may have been due to 
contamination or transformation of the compounds. Therefore, these two 
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Figure 2.3: Chromatograms of four gradient compositions, (a) method 1, (b) method 2, 
(c) method 3 and (d) method 4. Dashed line represents the gradient profile of Mobile 
Phase B (80 : 20) (v/v) of MeCN : 10 mM ammonium acetate in H2O. Dashed boxes 






































Method 4 was taken for further development with an additional time point 
at 40 min to resolve the peaks eluting after this time. The MeCN percentage was 
increased at 40 min from 45 % to 50 % and the best separation achieved was 
from method 5 (Figure 2.4). The temperature of this method was raised (45 oC) 
to increase mass transfer through decreases in mobile phase viscosity and 
increasing kinetic energy of the molecules involved in diffusion processes. Thus, 
efficiency was improved resulting in narrower peaks and better resolution of the 
method. Baseline resolution of all compounds was not considered a necessity, 
as the method would be transferred to MS. However, where compounds were 
baseline resolved, peak area was used for quantification as there was less 
variance associated with this measurement. The labelled chromatogram of all 
compounds separated by the final method is shown in Figure 2.4. In addition to 
available occurrence data, the compounds in the mixture were selected to cover 
a wide range of hydrophobicity (logP: -0.11 – 6.82) and included acidic (33 %), 
basic (53 %) and neutral compounds (14 %). If hydrophobicity is a dominant 
mechanism of uptake then the compounds selected should provide a wide 
enough coverage of the chemical space for modelling purposes. A wider range 
of chemical descriptors are given for the modelled compounds in Chapter 6. 
Additionally, as PhACs are developed according to Lipinski’s rule of 5, the 
chemical space occupied by these compounds is relatively narrow and well-
defined [34]. The sub-classes of the compounds included antibiotics, NSAIDs, 
TCAs, lipid regulators, beta-blockers and several others which cover various 
mode-of-actions. Chlorpyrifos was selected as a potential reference compound 
for use in bioconcentration experiments where it has been previously observed 






















2.3.3 Injection volume & column overload 
The instrumental response for the chromatographic method was 
determined using a 7-point calibration ranging from 0.1 - 10 µg mL-1 performed in 
triplicate. The correlation coefficient (R2) range from 0.8858 (sulfaphenazole) to 
0.9999 (temazepam), with only 5 compounds that showed a poor correlation of 
<0.98. The reason for the poor R2 with some compounds was due to the higher 
concentration working solutions (7.5 and 10 µg mL-1). When these points were 
removed, all compounds showed an increase in the linear response. The 
observed nonlinear response at the high concentrations can be explained by 
saturation of the UV detector, which defines the upper limit of the dynamic range. 
Figure 2.4: Example chromatogram of method 5. 1 - methimazole, 2 – amoxicillin, 3 – salicylic 
acid, 4 – atenolol, 5 – sulfamethoxazole, 6 – caffeine, 7 – sulfapyridine, 8 – cimetidine, 9 – 
ranitidine, 10 – sulfamethazine, 11 – sulfaphenazole, 12 – antipyrin, 13 – clofibric acid, 14 – 
trimethoprim, 15 – furosemide, 16 – metoprolol, 17 – tramadol, 18 – naproxen, 19 – ketoprofen, 
20 – chloramphenicol, 21 – warfarin, 22 – bezafibrate, 23 – flurbiprofen, 24 – propranolol, 25 – 
carbamazepine, 26 – diclofenac, 27 – ibuprofen, 28 – dextromethorphan, 29 – indomethacin, 30 
– mefenamic acid, 31 – meclofenamic acid, 32 – temazepam, 33 – nortriptyline, 34 – nimesulide, 
35 – nifedipine, 36 – fluoxetine, 37 – amitriptyline, 38 – diazepam, 39 – gemfibrozil, 40 – triclosan 
and 41 – tamoxifen. Dashed line represents the gradient profile of Mobile Phase B (80 : 20 (v/v) 
of MeCN : 10 mM ammonium acetate in H2O. Concentration of all standards were 10 µg mL-1. 
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Therefore, an increase in concentration above a certain threshold will not give a 
response that is linear. Thus, using the DAD, the dynamic range was from 0.1 to 





The injection volume was also varied to obtain the lower range of 
sensitivity whilst maintaining a linear response. As shown in Figure 2.5, the 5 µg 
mL-1 standard shows a two fold increase in peak height between the 10 and 20 
µL injection volume. However, the 40 µL injection volume did not have the same 
increase in signal therefore the gain in sensitivity is lower. The linear response 
was also better using a 10 µL injection for the majority of the compounds; 
however at this injection volume compounds such as metoprolol and nimesulide 
were not detected at the lower range of calibration curve, resulting in a loss of 
sensitivity which was undesirable for the application in trace analysis. At a 40 µL 
injection volume, band broadening occurred due to column overload, in the 
example of sulfamethazine the max column load was 150 ng. The band 
broadening observed could be explained by volume overload as the peaks in the 
chromatogram have become broader in contrast to mass overload. As the sample 
is injected in a larger volume longitudinal diffusion is more influential causing the 
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Figure 2.5: Comparison of calibration curves for the compound sulfamethazine when the 
injection volume is increased, 10 µL (left), 20 µL (centre), 40 µL (right). 
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peak to spread. The resolution has also decreased where compounds such as 
ibuprofen and diclofenac could not be separated (Figure 2.6). Therefore, it was 
determined that a 20 µL injection volume was the optimum in terms of sensitivity, 
resolution and linear response.  
 
Compounds were arbitrarily removed from this method where co-elution 
became problematic or for compounds that did not give a good response from 
the DAD, ss this detector is non-specific. However these compounds can be re-
introduced to the method when using ESI-MS if they determined to be of interest 
in bioconcentration. Other compounds were substituted in, for example 
triclocarban and chlorpyrifos. The reason for the selection of these two 
compounds is that due to their high hydrophobicity they would be expected to 
rapidly bioconcentrate, which has been shown in several studies (Schebb et al, 
2011 & Ashauer et al, 2006). Chlorpyrifos although not a PPCP has been picked 
as a ‘positive control’ so that exposures are performed correctly. This was chosen 
as a positive control with the reasoning that as this has been investigated in 
previous exposure studies, thus the compound could be used to cross-validate 






































Figure 2.6: Comparison of injection volume on the chromatographic separation of PPCPs. The 
solid line represents 20 µL injection volume whereas the dashed line indicated the 40 µL 
injection volume. Dashed boxes indicate areas in the chromatograph where separation has 
become worse due to volume overload.  
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2.3.4 Solid phase extraction  
Table 2.2: Comparison of recoveries using Oasis HLB SPE cartridges at an acidic, neutral and 
basic pH (n=6). Compounds spiked at 5 µg mL-1. 




    Recovery 
(%) 
    Recovery 
(%) 
    Recovery 
(%) 
    
Compound logPa pH 2   SD pH 7   SD pH 10   SD 
Methimazole -0.11 10 ± 1 20 ± 7 10 ± 3 
Atenolol 0.24 63 ± 3 61 ± 1 65 ± 8 
Sulfamethoxazole 0.65 105 ± 7 123 ± 4 53 ± 10 
Caffeine 0.28 86 ± 5 88 ± 1 90 ± 1 
Cimetidine 0.69 60 ± 10 67 ± 2 76 ± 2 
Ranitidine 1.86 31 ± 3 80 ± 5 94 ± 7 
Sulfamethazine 0.44 61 ± 5 83 ± 2 74 ± 0 
Antipyrin 0.72 73 ± 13 95 ± 1 97 ± 3 
Sulfaphenazole 1.68 76 ± 5 83 ± 5 73 ± 5 
Trimethoprim 1.12 91 ± 1 90 ± 2 90 ± 1 
Furosemide 2.35 80 ± 5 44 ± 3 69 ± 8 
Metoprolol  1.85 116 ± 16 104 ± 1 102 ± 3 
Naproxen 2.98 87 ± 3 92 ± 3 85 ± 9 
Ketoprofen 3.12 79 ± 4 84 ± 3 80 ± 7 
Chloramphenicol 1.02 118 ± 2 119 ± 2 114 ± 3 
Warfarin 3.11 61 ± 4 67 ± 9 60 ± 14 
Bezafibrate 3.48 79 ± 4 84 ± 5 81 ± 5 
Flurbiprofen 3.82 74 ± 5 82 ± 6 76 ± 13 
Propanolol 3.26 85 ± 2 78 ± 4 67 ± 5 
Carbamazepine 2.28 79 ± 3 83 ± 4 77 ± 8 
Diclofenac 4.48 59 ± 4 66 ± 10 58 ± 14 
Ibuprofen 3.37 74 ± 2 82 ± 2 77 ± 12 
Indomethacin 4.02 56 ± 4 67 ± 12 61 ± 17 
Mefenamic Acid 5.00 38 ± 3 57 ± 14 53 ± 15 
Meclofenamic 
acid 
6.02 22 ± 0 37 ± 12 36 ± 14 
Temazepam 2.12 74 ± 4 79 ± 9 70 ± 15 
Nortriptyline 4.76 77 ± 2 54 ± 5 0 ± - 
Nimesulide 2.70 64 ± 3 65 ± 10 60 ± 12 
Nifedipine 3.45 75 ± 3 77 ± 19 65 ± 17 
Fluoxetine 4.27 77 ± 2 59 ± 7 38 ± 1 
Diazepam 2.74 60 ± 2 58 ± 12 52 ± 14 
Gemfibrozil 4.19 51 ± 4 60 ± 13 55 ± 17 
Triclosan 5.27 4 ± 2 2 ± 2 3 ± 2 
Tamoxifen 6.82 13 ± 2 0 ± - 0 ± - 
Chlorpyrifos 4.78 4 ± - 0 ± - 0 ± - 
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SPE was performed initially at three pH values (acidic, neutral, and basic) 
to determine the optimum recovery values of a sample. The pH is an important 
aspect of SPE, when extracting ionisable compounds. The first eluting 
compound, methimazole is the most polar pharmaceutical compound in the 
method and thus was not retained well by the HLB cartridge, as the recovery at 
every pH remained below 20 %. This compound has two amine functional groups 
which could be protonated at more acidic pH values and become charged (where 
HLB cartridges lack an ion exchange groups). The pKa of methimazole is also 
12.37 indicating that a pH below this value will lead to the formation of the 
protonated species [35]. The histamine H2 receptor antagonists, ranitidine and 
cimetidine, displayed a better recovery at pH 10. If the pKa is taken into account 
at pH 7 and pH 2, these two compounds would be positively charged whereas at 
pH 10 the compound would remain neutral. The HLB cartridges are a dual phase 
sorbent containing a hydrophilic N-vinylpyrrolidone and hydrophobic 
divinylbenzene copolymer. Thus, the sorbent has capacity to retain both polar 
and non-polar compounds, and therefore neutral species are likely to show 
improved recoveries in comparison to their charged forms.  
The acidic pharmaceuticals (naproxen, flurbiprofen, ibuprofen, ketoprofen, 
diclofenac, meclofenamic acid and mefenamic acid) showed better recovery at 
pH 7. However, the acidic pH would be expected to show better recovery of these 
compounds as they would remain as a neutral species. Furosemide is the only 
compound that follows this theory as it shows a 40 % improvement in recovery at 
pH 2 when compared to the recovery at pH 7. The remaining compounds may 
have undergone acid hydrolysis, thus reducing their recovery. However, it should 
be noted that a majority of these acidic compounds had an observed recovery 
that was only between 5-10 % higher at the neutral pH, with the exception of 
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mefenamic and meclofenamic acid that was 15-20 % higher. These two 
compounds had a much greater variation in the recovery at pH 7 as shown by 
the standard deviation.  
The later eluting compounds such as triclosan and chlorpyrifos had 
recoveries below 5 %. The poor recoveries of these compounds may have been 
due to their logP. The low recovery could be due to the reconstitution solvent 
(mobile phase A) as the solubility of these compounds in water is relatively low 
(triclosan 1 µg mL-1 and chlorpyrifos 2 µg mL-1) [36-38]. With the addition of the 
other pharmaceuticals in the mixture, it is possible that the low recovery of these 
compounds was due to reduced solubility into the reconstitution solvent. The 
elution solvent was relatively strong with a mixture of ethylacetate and acetone 
(50:50 v/v). Therefore, it was not likely that these compounds remained adsorbed 
to the SPE cartridge. Furthermore, triclosan has been eluted from HLB cartridges 
with weaker elution solvents such as methanol [39]. Overall, the neutral pH 
showed the greatest recovery with an average recovery of 68±6 % compared with 
the acidic pH (65±4 %) and the basic pH (62±8 %). However, a single factor 
ANOVA was performed on the recovery means for each pH treatment and 
indicated that there was no significant difference between the treatment groups 
(p-value = 0.644).  
The SPE protocol was repeated at pH 7, but using a reconstitution solvent 
of water:acetonitrile (70:30 v/v). The change in the reconstitution solvent 
improved the recovery of 25 compounds in the mixture, with 23 compounds 
showing a recovery greater than 80% (Figure 2.7). The recovery of triclosan and 
chlorpyrifos both increased (≥44 %) indicating that the poor recovery from the 
previous experiment was in part due to a solubility issue. The precision also 
increased with 25 compounds achieving a SD of less than 10 %. This further 
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suggested that compound solubility was the reason for poor recovery and the 
greater variation, depending on the amount of solid residue that re-dissolved after 
drying down.  
Using 30 % acetonitrile in the reconstitution solvent affected the separation 
of the mixture slightly so that 3 compounds could not be quantified (diclofenac, 
sulfamethoxazole and chloramphenicol) due to co-elution and the early eluting 
peaks were also split. The final SPE extract concentrations used in these 
experiments were 10 µg mL-1, which is a relatively high concentration. 
Environmentally relevant concentrations were expected to be 103 to 106 fold 
lower than this, thus the original reconstitution solvent (Mobile Phase A) was 
selected. Due to the effect of biological matrices have on instrumental response, 
the final volume of the reconstitution solution was considered after an LC – MS 





Figure 2.7: Recoveries of PPCPs at a neutral pH using a reconstitution volume of 30:70 (v/v) 

































































































































































































































































2.3.5 Effect of sorption on ball-mill extraction tubes and glass beads 
The sorption of the PPCP mixture during the extraction procedure in the 
ball-mill tube was characterised by using both unsilanised and silanised glass 
beads (Figure 2.8). The data demonstrated that the difference between silanised 
and non-silanised glass beads was minimal for the majority of compounds in the 
mixture. Although, for some compounds; indomethacin, mefenamic acid, 
meclofenamic acid, triclocarban, triclosan and chlorpyrifos, there was better 
recovery using unsilanised glass beads. A possible reason for the better recovery 
using the unsilanised glass is that silanisation adds alkoxy groups to the silanol 
groups present on the surface of the glass [40]. Considering that the majority of 
the compounds had logP values greater 3, these compounds are likely to undergo 
hydrophobic interaction with these alkoxy groups and remain adsorbed to the 
surface. However, for triclocarban, triclosan and chlorpyrifos the recovery was 
low regardless of whether beads were silanised or not. Therefore, the main loss 
of compounds is assumed to be through sorption onto the plastic surface of the 









2.3.6 Liquid chromatography – mass spectrometry  
As environmentally relevant concentrations were expected to be at least 
two orders of magnitude lower than those concentrations using LC-UV, the 
method was further developed using a triple quadrupole mass spectrometer. This 
would allow a much greater gain in sensitivity and would also identify compounds 
by mass transitions for confirmatory analysis.  
 
2.3.7 Direct Infusions and fragmentation pathways 
The HPLC-UV method transfer to HPLC-MS/MS first required direct 
infusions of individual standards (1 µg mL-1), as these compounds eluted from 
the LC in different gradient compositions each standard was prepared in a solvent 
mixture that was similar to that point of elution in the LC gradient. The conditions 
of the mass analyser are displayed in Table 2.1. The fragments monitored are 
Figure 2.8: Comparison of sorption expressed by recovery for PPCPs used in the 
extraction procedure (n = 3). Black bars represent silanised glass beads, light grey bars 
































































































































































































































































































shown below in Table 2.3 with the collision energy used at each transition. For 
the confirmation of compounds, a secondary fragment ion was also monitored. 
However, for certain compounds no secondary ions were produced that was 
mainly observed in negative ESI mode. A possible reason for this is that many of 
the acidic compounds may not produce a measureable ion current or that 
fragmentation yielded anions that are unstable [41]. Triclosan revealed no 
measurable fragment ions from scanning a mass range of 50-500; however it 
could be identified by the m/z ratio caused by the isotopic mass differences and 
peak superposition from the presence of chlorine atoms, 35Cl and 37Cl. When 
operated in SRM mode, the CID cell (with no collision energy potential supplied) 
still provided enough internal energy to remove the triclosan molecule.Therefore, 
no detectable signal was observed for triclosan. Whilst, previous investigation 
have shown it is possible to monitor a transition from 287>35 [42], it is not good 
practice due to the commonality of Cl ions with other organic molecules thus 
leading to reduced selectivity and increased noise. Due to limitations of the 
software, it was not possible to perform a full scan and SRM scan during a single 




































2.3.8 Recovery and reconstitution volume  
As mentioned above, the reconstitution solvent type affected the recovery 
of PPCPs due to solubility issues. For this reason the reconstitution volume was 
also considered. A smaller volume will cause an increase in the concentration of 
matrix components. Thus, matrix effects are likely to be present to a higher 
degree than would be observed with a larger reconstitution volume. Matrix effects 
can either occur as suppression or enhancement of the signal response for 
analytes. Firstly, overall suppression was observed for a majority of the 
compounds. Two volumes were investigated 0.5 and 0.1 mL, as shown in Figure 
2.9. As expected, the suppression associated with 0.1 mL volumes were much 
greater than with the 0.5 mL volumes, and matrix effects decreased with 
Table 2.3: SRM transitions used for quantification and confirmation (where secondary ions are 

















Atenolol 20 [M + H]+ 267 C11H12NO2 190 C10H9O 145 
Caffeine 21 [M + H]+ 195 C6H7N3O 138 C5H7N3 110 
Cimetidine 16 [M + H]+ 253 C5H11N4S 159 C4H9N2S 117 
Ranitidine 16 [M + H]+ 315 C5H10N3O2S 176 C11H16N2OS 224 
Sulfamethazine 20 [M + H]+ 279 C6H8N3O2S 186 C6H10N3 124 
Antipyrin 20 [M + H]+ 189 C7H4O 104 C9H10N2 146 
Sulfaphenazole 30 [M + H]+ 315 C6H8NO2S 158 C9H8N3O2S 222 
Trimethoprim 20 [M + H]+ 291 C14H16NO2 230 C5H7N4 123 
Furosemide 15 [M - H]- 329 C11H10ClN2O3S 285 C6H6ClN2O2S 205 
Metoprolol 20 [M + H]+ 268 C6H14NO 116 C8H17NO2 159 
Naproxen 20 [M - COOH]- 185 C12H10O 169 C11H9O 157 
Ketoprofen 20 [M + H]+ 255 C7H5O 105 C15H13O 209 
Warfarin 20 [M - H]- 307 C9H5O3 161 C16H10O3 250 
Bezafibrate 20 [M + H]+ 362 C7H4ClO 139 C18H20ClNO2 316 
Flurbiprofen 13 [M - H]- 243 C14H12F 199 - - 
Propranolol 20 [M + H]+ 260 C6H14NO 116 C10H17NO2 183 
Carbamazepine 30 [M + H]+ 237 C14H12N 194 - - 
Diclofenac 20 [M - H]- 294 C13H9Cl2N 250 - - 
Ibuprofen 10 [M - H]- 205 C12H15 159 - - 
Indomethacin 20 [M + H]+ 358 C7H4ClO 139 C11H12NO 174 
Mefenamic acid 15 [M - H]- 240 C14H14N 196 - - 
Meclofenamic acid 14 [M - H]- 294 C14H10ClNO2 259 C13H10ClN 214 
Temazepam 20 [M + H]+ 301 C15H12ClN2 255 C16H12ClN2O 283 
Nimesulide 14 [M - H]- 307 C12H10N2O3 229 CH3O2S 79 
Nifedipine 10 [M + H]+ 347 C16H15N2O5 315 C16H17NO3 271 
Fluoxetine 18 [M + H]+ 310 C10H14N 148 - - 
Diazepam 27 [M + H]+ 285 C8H9NCl 154 C14H11N 193 
Gemfibrozil 18 [M - H]- 249 C8H9O 121 - - 
Triclocarban 9 [M - H]- 313 C6H5Cl2N 162 - - 
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increasing volume. One reason for such matrix effects is that the matrix 
components affected the droplet formation in the ESI source rather than affecting 
the gas phase ions. Therefore, the main problem arises from the transfer of 
analyte from solvent to gas phase ions. This could be due to a number of reasons 
such as changing the surface tension of the droplet so that more energy is 
required to overcome the Rayleigh limit or raising the boiling point so that solvent 
evaporation is less efficient [43]. It is also possible that analytes and matrix 
components will compete to reach the droplet surface for desorption into a gas 
phase ion. As described above, negative mode ESI will be likely to have greater 
matrix effects due to the lower intensity and poorer ionisation efficiency. This is 
shown as the negative mode analytes (diclofenac, ibuprofen, triclocarban, 
mefenamic acid, meclofenamic acid) generally have a much higher suppression 
than compared with compounds detected in the positive mode. There is also a 
greater matrix effect with compounds that are more hydrophobic, as the later 
eluting compounds show more suppression even with the largest reconstitution 
volume.  The 0.1 mL volume resulted in the greatest matrix effects and the 
highest variance associated with each measurement therefore for quantification 
purposes this volume is less suitable. In comparison, the 0.5 mL volume resulted 













The recovery of the method was also determined for the two different 
reconstitution volumes. Overall, most compounds showed an absolute recovery 
of 40 – 130 %. Fluoxetine had a recovery that was highly variable as also 
observed with the matrix effect determination which has been observed in 
previous studies by other researchers [44, 45]. The more polar analytes and 
those that were detected in negative mode ESI generally had an observed 
recovery of ≤ 50 %. As shown in the Figure 2.10, there were several compounds 
(warfarin, propranolol, temazepam and diazepam) that had lower recoveries with 
a decreased reconstitution solvent. The standard deviation shown as error bars 
in Figure 2.10 indicated that recovery was slightly less variable at 0.5 mL when 
compared to 0.1 mL, as the average standard deviation was 6 % for the 0.5 mL 
in comparison to 8 % for the 0.1 mL. However, the difference was not statistically 
significant (p-value = 0.306). This indicated the method was slightly more 
repeatable as the standard deviation remained below 15 % for all compounds 
Figure 2.9: Matrix effects of G. pulex on the signal response of selected PPCPs. Positive bars 
indicate enhancement, negative bars indicate suppression. Dotted bars are the 0.1 mL 











































































































































































































































































except triclocarban (31 %) and gemfibrozil (21 %). The 0.5 mL volume was 




2.3.9 Sample preparation  
For the extraction of G. pulex samples the sample clean-up procedure 
involved a protein precipitation step with acetonitrile followed by transfer of the 
supernatant to a 100 mL volume of buffered (10 mM ammonium acetate) ultra-
pure water for loading onto the HLB SPE cartridges. Further clean-up stages 
were investigated by the addition of a centrifugation step after the protein 
precipitation and the addition of neutral aluminium oxide. It is desirable to have 
efficient sample clean-up, as biological matrices contain many macromolecules 
which may increase signal suppression of the relatively low molecular weight 
PPCPs [46]. The centrifugation step was added to pellet the proteins and other 
Figure 2.10: The effects of matrix and reconstitution volume on the recovery of selected PPCPs. 
Error bars represent standard deviation. Black bars are 0.1 mL volume (n = 6), dark grey bars 
are 0.5 mL volume (n = 3) and light grey bars are 1.0 mL volume (n = 6). Fluoxetine was only 




























































































































































































































































solid particles to provide a cleaner extract. The addition of aluminium oxide was 
used to prevent the co-extraction of lipids, which has been used in previous 
studies to remove lipid and pigments (chlorophyll) from freshwater bivalves [47]. 
The removal of lipids from the samples is likely to involve either the retention 
(sorption) or degradation by peroxidation [48]. This new methodology was 
compared with the workflow without the additional clean-up stages by assessing 
recovery, suppression and enhancement (Table 2.4). As shown, overall there 
was little difference between the suppression and enhancement indicating that 
matrix components are still interfering with the signal response. However, the 
recovery and RSD, although only a small difference in some cases, was better 
with the method without the additional clean-up stages. A single factor ANOVA 
was performed for the recovery and RSDs which revealed that there was no 
statistically significant difference between either sample preparation method (p-
value 0.124 and 0.054, respectively). Therefore, the additional steps offered no 
advantage for quantitative purposes and were not included into the finalised 













Table 2.4: Comparison of sample preparation with centrifugation and Al2O3 steps (method A) 
versus extraction with only MeCN (method B). 
 
Method A (n = 3) Method B (n = 3) 
Compound Supp./Enhanc. Recovery 
(%) 
RSD Supp./Enhanc. Recovery 
(%) 
RSD 
Atenolol 10 12 0 -13 4 1 
Caffeine 22 48 17 -7 12 1 
Cimetidine -34 4 8 -17 6 0 
Ranitidine -48 0 1 -14 4 1 
Sulfamethazine 6 41 1 -12 41 2 
Antipyrin 9 65 4 -17 30 3 
Sulfaphenazole -5 32 1 37 32 4 
Trimethoprim -11 62 7 -12 65 1 
Metoprolol -16 66 14 -10 71 5 
Ketaprofen -11 37 4 -24 41 2 
Bezafibrate 18 64 7 -17 39 4 
Propranolol -61 30 26 -55 52 11 
Carbamazepine -51 42 2 -10 69 3 
Indometacin -21 33 15 -49 42 8 
Naproxen -23 28 8 -24 44 1 
Ibuprofen -43 23 9 6 44 7 
Flurbiprofen -36 26 14 -44 47 8 
Diclofenac -32 74 5 -56 30 5 
Warfarin -21 56 11 51 71 3 
Furosemide -16 44 1 1 39 3 
Mefenamic  Acid -46 25 18 -66 44 12 
Gemfibrozil -44 28 21 -42 79 21 
Meclofenamic  
Acid -47 25 16 -69 49 15 
Nimesulide -67 26 13 -35 87 4 
Triclocarban -62 34 13 -67 79 31 
Temazepam -16 66 5 -11 85 1 
Diazepam -30 55 11 -43 89 2 
Fluoxetine - - 
 
- - - 




Observation of the final reconstituted extract appeared to show an ‘oily’ 
red pigment that seemed to form insoluble globules (Figure 2.11). This pigment 
is likely to be the compound astaxanthin which is a carotenoid pigment often 
found in crustacea [49]. This pigment could also act as a source of signal 
suppression. Furthermore, the globules could have also potentially acted as a 
biphasic system in the reconstitution solvent. Thus, the pharmaceutical 
compounds may have sorbed to the asatxanthin leading to a reduction in the 
signal response of the determined analytes. A LLE procedure was attempted to 
remove the compound by using 50:50 hexane:acidified acetonitrile with HCl (aq). 
After a drying down step, a green pigment remained, however if the acetonitrile 
was not acidified the pigment remained red indicating that the pigment was not 
extracted by hexane and had only undergone a reaction such as acid hydrolysis 
to give the colour change. As the additional steps added no advantages the 




















(a)  (b) 
Figure 2.11: Reconstitution after sample extraction and cleanup. (a) 
followed the normal analytical method showing the red pigment 
(e.g. astaxanthin). (b) follows the analytical method with a LLE 
using hexane and acidified acetonitrile leaving behind a green 
pigment. In both cases the pigment has remained. 
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2.3.10 Method performance 
The method performance was assessed to identify which compounds 
were suitable for quantification. As few analytical methods to determine PPCPs 
from aquatic biological matrices exist, a large number of compounds with broad 
physicochemical properties were assessed with the expectation that several 
compounds would not pass performance criteria such as linearity, precision, 
accuracy etc. Table 2.5 shows the in matrix method performance parameters for 
each compound that was monitored. Overall, the method showed good 
performance for the selected compounds, retention time precision was ≤0.5 % 
for all compounds excluding propranolol (1.7 %) which might be expected as this 
compound has secondary interactions with silanol groups in the stationary phase 
and can also associate with counter-ions which would lead to variation in 
retention [50]. All compounds displayed ≥10 points per peak for reliable 
quantification and retention time measurement. Matrix effects were significant 
(>50 %) for several pharmaceuticals including triclocarban, propranolol, 
indomethacin, mefenamic acid, meclofenamic acid and diclofenac. In total 27 
compounds were supressed when compared to a working solution (n=3) of 









Table 2.5: Method performance for 29 selected compounds.  
aLinearity was assessed by a minimum of n=5 points in triplicate 
b3:1 signal-to-noise ratio with either a 75 ng g-1 or 750 ng g-1 spiked matrix (n=6). 
c10:1 signal-to-noise ratio with either a 75 ng g-1 or 750 ng g-1 spiked matrix (n=6). 
ddetermined using a 100 ng g-1 pre-extraction spiked sample (n=3) 



























Atenolol 6.3 500 - 10000 0.9543 62 191 30 ± 3 -17 ± 1 
Caffeine 8.4 250 - 10000 0.9909 75 194 4 ± 1 -12 ± 5 
Cimetidine 10.9 250 - 10000 0.8085 206 687 6 ± 0 -17 ± 1 
Ranitidine 13.3 500 - 10000 0.8001 38 145 4 ± 1 -13 ± 2 
Sulfamethazine 11.9 25 -10000 0.9987 4 15 41 ± 2 -11 ± 2 
Antipyrin 13.8 10 -10000 0.9973 13 43 30 ± 3 -17 ± 1 
Sulfaphenazole 12.2 10 -10000 0.9989 11 36 32 ± 4 -31 ± 1 
Trimethoprim 16.8 10 -10000 0.9987 2 5 65 ± 1 -13 ± 6 
Metoprolol 19.7 10 -10000 0.9992 1 4 71 ± 5 -11 ± 2 
Ketoprofen 20.9 10 -10000 0.9976 14 45 41 ± 2 -23 ± 5 
Bezafibrate 24.4 10 -10000 0.9807 17 57 39 ± 4 -16 ± 8 
Propranolol 30.9 10 -10000 0.9952 13 45 52 ± 11 -56 ± 4 
Carbamazepine 31.3 25 - 10000 0.9983 2 6 69 ± 3 -9 ± 2 
Indomethacin 32.8 10 -10000 a <0.950 - - 42 ± 8 -51 ± 5 
Naproxen 19.5 75 - 500 0.9861 17 56 44 ± 1 -24 ± 5 
Ibuprofen 31.1 500 - 10000 0.9714 111 371 44 ± 7 -44 ± 2 
Flurbiprofen 28.1 250 - 10000 0.9625 55 183 47 ± 8 -44 ± 2 
Diclofenac 32.6 10 - 10000 <0.950 - - 30 ± 5 -56 ± 2 
Warfarin 22.7 50 - 10000 0.9973 2 6 71 ± 3 -28 ± 4 
Furosemide 18.4 10 – 10000a 0.9912 14 45 39 ± 3 0 ± 6 
Mefenamic acid 35.1 10 -10000 a <0.950 - - 44 ± 12 -66 ± 4 
Gemfibrozil 47.1 10 -10000 a <0.950 - - 79 ± 21 -48 ± 5 
Meclofenamic 
acid 
37.1 10 -10000 a <0.950 - - 49 ± 15 -69 ± 5 
Nimesulide 44.0 25 - 10000 0.9945 3 11 87 ± 4 -35 ± 3 
Triclocarban 57.4 100 - 10000 0.9770 9 31 79 ± 31 -68 ± 3 
Temazepam 40.2 10 - 10000 0.9930 2 6 85 ± 1 -11 ± 3 
Diazepam 46.8 10 - 10000 0.9991 2 5 89 ± 2 -43 ± 3 
Fluoxetine 47.9 10 -10000 a <0.950 - - ND ND 
Nifedipine 44.4 10 - 10000 0.9985 1 4 70 ± 1 -39 ± 4 
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Method linearity ranged from R2 ≤0.9500 to 0.9992. The non-linear 
responses corresponded to several compounds that were detected in negative 
ESI (acidic pharmaceuticals) or that were very polar. The polar and acidic 
pharmaceuticals also displayed relatively higher LOD and LOQ ranges which is 
potentially due to low observed recoveries ≤6 % and those compounds detected 
in negative ESI which generally has lower sensitivity when compared to positive 
ESI. Intra-day precision was expressed as the standard deviation of the recovery 
and varied at ≤1 – 31 %. The large variance of 31 % was associated with the 
compound triclocarban which suffered from carry over leading to lower precision. 
The mean absolute recoveries ranged from 4 to 89 %, with several compounds 
achieving a recovery >70 %. Compounds that showed lower recoveries were 
accepted if the standard deviation was <5 % as with the compound 
sulfamethazine (41 % recovery).  Accuracy was assessed for only those 
compounds which had acceptable linearity (≥0.98) and method precision (≤20% 
RSD) by either by matrix matched calibration curves or internal standard (where 
available) quantification using a single calibrant (Table 2.6). Standard addition 
was not possible due to the variation in background levels of the contaminants 
between samples. Overall, the accuracy of the compounds was acceptable, 
however one compound (diazepam) displayed greater inaccuracy which is 
explained by larger variations of background concentrations present in the matrix 
as also shown by the SD. The accuracy assessment was limited by the 
background levels of contaminants present in the matrix and it was observed that 
due to the variation of these concentrations background correction was often not 
applicable. The performance of this method is similar to performance from other 
reported analytical methods for PPCP determination in aquatic invertebrates, 
fish, biosolids and other complex biological matrices [13-15, 33, 51]. Therefore, 
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from the method performance assessment it was deemed that 10 compounds 
displayed acceptable criteria for reliable and accurate quantification in line with 
guidelines from AstraZeneca. The remaining compounds were used for 
qualitative screening.    
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Nifedipine 44.4±0.1 (+) 10-10000 0.9985
3 13 ± 2
c
97 ± 7
f 87 ± 4
39 ± 4
35 ± 3
1 4 ± 1
d
104 ± 6
f 70 ± 1
Nimesulide 44.0±0.1 (-) 25-10000 0.9945
2 5 ± 2
c
176 ± 28
g 89 ± 2 43 ± 3Diazepam 46.8±0.1 (+) 10-10000 0.9991
2 6 ± 1
c
100 ± 3
g 85 ± 1 11 ± 3Temazepam 40.2±0.1 (+) 10-10000 0.993
2 5 ± 1
c
102 ± 9
g 71 ± 3 28 ± 4Warfarin 22.7±0.1 (-) 50-10000 0.9973
13 61  ± 9
e
81 ± 8
f 52 ± 11 56 ± 4Propranolol 30.9±0.5 (+) 50-10000 0.9952
13 ± 6
Metoprolol 19.7±0.1 (+) 10-10000 0.9992 1 4 ± 1
d
100 ± 6
f 71 ± 5 11 ± 2
11 ± 2
Trimethoprim 16.8±0.1 (+) 10-10000 0.9987 2 5 ± 4
c
126 ± 31
g 65 ± 1
25-10000 0.9987 4 15 ± 6
d
95 ± 3






aSD= standard deviation. 
bn=5 concentration data points each performed in triplicate. 
cSignal to noise ratio of 10:1 from 20 ng g−1 spiked matrix-matched sample. 
dSignal to noise ratio of 10:1 from 75 ng g−1 spiked matrix-matched sample. 
eSignal to noise ratio of 10:1 from 60 ng g−1 spiked matrix-matched sample. 
fUsing a 75 ng g−1 spiked sample (n= 3) and determined by matrix matched calibration (n= 3) 
in triplicate. 




2.3.11 Method application 
The optimised method was applied to determine the occurrence of the 
selected pharmaceuticals (carbamazepine, diazepam, temazepam, propranolol, 
metoprolol, nifedipine, nimesulide, sulfamethazine, trimethoprim and warfarin) 
from tributaries of the River Thames in the Greater London catchment area. 
Replicate grab samples of G. pulex and surface water were collected. The 
measurement of surface water concentrations were considered semi-quantitative 
as method performance was not assessed in water. In total, 6 compounds were 
quantified in G. pulex across all sites. Diclofenac was detected at every site 
however could not be quantified due to method performance limitations. To the 
authors’ knowledge, there were no reported occurrence data in G. pulex. 
However, after the time of this study a paper by Inostroza et al., [52] developed 
an analytical method using G. pulex but applied it in the field to a similar animal, 
Dikerogammarus spp. The authors of this study reported concentrations of 
PPCPs reaching up to 2.83 ng g-1 ww and pesticides reaching up to 6.52 ng g-1 
ww. Thus, occurrence data in other invertebrate species were used as a 
comparison for this study. Carbamazepine was the most frequently detected 
pharmaceutical across all the sites which may be expected due to the frequency 
of detection of this compound in different environmental compartments as 
reported by other authors [53, 54]. The maximum concentration of any 
pharmaceutical determined was 36 ng g-1 that corresponded to nimesulide. Both 
nimesulide and diazepam were detected across 4 sites at relatively higher 
concentrations when compared to the other pharmaceuticals that were detected. 
Nimesulide would be expected to have minimal input into the aquatic environment 
in the UK as it is not available for human consumption. However, the sources of 
input arise from veterinary purposes and it has also been detected in selected 
144 
 
nutritional supplements. The moderate hydrophobicity of this compound may 
explain the relatively higher concentrations and more frequent detection. Site 7 
and 8 were the most contaminated.  
Overall, the eight sites showed low contamination with many compounds 
detected below the LOQ or not detected at all. Diazepam and carbamazepine 
(among other PPCP residues) have been reported to reach up to 110 ng g-1 in 
fish liver tissues [51]. If hydrophobicity determines accumulation potential, it may 
explain the reason why these compounds are frequently detected across the sites 
as they have relatively high logP values for pharmaceuticals. However, 
carbamazepine and diazepam have been shown to have very low BCF in G. 
pulex of 7 and 38 respectively [31]. Temazepam and propranolol were not 
detected in any biota samples but were detected in surface water samples. 
However, both of these compounds are more hydrophobic than trimethoprim that 
was detected in G. pulex. This suggests that uptake of PPCPs in biota based on 
hydrophobicity models may not accurately reflect the accumulation potential of a 
compound in invertebrates and is the focus of later chapters. Other occurrence 
data has shown PPCP concentrations in fish reaching up to 22 ng mL-1 in plasma, 
910 ng g-1 in brain tissue and 16 ng g-1 in liver tissue [55]. McEneff et al. [13], 
reported pharmaceutical concentrations of trimethoprim reaching up to 9 ng g-1 
dw. Here, the maximum trimethoprim concentration reached 5 ng g-1 displaying 
comparable contamination. Klosterhaus et al. [14], also reported marine mollusc 
PPCP concentrations reaching up to 14 ng g-1 ww where carbamazepine was 
detected most frequently and reached up to 5 ng g-1 ww. Huerta et al., [56] 
determined the occurrence of pharmaceuticals in three freshwater invertebrates 
in which ibuprofen was determined reaching up to 183 ng g-1 dw and diclofenac 
reaching 12.4 ng g-1 dw. In addition endocrine disruptors were detected and 
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ranged between 7.7 ng g-1 dw (tris-(2-butoxyethyl)-phosphate) to 130 ng g-1 dw 
(nonylphenol).  
 
Table 2.7: Occurrence of six pharmaceutical compounds detected in field collected G. pulex 


























Diazepam  ND, 6 ND - 8 - ND - 6 - - ND - 9 - 
Temazepam 




















ND — not detected, all other compounds marked with ‘–’were also not detected. 
a Quantified by three-point standard addition calibration. 
 
 
These reported occurrence data are in agreement with the data reported 
here. Although the concentrations are low, potential adverse effects may be 
elicited through chronic exposure to these contaminants. Environmentally 
relevant levels of PPCPs have shown to lead to oxidative stress and tissue 
lesions in fish and molluscs [57]. An investigation into the behavioural effects, 
such as movement and feeding activity, of PPCP exposure have shown that the 
lowest observed effect concentration (LOEC) in G. pulex was 100 ng L-1 for 
fluoxetine and 10 ng L-1 for carbamazepine and ibuprofen [27]. When considering 
the measured surface water concentration of carbamazepine reached up to 344 
ng L-1, it leads to the possibility that these populations of animals may already be 
experiencing adverse effects. However, it should be considered that behaviour is 
a bespoke endpoint and as internal concentrations were not measured in the 
study by De Lange et al. [30] it is difficult to link cause and effect. Surface water 
data showed that carbamazepine and trimethoprim occurred at the highest 
concentrations of 344 ng L-1 and 289 ng L-1, respectively. Across the eight sites, 
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Site 8 was observed to contain the highest concentrations of all pharmaceuticals 
with the exception of propranolol which reached up to 253 ng L-1 at Site 5. The 
higher concentrations of pharmaceuticals at Site 8 could be explained by the 
close proximity of this site to a WWTP effluent outfall pipe. This site is also 
reported to have a ‘poor,’ ecological status by the Environment Agency in 2012 
[58]. However, these increased surface water concentrations did not correlate 
with higher concentrations in G. pulex (highest concentrations observed at Site 
7). Site 5 also displayed relatively higher water concentrations of carbamazepine, 
trimethoprim and propranolol which also correlated poorly with the internal 
concentrations in G. pulex at the same site.  
 
Table 2.8: Occurrence of pharmaceuticals (ng L-1) detected in surface water samples (grab 




ND – not detected 
In comparison to several other monitoring studies of surface waters in the 
UK, carbamazepine has been detected frequently in the River Ely and the River 
Taff, reaching up to 684 ng L-1 [59]. Other studies have detected trimethoprim 
and propranolol reaching up to 40 ng L-1 and 215 ng L-1, respectively [60, 61]. All 
six pharmaceuticals that were detected here have been reported across Europe 
and Asia in countries such as Spain, France and S. Korea [62-64]. Diazepam was 
the least detected compound with the highest concentration reaching 4 ng L-1. In 
contrast, this was a frequently detected compound reaching relatively high 
concentrations in the biota samples which may suggest a potential to accumulate. 
However, occurrence data is limited in drawing conclusions about the potential of 
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accumulation. Furthermore, this ‘snapshot’ method of grab sampling would be 
expected to show poor correlation between water and biota concentrations. 
Alternative sampling methods such as composite and passive sampling would 
provide more detailed information about temporal flow. Temazepam and 
propranolol were not detected in any biota samples but were detected in surface 
water samples. Temporal fluctuations of water concentrations are not accounted 
for by grab sampling. Thus, internal concentrations will also be in constant state 
of flux that will lag behind changes in the external exposure concentration. This 
assumption is supported by the poor correlation between environmental 
compartments measured here. With this consideration it is potentially more useful 
to monitor contamination of biota than surface water alone when considering 
environmental risk of pharmaceuticals.    
2.4 Conclusions 
The occurrence of six pharmaceuticals were quantified in a freshwater 
aquatic invertebrate in several tributaries of the River Thames, with internal 
concentrations reaching up to 36 ng g-1 dw. An analytical method was developed 
and optimised which made use of ball-mill extraction, SPE and LC-MS/MS to 
reliably quantify 10 pharmaceutical compounds. Six pharmaceuticals were also 
quantified in surface water samples, where five compounds were also detected 
within the biota samples. The concentrations of pharmaceuticals were in 
agreement with other reported occurrence studies for both surface water and 
other aquatic species. It was found that surface water concentrations do not 
translate well into biota concentrations and therefore demonstrated the 
importance of measuring both when performing monitoring campaigns to assess 
environmental risk. Conclusions of field derived bioaccumulation is also limited 
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due to the poor correlation between the environmental compartments suggesting 
that further work into uptake and elimination kinetics is key to understanding the 
accumulation potential of compounds. The optimised method has provided useful 
information regarding an ecologically important freshwater invertebrate and can 
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Chapter 3. The determination of uptake and elimination kinetics for 
selected pharmaceuticals using radiolabelled exposures in 
Gammarus pulex.  
 
3.1 Introduction 
As shown in the previous chapter, low level occurrence of several 
pharmaceuticals was determined in both surface waters and G. pulex collected 
in the Greater London catchment area. Other studies have also shown low level 
occurrence in biota such as mussels among other aquatic invertebrates [1-3]. The 
occurrence of these pharmaceuticals indicates that invertebrates have the 
potential to accumulate pharmaceuticals, which may lead to adverse effects 
throughout food chains. The effects of pharmaceuticals have previously been 
demonstrated in G. pulex, which led to significant changes in their behaviour 
including ventilation, feeding and locomotion when exposed to fluoxetine and 
ibuprofen between 10 – 100 ng L-1 [4, 5]. From reported occurrence data it can 
be assumed that acute effects such as mortality are unlikely to be observed in 
exposed organisms, as the concentrations are often several orders of magnitude 
below acute toxicity thresholds [6]. Therefore, measurement of sensitive sub-
lethal effects such as behavioural changes, oxidative stress and alterations to 
organ function in fish and invertebrates could indicate early warning signs of 
stress [7-9].  
Currently, environmental risk assessment of pharmaceuticals is required 
for licensing where standard acute toxicity tests (e.g. LC50) are employed, unless 
the PEC:PNEC ratio is <1 where no further testing is required. However, as 
mentioned previously acute toxicity is less likely to be observed in the 
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environment therefore these types of standard toxicity tests do not yield much 
information for reliable risk assessment. Furthermore, there is a lack of focussed 
studies on the uptake and elimination kinetics of pharmaceuticals in biota leading 
to a lack of knowledge on whether pharmaceuticals do accumulate. Many of 
these studies to date, also only focus on vertebrate species such as fish for 
ecotoxicological testing, thus the potential for adverse effects in invertebrates is 
not well understood. Aquatic bioconcentration or bioaccumulation studies are 
used to identify whether a compound can accumulate through water or food 
exposure of the selected xenobiotic. The ratio between the concentration in the 
exposure route and the concentration inside the organism leads to a quantitative 
measure of the accumulation potential. Early models of accumulation were 
determined for compounds such as methylmercury in fish which considered 
variables such as the volume of water passing over the gills, the assimilation 
across the gills and the body mass of the organism [10]. Development of these 
toxicokinetic models have continued to focus on the assessment of other factors 
such as fish lipid content, lipid phase resistance, water phase resistance and 
compound hydrophobicity [11-14].  
As mentioned, the BCF is a ratio between the concentrations in the water 
and in animals but it can also be determined using a kinetic estimation defined 
as the ratio between the uptake rate constant (k1) and the elimination rate 
constant (k2) [15]. The rate constants can be determined by using curve fitting 
algorithms in concentration-time plots of the toxicokinetic experiments. They can 
also be estimated simultaneously or sequentially, where the simultaneous 
method can be considered more biologically feasible, as uptake and elimination 
are not separate processes. REACH ANNEX XIII defines a compound to be 
accumulative when the ratio is ≥2,500 or very accumulative if the value is ≥5,000 
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[16]. Standard BCF tests such as the OECD 305 guideline [15] can be very time 
consuming (2-3 months), labour intensive studies that use a large number of fish 
and are considerably expensive. The combination of these factors with the sheer 
volume of pharmaceuticals to be tested leads to feasibility issues in risk 
assessment and is also counterproductive to policy aims such as the 3R’s. 
Therefore, recent approaches have encompassed shorter exposure times and 
less time points to reduce the number of fish and increase the throughput of 
accumulation testing such as the ‘minimised’ OECD 305 test guideline [15]. Other 
authors have selected non-standard organisms (fish) such as Gammarus, 
utilising exposure periods of 4 – 7 days to assess the accumulation potential of 
xenobiotics [17-19]. Whilst these studies offer a potential alternative to the 
standard fish tests, the number of studies with invertebrates is limited and 
therefore the reliability of using these non-standard organisms for 
ecotoxicological testing should be assessed.   
The aim of this work was to assess the accumulation potential of selected 
pharmaceuticals exposed at the upper range of environmental relevance in the 
non-standard organism G. pulex. Bioconcentration factors will be estimated using 
both sequential and simultaneous modelling as specified by the OECD 305 
guidelines. Finally, the reliability of using these models on non-standard animals 
to estimate BCFs will be critically evaluated for the first time.   
 
3.2 Materials & methods 
3.2.1 Reagents, chemicals and consumables  
Radio-labelled pharmaceuticals including 3H-propranolol hydrochloride 
(29.0 Ci mmol−1,) was acquired from Amersham Biosciences. 3H-metoprolol 
(29.7 Ci mmol−1), 3H-formoterol (18.5 Ci mmol−1) and 3H-terbutaline 
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(29.0 Ci mmol−1) were obtained from Vitrax. 14C-ibuprofen (2.03 Ci mmol-1) was 
obtained from American Radiolabelled Chemicals Inc., (St Louis, US). 3H-
ranitidine (2.5 Ci mmol−1) were obtained from Moravek Biochemicals, 14C-
diclofenac (0.063 Ci mmol-1) and 3H-imipramine hydrochloride (48.5 Ci mmol−1) 
from Perkin-Elmer. All stock solutions were stored in ethanol. Hydrogen peroxide 
solution (30 % w/w) and analytical grade salts (>99 %) including sodium hydrogen 
carbonate, magnesium sulphate, calcium sulphate, potassium chloride were 
purchased from Sigma (Dorset, UK). Tissue solubiliser (SolvableTM) and liquid 
scintillation cocktail (Hionic FluorTM) were purchased from Fischer Scientific Ltd 
(Loughborough, UK). Ultra-pure water was obtained from a Millipore Milli-Q water 
purification system with a specific resistance of 18.2 MΩ.cm or greater (Millipore, 
Bedford, MA, USA). 6-well culture plates were obtained from VWR 
(Leicestershire, UK). 
 
3.2.2 Sample collection and culture maintenance 
Gammarus pulex were collected by kick-sampling from the River Cray, 
South-East London, UK, 51°23'09.5"N 0°06'32.4"E. This site was previously 
shown (Chapter 2) to have low pharmaceutical contamination in both collected 
surface water and animal samples [20]. The populations were transported to the 
laboratory in 500 mL NalgeneTM flasks filled with surface water from the sample 
collection site. Populations were rinsed with artificial freshwater (AFW) and then 
acclimatised to laboratory conditions (as specified below) for a minimum of 7 days 
before any exposure experiments were performed. AFW was prepared from 1.15 
mM of NaHCO3, 0.50 mM MgSO4, 0.44 mM CaSO4 and 0.05 mM of KCl dissolved 
in 20 L of ultra-pure water [21]. This water was subsequently aerated for several 
hours to remove dissolved carbonic acid and maximise the dissolved oxygen 
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concentrations. Each culture tank (n=8) was filled with 2.5 L of AFW and animals 
were fed with alder leaves that were previously collected from the collection site 
and conditioned by submersion in surface water for two days prior to use.  
 
3.2.3 Toxicokinetic exposure and conditions 
Toxicokinetic experiments were performed separately for each 
pharmaceutical for a total of 96h, which included a 48h uptake phase followed by 
a 48h depuration period. Individual adult organisms, both male and female (>5 
mg wet weight) were placed in each well of 6-well culture plates. G. pulex were 
carefully transferred to well plates using blunt forceps to avoid any harm to the 
organisms before exposure.  A single well contained one organism in 10 mL of 
exposure media (AFW and test compound) and only non-parasitised individuals 
were used (absence of Pomphorhynchus laevis indicated by the lack of an orange 
dot on the dorsal side of the animal). G. pulex were exposed to individual PhACs 
at a concentration of 1 µg L-1, except for diclofenac and ibuprofen which were 
present at 10 µg L-1. The higher exposure of these two compounds was due to 
the low activity of the radiolabel. The exposure concentrations were well below 
mortality thresholds (>1000-fold) for several of the compounds in G. pulex 
(diclofenac, propranolol, ibuprofen, metoprolol, ranitidine and imipramine) [22].   
All exposure media contained <0.05 % of solvent (ethanol). A total of 33 
organisms were used per exposure and were sampled (n=3/time-point) at 2, 5, 
18, 24 and 48h in the uptake phase followed by the same time-points in the 
depuration phase.  
Along with G. pulex, 50 μL of water was also sampled from each well for 
analysis of radioactivity and determination of test compound concentration in the 
media. Each sampled organism was washed in 10 mL of ultra-pure water for 10 
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seconds (n=6) and gently blotted dry to remove any excess exposure media and 
unbound compound to the cuticle of the animal. Organisms were weighed after 
sampling to determine body mass and then transferred to scintillation tubes for 
tissue solubilisation. Three individual organisms were also exposed to unspiked 
AFW in culture plates and sampled after 96h in a control experiment to account 
for any background radiation. Additionally, for each experiment, three wells 
without G. pulex were filled with exposure media to account for losses of the 
compound by sorption to the walls of culture plates. Culture plates were stored in 
sealed plastic containers with wet tissue to prevent evaporative losses during the 
static exposure. The light cycle followed 12:12h light:dark without a dusk/dawn 
transition period. All experiments were performed in a temperature controlled 
room at 15 °C (± 2 °C) and water pH was also monitored across each experiment 
and measured 8.2 ± 0.1 pH.  
 
3.2.4 Sample preparation and liquid scintillation counting 
Water samples (50 µL) collected from each exposure well were added to 
2 mL of Hionic Fluor liquid scintillation cocktail and counted for radioactivity on a 
Beckman LS6500 instrument (Beckman Coulter, Inc.). Sampled G. pulex 
individuals were placed in a scintillation tube with 2 mL of tissue solubiliser and 
maintained at room temperature (approx. 20 °C) for 96h. Samples were shaken 
vigorously and then a 50 μL aliquot of the solubilised biotic extract was added to 
2 mL of Hionic Fluor to be counted. To account for any difference in counts 
caused by colour quenching, hydrogen peroxide (200 µL) was added to a 
previously counted biotic extract and re-analysed (n=30). No difference in counts 
was observed with or without the presence of hydrogen peroxide. Therefore, all 
other biotic samples were counted without the addition of hydrogen peroxide. In 
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addition, chemiluminescence accounted for <0.01 % of the overall counts, and 
was therefore ignored.  
3.2.5 Modelling bioconcentration factors  
Parameter estimation of uptake rate constant (k1) and depuration rate 
constant (k2) was performed using a curve fitting algorithm via  Minitab statistical 
software (Minitab Ltd., Coventry UK) and as outlined in the OECD 305 Fish 
Bioconcentration Guidelines [15]. The concentration of compound in the 




=  𝑘1 ×[𝐶𝑤𝑎𝑡𝑒𝑟] −  𝑘2 ×[𝐶𝑜𝑟𝑔𝑎𝑛𝑖𝑠𝑚]   (3.1) 
 
Where, dCorganism/dt is the rate of change in the concentration of a 
compound within/on G. pulex (mg kg-1 day-1), k1 is the uptake rate constant (L kg-
1 day-1), k2 is the elimination rate constant (day-1), Cwater is the concentration of 
test compound in the water (mg L-1) and Corganism is the concentration of test 
compound in the organism (mg kg-1). Equation 3.1 was integrated into Equations 
3.2 and 3.3 for fitting of curves to the uptake and depuration data. This method, 
known as the Levenberg–Marquardt algorithm, uses an iterative formula to 
minimise the residual errors between the observed and predicted data points and 
simultaneously estimates k1 and k2 values from the fitted curve i.e. 
  [𝐶𝑜𝑟𝑔𝑎𝑛𝑖𝑠𝑚] = [𝐶𝑤𝑎𝑡𝑒𝑟]×
𝑘1
𝑘2





 ×(1 − 𝑒−𝑘2(𝑡− 𝑡𝑒) −  𝑒−𝑘2𝑡), when t > te       (3.3) 
 
Where, t is the time (days) and te is the end time of the uptake phase 
(days). At steady-state, the rate of uptake should be equal to the rate of 
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depuration and there should be no overall change in analyte concentration within 
G. pulex, as expressed by Equation 3.4.  
 






= 𝐵𝐶𝐹           (3.4)          
 
Where, BCF is the bioconcentration factor (L kg-1). The BCF can also be 
estimated using a sequential method where a simple linear regression model is 
developed based on the depuration data only. With the assumption of first order 
kinetics, the model should fit a straight line and its slope represents the 
elimination rate constant as shown in Equation 3.5, i.e.  
 
𝑙𝑛[𝐶𝑜𝑟𝑔𝑎𝑛𝑖𝑠𝑚] =  −𝑘2 ×𝑡 + 𝑐                                (3.5) 
 
Where, ln[Corganism] is the natural log of the analyte concentration within G. 
pulex and c is the intercept, which here equals the natural log of the analyte 
concentration in the G. pulex (mg kg-1) at the start of the depuration phase. The 
k2 from Equation 3.5 can then be used as a parameter in the curve fitting 
algorithm to estimate k1. The rearrangement of Equation 3.2 allows the value for 
k1 to be calculated over the time interval specified, as shown in Equation 3.6 [23]. 
The assumptions of the equation are that the analyte water concentration and k2 
remain constant. The k2 used in Equation 3.6 was directly estimated by using 
linear regression of the depuration data to obtain the slope (k2). The value of k1 
should remain constant over the entire experiment. 
 
𝑘1 =  
[𝐶𝑜𝑟𝑔𝑎𝑛𝑖𝑠𝑚] × 𝑘2
[𝐶𝑤𝑎𝑡𝑒𝑟] ×(1 − 𝑒−𝑘2𝑡)
                                       (3.6) 
 
For this study, initial parameters for k1 and k2 were arbitrarily set at 0.1 in 
the software with Cwater set in μg L-1, t set at 48h and the maximum number of 
iterations was set at 200 upon which optimised k1 and k2 values were 
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subsequently derived. Confidence intervals (95 %) were plotted for curves and 
the overall model fits were assessed. The lack-of-fit test was calculated in the 
Minitab software and was used to assess the fit of the line by comparing the 
variation in response of the replicate data. Lack-of-fit was assessed at a 
significance level of 0.05. Correlation coefficients (R2) were evaluated when the 
sequential method was used to estimate k2. The distribution coefficient (LogD8.2) 
was generated using ACD Labs Percepta software (Berks, UK), for the 
interpretation of estimated BCF values.  
 
3.3 Results & discussion  
3.3.1 Initial toxicokinetic experiments  
Preliminary exposures were investigated to optimise experimental 
conditions to obtain the most reliable data. G. pulex individuals were placed into 
6 and 12-well culture plates (10 mL and 5 mL volumes, respectively) and 
monitored over a 48h period. The 12-well culture plates showed increased 
mortality when compared to the 6-well (> 50% mortality). The higher mortality was 
possibly a result of low oxygen content in the smaller volume of water. The OECD 
305 guidance document [15] states that mortality of exposures should be <20 %. 
Therefore, the 6-well culture plates were selected for all toxicokinetic experiments 
as the mortality of individuals in these plates remained <20 %.  
The first toxicokinetic exposure was performed with propranolol which 
resulted in an unexpected uptake and elimination profile. As shown in Figure 3.1, 
there was initially a very rapid uptake of compound in the first 2h period of the 
exposure reaching a mean concentration of 660 ng g-1. After this, the compound 
concentration in the animals was reduced significantly to a mean concentration 
of 127 ng g-1, which indicated there was a rapid turnover (elimination proceeded 
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faster than uptake) of compound inside the animal. Reduction of the internal 
concentration by ~80 % would suggest that the clearance of propranolol became 
more rapid than the uptake. However, this only occurred after a lag period of the 
first two hours which may indicate there was a threshold concentration before 
detoxification enzymes began metabolism and elimination. After the first 24h, the 
remaining concentration of propranolol in G. pulex reached a plateau (some small 
scatter) which would indicate steady state has been achieved. In the final 48h of 
the experiment, individuals were placed into ‘clean’ water to allow depuration. In 
this time period the concentration of propranolol did not reduce any further which 
again was unexpected due to the observed rapid elimination of propranolol in the 
uptake phase. A possible explanation is that the radiolabelled carbon atoms have 
been metabolised and incorporated into the animals themselves leading to a 
























































Figure 3.1: Toxicokinetic profile G. pulex exposed to propranolol 




Further investigation of this toxicokinetic profile was performed in the first 
instance to ensure repeatability. Additional time intervals were introduced for 
better characterisation of the initial uptake period. Early time intervals were 
selected at 0.5, 1, 2, 3 and 5h (Figure 3.2) and showed the same trend observed 
in the first exposure although the concentrations were lower in the earlier time 
intervals. The highest concentration was reached within 0.5h (mean = 379 ng g-
1), followed by significant decreases at 3h. A plateau was reached again in the 
uptake phase and when animals were removed to the depuration phase, the 
mean concentration remained at 32 n g-1. As mentioned previously, the observed 
toxicokinetic profiles were unexpected and whilst biological interpretation of the 
data was plausible the unusual data could have also been a result of 
contamination leading to false counts.  
A small experiment was performed which investigated two different tissue 
solubilisers (Soluene® 350 & Solvable™) and two scintillation cocktails 
(Ecolume™ & Hionic Fluor). When unexposed G. pulex organisms were 
























































Figure 3.2: Toxicokinetic profile G. pulex exposed to propranolol 
at 1 µg L-1. 
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Ecolume™ unusually high radioactivity measured by disintegrations per minute 
(DPM) were observed (Table 3.1).  
 
 
However, when Hionic Fluor was used the DPM were in line with 
background 14C radiation levels. The high DPM counts observed with Ecolume™ 
were the result of false counts from chemiluminescence. In liquid scintillation 
counting instruments, the counts are the indirect measurement of radioactivity 
through the detection of photons. Thus, any reactions between the sample and 
liquid scintillation cocktail may produce photons (chemiluminescence). These 
photon emissions mimic the counts that would otherwise be produced from 
radioactivity. As both tissue solubilisers are highly alkaline solutions it is likely that 
the chemiluminescence resulted from this. 
 
 





Solvable™ Hionic Fluor No 13.85 
Solvable™ Ecolume™ No 3938.58 
Soluene® 350 Hionic Fluor No 13.51 
Soluene® 350 Hionic Fluor Yes 14.45 
Soluene® 350 Ecolume™ Yes 48759.94 
Solvable™ Hionic Fluor Yes 15.48 


























































Table 3.1: Effect of tissue solubiliser and liquid scintillation cocktail on radiolabel 
activity. 
Figure 3.3: The effect of colour quenching on toxicokinetic profiles of G. pulex exposed to 
propranolol (1 µg L-1). A – no hydrogen peroxide, B – addition of hydrogen peroxide. Open 




The exposure with propranolol was repeated using Hionic Fluor as a liquid 
scintillation cocktail to supress chemiluminescence. As shown in Figure 3.3, the 
profile observed was much more expected for a toxicokinetic plot. The uptake 
followed a steady increase reaching a mean concentration of 22 ng g-1 at 48 h, 
after removal to the depuration phase concentrations were reduced to a mean of 
8 ng g-1. The kinetic BCF was estimated to be 32, indicating that propranolol has 
a very low potential to accumulate in G. pulex. To ensure no colour quenching 
occurred during analysis, hydrogen peroxide (200 µL) was added to the samples 
and re-counted. The addition of hydrogen peroxide made no significant difference 
to measured DPM and therefore it was assumed that no colour quenching had 
occurred (Figure 3.3).  
The OECD 305 model assumes that uptake and elimination follow first-
order kinetics. However, when a line was plotted through the mean 
concentrations an R2 of 0.991 was calculated indicating that over the plotted data 
the order of the reaction was zero-order, this was further supported by a natural 
logarithmic plot of concentration versus time which did not yield a straight line 
(Figure 3.4).  
 























































Figure 3.4: Concentration-time plots of propranolol in G. pulex. 
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Zero-order kinetics would suggest that propranolol is concentrated by 
carrier mediated uptake as the rate of uptake does not decrease over time. Thus, 
the uptake was independent of concentration and saturation of the carriers had 
occurred so that zero-order kinetics became predominant. This observation has 
potentially important implications as bioconcentration models often assume that 
uptake is by passive diffusion. Early models were developed using highly 
hydrophobic organic contaminants [11] and this could lead to unreliable uptake 
models for studies involving amphoteric compounds such as pharmaceuticals. 
Recently, several authors have stressed the importance of carrier mediated 




To further investigate the order of kinetics and the type of uptake that 
occurred, a dose-response curve was plotted for varying concentrations of 
propranolol (50 ng L-1 to 10 μg L-1). Figure 3.5 shows that at the lower 
concentrations from 0.05 to 2.5 μg L-1 there is slight curvature to the line indicating 
the instantaneous rate was slowing as the concentration of the exposure solution 
increased. The slowing of the uptake rate at a threshold concentration might 

































































Figure 3.5: Initial uptake rates versus exposure concentration of propranolol in G. pulex 
(0.05 – 10 µg L-1) 
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suggest a saturation event was occurring. At concentrations higher than 2.5 μg 
L-1 the line becomes linear (R2 = 0.9993), indicating that the instantaneous uptake 
rate continued to increase with exposure concentrations, as would be expected 
of passive diffusion. The observed change in the instantaneous rates is evidence 
that both passive diffusion and carrier mediated uptake process are taking place 
simultaneously. This finding was observed in a separate study that studied the 
permeation of fish gill cell cultures to propranolol [26]. In addition, a previous 
study also demonstrated saturable uptake of propranolol at low concentrations in 
rats but when doses were increased passive diffusion became dominant [27]. 
However, as these processes occur simultaneously it becomes difficult to 
investigate further the contribution of each process to the uptake of a compound.  
 
3.3.2 Population differences on the uptake and elimination of propranolol 
Propranolol was taken for further investigation to see what effect, if any, 
different populations and acclimatisation periods had when they were used. The 
acclimatisation period of 1, 2 and 7 weeks were investigated to identify any 
differences in uptake or elimination. Individuals were collected from the same site 
but held in laboratory conditions for these time intervals. The internal 
concentrations in both the uptake and elimination phases were compared using 
a two factor ANOVA with replication. This allowed the statistical interpretation of 
variances between each acclimatisation group, the time interval in the exposure 
and the interaction between them.  
The uptake data showed statistically significant differences between each 
group treatment and the time intervals when considered as separate factors. 
However, the interaction between these two factors showed no statistical 
significance (95 % confidence interval) which indicated that there was no 
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difference between acclimatisation on the uptake of propranolol in G. pulex. 
When comparing the elimination data, the same conclusion could be drawn as 
there was no statistical significance between the interaction between 
acclimatisation group and the time interval that samples were taken from. The 
ANOVA showed that overall there is no significant effect on the length of 
acclimatisation time on G. pulex. However, if samples are field collected a 
depuration period is still recommended of ≥ 1 week, so that any residual 
contamination is reduced or eliminated. Furthermore, unexposed organisms that 
have been depurated should also be screened for any residual contamination. 
Populations from different sites may also show variability in their potential 
to bioconcentrate a compound. For example, a population from a polluted site 
may have upregulated expression of detoxification enzymes compared to 
animals that are collected from a pristine site. This has been observed in killifish 
(Fundulus heteroclitus) where pollution induced tolerance to metals and 
PAHs/PCBs have reduced the toxic sensitivity in pristine and contaminated sites 
[28, 29]. Alternatively, it is possible that polluted sites may lead to more stress on 
animals therefore their ability to eliminate xenobiotics may be reduced. An 
exposure experiment was performed on three groups of animals collected from 
different sites to assess any variability between different populations. Two groups 
were collected from urban areas (River Wandle, 51°25'25.4"N 0°11'01.9"W & 
River Cray, London) and the final collection site was located in a rural area (Ashes 
Hollow, Shropshire 52°31'59.7"N 2°50'20.1"W). ANOVA of the uptake and 
elimination from the three sites showed that there was no statistical significance 
between the uptake data. However, the elimination data between all three 
populations gave a p-value of 0.03, indicating there was a significant variance 
arising between the groups. To identify where the variance had arisen from, 
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groups were placed in a pair-wise manner and the ANOVA analysis repeated. 
There was no significant difference between the variance in elimination between 
the urban sites. However, one of the urban sites (River Wandle, Colliers Wood) 
when compared with the site in Shropshire showed a p-value of 0.03. Comparison 
of the internal concentrations during the elimination phase showed that after 48h 
the concentration of propranolol from the urban site had reduced below that of 
the Shropshire population (Figure 3.6).  
Determination of BCFs resulted in 277 for the Shropshire population and 
55 for the population from Colliers Wood, a difference of 5-fold. The difference in 
BCF values resulted from the lower k2 value of the Shropshire population that 
was estimated at 0.002 d-1, ~8.5-fold lower than in the population from Colliers  
Wood.   
 
This data potentially indicates that the animals from the Shropshire site had a 
lower turnover of propranolol due to reduced elimination. In comparison both 
urban populations had a much lower BCF for propranolol although only one site 
showed a statistically significant difference to the Shropshire population. Analysis 
of the water from each site showed that both the urban sites had contamination 





























Figure 3.6: Elimination of propranolol from G. pulex, solid circles – River Wandle (urban 
site), open circles – Ashes Hollow (rural site).  Measured propranolol concentration in 
water phase was 0.91 ± 0.046 µg L-1 (uptake) and 0.006 ± 0.004 µg L-1 (depuration). 
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concentrations of propranolol were relatively high (>200 ng L-1) [20, 30]. In 
contrast, the Shropshire site had very low level contamination (Table 3.2) with the 
highest concentrations reaching 28 ng L-1 (warfarin). The maximum propranolol 
concentration in the water was determined at 24 ng L-1, approximately 10-fold 
lower than reported in the urban surface waters.  
 
 
Overall, this data may indicate a potential adaptation/tolerance of 
populations from contaminated urban rivers to eliminate xenobiotics better than 
those populations from less contaminated sites. Previous works have shown 
adaptions of killifish to contaminated sediments and PCB pollution through 
alterations in CYP expression that were shown to be heritable traits (genetic and 
non-genetic mechanisms) [31-33]. Increased tolerance of biota has also been 
observed for heavy metals which demonstrates the possibility that pollution 
induced tolerance is an adaptation of biota to reduce body burdens of 
contaminants [34]. Whilst this work supports this, it should be considered that 
further work would be needed to substantiate this argument. In particular, more 
replicates, sites, different compounds and life history examination of the selected 





  Surface Water (ng L
-1)  G. pulex (ng g-1 dw) 
Carbamazepine 5 6 5 N.D. <LOQ N.D. 
Propranolol 10 24 <LOQ <LOQ 160 N.D. 
Diazepam <LOQ <LOQ <LOQ 7 10 9 
Trimethoprim 6 8 14 6 140 9 
Temazepam <LOQ <LOQ <LOQ <LOQ <LOQ 7 
Warfarin 18 28 12 5 N.D. N.D. 
Table 3.2: Determined pharmaceutical concentrations in surface water and G. pulex 
from Ashes Hollow (Shropshire, rural site).  
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3.3.4 The uptake and elimination of selected pharmaceuticals in G. pulex 
Toxicokinetic experiments were performed for eight selected pharmaceuticals 




























Figure 3.7: Uptake and elimination data for PPCPs in G. pulex. Dashed lines 
indicate 95 % confidence limits. 
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All exposures resulted in uptake from the earliest time point (2h), with the 
two compounds diclofenac and ibuprofen reaching the highest internal 
concentrations by 48h. The higher concentrations determined in the organisms 
here, resulted from these compounds being exposed at a higher concentration 
(10 µg L-1) due to low activity of the radiolabel. The remaining six pharmaceuticals 
(1 µg L-1) showed maximal uptake phase concentrations of <80 ng g-1 ww. 
Analysis of water samples (Table 3.3) showed that the pharmaceuticals remained 
within 20 % of the nominal exposure concentrations with the exception of 
imipramine which showed a mean decrease of 52.2 %. The losses of analyte in 
the water phase could be due to several processes (separate from uptake into G. 
pulex) including photolysis, volatilisation, sorption and biotransformation by 
microorganisms. To account for these processes, control wells were set-up (no 
animals) to monitor for analyte loss. Analysis of water samples from the control 
wells resulted in RSDs of ≤5 % indicating that these processes involved with 
analyte loss were negligible. The variance observed could be explained by 
instrumental error. However, imipramine was again an exception to these 
observations (11% RSD) and showed a steady decrease in the control wells at 
each time interval measured. Imipramine had the highest logD8.2 of 3.3 and thus 
the losses are likely to have resulted from sorption by pi-pi stacking or Van der 
Waals interactions to the plastic (polystyrene) culture plates.  
After removal of the individuals to the depuration phase, animals showed 
varying elimination rates (Table 3.4). The lowest k2 values were determined for 
imipramine (0.007 d-1) and metoprolol (0.005 d-1). However, the BCF of these two 
compounds differed greatly which resulted from the lowest observed uptake rate 
constant for metoprolol (0.076 L kg-1 d-1) in contrast to imipramine which had the 
highest k1 value (1.408 L kg-1 d-1). With the exception of imipramine, 
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pharmaceuticals had relatively low uptake rates coupled with high elimination 
rates leading to low estimates of BCFs. All estimated BCFs remained ≤212 using 
the simultaneous method of estimation indicating that these selected 
pharmaceuticals were not accumulative. This is in line with regulatory guidelines 
which suggest that for a compound to be considered bioaccumulative a threshold 
value of 2,500 must be reached [16].  
The low BCFs determined here could be explained by the relatively low 
hydrophobicity, as indicated by logP and logD. Hydrophobicity is generally 
considered the main factor governing bioaccumulation and many studies have 
shown the importance of this physicochemical property in relation to uptake of 
organic contaminants [11, 35]. However, pharmaceuticals are unique to these 
standard uptake models as they often have low hydrophobicity and can be 
ionised at multiple sites. Thus, these compounds could have the potential to 
concentrate in biota via different mechanisms such as carrier mediated transport. 
The BCFs reported in this study are in the range of BCFs observed in a separate 
study by Meredith-Williams et al., 2012 [17].  
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(d-1) SE p-value BCF 
k1 
(L kg-1 
d-1) SE p-value 
k2 
(d-1) SE p-value BCF 
k1 
(L kg-1 
d-1) SE p-value 
k2 
(d-1) R2 BCF 
Propranolol 0.538 0.068 0.017 0.004 0.266 32 0.618 0.047 0.831 0.016 0.006 0.132 39 0.604 0.045 0.860 0.015 0.490 42 
Formoterol 0.408 0.093 0.029 0.009 0.335 14 0.451 0.051 0.914 0.025 0.014 0.279 18 0.357 0.040 0.942 0.011 0.121 33 
Imipramine 1.408 0.205 0.007 0.004 0.008 212 1.361 0.177 0.017 0.000 0.004 0.490 3811 1.360 0.177 0.017 0.000 0.001 4533 
Metoprolol 0.076 0.022 0.005 0.008 0.073 16 N/A 
Terbutaline 0.136 0.020 0.011 0.004 0.026 12 0.135 0.016 0.027 0.006 0.003 0.381 22 0.117 0.016 0.027 0.006 0.200 19 
Ranitidine 0.479 0.126 0.028 0.011 0.005 17 0.310 0.071 0.007 0.004 0.006 0.192 81 0.301 0.070 0.007 0.003 0.015 112 
Diclofenac 0.273 0.037 0.020 0.005 0.002 14 0.253 0.025 0.017 0.009 0.003 0.156 27 0.269 0.026 0.023 0.013 0.243 21 
Ibuprofen 0.338 0.094 0.012 0.008 0.000 27 0.582 0.097 0.013 0.022 0.014 0.004 27 0.488 0.073 0.029 0.010 0.093 50 
Compound Exposure Control (n=3) (ng mL-1) Uptake Phase (ng mL-1)   Depuration Phase (ng mL
-1) 
  2h 5h 18h 24h 48h 2h 5h 18h 24h 48h 2h 5h 18h 24h 48h 
diclofenac 9.99 9.49 9.76 9.88 9.99 9.86 9.43 9.51 9.44 9.46 0.05 0.02 0.00 0.01 0.05 
formoterol 1.08 1.01 1.00 1.07 0.96 0.92 0.96 0.90 0.96 0.85 0.02 0.03 0.03 0.01 0.04 
ibuprofen 9.72 9.60 10.05 9.84 9.70 10.18 10.34 9.67 9.56 9.51 0.01 0.00 0.00 0.02 0.04 
imipramine 0.79 0.73 0.64 0.63 0.61 0.57 0.55 0.54 0.60 0.48 0.01 0.01 0.03 0.04 0.04 
metoprolol 1.04 1.02 1.05 1.02 1.02 0.98 0.95 0.94 0.98 1.05 0.02 0.01 0.02 0.02 0.02 
ranitidine 1.05 1.03 1.04 1.02 0.98 0.99 0.96 0.88 0.99 0.94 0.01 0.01 0.03 0.01 0.02 
terbutaline 1.04 0.97 1.01 0.98 0.97 0.96 0.90 0.94 0.92 0.92 0.07 0.07 0.08 0.08 0.14 
propranolol  0.92 0.95 0.94 0.93 0.94 0.92 0.91 0.91 0.91 0.90 0.00 0.00 0.00 0.00 0.01 
                
Table 3.4: Toxicokinetic parameters and bioconcentration factors for eight PPCPs. 
asequential using curve fitting method, bsequential using linear regression.  
P-values were assessed via standard error (SE) and lack-of-fit tests.  
 
Table 3.3: Pharmaceutical water concentrations determined in the uptake and depuration exposure media. 
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The previous work reported BCFs of 6 pharmaceuticals in G. pulex, with 5 
compounds remaining below a BCF of 270. One pharmaceutical (fluoxetine) had 
a measured BCF of 185,900 indicating that it was very bioaccumulative in G. 
pulex. However, this high BCF may be explained by the pharmacokinetics of 
fluoxetine where this compound inhibits its own metabolism resulting in an 
increasing half-life. Furthermore, this study only detected the radiolabel. 
Metabolites of fluoxetine such as norfluoxetine has a longer half-life than 
fluoxetine, which also increases over time (self-induced metabolic inhibition). 
Therefore, this high BCF is likely a result of the inhibited biotransformation and 
elimination.  
The logD8.2 of the eight pharmaceuticals was plotted against the measured 
log[BCF] values (Figure 3.8) and no obvious trend was observed. Generally, 
there was a slight increase in BCF from logD 1-3, but the data was limited and 
conclusions should be carefully considered. A study that investigated the uptake 
of pharmaceuticals in plants [36] showed plots of logD versus log[BCF] gave no 
observable trends for compounds which were ionisable. However, non-ionised 
compounds showed an increasing BCF when logP increased (i.e 
carbamazepine).  
















Figure 3.8: Log[BCF] versus logD8.2 of the eight selected pharmaceuticals.  
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This suggests that bioaccumulation for non-ionisable pharmaceuticals 
may follow standard uptake models and assumptions with hydrophobicity as an 
important factor. However, for those compounds which are ionisable it is possible 
that hydrophobicity has less influence in determining the bioaccumulation 
potential of a compound. Other factors such as gill surface charge, pH of the gill 
boundary layer and carrier mediated transport (such as facilitated diffusion or 
active transport) may become more important in the uptake of these 
pharmaceutical compounds. The order of the uptake rate constants were 
imipramine > propranolol > formoterol and were also in agreement with the order 
of gill cell permeabilities (cm s-1) reported by Stott et al., 2015 [26]. Finally, the 
low BCFs observed show the potential for pharmaceutical metabolism in non-
target organisms. Metabolism suggests that there is conservation of cytochrome 
P450 enzymes within G. pulex, which has been shown in other aquatic 
invertebrates [37]. This is important for toxicokinetic modelling as 
bioaccumulation models do not often take into account metabolism of a 
xenobiotic and is a potential limitation for methods that use liquid scintillation 
counting for analysis.   
 
3.3.5 Uptake rate constant assumptions and model reliability  
OECD 305 guidelines specify that when estimating a kinetic BCF, two 
methods can be employed. The first is the simultaneous method where both k1 
and k2 are calculated together versus the sequential method where k2 is first 
estimated and the k1 is derived from this estimate. In Figure 3.7, the toxicokinetic 
plots showed a lack-of-fit in several of the compound exposures. This was usually 
observed by an under-fitting of the curves in the uptake phase that is most 
apparent with the diclofenac, imipramine, ranitidine, terbutaline and metoprolol 
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experiments. When estimating the parameters k1 and k2, a p-value was 
generated for model lack-of-fits. When the parameters were estimated by the 
simultaneous method, 5 models showed a statistically significant lack-of-fit. If 
lack-of-fit is significant then it has important implications for BCF values as they 
could be over/underestimated leading to inaccurate risk assessment. Due to the 
poor fits observed, the parameters were re-estimated using the sequential 
method. In the sequential method, linear regression of the depuration data yields 
a direct estimate of k2 that can be then input to calculate a k1 value. Here, the R2 
value is an indication of the goodness-of-fit (Figure 3.9) and when the sequential 
method was used a higher estimated BCF when compared to those values 
generated by the simultaneous method (Table 3.4).  
The over-estimation may result from poor estimates of the k2, if deviation 
from linearity is observed indicating higher order kinetics. Whilst, there was 
scatter in the linear regression of the depuration phase overall, it was assumed 
that there were no significant non-linear plots. As a check, plots of 1/[Corganism] 
versus time showed that second order kinetics were not taking place (Figure 
3.10). The k2 estimates from the linear regression showed significantly reduced 
values when compared to the simultaneous k2 estimates for the compounds 
imipramine (~7-fold), formoterol (~3-fold), terbutaline (~2-fold) and diclofenac 
(~1.5-fold). The reduced k2 estimates would likely lead to larger BCF values as 
was most markedly observed with the BCF of imipramine and ranitidine. These 
BCFs differed by approximately 10-fold and 4-fold, respectively. Imipramine in 
particular would be classed as non-bioaccumulative (BCF <2500) when using the 
simultaneous method but bioaccumulative when using the sequential method. 
This further highlights the problems that would be associated with risk 
assessment associated with unreliable BCF estimates.  
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Figure 3.10:Plots of 1/[Cogranism] for elimination phase data.  
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To further understand where the lack-of-fit arose from, the sequential 
method was repeated but a curve fitting algorithm (Levenberg-Marquardt) was 
used to estimate k2 instead of linear regression. This algorithm iteratively adjusts 
parameters (k1 and k2) to minimise the sum of squares of the residuals between 
the independent and dependent variables. Thus, a lack-of-fit test was performed 
on both of the k1 and k2 curves, separately (Table 3.4). The p-values indicated 
that a statistically significant lack-of-fit resulted from the uptake phase data for 
five of the eight compounds (imipramine, ranitidine, terbutaline, diclofenac and 
ibuprofen). The lack-of-fit tests on the depuration data showed only one 
significant p-value for ibuprofen (0.004). This suggested that the simultaneous 
models showed a lack-of-fits shown due to poor fits in the uptake phase, which 
also agreed with the visual observation that curves were under-fitted in several 
cases. Metoprolol showed a zero to mildly increasing slope in the depuration data 
resulting from scatter, thus an estimate of k2 could not be generated. The model 
uncertainties demonstrated, show that BCFs may potentially be limited from a 
regulatory perspective. As shown with imipramine, this compound triggered 
regulatory thresholds in one method of estimation but in a second estimation did 
not, which resulted from the model uncertainties in the uptake data. 
 The poor fit of the uptake curves indicated that the models used were not 
entirely reliable. Therefore, examination of the model assumptions was 
investigated to understand the reason for the lack-of-fit. The model assumes that 
Cw, k1 and k2 do not change over time. The first step was to investigate the k1 
assumption, which was performed as suggested by [38]. The k1 rate constants 
for all eight compounds were estimated over each time interval and plotted in 
Figure 3.11. The plots showed a decreasing trend of the constant over time for 
the compounds diclofenac, imipramine, ranitidine, terbutaline, formoterol and 
187 
 
metoprolol. These decreases coincide with lack-of-fits for diclofenac, imipramine, 
ranitidine and terbutaline. Formoterol had no lack-of-fit in either uptake or 
elimination phase and metoprolol lack-of-fit could not be calculated for the 
sequential estimation. A potential limitation of this method was that the estimation 
of k1 intervals required a k2 value which could cause an apparent change in k1, if 
it was in fact the k2 that changed. In some cases a decrease was not observed in 
the k1, for example the propranolol k1 remained relatively constant throughout the 
exposure time period with a mean value of 0.58±0.23 L kg-1 d-1. Good model fits 
in both the simultaneous and sequential methods for propranolol would suggest 
that a decrease in k1 was the main reason for significant lack-of-fits in the other 
cases.   
As mentioned previously, a changing k2 could also lead to apparent 
changes in k1. However, changes in k2 would most likely manifest as decrease in 
the elimination rate constant over time. This assumption would hold true unless 
the compound induced its own metabolism or there was growth dilution. 
Therefore, a decreasing k2 would result in increasing k1 values. Furthermore, 6 
of the elimination curves showed no statistically significant lack-of-fits and the 
linear regression of the elimination data showed no apparent trends (slope of the 
line). Changes in Cw would unlikely affect the rate constants as they should be 
independent of the pharmaceutical concentration in the water [39]. The 
measurement of pharmaceutical concentrations in the water phases also showed 
no significant losses except in the case of imipramine. Therefore, the lack-of-fits 
in the models are unlikely to be in response to either Cw or k2 and are assumed 
to be the result of the decreases of k1 over the exposure period.  
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Figure 3.11: Relationship of uptake rate constants (k1) over time for eight PPCPs 
(black circles) and the respective concentrations in water (Cw) over time (crosses). 






































































































































































































































































































3.3.6 Meta-analysis of micropollutant toxicokinetics in arthropod species to 
assess uptake rate constants  
It should be taken into consideration that the study here was limited in 
drawing strong conclusions about model reliability as it was a relatively small 
study using one alternative animal model with pharmaceuticals that are relatively 
understudied in comparison to models that have been used for organic micro-
pollutants [10, 12, 35] (e.g. PCBs, PAHs etc.) To identify whether this trend was 
observed with other classes of compounds and invertebrate species a meta-
analysis of two studies from the literature was performed [18, 40]. Ashauer et al., 
[18] presented work on the accumulation of 14 organic micro-pollutants in G. 
pulex which showed variable BAFs ranging from 2 - 4466. The authors found that 
certain compounds showed a similar lack-of-fit. The raw data from this study was 
re-analysed using the modelling methods used here to identify any similar trends 
in k1. The original study used bioaccumulation testing but showed that it 
accounted for a low proportion of the uptake. Therefore, it was assumed here in 
the re-analysis that uptake was via bioconcentration only. Similar to the finding 
presented in Table 3.4, models showed statistically significant lack-of-fits for 
several compounds in both simultaneous and sequential methods (Table 3.5). 
However, the sequential method again showed better model fits in the depuration 
data than in the uptake data again indicating that lack-of-fits were arising from 
the uptake phase. Although the models did not perform particularly well in several 
cases there was good agreement between the BAFs generated by Ashauer et 
al., [18] and the BCFs generated here. Interval values for k1 were plotted against 
time for the 14 micro-pollutants to identify if the k1 values were decreasing over 
time (Figure 3.12).  
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Compound   Simultaneous BCF Sequential BCF 
  BAFa 
k1 
(L kg-1 d-1) SE 
k2 
(d-1) SE p-value BCF 
k1 
(L kg-1 d-1) SE p-value 
k2 
(d-1) SE p-value BCF 
4-nitrobenzyl chloride 185 666 665.740 4.540 4.540 0.000 147 259 28.324 0.00 1.212 0.149 0.230 214 
2, 4-dichloroaniline 56 140 20.073 2.830 0.465 0.000 50 70 4.689 0.03 0.392 0.092 0.868 179 
2, 4-dichlorophenol 4466 600 34.196 0.066 0.024 0.000 9050 750 48.646 0.00 0.010 0.018 0.400 72728 
4, 6-dinitro-o-cresol 37 39 2.610 1.146 0.124 0.070 34 37 1.595 1.00 0.729 0.077 0.033 51 
1, 2, 3-trichlorobenzene 191 1142 403.773 10.648 3.781 0.513 107 167 32.257 0.06 0.475 0.300 0.986 351 
2, 4, 5-trichlorophenol 2635 941 79.280 0.252 0.064 0.001 3729 1091 109.906 0.21 0.131 0.039 0.001 8327 
aldicarb 2 16 1.421 10.419 0.938 0.000 2 3 0.245 0.00 0.936 0.140 0.003 3 
carbofuran 65 10 0.355 0.146 0.019 0.026 68 10 0.570 0.11 0.140 0.019 0.025 72 
diazinon 82 276 24.271 3.569 0.3264 0.005 77 161 10.418 0.00 1.590 0.287 0.259 101 
ethylacrylate 87 110 12.139 1.594 0.2446 0.000 69 67 5.122 0.00 0.204 0.033 0.000 331 
hexachlorbenzene 2915 553 36.8714 0.221 0.046 0.000 2505 631 56.518 0.00 0.152 0.031 0.637 4160 
imidacloprid 7 2 0.093 0.265 0.038 0.000 7 2 0.117 0.02 0.175 0.022 0.000 13 
malathion 114 86 6.782 0.721 0.113 0.000 120 80 5.059 0.02 0.378 0.072 0.001 212 
sea nine 1732 755 57.821 0.303 0.065 0.000 2491 950 69.141 0.05 0.123 0.020 0.084 7696 
Table 3.5: Toxicokinetic parameters and standard errors (SE) for 14 organic micropollutants with bioconcentrations factors and lack-of-fit tests for each compound. 
aReported from Ashauer et al., 2010 
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Figure 3.12: Measurement of k1 over time for 14 organic micro-pollutants. * indicates significant 
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Chaoborus obscuripesAnax imperator 
Figure 3.13: Measurement of k1 over time for 15 different arthropod species exposed to 
chlorpyrifos. Raw data analysed from [39]. 
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A systematic decrease of k1 over the uptake phase was apparent for 9 of 
14 compounds. The remaining 5 compounds showed less evident decreases in 
k1, and four of these compounds showed no statistically significant lack-of-fit (p 
>0.05). The compound 2,4-dichlorophenol showed no k1 trends as reasoning for 
the observed lack-of-fit in the uptake phase. In addition to the analysis of different 
micro-pollutants, a meta-analysis of raw data from Rubach et al., [40] was also 
performed. This previous study focused on the uptake of chlorpyrifos in 15 
different invertebrate species. When k1 versus time was plotted (Figure 3.13) 
similar decreases in the k1 value were observed. However, the trend was not as 
apparent as with previous examples and varied between the different species 
(Figure 3.11 & 3.12). This data would suggest that differences between the k1 
constancy may also result from specific species traits. However, trends in k1 could 
also be compound specific, thus analysis of more compounds between species 
would be required to draw further conclusions. For example, if the k1 constancy 
was solely dependent on a biological factor then all compounds would show a 
decrease in k1. Thus, as this is only seen in certain compounds it could be related 
to physico-chemical properties or mode-of-actions of a compound. 
If k1 constancy did vary on a compound basis then toxicokinetic modelling 
is inherently inaccurate for environmental risk assessment. Therefore, the 
method used here [38] could be employed to assess the reliability of generated 
BCF values. The reasoning behind decreasing trends of k1 over exposure time 
period could be explained by several mechanisms. The first of which is that a 
growth dilution effect may occur where the mass of the animals increases to give 
an increase in the elimination rate. This could cause an apparent decrease of k1 
in the uptake phase. However, the time scale used in these experiments [18, 40] 
were in the order of 4-6 days, thus growth would be assumed to be negligible but 
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further investigation would be required to show this. G. pulex has also been 
shown to alter respiration rates when fed on a poor diet [41]. As the animals were 
not fed here it is plausible that this may have affected uptake rates. However, the 
experiments by Ashauer et al., [18] were bioaccumulation experiments and so 
the animals were fed over the exposure period. Another possibility is that a 
toxicodynamic effect was occurring as a result of exposure of the compounds in 
non-target organisms. The work by Ashauer et al., [18] exposed organisms 
between 2-88 fold below the 24 h LC50 value which could be considered relatively 
high in some cases leading to toxic effects. In the pharmaceutical exposures 
presented here, the compounds were exposed ~1000 fold below LC50 toxicity 
values and thus toxic effects related to mortality were less likely [22]. Another 
consideration is that instantaneous sorption to the animals cuticle may have led 
to initially high k1 values at the early time intervals. The relative percentage 
decrease of k1 versus logP and logD is shown in Figure 3.14.  
 
 
The plots showed no correlation between k1 decrease and hydrophobicity. 





















































Figure.3.14: Relative decrease of k1 against logP/D at respective exposure pH for 
pharmaceuticals (this study) and organic micropollutants (Ashauer et al., 2010). LogP/D 
estimated by ACD Labs Percepta. 
195 
 
such as ionic states and polar topological surface area may have influence. 
Although it was not a part of the experimental design, animals that shed their 
exoskeleton during the pharmaceutical exposures were collected and analysed 
to determine the amount of compound bound to the cuticle. Table 3.6 shows the 
mass of pharmaceuticals that was determined from the exoskeleton and revealed 
that up to 24 % of the total compound mass determined from the animals was 
bound to the cuticle. However, it should be noted that the surface area of a shed 
exoskeleton is increased in comparison to a cuticle that is still attached to the 
animal. Thus, the relative mass of compound may be reduced. Furthermore, the 
data is limited and would need to be extended to more replicates and compounds 
to identify if this is the reason for a decreasing k1 value. If the sorption does indeed 
explain the decrease of k1 constants then it would suggest that physico-chemical 
properties rather than animal physiology determined the rate constant stability. 
Thus, k1 constancy would vary on a compound by compound basis which is 




Preliminary data suggested that uptake of pharmaceuticals is likely to 
occur by both passive diffusion and carrier mediated transport. The data 
presented here shows that BCFs for the pharmaceuticals selected, showed a low 
Compound 
Mean Compound 
Mass per Animal 






  (n=3, pg) (pg) (%) 
Propranolol  336 44 (n=1) 13 
Diclofenac 2070 368 (n=4) 18 
Imipramine 1921 50 (n=2) 3 
Ranitidine 238 58 (n=1) 24 
Metoprolol 74 14 (n=2) 19 
    
Table 3.6: Sorption of pharmaceuticals to G. pulex exoskeleton 
196 
 
potential for accumulation. However, analysis of the model fits showed 
statistically significant lack-of-fits for several models that stemmed from the 
uptake phase data. When uptake data was analysed to determine k1 values over 
specific time intervals, a decreasing trend was observed that explained the lack-
of-fits in the uptake data. To determine if this was seen in previous studies using 
different compounds and invertebrates, a meta-analysis of the raw data was 
performed which revealed the same decreasing trends of the k1 constants over 
time. The implications of these results are important as environmental risk 
assessment through BCF or BAF studies may potentially be somewhat 
inaccurate and lead to unexpected adverse effects in the aquatic environment. 
The mechanisms behind decreasing k1 constants can be explained, in part, by 
the sorption of compounds to the cuticle of the animal suggesting that model 
reliability is determined on a compound specific basis. However, further 
investigation into the effect of sorption-desorption phenomena would be required 
to fully understand the effect. Furthermore, the role of metabolism on these 
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Chapter 4. The uptake, metabolism and elimination of selected 
pharmaceuticals in G. pulex using targeted LC-MS/MS.  
 
4.1 Introduction 
Extensive research into organic micropollutants has enabled the 
elucidation of the mechanisms for the uptake and accumulation of several 
environmental contaminants [1-3]. Due to the hydrophobic nature of these types 
of micropollutants, uptake was considered to be by passive diffusion across 
cellular membranes. Therefore, models for the uptake of organic micropollutants 
used physico-chemical properties such as logP to describe and predict the 
concentration of these compounds in biota [4-6]. However, pharmaceuticals are 
somewhat different in that they are often ionisable and amphoteric molecules. 
Thus, uptake models that use hydrophobicity to describe the accumulation of 
compounds in biota may not reliably predict the uptake of these classes of 
compounds.  
Authors have shown that for compounds that remain neutral better 
correlations with hydrophobicity measurements (logP/D) are observed than for 
those compounds present in ionised states [7-9]. Other variables such as ion 
trapping, carrier mediated transport and partitioning to non-lipid components 
(protein binding) could influence the accumulation of pharmaceutical compounds 
[7, 8, 10]. Furthermore, much of the reported work has been performed in 
vertebrate species such as fish. Thus, the bioaccumulation of compounds in 
invertebrate species is not well understood. However, more recently several 
methods for the study of bioaccumulation of pharmaceuticals and other organic 
micropollutant compounds in several invertebrate species (bivalves and 
amphipods) have been developed using LC-MS [11-13].  
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A widely used method for estimating a bioconcentration factor or 
bioaccumulation factor in fish is described by the OECD 305 guidelines which 
has also been applied to invertebrates [14]. The BCF or BAF estimations using 
these guidelines can be determined using steady-state or kinetic measurements. 
The kinetic estimates utilise model equations for non-linear regression of the 
uptake and elimination data that generate the uptake rate constant (k1) and 
elimination rate constant (k2). These two parameters are used to estimate a BCF 
and the models assume that they do not change. However, recent investigation 
described in Chapter 3, showed that the OECD model led to significant lack-of-
fits for measured data [15]. The lack-of-fits potentially resulted from a decreasing 
trend of k1 over time. This finding was significant as model assumptions that do 
not hold true, could lead to under/over estimation of BCFs during risk 
assessment.  
Possible causes for the decreases in k1 could be related to several factors 
such as growth, metabolism and sorption processes. Metabolism in particular, is 
generally not considered in bioconcentration studies as analytical methods 
usually only monitor the total radioactivity of a compound by Liquid Scintillation 
Counting (LSC) [16] or the parent compound itself, if using LC- or GC-MS. 
Biotransformation could have a particularly strong effect on BCF estimates [17-
19]. Xenobiotics can induce or inhibit their own metabolism or the metabolism of 
other compounds that will affect the clearance rate and hence the BCF [20]. For 
example, carbamazepine has been shown to induce the metabolism of clozapine 
[21]. Furthermore, the compounds fluoxetine and its main metabolite 
norfluoxetine have been shown to inhibit CYP450-2D6 activity which is the main 
enzyme that is involved with fluoxetine metabolism [22]. Predictive BCF models 
are either too simplistic (using only logP inputs) or do not accurately include 
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biotransformation rates, as accepted methods to measure metabolic products 
and the kinetics of biotransformation currently do not exist [23]. Several authors 
have applied in vitro intrinsic clearance rates to extrapolate to whole body 
biotransformation rates for predictive BCF modelling [24, 25]. However, these 
extrapolations measure only the loss of parent compound to predict whole body 
biotransformation. Thus, in vitro clearance rates may not reliably reflect whole 
body metabolic rates [26].  
To the authors knowledge the only two studies have measured 
metabolites and their associated toxicokinetics. The authors used LC-HRMS or 
LC with a radioactivity detector to model the uptake and elimination profiles of 
organic micropollutants, fungicides and their metabolites in G. pulex [27, 28]. The 
Ashauer et al., study showed that the measurement of biotransformation 
improved the accuracy of BCF estimates when compared to estimates using total 
radioactivity counts. A further constraint to the study of xenometabolism is that a 
priori knowledge of biotransformation products in aquatic organisms is lacking 
leading to difficulty when developing targeted analytical methods [29]. Current 
methods have focussed on the determination of organic pollutants in fish, with 
little attention given to invertebrates or pharmaceutical biotransformation. 
Therefore, it is essential that methods are developed that can determine 
pharmaceutical metabolites to reliably assess the affect metabolism has on 
bioconcentration models.  
The aim of this work was to further assess the bioconcentration potential 
of pharmaceuticals in G. pulex using targeted LC-MS/MS methods described in 
Chapter 2. BCFs will be estimated using the OECD 305 guidelines and kinetic 
parameters will be checked for constancy over time. Finally, the optimised LC-
MS/MS method will be used for the determination of several Phase I and Phase 
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II biotransformation products of propranolol, carbamazepine and diazepam which 
have not been detected previously.  
 
4.2 Materials & Methods 
4.2.1 Reagents, chemicals and consumables  
HPLC grade methanol, acetonitrile, acetone, ethyl acetate, 
dichloromethane and dimethyldichlorosiloxane were purchased from Fischer 
Scientific (Loughborough, UK). Analytical grade ammonium acetate was sourced 
from Sigma-Aldrich (Dorset, UK). Propranolol hydrochloride, ketoprofen, 
diclofenac sodium salt, bezafibrate, warfarin, flurbiprofen, indomethacin, 
ibuprofen sodium salt, meclofenamic acid sodium salt, gemfibrozil, atenolol, 
sulfamethoxazole, sulfamethazine sodium salt, furosemide, carbamazepine, 
nimesulide, (±)-metoprolol (+)-tartrate salt, triclocarban,  cimetidine, ranitidine, 
antipyrin, temazepam, diazepam, fluoxetine, nifedipine, oxazepam, 
nordiazepam, carbamazepine-10, 11-epoxide, and mefenamic acid were all 
obtained from Sigma-Aldrich (Steinheim, Germany). Trimethoprim, caffeine, and 
naproxen were ordered from Fluka (Buchs, Switzerland). Stable isotope-labelled 
standards including carbamazepine-d10, propranolol-d7, temazepam-d5 and 
diazepam-d5 were ordered from Sigma-Aldrich. Sulfamethazine-d4, nifedipine-d4, 
metoprolol-d7, trimethoprim-d3 and warfarin-d5 were ordered from QMX 
Laboratories (Essex, UK). The propranolol metabolites; 4-hydroxypropranolol, 4-
hydroxypropranolol sulphate and 4-hydroxypropranolol glucuronide were 
sourced from Santa Cruz Biotechnology (Heidelberg, Germany). All 
pharmaceuticals were of a purity of ≥97 %. Analytical grade salts (>99 %) 
including sodium hydrogen carbonate, magnesium sulphate, calcium sulphate, 
potassium chloride were purchased from Sigma. Ultra-pure water was obtained 
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from a Millipore Milli-Q water purification system with a specific resistance of 18.2 
MΩ.cm or greater (Millipore, Bedford, MA, USA).  
 
4.2.2 Sample collection and culture maintenance 
Gammarus pulex were collected by kick-sampling from the River Cray, 
South-East London, UK, 51°23'09.5"N 0°06'32.4"E. This site was previously 
shown to have low pharmaceutical contamination in both collected surface water 
and animal samples (Chapter 2) [30]. The populations were transported to the 
laboratory in 500 mL NalgeneTM flasks filled with surface water from the sample 
collection site. Populations were rinsed with artificial freshwater (AFW) and then 
acclimatised to laboratory conditions (as specified below) for a minimum of 7 days 
before any exposure experiments were performed. AFW was prepared from 1.15 
mM of NaHCO3, 0.50 mM MgSO4, 0.44 mM CaSO4 and 0.05 mM of KCl dissolved 
in 20 L of ultra-pure water. This water was subsequently aerated for several hours 
to remove dissolved carbonic acid and maximise the dissolved oxygen 
concentrations. Each culture tank (n=8) was filled with 2.5 L of AFW and animals 
were fed with either alder or hose chestnut leaves that were previously collected 
from the collection site and conditioned by submersion in surface water for two 
days prior to use.  
 
4.2.3 Toxicokinetic exposure and conditions 
Toxicokinetic experiments were performed separately for each 
pharmaceutical for a total of 96h which included a 48h uptake phase followed by 
a 48h depuration period. Individual adult organisms (n=25), both male and female 
(>5 mg wet weight) were placed in pyrex glass beakers. G. pulex were carefully 
transferred to beakers using blunt forceps to avoid any harm to the organisms 
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before exposure.  Each beaker contained 25 organisms in 200 mL of exposure 
media (AFW and test compound). G. pulex were exposed to individual PPCPs at 
a concentration of 1 µg L-1, except for propranolol and warfarin which were 
exposed at 10 µg L-1. All exposure media contained <0.001 % of solvent 
(methanol). A total of 300 organisms were used per compound exposure and 
were sampled (n=3/time-point) at 6, 24, and 48h in the uptake phase followed by 
a single time point at 96h in the depuration phase. Control beakers were setup 
and sampled at the 96h time interval. These were subsequently analysed for any 
background contamination. The exposure media was replaced daily and water 
samples (n=3) were taken from working solutions and after 24h of exposure to 
ensure concentrations of the compounds remained constant in the AFW. Each 
animal sample was rinsed with ultra-pure water and then frozen at -20 oC.  The 
light cycle followed 12:12h light:dark without a dusk/dawn transition period. All 
experiments were performed in a temperature controlled room at 15 °C (± 2 °C) 
and water pH was also monitored across each experiment and measured at an 
average of 8.19 ± 0.05 pH.  
 
4.2.4 Sample preparation  
Water samples collected from exposure experiments were filtered using 
Whatman filters (0.2 μM) and directly injected onto the LC-MS/MS for analysis. 
G. pulex samples were prepared as specified by in Chapter 2 [30]. Briefly, 50 mg 
of lyophilised G. pulex was ball-mill extracted in 5 mL of acetonitrile and diluted 
with 100 mL of ammonium acetate buffer for loading onto Waters HLB SPE 
cartridges (6 cc, 200 mg sorbent). After loading, samples were eluted using a 
mixture of ethyl acetate:acetone (50:50 v/v) which was subsequently evaporated 
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under nitrogen (99% purity) and reconstituted in starting LC mobile phase (90:10 
v/v, 10 mM ammonium acetate buffer: acetonitrile).  
 
4.2.5 Instrumental analysis 
The determination of pharmaceuticals was previously outlined in Chapter 
2 [30]. Briefly, samples were injected (20 μL) onto a Waters SunFire reversed-
phase C18 column (150 mm x 2.1 mm, 2.5 μM particle size) and followed a 
gradient elution (total 75 min including 12.5 min re-equilibration time) using a 
mixture of acetonitrile and ultra-pure water with 10 mM ammonium acetate. 
Detection was performed using a Waters Quattro triple quadrupole mass 
analyser with an electrospray ionisation source operated in positive and negative 
polarity switching mode. Quantification of analytes was performed using 3-point 
internal standard calibration curves, where the ratio of non-labelled analyte 
area/concentration to a stable isotope labelled internal standard (SIL-IS) 
area/concentration form the graph axes. The exception to this was in the 
temazepam exposure where quantification was performed against a SIL-IS 
calibrant concentration. Compounds (hydroxypropranolol sulphate, 
carbamazepine epoxide, and imipramine) that were not quantified against 
internal standards due to availability issues, were quantified using 3-point 
external matrix matched calibration curves. Imipramine was included in the 
analysis due to the potential bioconcentration shown in Chapter 3. 
 
4.2.6 Modelling bioconcentration factors  
Parameter estimation of uptake rate constant (k1) and depuration rate 
constant (k2) was performed using a curve fitting algorithm via  Minitab statistical 
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software (Minitab Ltd., Coventry UK) and as outlined in the OECD 305 Fish 
Bioconcentration Guidelines [14]. Detailed calculations were previously 
described in Chapter 3 and were used here to estimate the BCF for the minimised 
test designs. 
 
4.3 Results & discussion 
4.3.1 Method performance assessment  
To perform each toxicokinetic experiment with G. pulex, each compound 
exposure would require approximately 750 animals. The requirement for this 
number of animals presents feasibility issues in terms of collecting animals, 
maintaining cultures and exposing organisms. Furthermore, the sheer volume of 
animals needed should require some ethical consideration for future best 
practices in invertebrate testing. Whilst, invertebrates are not a protected animal, 
policies that are aimed to reduce the number of animals in research (such as the 
3Rs) should be extended to the invertebrate species. To reduce the number of 
animals that was required per exposure, the analytical method presented in 
Chapter 2, was adjusted to use a lower mass of lyophilised G. pulex. The mass 
was decreased by half, to 50 mg of lyophilised material. However, the reduction 
of material could affect the performance of the analytical method, mainly through 
sensitivity. To reduce any effects caused by a mass change, the reconstitution 
volume was also scaled down (250 µL) so that the ratio between the matrix 
components and analytes was kept constant. A recovery experiment was 
performed to characterise changes in the method performance that may have 
occurred through use of a lower mass and lower reconstitution volume.  
Table 4.1 shows the comparison between analyte recovery when 100 or 
50 mg of lyophilised material was extracted. Overall, the mean recovery of 
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analytes was greater when using the lower sample mass by an average of 19 % 
with the exception of sulfamethazine, cimetidine, flurbiprofen and nimesulide. 
However, when comparing the RSDs the higher sample mass showed much less 
deviation and therefore had greater precision. All cases showed better precision 
with the exception of caffeine and atenolol that displayed much lower deviation in 















ANOVA of the recovery means and their respective RSDs was performed 
to identify if there was statistical significance between the sample mass 
extraction. The p-value generated for the means was 0.138 and for the RSDs 
was 0.125, which was above the alpha level of 0.05 indicating that there was no 
statistically significant difference between the recovery and precision of the 
analytical method when using a lower sample mass. However, the analytical 
  100 mg 50 mg 
  
Recovery 
(%) SD RSD (%) 
Recovery 
(%) SD RSD (%) 
Atenolol 4 1 22 6 0 5 
Caffeine 8 7 87 19 2 13 
Cimetidine 6 0 6 2 1 42 
Sulfamethazine 41 2 5 37 7 20 
Antipyrin 30 3 9 37 2 4 
Trimethoprim 65 1 2 91 11 13 
Furosemide 39 3 7 73 6 9 
Metoprolol 71 5 7 99 14 15 
Naproxen 44 1 2 66 13 20 
Ketoprofen 41 2 5 69 28 40 
Warfarin 71 3 4 86 4 5 
Bezafibrate 39 4 10 42 6 14 
Flurbiprofen 47 8 18 44 18 42 
Propanolol 52 11 20 59 21 36 
Carbamazepine 69 3 5 95 20 21 
Indometacin 42 8 20 73 22 30 
Temazepam 85 1 1 114 10 9 
Nimesulide 87 4 5 64 5 8 
Nifedipine 70 1 1 88 22 25 
Diazepam 89 2 2 101 11 10 
Gemfibrozil 79 21 27 100 54 54 
Table 4.1: Comparison of method recovery and precision between different mass 
extractions of G. pulex. 50 mg extraction spiked at 200 ng g-1 (n=6). 100 mg extraction 
spiked at 1000 ng g-1 (n=3). 
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method was validated for 10 pharmaceuticals (Table 4.2), thus a second ANOVA 
was performed for these 10 compounds. The p-values were 0.139 and 0.006 for 
the recovery mean and RSDs, respectively. This indicated that whilst the mean 
recoveries were not significantly different, the RSDs were. Comparison of the 
RSDs showed that extraction of a lower sample mass led to decreased precision. 
All 10 analytes had lower precision (mean difference of 12 ± 7 %) when compared 
to the extraction with 100 mg of G. pulex.  
 










Sulfamethazine 41 5 37 20 
Trimethoprim 65 2 91 13 
Metoprolol 71 7 99 15 
Warfarin 71 4 86 5 
Propanolol 52 20 59 36 
Carbamazepine 69 5 95 21 
Temazepam 85 1 114 9 
Nimesulide 87 5 64 8 
Nifedipine 70 1 88 25 
Diazepam 89 2 101 10 
 
The lower precision could be due to two variables, the first of which was 
that the reconstitution volume was lower and therefore using smaller volumes led 
to lower precision due to less reliable volume measurement (i.e. pipetting errors). 
Secondly, whilst the ratio of matrix to analyte was kept constant, due to solid 
sample inhomogeneity there was the potential that inter-sample matrix varied 
more significantly than when compared to the use of a larger mass of G. pulex 
material.  The variation in matrix between samples could lead to larger variation 
in extractions when using SPE cartridges and also greater variability in ionisation 
efficiency during MS analysis.  
Table 4.2: Comparison of method recovery and precision 
for method validated compounds.  
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The quantification of matrix effects is presented in Table 4.3. Suppression 
was enhanced for 9 of the 10 compounds when compared to extraction of a larger 
mass. The average suppression effect was -51 ± 12 % for the 50 mg extraction 
whereas the suppression effect for the 100 mg extraction was -26 ± 3 %. The 
matrix effects were also more variable with the lower mass extraction. All 
compounds had higher variance with the exception of trimethoprim. ANOVA of 
the matrix effect and variance showed that the difference between the 100 mg 










A previous investigation into the effect soil sample mass on the precision 
of an analytical method for four heavy metals showed that between 1-5 g had no 
effect on the precision of three metals. However, the last heavy metal (lead) 
showed that the poorest RSDs were observed with the lowest mass of soil used 
in the method [31].  Whilst this method involved the analysis of heavy metals by 
flame atomic absorption spectroscopy (FAAS) which is different to the samples, 
analytes and instruments used here, it demonstrates the possibility that specific 
analytes can be affected by sample mass.   
  50 mg 100 mg 
 Matrix  Matrix  
Compound  Effect (%)  SD  Effect (%)  SD 
Sulfamethazine -26 8 -11 2 
Trimethoprim  -60 5 -13 6 
Metoprolol  -32 14 -11 2 
Propranolol -74 13 -56 4 
Carbamazepine  -63 16 -9 2 
Warfarin -23 19 -28 4 
Nimesulide -67 9 -35 3 
Temazepam -38 9 -11 3 
Diazepam -73 6 -43 3 
Nifedipine -53 18 -39 4 
Table 4.3: Comparison of matrix effects between different 
mass extractions of G. pulex. 50 mg extraction spiked at 200 
ng g-1 (n=6). 100 mg extraction spiked at 1000 ng g-1 (n=3). 
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Whilst there was a statistical significance between the precision of the 
methods used, the lower mass still resulted in an acceptable method precision of 
≤ 20 % RSD for 6 of the 10 compounds. The two compounds nifedipine and 
carbamazepine had RSDs of 25 % and 21 %, respectively. The final compound 
propranolol had an observed RSD of 36 %. This compound in the original method 
was also observed to have the lowest precision of the ten pharmaceuticals. The 
lower precision is likely to result, in addition to the variables mentioned above, 
from the variation in retention time reported in Chapter 2. The tR will affect 
precision as the co-elution of matrix components will lead to greater variation in 
the MS signal response either through effects in droplet formation, transfer to gas 
phase ions or analyte charging [32]. Finally, whilst the precision may be lower for 
these compounds the recoveries and RSDs were determined without the addition 
of a stable isotope labelled internal standard (SIL-IS). The use of SIL-IS improved 
method precision for all compounds with RSDs ranging from 1 – 11 %. The 
compounds carbamazepine, nifedipine and propranolol showed significant 
improvement with RSDs of 2 %, 3 % and 11 %, respectively. It has been 
demonstrated that SIL-IS have improved precision during analytical method 











4.3.2 Experimental design: reduction of time intervals 
In addition to the reduction in the number of organisms, a reduction in the 
number of sampling time intervals was also required to ensure that these 
experiments remained feasible. Time points were selected at 6, 24, 48 and 96h 
so that the uptake phase had three time points and elimination phase contained 
two intervals. The additional time point in the uptake phase was selected so that 
any trends in k1 could be identified. As discussed in the previous chapter, the 
lack-of-fits in the toxicokinetic modelling stemmed from the uptake phase data 
that was caused due to a decreasing trend of the k1 rate constant. Whereas, the 
elimination data showed no obvious trends in relation to the lack-of-fits. The 
potential limitation when using a small number of time intervals is that the data 
may not reflect reliably the ability of a compound to concentrate as modelling is 
limited to a few data points. However, the OECD 305 guidelines contain a 
minimised test with just two time intervals in the uptake and elimination phase, 
respectively (e.g. day 14, 28, 35 & 42).  This minimised test was proposed to 
reduce the number of animals used and reduce the cost of running a full study.  
The minimised study design was evaluated in the literature and authors 
concluded that the test was valuable and offered reliable BCF estimation for 
regulatory purposes [34]. A second publication proposed that a minimised test 
design involving only two sampling time intervals in a 14d depuration period [35]. 
The authors of this work evaluated the previous published BCF studies and found 
that the use of this minimised test design was viable alternative to a full study 
design. Whilst support is for the use of minimised design, as our experiments 
here involved a non-standard species and much shorter uptake and depuration 
phases, re-evaluation of the uptake and elimination data from Chapter 3 was 
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performed to confirm whether a minimised test design here could also adequately 
estimate BCF values (Table 4.4).   
A comparison was made between the BCFs generated by the full test 
design and a minimised test for both simultaneous and sequential methods of 
estimation. To determine if BCFs differed significantly an ANOVA was performed 
for each method of estimation and resulted in p-values of 0.95 for simultaneous 
BCFs, 0.43 for sequential BCFs and 0.45 for sequential BCFs determined using 
linear regression in the elimination phase data. These three p-values were >0.05 
indicating that there were no statistically significant differences between the BCFs 
estimated using the full study design or the minimised design. Therefore, all non-
radiolabelled exposures were performed using the minimised design.   
 
 
4.3.3 Exposure of G. pulex to non-radiolabelled pharmaceuticals  
Non-radiolabelled toxicokinetic exposures were performed for a total of 11 
compounds, the ten compounds previously validated plus the compound 
imipramine as this compound displayed increased bioconcentration relative to 
several other pharmaceuticals tested by LSC (Chapter 3). Quantifications of 
exposures were initially performed against a single SIL-IS calibrant fortified in 
each sample at 100 ng g-1 dw pre-extraction. The ratio between the non-labelled 
 Full Design Minimised Design 
  SimBCF SeqBCF SeqBCF SimBCF SeqBCF SeqBCF 
Propranolol 32 39 42 36 34 34 
Formoterol 14 18 33 26 26 29 
Imipramine 212 3811 4533 177 420 685 
Metoprolol 16 - 20 - 
Terbutaline 12 22 19 12 16 15 
Ranitidine 17 81 112 30 - 9 
Diclofenac 14 27 21 19 23 22 
Ibuprofen 27 27 50 40 29 - 
Table 4.4: BCF estimation using a full study design and a minimised design using 4 
time intervals (5, 24, 48 and 96h). SimBCF = simultaneous method, SeqBCF = 
sequential BCF as described in Chapter 3. 
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standard and SIL-IS was used to quantify the amount of each pharmaceutical 
accumulated during the exposure period. Initial exposures were performed for 
carbamazepine, diazepam, temazepam and trimethoprim.  
The toxicokinetic profiles for carbamazepine, diazepam and temazepam 
showed low level concentration of pharmaceuticals in the uptake phase reaching 
a maximum of 64 ng g-1 dw for the compound diazepam. The profiles showed 
that carbamazepine, diazepam and temazepam had reached or were very close 
to approaching apparent steady-state where the rate of uptake is equal to the rate 
of elimination and the system was in equilibrium. The short steady-state times 
indicated that these pharmaceuticals had a rapid turnover and were unlikely to 
accumulate significantly in these animals. Indeed, by the end of the 48h 
elimination phase, pharmaceutical response signals reached below the LOQ or 
LOD. Thus, supporting very rapid elimination of these pharmaceuticals.  Figure 
4.1 shows the concentration-time plots for these three pharmaceuticals modelled 
using the simultaneous method for BCF estimation. The BCFs were calculated 
as 21, 37 and 40 for carbamazepine, temazepam and diazepam. When 
considering factors that influence bioaccumulation, logP has been suggested to 
be a major factor when the value is <6 [36]. It would be expected that diazepam 
would have the highest BCF of these three pharmaceuticals as it has the greatest 
measure of hydrophobicity with a logP of 2.8 [37], in comparison to 
carbamazepine (2.45) and temazepam (2.2) [38, 39]. Therefore, it may be 
assumed that the BCFs should follow the order of diazepam > carbamazepine > 
temazepm. However, logP measurements can be considerably variable as 
reported in the literature. For example carbamazepine has reported logP values 
from 1.51 to 2.67 in which the lowest value may suggest that this compound 























Further consideration of logP would also suggest there should be a 
significant difference between the BCFs of temazepam and diazepam as the 
difference in their logP values is considerable. Thus, suggesting logP as a sole 
predictor of bioconcentration may not be reliable.  
 
Figure 4.1: Toxicokinetic profiles of carbamazepine (top), 
diazepam (middle) and temazepam (bottom) in G. pulex 




The last compound exposed using a single calibrant was trimethoprim. 
However, the quantification of this exposure was inconsistent as the scatter of 
internal concentrations was significant as shown in Figure 4.2. The 
concentrations in the uptake phase of the trimethoprim exposure ranged from 54-
2635 ng g-1 dw and in the elimination phase ranged 63-470 ng g-1 dw. These high 
values could have potentially been caused by residual contamination from the 
environment where they were collected. However, concentrations in the µg g-1 
range have not been previously reported and it is unlikely that these represented 
true measurements of uptake. A potential problem may have been the use of a 
single SIL-IS calibrant for quantification. Therefore, future toxicokinetic 
experiments were performed using a 3-point SIL-IS matrix matched calibration 
curve.  
Using internal standard matrix matched calibration curves resulted in good 
linearity with R2 ranged between 0.9897 – 1.000. This method was much superior 
for quantification than when compared to matrix matched calibration curves 
without the addition of SIL-ISs which had R2 ranged from 0.8866 – 0.9972 (Figure 
4.3). The compound imipramine had poor linearity (<0.95 R2) and method 


























Figure 4.2: Toxicokinetic profile of trimethoprim in G. pulex exposed at 1 μg L-1. 
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from analysis. The trimethoprim exposure was repeated and gave improved 
results which showed much less variability and scatter in the data points. The 
maximum uptake concentration reached 22 ng g-1 dw and by the end of the 
elimination phase concentration reduced to below the LOD of 2 ng g-1. Warfarin 
was exposed to animals at a concentration of 1 µg L-1. However at this 
concentration no peaks were detected in any sample and the calibration curve 
gave a much lower response than was expected at the concentrations used (100 
– 300 ng g-1 dw) when considering that the reported LOQ for this compound was 






The exposure with warfarin was repeated at 10 µg L-1 and here peaks were 
detected but again the signal response for the analyte was approximately 10-fold 
lower than expected. A toxicokinetic exposure was also performed with 
nimesulide at 1 µg L-1 and similar to the initial warfarin exposure no peaks were 
detected in any sample that was analysed. The calibration series that was 
prepared was also not detected, even at the highest concentration of 200 ng g-1 
dw. It was determined that the negative mode ESI on the mass analyser had a 
Figure 4.3: Comparison of matrix matched calibration curves with and without the addition of 
SIL-IS.  
Warfarin Warfarin - IS 
Metoprolol - IS 
Nifedipine - IS 
Propranolol - IS 
Trimethoprim - IS 
Carbamazepine - IS 
Sulfamethazine - IS 










severe loss of sensitivity. The nimesulide exposure was not replicated with a 
higher concentration because of the loss in sensitivity. Furthermore, water 
concentrations of nimesulide were only detectable at concentrations of 40 µg L-1 
which were far above reported environmental levels of < 12 ng L-1 [42, 43]. 
Therefore, concentrations of this magnitude had lost environmental relevance in 
the exposure of this organism. The modelled toxicokinetic profiles for the 
remaining compounds are shown in Figure 4.4. The respective concentration of 
each pharmaceutical in the exposures is shown in Table 4.5. Water 
concentrations of the pharmaceuticals remained stable across the exposure 
period for carbamazepine, diazepam, temazepam, sulfamethazine, metoprolol 
and trimethoprim. Propranolol showed stable water concentrations over the first 
24h however this declined by 28 % to an average of 6.41 µg L-1. Nifedipine 
showed an average decrease of 39 % across both days of the uptake phase. It 
is possible that sorption was the cause in the reduction of nifedipine in the 
exposure media. However, an experiment was setup to monitor for sorption and 
it was found that nifedipine did not sorb to the glass beakers. Furthermore, no 
losses could be attributed to other processes such as volatilisation or 
degradation. This suggested the observed reduction of nifedipine in the water 
phase was attributed to the uptake by G. pulex. The final compound warfarin was 
unable to be quantified due to sensitivity issues with the MS whilst operated in 
the negative polarity mode. Maximal uptake concentrations in the animals were 
observed for the compound propranolol where this compound was exposed at a 
higher concentration of 10 µg L-1 due to a relatively high LOQ value. In this 
exposure, internal concentrations reached up to 519 ng g-1 with a mean value of 
210 ng g-1 at the end of the uptake period. Warfarin also showed relatively higher 
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Figure 4.4: Toxicokinetic profiles of selected pharmaceuticals in G. pulex 
measured using LC-MS/MS. Solid line represents model fit, dashed 
lines represent 95 % confidence interval. (a) carbamazepine, (b) 
diazepam, (c) metoprolol, (d) nifedipine, (e) propranolol, (f) trimethoprim, 

































The data for this compound suggested that in contrast to other compounds 
this did not reach/approach steady state in the uptake period as no plateau was 
observed in the toxicokinetic profile. The remaining pharmaceuticals 
carbamazepine, diazepam, metoprolol, nifedipine, trimethoprim and temazepam 
exposed at 1 µg L-1 showed internal concentrations of ≤51 ng g-1 during the 
uptake phase. These internal concentrations showed rapid elimination and were 
reduced to ≤LOQ/LOD.  The rapid turnover of all the pharmaceuticals suggests 
that bioaccumulation could be less relevant for these types of ionisable 
compounds.  
 
 Concentration (μg L
-1) 
Compound D1  SD 24 h SD D2 48 h  SD 
Carbamazepine 1.12 0.03 1.01 0.05 1.08 1.07 0.02 
Diazepam 1.02 0.03 0.86 0.05 1.04 0.89 0.11 
Temazepam  0.96 0.03 0.85 0.03 1.17 1.03 0.00 
Nifedipine 0.94 0.09 0.59 0.06 0.82 0.49 0.18 
Sulfamethazine  1.06 0.07 0.99 0.17 0.89 0.71 0.15 
Trimethoprim 1.09 0.04 1.01 0.11 0.99 0.97 0.04 
Metoprolol 0.77 0.18 0.72 0.15 0.86 0.87 0.21 
Propranolol 9.22 0.50 8.92 0.29 8.98 6.41 - 
 
BCFs were generated using either simultaneous or sequential modelling 
as described previously in Chapter 3 (Table 4.6). The BCFs generated were in 
the order of trimethoprim and nifedipine < metoprolol < warfarin < carbamazepine 
< propranolol < temazepam < diazepam. The highest BCF generated by the 
simultaneous method was 41 for diazepam and the lowest estimation was 16 for 
both trimethoprim and nifedipine. These values remain significantly lower than 
any regulatory threshold to be considered bioaccumulative or very 
bioaccumulative [44]. The BCF values for propranolol and metoprolol were also 
compared with the BCFs generated by LSC in Chapter 3.  
Table 4.5: Water concentrations of pharmaceutical exposures. D1 and D2 represent initial 
pharmaceutical concentrations on day 1 and day 2, respectively. 24 h and 48 h represent the 
concentration after 24 h of exposure with either D1 or D2 solutions. All samples were taken in 









Compound Simultaneous  Sequential Sequential 
  k1 SE k2 SE 
p-
value BCF k1 SE k2 SE 
p-
value BCF k1 SE k2 r2 
p-
value BCF 
Carbamazepine 0.5307 0.115 0.0214 0.008 0.049 25 0.4418 0.054 0.014 0.007 0.07 32 0.4643 0.056 0.0158 0.534 0.08 29 
Diazepam 9.5942 2.126 0.2349 0.058 0.028 41 2.6469 0.265 0.046 0.011 0 58 3.0917 0.280 0.0582 0.953 0.001 53 
Temazepam  4.3326 0.556 0.1186 0.018 0.131 37 2.8514 0.116 0.0702 0.027 0.022 41 2.751 0.117 0.0669 0.9965 0.016 41 
Trimethoprim 2.325 0.916 0.1488 0.066 0.376 16 0.8451 0.105 0.0402 0.017 0.066 21 0.837 0.105 0.0396 0.8468 0.064 21 
Nifedipine 4677.31 n/a 295.66 n/a n/a 16 0.7802 0.146 0.0248 0.001 0 31 0.7802 0.146 0.0248 0.9967 0 31 
Warfarin* 0.2242 0.022 0.0119 0.003 0.043 19 0.2091 0.012 0.0096 0.003 0.066 22 0.2118 0.012 0.01 0.6989 0.072 21 
Metoprolol 0.4413 0.135 0.0259 0.015 0.005 17 0.2788 0.046 0.0071 0.006 0.005 39 0.2855 0.047 0.0078 0.39 0.006 37 
Propranolol* 6.596 5.797 0.2348 0.221 0.027 28 0.8059 0.181 0.0111 0.002 0.006 73 0.8116 0.182 0.0113 0.8543 0.006 72 
SE = standard error 
* 10 μg L-1 exposure 
Table 4.6: Determination of BCFs using either simultaneous or sequential parametrisation of k1 and k2.  
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Propranolol BCF was estimated to be 32 and metoprolol BCF was 16 
(Chapter 3), which showed very good agreement with the values of 28 and 17 
determined by LC-MS/MS here. The compound sulfamethazine was not detected 
in any sample and indicated that there was no accumulation of this compound in 
G. pulex. Sulfamethazine and metoprolol are relatively polar pharmaceuticals and 
it may be expected that these two compounds would not bioconcentrate. 
However, the compound nifedipine which is much more hydrophobic also shows 
a very low BCF. This further suggested that logP is not a reliable indicator for the 
bioconcentration of pharmaceuticals and the degree of ionisation may also play 
an important role in uptake and bioconcentration. Table 4.7 shows the logP, logD 










(n=4) SD LogP LogD 
Predominant 
Form 
Carbamazepine 8.09 0.03 2.28 2.3 Neutral 
Diazepam 8.09 0.03 2.74 2.7 Neutral 
Temazepam  8.50 0.12 2.12 2.1 Neutral 
Trimethoprim 8.50 0.12 1.12 1.1 Neutral 
Nimesulide 8.05 0.15 2.7 0.9 Anionic 
Nifedipine 8.05 0.15 3.45 3.4 Neutral 
Sulfamethazine  7.93 0.02 0.44 0.1 Neutral/Anionic* 
Warfarin 8.20 0.08 3.11 -0.2 Anionic 
Metoprolol 8.20 0.08 1.85 0.5 Cationic 
Propranolol 8.27 0.11 3.26 2 Cationic 
Table 4.7: pH measurement of toxicokinetic experiments and the respective 
logP/D and ionisation states of each pharmaceutical.   
*approximately 1:1 of each state  
LogP/D estimated using ACD Labs 
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At the exposure media pH the pharmaceuticals carbamazepine, 
diazepam, temazepam, trimethoprim and nifedipine would have been in a 
predominantly neutral form. Nifedipine displayed the highest logP of 3.45 but had 
the same BCF estimated as trimethoprim a much more polar pharmaceutical with 
a logP value of 1.12. As mentioned previously, temazpam diazepam and 
carbamazepine all remain neutral however their respective BCFs do not follow 
any specific order when compared to their logP. Uptake models are usually based 
on neutral organic microcontaminants and is the reason that logP can be a good 
indicator of bioconcentration for these compounds when logP is <6. Therefore, 
neutral pharmaceuticals should be expected to show similar behaviour which is 
not observed in these experiments. However, the selection of pharmaceuticals is 
limited in size and therefore discernible trends may not be apparent. A plot of 
logD/P versus BCF showed that there were no identifiable trends (Figure 4.5) and 
supports that logP or logD measurements may not be reliable for risk 
assessments of pharmaceuticals.  
 
Consideration of the complexity of biological systems and the unique 
characteristics of pharmaceuticals it may be expected that uptake and 



































Figure 4.5: Comparison of log[BCF] and logP/D of the pharmaceuticals 
selected in the toxicokinetic experiments.   
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simple physicochemical properties. Many factors have been proposed and 
reported to influence the bioconcentration of pharmaceuticals including 
hydrophobicity, metabolism, bioavailability, environmental exposure scenarios, 
and carrier mediated uptake [45]. A particularly important factor is the 
environmental exposure as the complexity of environmental matrices on BCF 
may well increase or decrease predicted BCFs or BCF measured from in vivo 
laboratory exposures. Surface water temperature, pH, sediment layer and the 
composition of other components (pharmaceuticals, colloids, surfactants, organic 
chemicals etc.) can have an effect on the BCF [46].  
Field-derived BAFs could be estimated for four compounds from the 
occurrence data presented in Chapter 2. These values were 4500, 1400, 556 and 
19 for diazepam, warfarin, trimethoprim and carbamazepine, respectively. The 
only value that was in agreement with the BCFs estimated through the in vivo 
exposures was carbamazepine. The remaining three compounds showed field-
derived BAFs that were significantly higher. Therefore, laboratory exposures my 
not present a reliable assessment for the accumulation potential of a compound 
in a ‘real’ exposure scenario. However, the main limitation of field derived BAFs 
is that surface water concentrations are subject to considerable temporal 
fluctuation and therefore it is difficult to understand what an individual has been 
exposed to over time leading to uncertainties in BAF measurement [47]. 
Comparison of the BCFs here with literature reported data showed good 
agreement for the two compounds carbamazepine and diazepam in G. pulex [11]. 
A second study also showed a BCF of 51 for diazepam in a marine mussel, 
Mytilus galloprovincialis [48]. In Daphnia magna, the BCF of propranolol varied 
from 18-83 which varied with exposure concentration [49]. However, few data or 
studies exist on the uptake of pharmaceuticals in invertebrates. Review of fish 
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data generally showed low level bioconcentration. For example, diazepam BCF 
in fish ranged from 2 - 146 depending on the tissue type [50], sulfamethazine 
BCF in sturgeons was shown to be 1 [51], carbamazepine BCF in two species of 
fish was < 7 depending on tissue [50] and propranolol was also estimated to have 
a BCF of < 1 [52]. These data further indicate that pharmaceuticals have a low 
potential of bioconcentration in biota and are in agreement with the values 
generated here for G. pulex.   
The low accumulation of pharmaceuticals may be expected by relatively 
low hydrophobicity values. However, pharmaceuticals are innately designed to 
be metabolised and excreted from the body so that any adverse effects of drug 
accumulation are not experienced with the use of human and veterinary 
medicines [53]. Whilst, these organisms tested are not the target species, 
conservation of cytochrome enzymes among biota has widely been observed 
suggesting the ability of invertebrates to readily metabolise pharmaceuticals [54]. 
Therefore, accumulation of pharmaceuticals may not be as important as the 
determination of adverse effects such as sub-lethal endpoints for environmental 
risk assessment purposes.  
 
4.3.4 Model fits and the estimation of uptake rate constants  
As described previously in Chapter 3, the model fits of simultaneous and 
sequential BCF estimation showed a significant lack-of-fit for several 
pharmaceuticals. The lack-of-fit seemed to arise from the uptake phase data and 
therefore the rate constant was estimated over each time interval during the 
uptake period. This revealed that there was a decreasing trend in the k1 rate 
constant which again violated one of the models assumptions. Lack-of-fits were 
observed from the simultaneous method of estimation for 5 compounds 
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(carbamazepine, propranolol, metoprolol, warfarin and diazepam) with 2 
compounds showing no significant lack-of-fits (temazepam and trimethoprim). 
However, the p-value for carbamazepine and warfarin were 0.049 and 0.043 
which indicated that the statistical significance was not as severe. Lack-of-fit for 
the final compound nifedipine was not possible to estimate due to the fit of the 
line as shown in Figure 4.4. The reason for this unusual fit is due to the large 
estimates of k1 and k2, which resulted from apparent steady state being reached 
≤ 6 h. The sequential determination for BCF was performed to identify if better 
model fits were observed. As the elimination phase data contains only two time 
intervals, a lack-of-fit was not possible to calculate. Therefore, lack-of-fits were 
determined for the whole model. Using the sequential method led to the 
compounds warfarin and carbamazepine no longer having significant lack-of-fits 
(p-values > 0.05). However, temazepam showed a lack-of-fit in comparison to the 
simultaneous method. The BCFs generated by the sequential method showed 
higher estimates for all compounds studied. When linear regression was used to 
estimate k2, the sequential estimation of k1 showed very good agreement with the 
sequential curve fitting methods. The agreement resulted from only two time 
intervals in the elimination phase data which led to very similar estimates of k2 as 
shown in Table 4.5.  
As several significant lack-of-fits were observed, the k1 rate constant was 
calculated over the time intervals for the uptake phase data (Figure 4.6). Similar 
to previous trends seen, k1 was observed to decrease over time. These 
decreases again are potentially the cause of the lack-of-fits, as suggested in 
Chapter 3. However, in the cases of warfarin, carbamazepine, diazepam and 
temazepam an apparent plateau has been reached indicating that the k1 is no 
longer decreasing with time. If k1 has reached a constant value then it would be 
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possible to use this value to estimate a BCF using elimination phase k2 value. 
For example, the average of the k1 over the 48h time interval for these 
compounds resulted in BCFs of 20, 26, 40 and 48 for warfarin, carbamazepine, 




These values showed good agreement between the BCFs generated by 
the simultaneous method indicating this could provide an alternative method for 
BCF estimation when k1 values are found to decrease over time. The initial 
decrease in k1 between the 6 and 24h time points also showed a larger decrease 
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Figure 4.6: plots of k1 over time for eight pharmaceuticals.   
233 
 
point could be a result of sorption of the compound to the cuticle of the animal as 
discussed previously in Chapter 3. Whilst, several of the models showed lack-of-
fits potentially arising from the decreasing value of k1, due to the rapid turnover 
of these pharmaceuticals it is possible to calculate a BCF using steady state 
concentrations. The OECD 305 guideline suggests that it is appropriate to use 
BCFss if the concentrations have reached ≥95 % steady state [14]. A quick 
estimate of the time to reach 95 % steady state can be calculated using logP [14]. 
The maximum time for the compounds to reach 95 % steady state (based on 
logP) would be approximately 2.7 days. Therefore all compounds should have 
reached or approached apparent steady state in the uptake phase. Apparent 
steady state is recognised when the internal concentrations of three successive 
time intervals across 2 days are within ± 20 % of each other [14]. Table 4.8 shows 
the BCFs generated using steady state concentrations.  
 
 Concentration (ng g
-1 dw) 
 6h  24h  48h    
Compound Mean SD Mean SD Mean SD 
Steady 
State? BCFss 
Warfarin  25 5 50 10 77 15 No - 
Metoprolol 6 1 11 2 9 2 Yes 9 
Nifedipine 19 4 20 4 16 3 Yes 16 
Propranolol 206 41 355 71 210 42 * 21 
Trimethoprim 47 9 55 11 52 10 Yes 52 
Carbamazepine 8 2 11 2 14 3 Yes 14 
Diazepam 31 6 37 7 45 9 Yes 45 
Temazepam 20 4 32 6 38 8 * 38 
 
Warfarin is the only compound observed to not approach steady state. 
Propranolol and temazepam are assumed to approach steady state as the 
concentrations are relatively constant and therefore a steady state BCF (BCFss) 
was also estimated for these two compounds. Comparison of BCFss and kinetic 
BCFs (BCFk) showed that these values are all within good agreement of each 
Table 4.8: Mean [pharmaceuticals] at each time interval in the toxicokinetic exposures, (n=3).   
* Approaching steady state  
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other. BCFss may be considered more reliable for BCF estimates as it does not 
rely on modelling assumptions to generate a value. The agreement of the values 
also suggests that whilst modelling approaches may show statistically significant 
lack-of-fits they are adequate enough to give a good estimate of the potential of 
a compound to bioconcentrate or bioaccumulate in an organism for regulatory 
purposes.  
4.3.5 Metabolism of selected pharmaceuticals by G. pulex  
It is important to consider metabolism of xenobiotics in non-target species. 
As data supports factors other than hydrophobicity can be important in 
accumulation, biotransformation could explain the variability of BCFs. Authors 
have demonstrated that G. pulex are able to metabolise a range of organic 
micropollutants, biocides and pharmaceuticals [27, 55]. Pharmaceuticals have 
been shown to undergo biotransformation through oxidative and conjugation 
reactions [56]. As the targeted LC-MS/MS method only determines the amount 
of parent compound, the BCFs presented above (Table 4.6) do not take into 
account the formation or accumulation of any metabolites. The metabolite half-
lives in the body can be longer or shorter than the parent compound as they are 
modified by phase I or phase II metabolic processes leading to increased or 
decreased accumulation.  
Selected pharmaceuticals (propranolol, carbamazepine and diazepam) 
were used in metabolism studies and several metabolites were targeted in the 
analytical method including 4-hydroxypropranolol (HP), 4-hydroxypropranolol 
sulphate (HP-SULPH), 4-hydroxypropranolol glucuronide (HP-GLU), 
carbamazepine-10,11-epoxide (CBZ-EPOX), oxazepam (OXAZ) and 
nordiazepam (NORDIAZ). The analytical method was previously optimised for 
the last diazepam metabolite, temazepam. A matrix effect and recovery 
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experiment was performed for these additional analytes before exposures were 
performed (Table 4.9).  
 
 
 Matrix  Recovery   
  Effect (%) SD  (%) SD RSD (%) 
CBZ-EPOX 8 4 103 14 13 
HP-SULPH -4 8 34 7 20 
HP -93 4 41 11 27 
HP-GLU -4 6 0 0 128 
OXAZ 9 7 82 5 7 
NORDIAZ -31 9 92 7 8 
 
The matrix effects or recovery for 4-hydroxypropranolol were unable to be 
determined due to poor stability in solution. 4-hydroxypropanolol has previously 
been reported to be particularly unstable [57] with samples that required additives 
to maintain stability. Overall, matrix effects were relatively similar between the 
metabolites ranging from 4 % suppression to 9 % enhancement. However an 
exception to this was nordiazepam which showed 31 % signal suppression. 
Metabolites showed good absolute recoveries ranging 82 – 103 % (≤13 % RSD) 
with the exception of the propranolol metabolites. 4-hydroxypropranolol sulphate 
had a lower recovery of 34 % with a 20 % RSD whilst 4-hydroxypropranolol 
glucuronide showed no recovery from the analytical method. 
The lower recoveries and precision could arise from the fact that these two 
propranolol metabolites are transformed through phase II metabolism which 
involves conjugation to a moiety such as a glucuronide or sulphate. These 
conjugates therefore have very different physico-chemical properties to the 
parent compound and may lead to the lower recovery and precision by HLB 
sorbents. In particular sulphate and glucuronides are charged moieties and could 
potentially have better retention using ion exchange sorbents due to the 
Table 4.9: Matrix effect and recovery for the metabolites of selected 
pharmaceuticals (HLB sorbent). Samples spiked at 200 ng g-1 (n=6).  
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electrostatic interaction between the functional groups on the sorbent. The 
propranolol metabolites were extracted with three different cartridges, two of 
which were HyperSep™RetainCX and HyperSep™RetainAX cartridges 
containing ion exchange (electrostatic interaction) and non-polar sorption 
capacities through either sulfonic acid or quaternary amine functional groups on 
a modified polystyrene divinylbenzene polymer. The remaining sorbent was 
HyperSep™RetainPEP a polymeric cartridge containing polar and non-polar 
sorption capacities.  
The recovery was performed without matrix (Table 4.10) and overall the 
ion exchange sorbents showed better recovery and precision of the metabolites 
in comparison to the PEP sorbent. Propranolol also showed the best recovery 
and precision on the RetainCX cartridge. The RetainAX showed a 356 % 
recovery which indicates that the propranolol metabolites may have been 
deconjugated by an acid/alkaline hydrolysis reaction during the loading or elution 
phase of the SPE cartridge.  
 
 
Improved recoveries and precision were achieved using RetainCX 
cartridges, therefore these sorbents were used in a matrix effect and recovery 
experiment (Table 4.11) Matrix effects ranged from 12 % enhancement to 59 % 
suppression. Absolute recoveries were acceptable for propranolol and 4-
hydroxypropranolol sulphate whereas the glucuronide metabolite showed very 
low recovery (3 %). Overall, the CX cartridges showed slightly better performance 
 CX AX PEP 
 Recovery  Recovery  Recovery  
Compound (%) SD (%) SD (%) SD 
Propranolol 114 17 356 104 53 42 
HP-GLU 44 5 52 5 21 14 
HP-SULPH  88 10 40 4 50 12 
Table 4.10: Comparison of SPE sorbents for the pre-concentration of 
propranolol and metabolites. Samples were spiked at 20 μg L-1 (n=6).  
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than the HLB sorbent for the propranolol metabolites. However, as the recoveries 
and precision were not significant the propranolol metabolism experiment was 
performed in duplicate so quantification could be performed with both cartridges 







The exposure with carbamazepine, resulted in detectable peaks for 
carbamazepine-10,11-epoxide at 24h and 48h. The peak was confirmed by a 
single m/z transition and chromatographic retention time. The peaks were not 
quantifiable as they were below a signal to noise ratio of 10. The carbamazepine-
10,11-epoxide peak was not detected at 96h suggesting that the metabolite had 
been eliminated from the organisms. The elimination would either be by excretion 
or further biotransformation as the epoxide is converted to carbamazepine-
10,11–diol which is excreted as a free form or conjugate [58]. However, these 
metabolic pathways have been observed in human trials and therefore may vary 
in invertebrates. Limited data is available for biotransformation of xenobiotics in 
invertebrates. A previous study identified that carbamazepine was converted to 
its epoxide form and was the main metabolic pathway in the mussel, Mytilus 
galloprovincialis. Fish exposed to carbamazepine have also shown the presence 
of two carbamazepine metabolites, carbamazepine-10,11-epoxide and 2-
hydroxycarbamazepine [59]. Quantification of the propranolol exposure made 
use of the data from the analytical method using the HLB SPE sorbent (Figure 
 Matrix  Recovery   
Compound 
Effect 
(%) SD (%) SD 
RSD 
(%) 
HP-SULPH 12 8 45 6 13 
HP-GLU -33 5 3 1 33 
PROP -59 15 102 19 19 
Table 4.11: Matrix effect and recovery of propranolol and metabolites 
on a RetainCX cartridge. Samples were spiked at 200 ng g-1 (n=6).  
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4.7). Analysis of the RetainCX data gave a poor linearity (R2 ≤0.95) in the 
calibration curves for propranolol and 4-hydroxypropranolol sulphate.  
 
 
The data showed that 4-hydroxypropranolol sulphate reached a mean 
concentration of 75 ng g-1 dw by the end of the uptake phase. The elimination 
phase showed no decreases in the concentration 4-hydroxypropranolol sulphate 
which showed a mean concentration of 84 ng g-1 dw at 96h. The increase in 
concentration of this metabolite could be attributed from the continued 
biotransformation of the parent compound. Determination of the parent 
compound propranolol showed a peak in the mean concentration at the 24h time 
interval which decreased by 48h. Decreases of internal concentrations during the 
uptake phase are indicative of active metabolic pathways. To the authors’ 
knowledge, no propranolol metabolites have been identified in either fish or 
invertebrate. Human trials show that the major metabolites of propranolol were 
4-hydroxypropranolol and napthoxylactic acid [60]. The relative importance of this 
sulphate conjugation pathway in G. pulex is not known as the napthoxylactic acid 





























Figure 4.7: Concentration-time profile for propranolol (solid 
circles) and 4-hydroxypropranolol sulphate (crosses) in G. pulex. 
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authors have suggested that sulphate and glucoside conjugation is the major 
metabolic process in invertebrates for the metabolism of aryl compounds [61, 62].  
The final experiment was performed with diazepam and three metabolites 
were determined and quantified (Figure 4.8). Nordiazepam showed 
concentrations that reached a mean concentration of 60 ng g-1 dw in contrast to 
temazepam that reached a maximum mean concentration of 6 ng g-1 dw at 48h. 
The 10-fold difference in concentrations suggested that the biotransformation of 
diazepam to nordiazepam is the major metabolic pathway in contrast to the 
conversion of diazepam to temazepam.  
 
 
This agrees with mammalian data that shows the desmethylation of 
diazepam to nordiazepam is the primary metabolic pathway [63]. Temazepam 
was not detectable by the 96h time interval, suggesting this compound had been 
either excreted or further biotransformed to oxazepam. The elimination rate 
constant was determined at 0.0194 d-1 which is 3-fold lower than the elimination 




























Figure 4.8: Concentration-time profile for diazepam (solid circles), 
nordiazepam (triangles), oxazepam (squares) and temazepam 
(crosses) in G. pulex  
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12h and 36h, respectively. The difference observed is also in agreement with the 
reported half-lives, as nordiazepam has a longer half-life (50-120h) than its parent 
compound diazepam (44h) [64]. The k2 of temazepam was estimated at 0.016 d-
1, approximately 4-fold lower than the k2 of temazepam when exposed to G. pulex 
as a parent compound. The lower k2 may be explained by the apparent 
preferential metabolism of diazepam to nordiazepam. Thus, enzymes involved in 
the temazepam pathway may be less active. The final metabolite oxazepam was 
not detectable until 48h reaching a mean concentration of 50 ng g-1 dw. The 
biotransformation of diazepam to either nordiazepam or temazepam and further 
conversion to oxazepam would be rate liming steps leading to the apparent lag 
phase in the detection of oxazapem. The k2 estimated for oxazepam was 0.009 
d-1, with mean internal concentrations reduced by 21 ng g-1 dw over the 48h 
depuration period.  The half-life determined for oxazepam was 70h which is much 
greater than the reported single or multiple dose half-life in humans (9 – 11.6h) 
[65]. The difference in half-lives could be due to the continued conversion of 
nordiazpeam or temazepam to oxazepam after the uptake phase ended giving 
an apparent longer half-life. Furthermore, oxazepam is primarily excreted by 
conjugation with glucuronide moieties indicating that G. pulex may not readily 
metabolise oxazepam as well as in humans. The metabolite enrichment factors 
(MEFs) [27] for 4-hydroxypropranolol, nordiazpeam, temazpeam and oxazepam 
were determined to be 7.5, 64, 6 and 50, respectively. These MEFs can be 
compared to a ‘pseudo-BCF’ which would further indicate that these metabolites 
are not accumulative but the nordiazpeam and oxazepam bioconcentrate more 
than their parent compound diazepam. Furthermore, the summation of the parent 
BCFs and MEFs can give a BCF that would be comparable to those determined 
by total radioactivity counts [27]. For example the BCF of diazepam ranged from 
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41 – 58 whereas summation of the diazepam BCF and the MEFs would give a 
total BCF of 165. Thus, studies that only monitor the parent compound should be 
cautious when reporting BCFs if there is a high potential for biotransformation. 
Comparison of BCFtotal (BCFparent + MEF) to BCFs determined by LSC was not 
possible here. However, Ashauer et al., [27] reported that comparison BAFtotal 
and BAF by LSC gave values that were within a single order of magnitude. 
However, the differentiation between metabolites and their parents gave better 
accuracy in parameter estimates (k1/k2) compared to radioactivity measurements 
[27]. The reason for this is that radioactivity measurements can over or 
underestimate elimination if biotransformation is not taken into account.  
 
4.4 Conclusions 
The data show that LC-MS/MS is a suitable technique for the 
measurement of uptake and elimination kinetics compared with more traditional 
approaches using liquid scintillation counting. The BCF estimates ranged from 16 
– 41 for eight compounds (diazepam, temazepam, nifedipine, propranolol, 
metoprolol, carbamazepine, warfarin and trimethoprim) using the simultaneous 
method. Sequential parameterisation resulted in BCFs of 21 – 72 showing 
overestimates compared to the simultaneous method as also observed in 
Chapter 3. Similarly, models were shown to have significant lack-of-fits for six of 
the eight pharmaceuticals. The lack-of-fits also coincided with decreases in the 
uptake rate constant over time suggesting that poor model fits may have resulted 
from this trend. No trends were observed with BCF or logD or logP suggesting 
other factors other than compound hydrophobicity are important in 
bioconcentration. The role of metabolism was investigated for three selected 
pharmaceuticals (carbamazepine, propranolol and diazepam). G. pulex were 
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shown to metabolise all three pharmaceuticals into several different 
biotransformation products, indicating the conservation of cytochrome P450 
enzymes in this species. The ability of G. pulex to readily metabolise these 
xenobiotics may explain, in part, the relatively low BCFs determined for 
pharmaceuticals in this work and the literature. Metabolic pathways and 
metabolites were found to be the same between vertebrate data. However, 
differences between half-lives were observed for the benzodiazepine compounds 
suggesting that rates of metabolism and elimination are different. Whilst, kinetics 
may differ the same metabolic pathways involved in elimination mean that human 
pharmacokinetic data is valuable for consideration of pharmaceuticals in 
environmental risk assessment. Analytical methods that only target and 
determine the parent compound in toxicokinetic studies may not reliably measure 
a ‘true’ BCF of the selected compound. It is advised that MS methods account for 
metabolites when estimating BCFs. Finally, the MEFs for the diazepam 
metabolites nordiazpeam and oxazepam showed that some metabolites had a 
higher potential to accumulate than the parent and remain in the body longer. 
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Chapter 5. The application of artificial neural networks to model 
sampling rates onto polar organic chemical integrative samplers. 
 
5.1 Introduction 
The contamination of the aquatic environment with various organic 
contaminants have been the focus on environmental monitoring campaigns, 
especially where chemical regulation has been introduced by the Water 
Framework Directive (WFD) and the EU Registration, Evaluation, Authorisation 
and Restriction of Chemicals (REACH) [1, 2]. Monitoring of the aquatic 
environments can often involve high frequency sampling using either grab or 
composite samples. Both, grab and composite sampling have limitations that they 
do not represent the temporal variation of contaminant concentrations. These 
types of sampling are also labour and resource intensive leading to difficulties in 
practical application of long term monitoring campaigns. In an alternative 
approach, passive sampling devices (PSDs) are being increasingly employed in 
the monitoring of aquatic environments. PSDs offer the capability to determine a 
time-integrated average of contaminant concentrations in surface and 
wastewaters over extended periods [3]. These sampling devices minimise 
sample preparation and allow in situ pre-concentration of analytes that increase 
sensitivities of analytical methods when compared with point-sampling [4].  
Similar to the bioconcentration work, much of the early investigations 
focused on non-ionisable organic micropollutants. PSDs such as semi-permeable 
membrane devices (SPMDs) have been used for the determination of 
compounds such as organochlorines and other hydrophobic organic 
contaminants over the last three decades [5-8]. However, an emerging type of 
PSD is the polar organic chemical integrative sampler (POCIS) that can be used 
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to determine a range of chemically diverse compounds (polar and nonpolar), 
including pharmaceuticals [9-15]. Whilst these POCIS devices have several 
advantages, they also suffer from limitations when performing quantitative 
studies. The accuracy and reliability of experimental measurements in the 
estimation of sampling rates including the limited amount of reported Rs and the 
variability of Rs between experimental determinations are the main limitations of 
POCIS devices [9, 16, 17]. Furthermore, calibration of POCIS devices are also 
resource intensive leading to the possibility that in silico modelling approaches 
could overcome these limitations by predicting Rs without the need for 
experimental determinations.  
A previous investigation by Stephen et al., [18] used Sherwood’s 
correlation to the estimate the kinetic parameter, aqueous boundary layer mass 
transfer coefficient (kf). This empirical approach led to errors ranging from +40 % 
to -20 % for a limited number of compounds. Alternative to empirical approaches, 
quantitative structure-property relationships (QSPR) methods for the 
parameterisation of desired output functions are becoming more frequently used 
in ecotoxicological fields [19-21]. The reason for the increased use is that the 
experimental determination of variables such as occurrence, fate and effects of 
contaminants is unfeasible due to the sheer volume of compounds available and 
with regulatory directives in place such as REACH [22]. QSPR models used a set 
of predictor variables to model a desired output function, where predictors are 
often molecular descriptors describing the topology, geometry or physico-
chemical properties of a molecule [23]. These models can vary from simple 
regressions, or can be more complex involving non-linear functions such as those 
used by machine learning methods. One type of machine learning algorithm is an 
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artificial neural network (ANN) that have been used to predict logP, biosolid and 
soil sorption coefficients (KD) and chromatographic tR [24-30].   
ANNs are comprised of several layers including an input layer 
(descriptors), hidden layer (nodes) and output layer (response). The molecular 
descriptors are related to the output layer by non-linear functions in the hidden 
layer, which can contain several interconnected layers and nodes. The residual 
errors are monitored and reduced iteratively by adjusting statistical weights 
attached to each descriptor and node in the hidden layer(s). ANN testing is split 
into a training subset where the model learns, a verification subset for supervised 
learning where the model knows the output but does not use them to learn and a 
test set where the output is hidden from the network. The predictive ability of the 
network is evaluated by the verification and test subsets. In addition, ANN can be 
used for mechanistic interpretation of important descriptors to the response 
variable leading to knowledge discovery of underlying processes. Therefore, the 
application of ANN to POCIS could greatly increase the applicability of PSDs in 
environmental monitoring studies through bypassing the need for laboratory or in 
situ calibrations. 
The aim of this work was to investigate the applicability of ANNs to model 
and predict Rs for POCIS devices for a range of compounds including 
pharmaceuticals, herbicides, pesticides and steroid hormones. Successful 
application could suggest the applicability of ANNs to model more complex 
uptake processes such as bioconcentration. Objectives were to identify suitable 
molecular descriptors to build, train and test ANN models and then finally to 
externally validate the ANN model using new Rs data determined by laboratory 
calibrations.  




All chemical reagents were of analytical grade purity (>98 %). Alprazolam, 
clonazepam, diazepam, flunitrazepam, lorazepam, midazolam, nitrazepam, and 
oxazepam were obtained from Nerliens Meszansky (Oslo, Norway). All reagents 
were prepared as stock solutions in methanol (MeOH) at a concentration of 100 
µg mL-1 and stored at –20 oC. Standard mixtures were prepared for spiking in 
POCIS exposures, at 1 µg mL-1 and stored in MeOH at -20 oC. Diazepam-d5 and 
oxazepam-d5 were purchased at 100 ng mL-1 in MeOH (Nerliens Meszansky) and 
stored at -20 oC. Ultrapure water was obtained by the purification of 
demineralised water in an Elga Maxima Ultrapure Water purification system to a 
resistivity of ≥18 MΩ cm (Elga, Lane End, UK). Ammonium formate (≥99 %), 
HPLC grade formic acid, water, MeOH and MeCN were purchased from Sigma-
Aldrich (Oslo, Norway). Sodium hydrogen carbonate was acquired from Merck 
(Oslo, Norway). Oasis HLB bulk sorbent was purchased from Waters (Oslo, 
Norway) and polyethersulfone (PES) membranes were acquired from VWR 
(Oslo, Norway) 
 
5.2.2 POCIS assembly  
POCIS were assembled in-house as detailed in previous investigations 
[31]. Briefly, 220 mg of Oasis HLB bulk sorbent was sandwiched between two 
PES membranes. The PES membranes were then placed between two stainless 
steel rings, with exposure area of 46 cm2 which were then tightened together with 
nuts and bolts to physically compress and seal the sorbent inside the device. 
Once devices were assembled they were stored in air tight aluminium foil lined 




5.2.3 Laboratory calibration of sampling rates to test ANN generalisability 
Sampling rates (L d-1) were determined using a static renewal method over 
a 14-day exposure period and in a similar manner to those data generated in the 
literature which was used for ANN modelling in the present study [32]. Briefly, 3 
L high-density polyethylene vessels were filled with ultra-pure water, pH adjusted 
to 7.6 with 20 mg L-1 NaHCO3 and spiked with the mixture of respective 
compounds to expose the POCIS. Each vessel contained three POCIS devices 
for exposure to an aqueous-based standard mixture of 200 ng L-1 of each target 
compound (solvent <0.001 %). This standard solution was prepared and replaced 
daily in 3 L volumetric flasks to maintain the nominal concentration. Following 
this, all three POCIS were removed from each vessel at day 4, 7 and 14, rinsed 
with ultrapure water and frozen at -20oC. A control vessel containing only fortified 
exposure medium (no POCIS) was also set up to monitor losses due to 
transformation, volatilisation and sorption. Exposure media in all vessels was 
agitated using a magnetic stirrer at 200 rpm during this time. Vessels were stored 
in the dark and Parafilm (VWR International, Oslo, Norway) was used as a seal 
to prevent evaporative losses. Water samples (1 mL) were taken from each 
beaker on day 4, 7 and 14 for analysis. Control POCIS devices (n=3) were also 
exposed in parallel (no analytes present) and extracted at the end of the 
experiment on day 14. All elements of the calibration experiment were performed 
in a temperature controlled room at 20oC.  
 
 
5.2.4 POCIS extraction 
Frozen POCIS discs were carefully disassembled and the HLB sorbent 
material rinsed with ultra-pure water into an empty SPE cartridge housing 
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containing a single frit (20 μm pore size). Once all sorbent material was in the 
cartridge, the top frit was added and the sorbent bed washed with 5 mL of ultra-
pure water. SPE tubes were dried under low vacuum for 30 min. Elution was 
carried out with 5 mL of MeOH in two stages and the eluate dried down under 
nitrogen (purity >99 %) at 35oC for 40 min. The dried residue was then 
reconstituted in 0.5 mL of starting mobile phase.    
 
5.2.5 Analytical and instrumental conditions  
The analysis of the 8 benzodiazepines was performed on an Acquity UPLC 
System coupled to a Xevo™ G2-S QTof mass spectrometer (Waters, Milford, 
MA, USA) with an on-line two-dimensional method for both sample extraction and 
analyte separation. The pre-column used for the sample extraction was an Oasis 
HLB Direct Connect HP loading column (2.1 x 30 mm, 20 μm, Waters Corp). 
Mobile phase (isocratic 0.5 mL min-1) for the loading pump (i.e. sample extraction) 
was 0.2 % (v/v) ammonium hydroxide and 10 % (v/v) methanol in water. Washing 
of the loading column was performed with 0.1 % formic acid in methanol (isocratic 
1.5 mL min-1) in between each injection. Analyte separation was performed on an 
Acquity UPLC BEH C18 column (1.7 μm, 50 x 2.1 mm) from Waters (Milford, MA, 
USA) at 50 °C. Gradient elution (0.6 mL min-1) for analyte separation was with 
0.1% (v/v) formic acid in water (phase A) and 0.1 % formic acid in methanol 
(phase B). Sample volumes of 200 μL were injected onto the loading column. 
After 1.5 minutes the flow direction was reversed and the analyte was back-
flushed onto the chromatographic column for elution and separation. The 
chromatographic separation gradient was as follows: Initial conditions of 1% 
Phase A then a ramp to 98% Phase A over 3 minutes. Hold and wash at 98% 
Phase A for 1 minute before returning to initial conditions. MS data was acquired 
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in MSE-mode where exact mass of precursor and fragment ions were collected 
over the range 50 – 600 m/z. The MSE acquisition mode provides two traces; one 
with low energy (LE) for molecular ions; and one with high energy (HE) for 
generating fragment ions. Quantification was performed on the accurate 
molecular ion (see Table 5.1). Confirmation was via the identification of at least 
two-fragment ions using HE within an accuracy of 5 ppm and a retention time 













Oxazepam 3.26 Oxazepam-d5 287.05817 241.0528 
Nitrazepam 3.26 Oxazepam-d5 282.08731 236.0945 
Clonazepam 3.29 Oxazepam-d5 316.04833 270.0555 
Lorazepam 3.29 Oxazepam-d5 321.0192 275.0138 
Alprazolam 3.31 Oxazepam-d5 309.09014 281.0715 
Midazolam 3.31 Diazepam-d5 326.08547 291.1167 
Flunitrazepam 3.37 Diazepam-d5 314.09353 268.1007 
Diazepam 3.58 Diazepam-d5 285.07891 193.0886 
 
5.2.6 Estimation of Rs from laboratory calibrations  
Determination of time-weighted average concentrations of compounds in 
the bulk phase require calibration of POCIS devices by estimating the Rs [33]. A 
first order single compartment model can be used to represent the uptake and 
elimination of a compound on the PSD shown by Equation 5.1. 
𝐶𝑠(𝑡) =  𝐶𝑤
𝑘1
𝑘2
 (1 − 𝑒−𝑘2𝑡)                                   (5.1) 
Where, Cs(t) is the concentration of compound (ng g-1) on the receiving 
phase (sorbent) at time, t. Cw is the concentration of compound in the water phase 
(ng L-1), k1 is the uptake rate constant of the compound onto the sorbent (L g-1 d-
1), k2 is the elimination rate constant of the compound from the sorbent (d-1) and 
t is the time (d). However, calibration requires that POCIS devices are operated 
Table 5.1: LC-HRMS parameters for determination of benozdiazepines. 
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in the kinetic regime where the sorbent acts as a ‘sink,’ and thus k2 is negligible, 
reducing the expression to Equation 5.2.  
𝐶𝑠(𝑡) =  𝐶𝑤𝑘1𝑡                                               (5.2) 
Equation 5.2 can be re-expressed to link the concentration in the sorbent 
to the concentration in the water phase using the sampling rate shown in Equation 
5.3.  
𝐶𝑠 =  
𝐶𝑤𝑅𝑠𝑡
𝑀𝑠
                                                     (5.3) 
Where, Rs is the sampling rate (L d-1) and Ms is the mass of sorbent used 
in the PSD (g). Thus, Equation 5.3 can be rearranged to determine the Rs when 
the Cs and Cw are measured.  
 
5.2.7 Selection of datasets, molecular descriptors and ANN architecture 
POCIS Rs data were compiled into a database from reported publications 
from 2007 to present. Of these, the sub-selection of Rs for ANN modelling was 
from two articles by Fauvelle et al. [32] and Morin et al. [34], which were 
generated using similar experimental conditions and gave the largest suitable 
dataset overall (Table 5.2). In total, n=73 compounds were used covering 
herbicides, pesticides, endocrine disrupting compounds and pharmaceuticals. 
Where duplicate compound Rs data existed, both values were removed entirely 
from the dataset. Simplified molecular input line entry system (SMILES) strings 
were generated from Chemspider (Royal Society of Chemistry, UK). From these 
strings n=185 molecular descriptors were generated from Parameter Client 
freeware (Virtual Computational Chemistry Laboratory, Munich, Germany) and 
an additional n=16 descriptors were from ACD labs Percepta software (Advanced 




For optimisation of ANN models, two sub-selections from all 201 
descriptors were investigated for comparative performance. The first was made 
by applying genetic selection algorithms which short-listed 24 molecular 
Case 
# 
Compound Rs (L d-1) 
Case 
# 
Compound Rs (L d-1) 
1 2,4 dichlorphenol 0.068 38 ketoprofen  0.118 
2 2,4-D 0.045 39 lorazepam 0.205 
3 3,4-dichloroaniline 0.241 40 MCPA 0.037 
4 4-methylbenzylidene  
camphor 
0.215 41 mecoprop 0.053 
5 acebutolol 0.166 42 megesterol Acetate 0.265 
6 acetochlor ESA 0.201 43 mesotrione 0.078 
7 acetochlor OA 0.14 44 metazachlor 0.148 
8 atenolol  0.025 45 methomyl 0.146 
9 azoxystrobine 0.202 46 metolachlor 0.305 
10 bentazon 0.16 47 metolachlor ESA 0.17 
11 betaxolol 0.217 48 metolachlor OA 0.124 
12 bezafibrate 0.146 49 metoprolol 0.195 
13 bisphenol A  0.245 50 metoxuron 0.245 
14 bisprolol 0.161 51 metsulfuron-Me 0.127 
15 carbamazepine  0.188 52 nadolol  0.114 
16 chlorfenvinphos 0.279 53 naproxen  0.084 
17 chlorsulfuron 0.13 54 nicosulfuron 0.09 
18 chlortoluron 0.264 55 oxazepam 0.226 
19 DEA 0.286 56 oxprenolol 0.185 
20 DET 0.421 57 prochloraz 0.208 
21 DIA 0.323 58 progesterone  0.346 
22 dichlorprop 0.053 59 propranolol  0.165 
23 diclofenac 0.225 60 pyrimicarb 0.259 
24 diclofop 0.085 61 simazine 0.216 
25 dimetomorph 0.261 62 sotalol  0.036 
26 estriol 0.185 63 sulcotrione 0.09 
27 estrone 0.23 64 sulfamethoxazole  0.03 
28 ethinylestradiol  0.26 65 t-butylphenol  0.398 
29 fenoprop 0.113 66 terbuthylazine 0.321 
30 furosemide 0.129 67 testosterone 0.28 
31 ibuprofen 0.118 68 thiodicarb 0.21 
32 iodosulfuron 0.187 69 timolol 0.21 
33 ioxynil 0.343 70 t-Octylphenol  0.065 
34 IPPMU 0.234 71 trimethoprim  0.162 
35 IPPU 0.232 72 α-Estradiol  0.239 
36 irgarol 0.287 73 β-Estradiol  0.221 
37 isoproturon 0.207       
2,4-D – 2,4-dichlorophenoxyacetic acid, ESA - ethanesulfonic acid, OA – oxanilic acid, DEA – 
deethylatrazine, DET – diethyltryptamine, desisopropylatrazine, IPPMU – monodesmethyl-
isoproturon, IPPU – didesmethyl-isoproturon, MCPA - 2-methyl-4-chlorophenoxyacetic acid, Me 
– methyl. 
 
Table 5.2: Dataset used for modelling Rs with ANN 
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descriptors for subsequent ANN modelling (see Table 5.3 for shortlisted 
descriptors). The second sub-set of molecular descriptors was chosen based on 
previous work for prediction of chromatographic retention time (16 molecular 
descriptors in total). For both datasets, several network types were tested for 
predictive ability using Trajan 6.0 neural network software (Trajan Software Ltd., 
Lincolnshire, UK), these included radial basis function (RBF), generalised 
regression neural networks (GRNNs) and multi-layer perceptrons (MLPs). The 
optimised network architecture was a four-layer MLP using two types of training 
algorithms, the first was back propagation (BP) and the second being conjugate 
gradient descent (GCD). The first and fourth layers were the inputs (using the set 
of descriptors previously used for chromatographic retention modelling) and 
outputs (Rs), respectively, and the second and third layers (hidden layers) 
contained 14 and 9 nodes, respectively. The subsets of cases presented to the 
retention time descriptor model (RTD) were split so that 51 compounds were used 
for training, 11 compounds for verification and 11 compounds for testing the 
networks (optimised). The genetic algorithm feature selected model (GSD) was 







































Ss sum of Kier-Hall electrotopological states 
Ms mean electrotopologcial state  
nAT number of atoms   
nBO number of non-H bonds  
ZM2 second Zagreb index   
ICR radial centric information index  
ZM1V first Zagreb index by valence vertex degrees 
MAXDN maximal electopological negative variation 
SCBO sum of conventional bond orders (H-depleted) 
RBF rotatable bond fraction  
Snar Narumi simple topological index (log function) 
Xt total structure connectivity index 
Dz Pogliani index   
Pol polarity number   
MSD mean square distance index (Balaban) 
Har Harary H index   
RHyDP reciprocal hyper-distance-path index 
ww hyper detour index   
S0K Kier symmetry index   
SE1G absolute eigenvalue sum on geometry matrix 
Har2 square reciprocal distance sum index 
ALogP Ghose-Crippen octanol-water partition coefficient 
AlogP2 squared Ghose-Crippen octanol-water partition coefficient 
LogD distribution coefficient  
nTB number of triple bonds  
nC number of carbon atoms  
nO number of oxygen atoms  
nR04 number for 4-membered rings  
nR05 number for 5-membered rings  
nR06 number for 6-membered rings  
nR07 number for7-membered rings  
nR08 number for 8-membered rings  
nR09 number for 9-membered rings  
Ui Unsaturation index   
Hy Hydrophilic factor   
nBnz number of benzene-like rings  
MLOGP Moriguchi octanol-water partition coefficient 




5.3 Results & discussion 
5.3.1 The application of ANNs to model Rs on POCIS  
The selection of the molecular descriptors yielded two optimised models 
for the prediction of Rs onto POCIS. Feature selection using a genetic algorithm 
which shortlisted 24 descriptors for modelling the selected dataset, whereas 16 
descriptors were selected from a previous investigation that used ANNs to predict 
tR on a C18 reversed-phase chromatographic column [27, 28]. The genetic 
algorithm, similar to neural networks, was created to mimic a biological function 
(evolution). The algorithm converts the molecular descriptors into a binary string 
and maps them against an output function (Rs). These binary strings are used to 
produce ‘progeny’ strings that reduce the error associated with the output 
function. After feature selection, the descriptors were used for modelling where 
an optimised multilayer perceptron (MLP) was produced with a 24:17:14:1 
architecture (GSD-model).  
Regression analysis of the training, verification and test subsets showed 
an R2 of 0.8800, 0.8694 and 0.8050, respectively for the GSD-model (Figure 5.1). 
The residual error for each subset was 0.084, 0.062 and 0.116, respectively. 
Overall, the model showed good predictive accuracy for 16 compounds with 
predicted Rs values within 20 % of the measured value. Larger inaccuracies were 
observed for two compounds, 2,4-dichlorophenoxyacetic acid (59 %) and timolol 
(31 %), in the verification subset. The test subset showed greater errors for 
compounds such as sotalol (80 %), acetochlor ethaneslufonic acid (40 %), 
diclofenac (39%) and suclotrione (38 %). The reason for this could be related to 
poor learning on the training set. For example, mesotrione has a large inaccuracy 










































Figure 5.2: Raw residuals for the verification and test case predictions by the GSD-
model. Circles represent verification data and triangles test data. 
Training: y = 0.84x + 0.0316, R² = 0.88
Verification: y = 0.9246x + 0.0062, R² = 0.8694
























Measured Rs (L d
-1)
Figure 5.1: Regression analysis of the GSD model. Crosses 
















The larger inaccuracies may also relate to sulfonated compounds where 
training was not optimal for these functional groups.  The average predicted Rs 
values for both verification and test subset were within 19 % of the experimental 
value. The average absolute error for both subsets was 0.028 ± 0.025 L d-1 
indicating that the model showed good predictive accuracy. The plot of residuals 
for model (Figure 5.2) indicated that there may have been some bias in the 
predictions as the data points were skewed towards the negative y-axis. A normal 
probability plot of the residuals (Figure 5.3) showed that they followed a normal 
distribution which suggested the data were not biased and the model was 
appropriated for predictive application.  
In an alternative approach, descriptors used for retention time modelling 
were applied here to predict Rs [27, 28]. The POCIS sorbent material was Oasis 
HLB, a copolymer of divinylbenzene and N-vinylpyrrolidone that allows 
interaction with both polar and non-polar compounds. Previous authors have 
Figure 5.3: Normal probability plot of residuals in the GSD-
































demonstrated that sorption to HLB polymers is achieved predominantly through 
Van der Waals interaction attributed to the non-polar surface area of the sorbent 
(London dispersion forces) [35]. As retention on reversed-phase columns is also 
mainly attributable to dispersion forces. The use of previously validated 
descriptors for retention time modelling could offer a suitable approach Rs [36]. 















The model architecture was a four-layered MLP with a 16:15:9:1 structure. 
Overall the R2 was 0.8511, 0.9085 and 0.6425 for the training, verification and 
test subsets respectively. The correlation coefficients showed slightly better fits 
for the verification subset in the RTD-model whereas the R2 was better for the 
test subset in the GSD-model. However, it should be noted that the cases in each 
subsets were not identical as they were selected at random. The GSD-model also 
Training: y = 0.8319x + 0.0316, R² = 0.8511
Verification: y = 0.938x + 0.0043, R² = 0.9085
























Measured Rs (L d
-1)
Figure 5.4: Regression analysis of the RTD-model. Crosses represent 
training data, circles verification data and triangle test data. 
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contained a larger number of predictors that could lead to overfitting and reduce 

































Figure 5.5: Raw residuals of the verification and test cases predicted by the RTD-






























Figure 5.6: Normal probability plot of the raw residuals from the 
RTD-model. P-value = 0.492, alpha = 0.05. 
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The residual error was for the training, verification and test subsets were 
0.092, 0.062 and 0.121, respectively.  Similar to the previous model, the RTD-
model showed good predictive accuracy with Rs values predicted within an 
average of 22 % of the measured value for both verification and test subsets. The 
plot of residuals showed that all data points were randomly distributed and a 
normal probability plot also showed the distribution was normal which indicated 
the molecular descriptors had appropriate explanatory power for the output 
function (Figure 5.5 & 5.6). The average predicted error was 0.031 ± 0.021 L d-1 
showing that the average prediction was slightly worse for the RTD-model, whilst 
the variance was slightly better compared to the GSD-model. The verification 
subset showed no large errors with all predictions ≤ 20 % of the measured Rs 
value. The test subset showed two large errors which corresponded to the 
compound atenolol (168 %) and chlorsulfuron (39 %). 
The lowest measured Rs was atenolol (0.025 L d-1) in the RTD-model test 
subset which gave a relatively poor prediction of 0.067 L d-1. A possible 
explanation was that the high polarity (logP = 0.34) of this molecule resulted in a 
poor prediction. However, in both residual plots (Figure 5.2 & 5.5) when 
compounds were ordered by logD no trend was observed with the predictive 
accuracy of the ANNs. The removal of atenolol, resulted in an average prediction 
error of 15 % for both the verification and test subsets. Whilst no trend was 
observed between logD and predictive accuracy, the HLB copolymer does not 
retain very polar compounds well (See Chapter 2, Section 2.3.3). Thus, 
experimentally determined Rs values may suffer from inaccurate estimations 
which could translate into poor predictive accuracy for modelling approaches. 
This highlights the importance of accurate and reliably measured data when used 
as an output function. Furthermore, the dataset used was from two separate 
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investigations that whilst had relatively similar experimental designs, 
inconsistencies between the laboratory estimations may also contribute to 
modelling inaccuracies. Overall, considering the potential inaccuracies of 
measured Rs data both models presented here, showed good predictive accuracy 
for application in passive sampling fields [9]. 
 
5.3.2 Interpretation of molecular descriptors used to model Rs data  
A sensitivity analysis was performed to identify which molecular 
descriptors in either model were important to the prediction of Rs. Figure 5.7 
shows the relative importance of each descriptor to the RTD- model. The top five 
descriptors were LogD, MlogP, AlogP and nBnz and nC which agreed with 
Bäuerlein et al., [35] that showed hydrophobicity and pi-pi bonds were dominant 
in sorption of compounds to HLB copolymers. Furthermore, these authors 
showed that hydrophilic surface area did show contribution to chemical sorption. 
Interestingly, the molecular descriptors Hy, nO were also relatively important to 
the network with error ratios of 1.108 and 1.2034, respectively. The descriptor Hy 
relates to the number of hydrophilic groups (such as hydroxyl and thiol) and nO 
is the number of oxygen atoms which due the electronegativity in organic 
compounds will contribute to dipole or induced dipole interactions. Other 
important descriptors were shown to be the nTB (1.2165), nR05 (1.2041) and 
nR09 (1.4544). The importance of the n-membered ring descriptors could be 
attributed to molecular size and thus could affect the diffusivity of molecules 
through the water boundary layer and PES membrane [37] or could lead to steric 
effects between the sorbent and sorbate. A previous investigation showed that 
size descriptors were important for predicting soil sorption coefficients in non-














The nR04 descriptors and nR08 descriptors showed an err 
or ratio of 1, which indicated that they had no effect on the predictive accuracy of 
the model. The reason for this was that no cases in the dataset had 4- or 8-
membered rings, thus, these were ignored by the ANN model. LogD was 
identified as the most important descriptor to the model. A plot of logD versus 
measured Rs revealed a weak correlation of R2 = 0.3191 (Figure 5.8). The weak 
correlation suggested that logD does influence sampling rates but it is likely 
affected by several other factors related to either the molecule itself or 















































































Figure 5.7: Sensitivity analysis of descriptors used in the 
chromatographic RTD-model. Error ratios > 1 indicate relative 










Furthermore, sorption of the compounds to the PES membrane can affect 
Rs, such that more hydrophobic compounds cross the membrane at a slower rate 
leading to an observed lag phase in the accumulation on the HLB sorbent [39]. A 
separate study showed a plot of logD versus Rs gave a correlation coefficient of 
R2=0.37 (n=322 cases) [40]. The authors suggested that ionised species have 
lower Rs values than when compared to neutral forms [40, 41]. In addition to the 
sorption of the compounds to the passive sampler, diffusion is also an important 
mechanism in PSD uptake. Authors have suggested that diffusion is the sole 
factor governing sampling rates for PSDs [42]. The descriptors mentioned above 
whilst are involved with the HLB sorbent interactions, may also relate to diffusion 
processes due to the number of factors to affect diffusion such as dipole 
moments, polarizability, molecular size and electrostatic charge. Furthermore, 
diffusion-only uptake rates were determine using partition samplers such as 
silicone rubbers [42] whereas POCIS are an adsorption sampler and therefore 
suggests that sorption in addition to diffusion may affect sampling rates. This is 
demonstrated by the performance reference compound method where it has 




















Figure 5.8: Correlation between logD descriptor (ACD labs) 
and sampling rate (Rs) 
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sample due to adsorption on the copolymer [43-45]. However, the contribution 
from diffusion and adsorption processes which govern the sampling rate in 
adsorption samplers remains unclear. Thus, more studies are required to 
understand the mechanisms of diffusion across the water boundary layer/PES 
membrane and the sorption to the PES membrane/HLB sorbent.  
Prediction of sampling rate may also be improved by including alternative 
descriptors such as diffusion coefficients. However, including descriptors such as 
these could lead to greater uncertainty as estimated of diffusion coefficients can 
be based off several different methods [46]. Furthermore, diffusion will be affected 
by several different environmental factors including hydrodynamic conditions that 
could not be accounted for in modelling approaches. Finally, including large 
numbers of descriptors to account for the number different mechanisms that 
govern sampling rates could be disadvantageous as it would limit the 
generalisability of the model to new data. A collinearity assessment of the 
descriptors was performed so that interpretations of individual predictors in the 
ANN were appropriate. Table 5.4 shows the correlation coefficients of each 







                                  
  nDB nTB nC nO nR04 nR05 nR06 nR07 nR08 nR09 Ui Hy nBnz MLOGP ALOGP logD 
nTB -0.108                
nC 0.23 0.144               
nO 0.705 0.001 0.405              
nR04 * * * *             
nR05 0.014 0.061 0.41 -0.094 *            
nR06 0.184 0.221 0.723 0.212 * 0.42           
nR07 0.082 -0.043 0.079 -0.127 * -0.097 0.131          
nR08 * * * * * * * *         
nR09 -0.012 0.148 0.509 -0.061 * 0.638 0.682 -0.073 *        
Ui 0.321 0.113 0.209 0.439 * -0.175 0.254 0.269 * -0.383       
Hy -0.279 -0.11 -0.318 -0.116 * -0.145 -0.169 0.039 * -0.157 0.047      
nBnz -0.018 0.125 0.332 0.204 * -0.189 0.303 0.357 * -0.205 0.671 -0.136     
MLOGP -0.273 0.2 0.36 -0.361 * 0.308 0.477 0.129 * 0.43 -0.014 -0.455 0.296    
ALOGP -0.276 0.218 0.387 -0.266 * 0.329 0.366 0.081 * 0.35 0.04 -0.53 0.371 0.898   
logD -0.368 0.172 0.187 -0.607 * 0.384 0.306 0.113 * 0.405 -0.245 -0.275 -0.03 0.677 0.615  
Rs -0.253 0.191 0.021 -0.487 * 0.134 0.114 0.046 * 0.263 -0.309 -0.051 -0.295 0.35 0.199 0.59 
Table 5.4: Collinearity assessment using Pearson’s correlation between molecular descriptors used in the RTD-model.  
* Could not be calculated as molecules were absent of 4- and 8-membered rings.  
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A threshold value for high collinearity has been given in the literature of 
R>0.7 [47]. In total, three descriptor pairs showed high collinearity that were 
nDB:nO (0.705), nC:nR06 (0.723) and MlogP:AlogP (0.898). These collinearities 
may be expected as the Ghose-Crippen logP and Moriguchi logP are measures 
of the octanol-water partition coefficient estimated by regression equations. 
Similarly, the number of double bonds would be correlated with the number of 
oxygen atoms, as oxygen atoms will often form double bonds in organic 
molecules (carbonyl groups). The consequence of collinearity is that the relative 
importance of the paired descriptors cannot be determined and therefore the 
sensitivity analysis can be limited. Whilst, collinearity may lead to descriptor 
redundancy it does not, however, affect predictive ability [48]. Thus, whilst it is 
more difficult to interpret, understanding of the underlying process will reduce the 
limitations associated with collinearity [47]. Furthermore, the focus of machine 
learning is primarily concerned with prediction rather than interpretation. As 
collinearity does not affect predictive accuracy, it is not of concern for the sole 
purpose of predicting Rs [48]. A sensitivity analysis was also performed for the 
GSD model. However, assessment of collinearity was very high for multiple 





Table 5.5: Collinearity assessment of the GSD-model using Pearson’s correlation.  
Ss Ms nAT nBO ZM2 ICR ZM1V MAXDN SCBO RBF Snar Xt Dz Pol MSD Har RHyDp ww S0K Seig Har2 ALOGP ALOGP2 LogD
Ms 0.402
nAT 0.57 -0.446
nBO 0.845 -0.115 0.845
ZM2 0.742 -0.174 0.798 0.958
ICR 0.613 -0.151 0.759 0.717 0.588
ZM1V 0.973 0.376 0.528 0.823 0.708 0.582
MAXDN 0.682 0.735 0.049 0.309 0.245 0.15 0.641
SCBO 0.913 0.079 0.695 0.961 0.9 0.637 0.907 0.448
RBF 0.332 0.259 0.2 0.101 -0.142 0.465 0.329 0.305 0.112
Snar 0.791 -0.181 0.829 0.991 0.956 0.704 0.776 0.235 0.948 0.049
Xt -0.773 0.191 -0.837 -0.96 -0.916 -0.726 -0.742 -0.274 -0.913 -0.118 -0.962
Dz 0.933 0.059 0.801 0.966 0.868 0.745 0.917 0.454 0.956 0.299 0.933 -0.912
Pol 0.735 -0.126 0.755 0.927 0.984 0.512 0.7 0.262 0.879 -0.187 0.921 -0.876 0.84
MSD -0.476 0.039 -0.387 -0.612 -0.742 0.026 -0.448 -0.262 -0.617 0.444 -0.61 0.608 -0.507 -0.795
Har 0.843 -0.098 0.831 0.995 0.975 0.666 0.817 0.324 0.957 0.042 0.982 -0.945 0.954 0.956 -0.67
RHyDp 0.845 -0.09 0.827 0.993 0.974 0.657 0.82 0.33 0.957 0.04 0.979 -0.941 0.953 0.958 -0.677 1
ww 0.527 -0.283 0.699 0.813 0.891 0.49 0.514 0.02 0.724 -0.264 0.834 -0.718 0.688 0.891 -0.606 0.838 0.839
S0K 0.885 -0.01 0.819 0.976 0.909 0.719 0.862 0.38 0.945 0.206 0.955 -0.909 0.977 0.885 -0.55 0.97 0.97 0.78
Seig 0.606 -0.416 0.997 0.875 0.835 0.751 0.561 0.079 0.732 0.178 0.859 -0.861 0.828 0.796 -0.438 0.865 0.862 0.732 0.848
Har2 0.869 -0.058 0.823 0.992 0.956 0.667 0.848 0.35 0.963 0.09 0.974 -0.927 0.968 0.94 -0.645 0.996 0.997 0.823 0.98 0.857
ALOGP -0.128 -0.393 0.097 0.146 0.236 0.002 -0.191 -0.402 0.1 -0.294 0.193 -0.185 -0.008 0.24 -0.298 0.153 0.15 0.257 0.075 0.125 0.12
ALOGP2 -0.059 -0.355 0.128 0.196 0.282 0.056 -0.128 -0.347 0.155 -0.265 0.238 -0.223 0.051 0.276 -0.294 0.203 0.199 0.283 0.125 0.157 0.171 0.975
LogD -0.394 -0.664 0.035 -0.015 0.112 -0.135 -0.369 -0.675 -0.102 -0.525 0.046 0.022 -0.192 0.11 -0.168 0 -0.002 0.261 -0.122 0.043 -0.031 0.615 0.588
Rs -0.297 -0.511 0.051 -0.05 0.027 -0.242 -0.255 -0.446 -0.135 -0.337 -0.024 0.073 -0.145 0.041 -0.161 -0.031 -0.029 0.142 -0.097 0.052 -0.039 0.199 0.142 0.59
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5.3.3 Comparison of measured with predicted Rs variance 
As mentioned previously, the input data to the model has a strong 
influence on the accuracy of a models predictive ability. Measured Rs data can 
vary considerably when calibration studies are performed in the laboratory or 
field. Figure 5.9 showed the variance of experimental Rs and predicted Rs (across 
triplicate networks). The largest observed variance in the used dataset 
corresponded to the compound diclofop that had an RSD of (60 %, n=15 
measurements) [32]. Furthermore, Rs can often vary by more than two-fold 
depending on the experimental design used for estimation [33]. Thus, measured 
Rs data are not true values and so the predictive ability of the ANN could be 
hindered.  
The main difference between the two studies in the dataset, is that one 
method used static renewal whereas the second study used a flow-through 
system for Rs measurement [32, 34]. Whilst the experimental conditions were 
similar (pH, temperature) the difference between flow through and static renewal 
could result in significant difference between the Rs estimates. For example, 6 
compounds that were included in both studies had variable Rs values where the 
absolute variance for all 6 compounds was 0.088 ±0.072 L day-1 between 
measurements. The average RSD of the measured Rs data was 11 % with a 
mean standard deviation of ± 0.017 L d-1. The average variance across triplicate 
networks (RTD-based) for verification and test subsets was ± 0.023 L d-1 
indicating that the variance across predictions was similar to that of 
experimentally determined data. In 45 % of all cases the standard deviation was 
lower through predictive estimation of Rs than compared with experimental 
estimation of Rs.  
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Figure 5.9: Comparison of the measured variance in Rs against the variance in predicted Rs (n=73) from replicate RPLC-descriptor 
networks (n=3). Inset: Optimised 16-14-9-1 ANN model built using RPLC-derived molecular descriptors. 
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In particular cases, the experimental deviation was large for compounds 
such as diclofop, DET, DIA and ioxynil. The larger variations in measured values 
could potentially be caused by several factors such as flow rate, temperature and 
pH. Consideration of ANN predictions where experimental variation is large is 
important for evaluating the model performance. For example, acetochlor ESA 
had a poor predictive accuracy however the variance of the predicted values 
(across triplicate networks) overlapped with the reported experimental variation. 
A review by Harman et al., suggests that due to the influence of several factors 
and the error associated with measurements, reported Rs data should be 
considered as an approximation [49].  
A limitation in the passive sampling field for POCIS is that no standardised 
methods or guidelines for Rs determination exist. Therefore, comparison of 
literature values is difficult and the number of Rs data available for modelling 
applications is also limited. In the absence of these guidelines, the models shown 
herein offers similar accuracy and precision without the drawbacks of 
experimental determinations. Calibration experiments can take up to several 
weeks to several months that require large masses of reference material for flow-
through or static renewals. Furthermore, in situ experiments require high 
frequency sampling to determine water concentration leading to high costs in 
analysis. Overall, experimental determination is resource and labour intensive in 
comparison to modelling approaches that avoid these factors.  
 
5.3.4 Laboratory calibration of Rs and external validation of the ANN models  
In addition to the 73 compound dataset, the Rs was determined for several 
benzodiazepines to be used as an external test set to validate the models. Eight 
compounds including nitrazepam, clonazepam, lorazepam, oxazepam, 
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alprazolam, flunitrazepam, diazepam and midazolam were exposed to POCIS 
devices in a static renewal method at the same temperature and pH used in the 
original dataset. The selection of structurally similar compounds for the external 
test set was deliberate to ensure that the model could accurately predict Rs for 
compounds with similar molecular descriptors. Pharmaceuticals in the bulk and 
receiving phase were determined by a 5-point standard calibration curve fortified 



















Figure 5.10: SIL-IS 5-point calibration curve (50- 1000 ng L-1) for the 
eight benzodiazepine compounds. SIL-IS spiked at 1000 ng L-1. 
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The linearity of the calibration curves for all compounds ranged from R2=0.9856 
– 0.9994 and was acceptable for quantification purposes. The pharmaceutical 








      SD – standard deviation 
The initial concentrations of the pharmaceuticals were all close to the 
nominal value of 200 ng L-1 with the exception of midazolam that was determined 
at an average of 350 ng L-1. The concentrations of all pharmaceuticals declined 
by an average of 66 ng L-1 for samples that were taken at each time interval. The 
loss of compounds is attributed solely to the sorption of compound onto the 
receiving phase. A small degradation study (beaker with no POCIS devices) 
revealed that concentrations of compounds did not decrease over the two week 
period which indicated that degradation, volatilisation or sorption (to the beaker) 
were not significant. The total mass of pharmaceuticals accumulated by the 
POCIS devices were plotted over time in Figure 5.11.  
 
 ng L-1 







Nitrazepam 193 4 137 142 138 
Clonazepam 197 7 135 137 140 
Lorazepam 195 8 136 137 134 
Oxazepam 195 5 136 137 134 
Alprazolam 190 4 138 128 133 
Flunitrazepam 185 6 129 135 129 
Diazepam 226 12 144 143 145 
Midazolam 350 25 257 259 283 
Table 5.6: Benzodiazepine concentration determined in the exposure 
media. Initial concentration was determined in triplicate (nominal 
concentration was 200 ng L-1). 
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Figure 5.11: Accumulation of respective benzodiazepine compounds 
per POCIS device determined in triplicate across the two week 
exposure period.  
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The compounds alprazolam accumulated the least onto the HLB sorbent 
with an average total mass of 215 ng on day 14. Oxazepam accumulated the 
most with an average mass of 692 ng by the end of the exposure period. The 
deviation from linearity in the plots of sampler concentration versus time indicates 
that at 14 days these compounds are approaching the pseudo-linear phase 
where they are no longer suitable for calibration of Rs. Table 5.7 shows the 
estimated Rs for the eight benzodiazepines and the respective standard 
deviations.  
 
Compound Rs (L d-1) SD (L d-1) RSD (%) 
Nitrazepam 0.192 0.025 13 
Clonazepam 0.198 0.025 13 
Lorazepam 0.302 0.033 11 
Oxazepam 0.327 0.038 12 
Alprazolam 0.135 0.040 29 
Flunitrazepam 0.186 0.036 19 
Diazepam 0.173 0.039 23 
Midazolam 0.153 0.053 35 
 
The two compounds lorazepam and oxazepam were originally included 
the 73 compound dataset but were determined here to characterise the difference 
between the method of estimation used here and the method of Morin et al., [34]. 
The Rs determined by Morin et al., were lower by approximately 0.1 L d-1 for both 
compounds, indicating that the difference between static renewal and flow-
through estimates can be considerable. The standard deviations for the six 
compounds varied from ±0.024 to ±0.055 L d-1. The average RSD for all 
compounds was 20 ±6 % (flunitrazepam: 19 %; clonazepam: 13 %; nitrazepam: 
13 %; midazolam: 23%; diazepam: 23 %; and alprazolam: 29 %). The Rs for these 
six benzodiazepines were predicted by both optimised ANNs (RTD- and GSD-
models) and are shown in Figure 5.12.  
Table 5.7: Estimated Rs values (n=9) determined by 





Each model had only one benzodiazepine present in the training subset, 
which for the RTD-model was lorazepam and for the GSD-model was oxazepam. 
The RTD-model showed very good predictive accuracy for the external test set 
with all compounds predicted within 20 % of thee measured value. The two 
largest errors were predicted for diazepam and alprazolam with a 16 % and 17 
% inaccuracy, respectively. However, these two compounds also had the largest 
RSDs which indicated the variance could affect the predictive ability of the ANN. 
The remaining four benzodiazepines were ≤ 5 % inaccurate. The average 
absolute error for all compounds was 0.0145 L d-1. In comparison, the GSD-
model performed more poorly. The average absolute prediction error was ~3 fold 
higher at 0.0437 L d-1. The two largest errors corresponded to nitrazepam and 
midazolam that were 37 % and 43 % inaccurate, respectively.   
The poorer predictive accuracy of the GSD-model might have been related 
to the higher number of descriptors used by this model. As model complexity 






Figure 5.12: Raw residuals of predicted Rs for the 
benzodiazepine test set by both the GSD-model and RTD-
model. Parentheses show measured Rs value.  
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hidden layer, the potential for overfitting and a reduction in the generalisability of 
the model becomes greater. These predictions show that ANN modelling 
approaches are accurate enough for practical use in passive sampling works. 
Furthermore, future applications could be used for in situ calibrations where 
laboratory Rs estimates do not translate well into field Rs due to matrix effects and 
cases where Rs cannot be determined in the field [40]. In silico approaches offer 
a viable alternative to overcome these limitations. PSDs also have the potential 
to be used as a surrogate for biota in the determination of BCFs. Previous studies 
have demonstrated that concentrations in PSD devices are correlated with 
concentrations accumulated in benthic polychaetes and terrestrial Eisenia fetidia 
[50, 51]. However, in contrast to estimating Rs data, the PSDs are allowed to 
reach equilibrium where the elimination rate from the device is no longer 
negligible.  
 
Figure 5.13: Correlation of Rs and BCF for selected pharmaceutical 
compounds including; propranolol, metoprolol, warfarin, diclofenac, 
trimethoprim, ibuprofen, sulfamethazine, temazepam and carbamazepine. 
BCFs determined in Chapter 3 & 4, Rs data taken from [14, 15, 34].  



















Rs is very weakly correlated with BCF in biota (Figure 5.13). The reason 
for the poor correlation is that Rs is estimated when the device acts as a ‘sink,’ 
thus elimination is negligible. The equilibrated concentrations could be used to 
predict bioaccumulation potentials. However, whilst PSDs would take into 
account environmental influence (pH, flow, temperature etc.) and physico-
chemical properties of the compounds, they would fail to take into account biotic 
factors (i.e. metabolism, growth, respiration etc.). Thus, effects of elimination and 
uptake where carrier mediated uptake is also involved, will likely mean that 
bioaccumulation would be overestimated. The biomimetic properties of PSDs to 
be used as surrogates for BCF estimations is understudied and further works 
would be need to fully evaluate the potential of this application. Nevertheless, in 
silico modelling could offer a powerful approach in this type of application.   
 
5.3.5 The limitations of ANNs to modelling selected outputs  
As mentioned previously, model complexity can affect the performance of 
the models predictive ability. Complexity in the form of number of descriptors, 
hidden layers or hidden nodes all lead to an overfitting phenomenon. Overfitting 
occurs where models have learned the data they are given and have lost 
generalisability to make new predictions. However, increased model complexity, 
in some cases, is required to adequately model a desired response. With these 
cases, it essential to have a larger number of observations than inputs, otherwise 
models can lack any degrees of freedom thus losing statistical power to reject or 
accept a model. An initial ANN model was developed for the estimation of Rs 
(previous to the two models presented above). The model was feature selected 
using a forward selection algorithm, which down-selected 55 descriptors. Figure 
5.14 shows the 55:20:11:1 MLP, with R2 of 0.7168, 0.9721 and 0.9303 for the 
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training, verification and test subset, respectively. The verification and test subset 
showed excellent predictive accuracy whilst the training subset showed relatively 
lower accuracy. The training of the network can be halted early, when the 
verification error is low and the training error can remain relatively high. This is a 
form of regularisation known as early stopping which is used to prevent overfitting 
of ANNs [52].    
 
However, the model shown in Figure 5.14 was applied to the external test 
set of benzodiazepines which resulted in extremely poor predictions of ≥ 0.6 L d-
1, ~3-fold larger than the measured Rs values. The poor predictive accuracy 
suggested that the model was over-fitted to the data and had lost generalisability. 
Even with the use of regularisation, overfitting can remain problematic with the 
use of ANNs and likely resulted from the combination of a high number of input 
descriptors and small dataset used (n=73 cases).  To overcome potential 
Training: y = 0.9189x + 0.0179, R² = 0.7168
Test: y = 0.8332x + 0.0469, R² = 0.9721




















Measured Rs (L d
-1)
Figure 5.14: Regression analysis of predicted versus measured Rs data by 
a forward selected, 55:20:11:1 MLP. Crosses represent training data, circles 
varication data and triangles test data.  
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problems caused by overfitting it is essential that developed models are well 
tested with large datasets to ensure machine learning approaches are reliable 
when it comes to ‘real world’ application.  
 
5.4 Conclusions 
  Two ANN models were developed to predict Rs from POCIS samplers for 
a range of chemically diverse compounds covering pharmaceutical, pesticides, 
herbicides and endocrine disruptors. A feature selection algorithm known as a 
genetic algorithm was used to down-select descriptors relevant to prediction of 
Rs. This model showed good predictive accuracy for the verification and test 
subsets with an average absolute error of 0.028 ± 0.025 L d-1. An alternative 
approach used previously selected descriptors for chromatographic retention 
time prediction. This model again showed similar predictive ability with an 
average absolute error of 0.031 ± 0.021 L d-1. The interpretation of the models 
showed that descriptors related to hydrophobicity and Van der Waals interactions 
were dominant which agreed with previous mechanistic studies on sorption to 
POCIS sorbents. However, mechanistic interpretation of ANNs should be treated 
cautiously where collinearity or multicollinearity exists between input descriptors. 
Both optimised models were externally validated using laboratory calibrated Rs 
for several benzodiazepines. The calibrations showed that due to the decrease 
in water concentrations of static renewals, the use of flow-through calibrations 
allow more reliable and accurate determination of Rs. The model using retention 
descriptors showed better predictive performance in comparison to the model 
selected using the genetic algorithm. ANNs gave comparable reliability in 
predictions to experimental determinations of Rs showing that they have a good 
potential to be used for this application. However, the number of cases was 
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relatively small and so future works would need to be performed with a larger 
datasets to fully assess the applicability of ANNs in Rs prediction. Although, 
without established standardised guidelines and methods of Rs measurement the 
application of modelling approaches are likely to be hindered. Finally, critical 
evaluation of ANNs is of key importance as models can be prone to overfitting 
available data leading to poor predictive ability. With this in mind the performance 
of ANNs discussed in this Chapter suggest that ANNs could be used to model 
more complex uptake processes such as the accumulation potential of 
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Correction for Polar Passive Samplers  The PRC and the POCIS. 
Environmental Science & Technology, 2011. 45(21): p. 9120-9121. 
294 
 
18. Stephens, B.S., A. Kapernick, G. Eaglesham, and J. Mueller, Aquatic 
Passive Sampling of Herbicides on Naked Particle Loaded Membranes:  
Accelerated Measurement and Empirical Estimation of Kinetic 
Parameters. Environmental Science & Technology, 2005. 39(22): p. 8891-
8897. 
19. Niu, J., L. Wang, and Z. Yang, QSPRs on photodegradation half-lives of 
atmospheric chlorinated polycyclic aromatic hydrocarbons associated with 
particulates. Ecotoxicology and Environmental Safety, 2007. 66(2): p. 272-
277. 
20. Samghani, K. and M. HosseinFatemi, Developing a support vector 
machine based QSPR model for prediction of half-life of some herbicides. 
Ecotoxicology and Environmental Safety, 2016. 129: p. 10-15. 
21. Xu, H.-Y., J.-W. Zou, J.-Q. Min, and W. Wang, A quantitative structure–
property relationship analysis of soot–water partition coefficients for 
persistent organic pollutants. Ecotoxicology and Environmental Safety, 
2012. 80: p. 1-5. 
22. Sahlin, U., Uncertainty in QSAR predictions. Altern Lab Anim, 2013. 41(1): 
p. 111-25. 
23. Katritzky, A.R., V.S. Lobanov, and M. Karelson, QSPR: the correlation and 
quantitative prediction of chemical and physical properties from structure. 
Chem. Soc. Rev., 1995. 24(4): p. 279-287. 
24. Bade, R., L. Bijlsma, J.V. Sancho, and F. Hernández, Critical evaluation 
of a simple retention time predictor based on LogKow as a complementary 
tool in the identification of emerging contaminants in water. Talanta, 2015. 
139: p. 143-149. 
295 
 
25. Barron, L. and G. McEneff, Gradient liquid chromatographic retention time 
prediction for suspect screening applications: A critical assessment of a 
generalised artificial neural network-based approach across ten multi-
residue reversed-phase analytical methods Talanta, 2015. In Press. 
26. Luan, F., C. Xue, R. Zhang, C. Zhao, M. Liu, Z. Hu, and B. Fan, Prediction 
of retention time of a variety of volatile organic compounds based on the 
heuristic method and support vector machine. Analytica Chimica Acta, 
2005. 537(1–2): p. 101-110. 
27. Miller, T.H., A. Musenga, D.A. Cowan, and L.P. Barron, Prediction of 
Chromatographic Retention Time in High-Resolution Anti-Doping 
Screening Data Using Artificial Neural Networks. Analytical Chemistry, 
2013. 85(21): p. 10330-10337. 
28. Munro, K., T.H. Miller, C.P.B. Martins, A.M. Edge, D.A. Cowan, and L.P. 
Barron, Artificial neural network modelling of pharmaceutical residue 
retention times in wastewater extracts using gradient liquid 
chromatography-high resolution mass spectrometry data. Journal of 
Chromatography A, 2015. 1396: p. 34-44. 
29. Padmanabhan, J., R. Parthasarathi, V. Subramanian, and P.K. Chattaraj, 
QSPR models for polychlorinated biphenyls: n-Octanol/water partition 
coefficient. Bioorganic & Medicinal Chemistry, 2006. 14(4): p. 1021-1028. 
30. Barron, L., J. Havel, M. Purcell, M. Szpak, B. Kelleher, and B. Paull, 
Predicting sorption of pharmaceuticals and personal care products onto 
soil and digested sludge using artificial neural networks. Analyst, 2009. 
134(4): p. 663-670. 
31. Alvarez, D.A., J.D. Petty, J.N. Huckins, T.L. Jones-Lepp, D.T. Getting, J.P. 
Goddard, and S.E. Manahan, Development of a passive, in situ, 
296 
 
integrative sampler for hydrophilic organic contaminants in aquatic 
environments. Environmental Toxicology and Chemistry, 2004. 23(7): p. 
1640-1648. 
32. Fauvelle, V., N. Mazzella, F. Delmas, K. Madarassou, M. Eon, and H. 
Budzinski, Use of Mixed-Mode Ion Exchange Sorbent for the Passive 
Sampling of Organic Acids by Polar Organic Chemical Integrative Sampler 
(POCIS). Environmental Science & Technology, 2012. 46(24): p. 13344-
13353. 
33. Morin, N., C. Miège, M. Coquery, and J. Randon, Chemical calibration, 
performance, validation and applications of the polar organic chemical 
integrative sampler (POCIS) in aquatic environments. TrAC Trends in 
Analytical Chemistry, 2012. 36: p. 144-175. 
34. Morin, N., J. Camilleri, C. Cren-Olivé, M. Coquery, and C. Miège, 
Determination of uptake kinetics and sampling rates for 56 organic 
micropollutants using “pharmaceutical” POCIS. Talanta, 2013. 109: p. 61-
73. 
35. Bäuerlein, P.S., J.E. Mansell, T.L. ter Laak, and P. de Voogt, Sorption 
Behavior of Charged and Neutral Polar Organic Compounds on Solid 
Phase Extraction Materials: Which Functional Group Governs Sorption? 
Environmental Science & Technology, 2012. 46(2): p. 954-961. 
36. Dorsey, J.G. and K.A. Dill, The molecular mechanism of retention in 
reversed-phase liquid chromatography. Chemical Reviews, 1989. 89(2): 
p. 331-346. 
37. Vrana, B., G.A. Mills, M. Kotterman, P. Leonards, K. Booij, and R. 
Greenwood, Modelling and field application of the Chemcatcher passive 
297 
 
sampler calibration data for the monitoring of hydrophobic organic 
pollutants in water. Environmental Pollution, 2007. 145(3): p. 895-904. 
38. Gramatica, P., M. Corradi, and V. Consonni, Modelling and prediction of 
soil sorption coefficients of non-ionic organic pesticides by molecular 
descriptors. Chemosphere, 2000. 41(5): p. 763-777. 
39. Vermeirssen, E.L.M., C. Dietschweiler, B.I. Escher, J. van der Voet, and 
J. Hollender, Transfer Kinetics of Polar Organic Compounds over 
Polyethersulfone Membranes in the Passive Samplers Pocis and 
Chemcatcher. Environmental Science & Technology, 2012. 46(12): p. 
6759-6766. 
40. Moschet, C., E.L.M. Vermeirssen, H. Singer, C. Stamm, and J. Hollender, 
Evaluation of in-situ calibration of Chemcatcher passive samplers for 322 
micropollutants in agricultural and urban affected rivers. Water Research, 
2015. 71: p. 306-317. 
41. Li, H., P.A. Helm, G. Paterson, and C.D. Metcalfe, The effects of dissolved 
organic matter and pH on sampling rates for polar organic chemical 
integrative samplers (POCIS). Chemosphere, 2011. 83(3): p. 271-280. 
42. Rusina, T.P., F. Smedes, M. Koblizkova, and J. Klanova, Calibration of 
silicone rubber passive samplers: experimental and modeled relations 
between sampling rate and compound properties. Environmental science 
& technology, 2009. 44(1): p. 362-367. 
43. Alvarez, D.A., J.D. Petty, J.N. Huckins, T.L. Jones‐ Lepp, D.T. Getting, 
J.P. Goddard, and S.E. Manahan, Development of a passive, in situ, 
integrative sampler for hydrophilic organic contaminants in aquatic 




44. La-Scalea, M.A., C.M.S. Menezes, and E.I. Ferreira, Molecular volume 
calculation using AM1 semi-empirical method toward diffusion coefficients 
and electrophoretic mobility estimates in aqueous solution. Journal of 
Molecular Structure: THEOCHEM, 2005. 730(1): p. 111-120. 
45. Gharagheizi, F., Determination of diffusion coefficient of organic 
compounds in water using a simple molecular-based method. Industrial & 
Engineering Chemistry Research, 2012. 51(6): p. 2797-2803. 
46. Schramke, J.A., S.F. Murphy, W.J. Doucette, and W.D. Hintze, Prediction 
of aqueous diffusion coefficients for organic compounds at 25 C. 
Chemosphere, 1999. 38(10): p. 2381-2406. 
47. Dormann, C.F., J. Elith, S. Bacher, C. Buchmann, G. Carl, G. Carré, J.R.G. 
Marquéz, B. Gruber, B. Lafourcade, P.J. Leitão, T. Münkemüller, C. 
McClean, P.E. Osborne, B. Reineking, B. Schröder, A.K. Skidmore, D. 
Zurell, and S. Lautenbach, Collinearity: a review of methods to deal with it 
and a simulation study evaluating their performance. Ecography, 2013. 
36(1): p. 27-46. 
48. Mason, C.H. and W.D. Perreault Jr, Collinearity, power, and interpretation 
of multiple regression analysis. Journal of marketing research, 1991: p. 
268-280. 
49. Harman, C., I.J. Allan, and E.L.M. Vermeirssen, Calibration and use of the 
polar organic chemical integrative sampler—a critical review. 
Environmental Toxicology and Chemistry, 2012. 31(12): p. 2724-2738. 
50. Vinturella, A.E., R.M. Burgess, B.A. Coull, K.M. Thompson, and J.P. 
Shine, Use of Passive Samplers To Mimic Uptake of Polycyclic Aromatic 
Hydrocarbons by Benthic Polychaetes. Environmental Science & 
Technology, 2004. 38(4): p. 1154-1160. 
299 
 
51. Gomez-Eyles, J.L., M.T.O. Jonker, M.E. Hodson, and C.D. Collins, 
Passive Samplers Provide a Better Prediction of PAH Bioaccumulation in 
Earthworms and Plant Roots than Exhaustive, Mild Solvent, and 
Cyclodextrin Extractions. Environmental Science & Technology, 2012. 
46(2): p. 962-969. 
52. Almeida, J.S., Predictive non-linear modeling of complex data by artificial 





Chapter 6. The application of artificial neural networks to predict 
bioconcentration factors in fish and invertebrates. 
 
6.1 Introduction 
Under REACH [1], guidelines are provided for industries to ensure that 
their products do not cause adverse harm to human health and the environment. 
The document states that any chemical manufactured in quantities exceeding 10 
tonnes per annum must submit a chemical safety assessment (CSA).  
For environmental risk assessment, one important part of the CSA is the 
persistent, bioaccumulative and toxicity (PBT) assessment that evaluates the 
potential of environmental harm using a weight-of-evidence approach. This 
approach involves the use of all available data to assess a chemical substance. 
The bioaccumulation potential is important to characterise the risk posed to biota 
and this part of the assessment uses all available screening and assessment 
information to identify whether a chemical will reach the thresholds of 
bioaccumulative (B) or very bioacccumlative (vB). Screening information 
comprises relatively simple data such as physico-chemical properties including 
molecular size, logP, octanol solubility, biomimetic properties of passive sampling 
devices and read-across information [2].  
Part of the read-across information is the use of quantitative structure 
activity relationships (QSAR) which use a set of molecular descriptors to predict 
an output such as a BCF. Read-across can either have a biological or chemical 
basis [3], where chemical read-across uses similarity of chemical classes to 
predict endpoints. In the biological read-across the conservation of molecular 
targets and receptors across different taxonomic groups are used to predict 
endpoints. QSARs are becoming increasingly popular within ecotoxicological 
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fields as they represent, perhaps, the only realistically feasible scenario to assess 
the environmental risk of the several thousand chemicals that are available on 
the market [4]. In addition, QSAR models can be used to reduce or replace animal 
testing as suggested by the replacement, reduction and refinement (3Rs) 
framework which is an important ethical consideration [5].  
QSARs can be relatively simple using linear regression methods or can 
become increasingly complex where in silico approaches are used such as 
artificial neural networks (ANNs) or support vector machines (SVMs). Many early 
models were linear regressions that were trained on a relatively small number of 
hydrophobic organic contaminants [6-8]. As hydrophobicity has been 
demonstrated to be a predominant factor in bioaccumulation these models often 
used logP as an input descriptor which fails to take into account the ionisation 
state of a compound [9]. Other input descriptors used have covered molecular 
size, topological and geometrical descriptors among others [10-12]. More 
recently, authors have used more complex QSARs involving artificial neural 
networks and support vector machines to model BCFs [13-15]. However, the 
ANN modelling used in only one investigation showed predictions for only 9 test 
compounds. Therefore, the reliability of the model for BCF estimation is low. The 
use of complex models has been demonstrated to offer better predictive accuracy 
than simpler models [16]. In addition to the use of QSARs for PBT assessments, 
modelling approaches can allow mechanistic interpretation of descriptors to 
identify factors that influence the bioaccumulation potential. QSAR models have 
only been applied to modelling fish BCF data (e.g. Cyprinus carpio, Pimephales 
promelas and Onchorhynchus mykiss) due to the availability of relatively large 
datasets [9]. However, the potential for bioaccumulation in other taxa such as the 
invertebrates is not well characterised. At present, invertebrate models do not 
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exist as there is a lack of available data. The development of QSAR models for 
the invertebrate phyla would begin to address the knowledge gap relate to the 
bioaccumulation potential in these animals.  
The aim of this work was to evaluate the use of ANNs to model BCFs in 
both fish and invertebrates. A large fish dataset would be used to develop ANN 
models to improve the accuracy and reliability in comparison to the single ANN 
study reported in the literature. The developed model would be applied to 
invertebrate BCF data reported from the literature and in previous chapters to 
assess the potential for cross-species prediction. In addition, separate modelling 
was applied to the available invertebrate data. Finally, the developed models 
would be used to interpret the importance of molecular descriptors to the ability 
of a chemical to accumulate in biota. The presented work aims to improve on 
currently available QSAR models for environmental risk assessment.  
 
6.2 Materials & methods 
6.2.1 Descriptor generation  
Bioconcentration factors were collated from the Cefic LRI project EC07 in 
collaboration with EURAS which established the BCF gold standard database 
across multiple fish species and is freely available at 
http://ambit.sourceforge.net/euras/. BCFs were down-selected to reduce 
variability between different species and experimental conditions. The BCFs were 
selected from the fish species Cyprinus carpio reported from the Chemicals 
Inspection and Testing Institute (now the Chemicals Evaluation and Research 
Institute, CERI). Using the single reference source resulted in the largest sample 
(n=353) of BCFs for modelling purposes. The reported BCFs covered compounds 
including pigments, pesticides, fungicides, herbicides, insecticides, polyaromatic 
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hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs). Other compounds 
within the dataset included organochlorines, nitroaromatics, alkylphenols, 
aromatic hydrocarbons, organosulfurs and organotins which generally serve as 
precursors to compounds such as pesticides, plastic polymers, detergents, dyes 
etc., during industrial synthesis. The invertebrate BCF dataset (n=34) was 
collated from literature reported data [17-20] and from data presented in Chapters 
3 & 4 for the species G. pulex. The dataset was comprised of only 
pharmaceuticals and pesticides. Simplified molecular input line entry system 
(SMILES) strings were generated from Chemspider (Royal Society of Chemistry, 
UK). Molecular descriptors as inputs for BCF prediction were generated from 
SMILES strings using Parameter Client (Virtual Computational Chemistry 
Laboratory, Munich, Germany), and ACD Labs Percepta (Advanced Chemistry 
Development Laboratories, ON, Canada). A total of 180 descriptors were 
generated which covered constitutional, topological, geometrical and physico-
chemical properties.   
 
6.2.2 Descriptor selection for ANN modelling 
Descriptors were down-selected using three different algorithms, the first 
of which was a genetic algorithm (GA). The GA converts descriptors into binary 
strings which are then used in a generalised neural network (GRNN) to assess 
accuracy. The GA parameters were set to population = 500, generations = 250, 
mutation rate = 0.1 and cross-over rate = 1. The remaining two selection methods 
were part of stepwise regression which included a forwards selection algorithm 
(FA) and backwards selection algorithm (BA). The FA is initialised by including 
only 1 descriptor to model the desired output, then a second descriptor is included 
and a new model is assessed for performance. This process is repeated until 
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model performance does not improve. In BA the opposite occurs, initially all 
descriptors are included and then single descriptors are sequentially removed 
until model performance no longer increases. The feature selection algorithms 
used a GRNN to monitor the error associated with the selected descriptors, where 
descriptor sets were optimised when the error showed no improvement. The use 
of GRNN for descriptor selection is that they are very fast and require minimal 
processing power.   
 
6.2.3 Model design and optimisation  
Several neural network types were tested Trajan 6.0 neural network 
software (Trajan Software Ltd., Lincolnshire, UK) which included generalised 
regression neural networks (GRNN), radial basis function networks (RBF) and 
multilayer perceptrons (MLP). From the down-selection of input descriptors the 
optimised model was a four layer MLP which used two training algorithms 
referred to as back propagation (BP) and conjugate gradient descent (CGD). The 
first and fourth layers were the inputs (molecular descriptors) and outputs 
(logBCF), respectively. The second and third layers (hidden layers) contained 10 
and 8 nodes, respectively. Regularisation was performed with the use of early 
stopping to prevent over-training of the dataset. The subsets of cases presented 
to the neural networks were split so that 242 compounds were used for training 
(70 %), 55 compounds for verification (15 %) and 55 compounds for testing the 







6.3 Results & discussion 
 
6.3.1 Feature selection of descriptors to predict bioconcentration factors 
The reduction in the number of descriptors is desirable so that inputs which 
are not associated to the selected output are removed. The decrease in the 
number of inputs can also prevent over-fitting of the model, allowing better 
generalisablity. In particular, for applications when the sample size is relatively 
low. The first stepwise algorithm was FA that was used in two successions. The 
descriptor sets that were down-selected were then used to model logBCF (Figure 
6.1). These models showed the lowest errors across the verification and test 
subsets and gave overall R2 of 0.7448 and 0.7629 between the successive 
rounds of forwards selection.  
In a second approach, BA was used in two successive rounds of feature 
selection. Training of the BA selected descriptor sets also produced identical 
models to those shown in Figure 6.1, indicating that either FA or BA selection did 
not differ during feature selection and selected the same descriptors. Training 
length of the descriptor set was increased to observe any possible improvement 













































Figure 6.1: Regression analysis of the forwards selected MLPs. (a) first round of forwards 




in the performance of the models. The training resulted in an improved model 
shown in Figure 6.2, which had an overall R2 of 0.7825 which showed a slight 
improvement to the models presented in Figure 6.1. The individual subsets had 
an R2 of 0.8377 for the training set, 0.738 for the verification set and 0.6025 for 
the test set. As an alternative to stepwise feature selection, a GA was used to 
down select the number of independent variables. The again successive rounds 
of the GA was used to reduce the number of descriptors to a total of 66 from 180. 




Training of MLPs using the GA-descriptors resulted in a model (Figure 6.3) 
that showed similar performance to the BA-model previously shown. The 
individual R2 for the training, verification and test subsets were 0.8765, 0.7734 
and 0.5967, respectively. The root mean square error (RMSE) of the verification 
and test set was 0.55 and 0.70, respectively. The model showed good 
improvement in the training set whereas the verification and test subset were 
Training Set R² = 0.8377
Verification Set R² = 0.738





















Figure 6.2: Regression analysis of the backwards selected 
MLP. Crosses represent the training set, circles represent 
the verification subset and triangles represent the test set.  
307 
 
slightly worse than when compared to the BA-model. Whilst the performance of 
the models were relatively good the number of descriptors remained high and 
further optimisation of the models was required. The descriptor set selected by 
the GA was used in further modelling attempts. The reason for the selection of 
the GA descriptor set over the stepwise algorithms is that GA finds a solution 
from multiple points in the population of the descriptors whereas stepwise will find 




The 66 descriptors from the GA-model were reduced in number by 
arbitrarily selecting the 22 most important descriptors to the model shown in Table 
6.1. In addition to these descriptors, an additional two were included that were 
logD and the number of hydrogen acceptor groups (Hacc) as these descriptors 
might be important when predicting BCFs of pharmaceuticals. Previous 
investigations have shown varying relationships between logD and 
bioconcentration. Furthermore, the majority of pharmaceuticals contain amine 
groups which act as weak bases. The final descriptor list is shown in Table 6.1 
and was used to optimise ANNs further.  
Training SetR² = 0.8765
Verification Set R² = 0.7334





















Figure 6.3: Regression analysis of the GA MLP. Crosses 
represent the training set, circles represent the 


















Initially, all descriptors were included and used to train MLPs until the 
lowest error across the verification and test subset was observed. A four-layer 
MLP was selected (Figure 6.4) which demonstrated RMSE across the verification 
and test subset of 0.53 and 0.68, respectively.  The model showed an R2 of 
0.8153 for the training subset, 0.813 for the verification subset and 0.6469 for the 
test subset. Overall, the model showed slightly better performance compared to 
previous models using larger numbers of descriptors. Whilst the number of 
descriptors was decreased substantially from the original dataset there is the 
Descriptor  
Error 
Ratio  Rank  
MAXDP 1.4036 1 
TPSA(Tot) 1.3564 2 
SPI 1.154 3 
STN 1.1336 4 
MAXDN 1.0947 5 
MW 1.0932 6 
ICR 1.0911 7 
ASP 1.088 8 
nN 1.0772 9 
Ms 1.0757 10 
nR06 1.075 11 
nH 1.074 12 
Ram 1.074 13 
nCL 1.073 14 
Hdon 1.071 15 
nX 1.068 16 
Dz 1.067 17 
nCIC 1.064 18 
Me 1.062 19 
Hnar 1.06 20 
nO 1.055 21 
nC 1.055 22 
Table 6.1: Top 22 descriptors selected from the GA-MLP 
based on ranking determined by their respective error ratio.  
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potential that 24 descriptors was still too many and could be limiting the 
performance of the network and the generalisability to new data.  
An ideal model should maintain simplicity whilst still being able to map the 
output function. Therefore, a subset of the 24 descriptors was selected at random 
by the software based on improved model accuracy. The subset contained 14 
descriptors and was used to develop an optimised model with a 14:14-10:1 
architecture. The model showed improvement in all data subsets when compared 
to the previous model with 24 input descriptors. The R2 of the 14 descriptor model 
was 0.8874 for the training set, 0.8191 for the verification set and 0.7021 for the 
test set (Figure 6.5). Analysis of the raw residuals for both the verification and 
test subsets showed that 64 % of the cases were predicted to within ±0.5 logBCF 
units (Figure 6.6). The average absolute error (± SD) of the verification subset 
was 0.38 ±0.36 logBCF units and 0.53 ±0.36 logBCF units for the test subset. 
These errors when transformed correspond to average absolute errors of 2037 L 
kg-1 for the verification and 1092 L kg-1 for the test set.   
Training Set R² = 0.8153
Verification Set R² = 0.813





















Figure 6.4: Regression of the 24 descriptor MLP. Crosses represent the training 




Previous investigations have used linear regressions in QSARs to predict 
BCFs with some success [8, 9]. Dearden and Shinnawei used a QSAR approach 
to predict BCFs for 135 chemicals with an R2 of 0.637 and a standard error of the 
estimate of 0.661 logBCF units, in comparison to the 14 descriptor MLP 
Training Set R² = 0.8874
Verification Set R² = 0.8191






















Figure 6.5: Regression of the 14 descriptor MLP. 
Crosses represent the training set, circles represent the 


















Figure 6.6: Raw residuals of the verification and test 
subsets in the 14 descriptor MLP. 
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presented herein with an average standard error 0.58 logBCF units [11]. Another 
QSAR model by Sahu and Singh [21] used multiple linear regression to predict 
BCFs for 131 organic compounds with a standard error of estimate of 0.556 log 
units. However, this model was not applied to a test dataset, thus the reliability of 
the model is unknown. A majority of QSAR approaches use logP as a descriptor 
and therefore were limited for those compounds with logP >6 due to poor diffusion 
through cellular membranes [22] or those which are ionisable such as 
pharmaceuticals. In alternative approaches to linear QSAR models, ANNs have 
been applied to BCF prediction similar to this work. A MLP predicted BCFs for 9 
test compounds with an average absolute error of 0.33 ±0.22 log units [15]. 
Whilst, the error is relatively low, the assessment of the MLP performance and 
generalisability is extremely limited due to the low number of compounds used 
for testing. In a second attempt to use machine learning, Zhao et al., used support 
vector machines to predict BCFs [14]. The model showed an R2 of 0.6917 for an 
external test set with a standard deviation in error of prediction of 0.69 logBCF 
units for 119 compounds.  
Comparison of literature data with the model presented above 
demonstrated that the performance of the MLP herein showed improvement to 
the predictive models currently available. Whilst the 14 descriptor MLP showed 
relatively good predictive accuracy, there were particular cases within the 
verification and test subsets showed large relative percentage errors of their 
measured value. The percentage error was plotted against the measured BCF 
value which indicated that below a threshold the BCF prediction error increased 
(Figure 6.7). For cases that had a logBCF <1 the percentage error increased 




The largest error corresponded to a dye referred to as azoic coupling 
component 5 which is a moderately hydrophobic compound (logD7 = 3.41) that is 
insoluble in water which may potentially explain its low logBCF of 0.2. Several 
other large errors (>50 %) corresponded to range of chemically diverse 
compounds which were absent of structural similarity. The lower errors for these 
compounds may be explained by analogous training cases. Azoic coupling 
component 2 was present in the training set and showed poor predictive accuracy 
(77 % inaccuracy) which could potentially explain the poor prediction of azoic 
coupling component 5. In a second example, two benzoic acid analogues that 
showed poor performance in the verification/test subset also corresponded to 
benzoic acid in the training data that was 78 % inaccurate. In another case, two 
compounds which contained phosphate (triallylphosphate and triethylphosphate) 
showed poor training accuracy which also paralleled two inaccurate compounds 
with phosphate groups in the verification/test subsets (tris(1,3-dichloroisopropyl) 


















Figure 6.7: The percentage inaccuracy of the verification and test subsets from 
the 14 descriptor MLP relative to the measure logBCF. Structure inset is azoic 
coupling component 5 and corresponded to the largest relative error.  
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predictive accuracy may not always be explained by the training data. Two 
phosphate containing compounds in the training subset showed relatively good 
predictive accuracy, tris(2-ethylhexyl) phosphate (23 % error) and tris(2-
butoxyethyl) phosphate (34 % error).  
BCFs should only be considered an estimate as they are subject to 
experimental error and variance in their determination. Therefore, the precision 
and absolute error of predictions might not be considered as important as in other 
modelling applications. What is of crucial value for modelling BCFs is whether 
models can correctly classify molecules as bioaccumulative (B) or very 
bioaccumulative (vB) during PBT testing under REACH guidelines. The threshold 
values of B is a BCF of 2000 and for vB is a BCF of 5000, regardless of the exact 
value if these thresholds are exceeded regulation around the chemical will be 
enforced. The use of the 14 descriptor MLP as a categorical classifier was 
evaluated by assessing the number of correctly classified cases in the verification 
and test subsets (Figure 6.8). The model demonstrated good performance as a 
classifier with 98 compounds correctly classified as either non-bioaccumulative, 
B or vB. However, the model incorrectly classified a total of 12 cases with 5 
identified as false positives and 7 as false negatives. Within the false negative 
category two cases, 2,2',3,3'-tetrachloro-4,4'-diaminodiphenylmethan and 
1,2,4,5-tetrachlorobenzene, were identified as vB instead of B and the remaining 
compounds were predicted as non-bioaccumulative instead of B/vB. The false 
negatives classed as non-bioaccumulative would pose the most risk to the 
environment whereas false positives would likely lead to economic losses for the 
producers of the chemical. With this in mind it should still be considered that this 
model could aid in prioritisation efforts. Furthermore, to avoid a situation of 
over/under regulation a threshold tolerance could be applied to the predicted 
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values so that if the BCF was within a certain percentage of the REACH threshold 
for B or vB experimental testing could be pursued.  
Zhao et al., also showed a similar misclassification rate of 10 % for all 
compounds tested [14]. However, a bias was applied to the data which reduced 
to the misclassification to 0 %. Whilst the MLP showed acceptable predictive 
accuracy for the tested data, the model will only perform as well as the data it is 
trained on. It has been shown that estimation of BCFs can suffer from many 
sources of error and variation including instrumental performance (analysis), 
kinetic modelling approaches (Chapter 3), biological variability (age, health, lipid 
content etc.) and experimental conditions (pH, temperature, dissolved oxygen 
etc.) [23-26]. Due to these numerous sources of error and variation, reported 
BCFs have differed by 1-2 orders of magnitude [27] even within the same 
species. Furthermore, experimental conditions may not be recorded or reported. 
For example, the BCF gold standard dataset used herein did not report individual 
pH values for the BCF experiments. Instead the dataset described only the range 
of pH which varied from 6.0 to 8.5. BCFs have been previously demonstrated to 
















Figure 6.8: The percentage of compounds in the verification 
and test subsets (n =110) correctly classified or predicted as 
a false positive or negative relative to PBT testing thresholds. 
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be limited by descriptors that require pH data, such as logD unless it is measured 
during experiments. For simplicity here, the logD descriptor was calculated at a 
pH of 7 but this value could differ significantly if the exposure pH was different, 
thus leading to limitations in the current modelling approach. Furthermore, 
predicted physicochemical properties such as those used here (i.e. logD from 
ACD labs) could also limit the predictive ability of the model. As these estimated 
properties will contain some uncertainty it is possible that departure from the true 
value may hinder the model from learning the trends in the data. Furthermore, as 
the majority of chemical descriptors (with the exception of constitutional 
descriptors) are estimated the full extent to which this will affect the predictive 
ability of machine learning approaches is beyond the scope of this work. Thus, 
where available experimentally determined data is recommended over the use of 
predicted input descriptors (even with the errors associated with experimental 
measurement) as suggested by [28].   
In addition to the reliability of BCF estimates, it is also possible that BCF 
prediction will be limited by biotic factors. The descriptors used in the model are 
abiotic and only cover the physico-chemical properties of the compounds studied. 
Biotic factors such as ventilation rates, age, and metabolic rates could affect BCF 
estimates and thus the model would not account for these variables [29]. Thus, 
QSAR approaches, whether linear or non-linear, omit the biology which would 
likely explain the variation in the data not described by the chemistry of the 
molecules. However, even with the limitations discussed, the in silico approach 
presented could potentially offer a much needed alternative to the experimental 
determination of BCFs that are costly and both time and labour intensive. At the 
very least the use of ANNs could direct prioritisation efforts for compounds that 
may lead to the greatest environmental risk.  
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6.3.2 Cross-species prediction of bioconcentration factors in invertebrates 
Bioconcentration studies at present have focussed on fish species with 
little attention towards the invertebrate phyla. This phyla is the largest and most 
diverse animal group. Thus, determining the behaviour of contaminants across 
the invertebrates will be crucial to assessing environmental risk. The primary site 
of bioconcentration in aquatic animals is across the gills [30] with the exception 
of sediment-dwelling organisms that is likely to be through dermal contact. There 
is a potential for significant difference of BCFs between the vertebrate and 
invertebrate phyla. The difference between the phyla will manifest through 
biological and physiological variables including size, enzyme specification, lipid 
content, and respiration strategy among others [31]. Even within the same taxa 












Whilst models exist for the prediction of BCF in fish currently there are no 
models available for invertebrates. The lack of available BCF data is the main 
limitation for modelling approaches to predict the bioconcentration potential in 




















Figure 6.9: Cross species prediction using the 14 
descriptor MLP to predict the measured G. pulex BCFs. 
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invertebrates. However, as the model above demonstrated acceptable predictive 
accuracy for prediction of BCFs in a fish species it had the potential to be used in 
cross species prediction. BCFs generated in Chapters 3 & 4 along with literature 
reported data were used to determine whether the previously described model 
would adequately predict bioconcentration in the arthropod, G. pulex. The 
regression between predicted BCFs using the fish-based model and the 
measured BCFs in G. pulex showed a weak correlation of R2 0.3295 suggesting 
that the generalisation between the species was relatively poor (Figure 6.9). The 
average absolute error was 0.80 ±0.65 log units which corresponded to 45 % 
inaccuracy, indicating lower predictive accuracy and greater variance compared 
with the BCF predictions for fish. The largest absolute error corresponded to the 
compound imipramine which was over estimated by 2.7 logBCF units (Figure 
6.10).  
The over-estimation was interesting as this compound was previously 
shown in Chapter 3 to have a variable BCF (212 – 4533) depending on the 
method of estimation (simultaneous versus sequential). The variability stemmed 
from statistically significant lacks-of-fit of the kinetic models which further 
indicates that the reliability of BCFs may limit the predictive ability of modelling 
approaches. The low accuracy of the cross-species prediction may also be in 
relation to the factors mentioned above where biological and physiological traits 
are considerably variable between fish and invertebrates. A previous 
investigation found that there is a significant difference in BCFs between trophic 
levels with higher trophic levels having increased BCFs [32]. This trend would 
suggest that the BCF predictions of the invertebrates might be overestimated but 
the opposite was observed with approximately 62% of cases underestimated. In 
addition to the biological complexity between species, another confounding factor 
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The fish-based modelling included no pharmaceutical compounds within 
the dataset whereas the invertebrate BCFs contained 18 compounds that were 
classed as pharmaceuticals. This class of compounds is uniquely placed relative 
to the other classes of compounds present in the dataset. Pharmaceuticals are 
amphoteric molecules with multiples sites of ionisation. Thus, their 
bioconcentration potential may not follow similar relationships with neutral 
hydrophobic organic contaminants such as PCBs and PAHs. As the model has 
not encountered pharmaceuticals previously, it is possible that the 































































































































































































































































































reinitialised and trained ab initio using the invertebrate BCF data with the same 













A 4-layer MLP with a 14:14-10:1 architecture demonstrated good 
predictive accuracy for this limited dataset (Figure 6.11). The regression of the 
data subsets gave an overall R2 of 0.9605 with 0.972 for the training set, 0.9932 
for the verification set and 0.9323 for the test set. The successful retraining of the 
model to invertebrate data suggests that cross species prediction might be 
difficult due to the biological variation between different taxa. Overall, the model 
demonstrated good accuracy across the verification and test subset with an 
average absolute error of 0.07 ±0.08 logBCF units for the verification set and 0.29 
±0.27 logBCF units for the test set. Whilst the predictive accuracy of the retrained 
model is relatively good it is also limited due to the number of cases used in the 
verification and test subsets. A much larger dataset would be needed to fully 
Training Set R² = 0.972
Verification Set R² = 0.9932




















Figure 6.11: Regression of the 14 descriptor MLP 
retrained using the invertebrate dataset. Crosses 
are training data, circles are verification data and 
triangles are test data. 
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validate the models performance but nevertheless the model demonstrates a 
very good potential for the prediction of BCF data for an invertebrate species.    
6.3.4 Importance of descriptors related to species and compound class 
The importance of the 14 descriptors to the MLP for the fish-based and 
invertebrate-based models was assessed. The sensitivity of the network to the 
input descriptors for the fish-based model is shown in Figure 6.12. The most 
important descriptor determined was the topological polar surface area (TPSA) 
with an error ratio of 2.08 which indicated that the model error increased the most 
upon removal of this descriptor. Previous investigations have demonstrated that 
descriptors related to polarizability, hydrophobicity and hydrogen bonding of the 
molecule is important to modelling BCFs [11, 14, 33]. TPSA is defined as the 
surface area occupied by nitrogen and oxygen atoms including connected 
hydrogen atoms [34].  
This descriptor is related to both polarity of the molecule and the hydrogen 
bonding capacity and thus will reflect the ability of the molecule to permeate 
membrane barriers. In medicinal applications, a lower TPSA is more successful 















































Figure 6.12: Sensitivity analysis of the 14 
descriptors in the fish-based MLP. 
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collinearity assessment, where there was an observed negative Pearson’s 
correlation of -0.403 between logBCF and TPSA (Table 6.2). The negative sign 
also agrees with an investigation by Papa et al., which identified the same trend 
between TPSA and bioconcentration [35]. The relationship between 
bioconcentration and TPSA may be as a result of several factors. First, the 
increased permeation of molecules with lower TPSA through membranes may be 
explained by the hydrophobic lipid bilayer as it would retard diffusion of 
increasingly polar molecules. Secondly, it is also possible that the polar groups 
may bind to membrane surfaces instead of diffusing across the epithelium. The 
final consideration of TPSA is that it will also relate to the hydration shell around 
a molecule and thus a compounds solubility in water [36, 37].  
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Table 6.2: Collinearity assessment of the 14 descriptors used in the fish-based MLP using Pearsons’ correlation. 
MW Me nH nC nN ICR MAXDN MAXDP Hnar STN TPSA logD Ram SPI
Me 0.135
nH 0.401 -0.55
nC 0.619 -0.448 0.774
nN 0.097 0.003 0.035 0.139
ICR 0.581 -0.273 0.603 0.768 0.258
MAXDN 0.385 0.61 -0.052 0.001 0.11 0.192
MAXDP 0.466 0.181 0.243 0.396 0.203 0.452 0.653
Hnar 0.023 -0.549 0.216 0.506 0.13 0.309 -0.362 -0.06
STN 0.275 -0.241 0.02 0.56 0.177 0.306 -0.132 0.19 0.748
TPSA 0.274 0.095 0.124 0.183 0.589 0.391 0.505 0.589 -0.016 0.095
logD 0.453 -0.092 0.358 0.475 -0.213 0.347 0.002 0.029 0.179 0.211 -0.221
Ram 0.696 0.231 0.107 0.497 0.156 0.361 0.443 0.526 0.015 0.522 0.305 0.259
SPI 0.794 0.169 0.437 0.558 0.21 0.566 0.557 0.634 -0.227 0.074 0.442 0.28 0.787
logBCF 0.295 -0.147 0.137 0.341 -0.295 0.104 -0.228 -0.197 0.248 0.368 -0.403 0.455 0.309 0.121
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Another important descriptor was molecular weight (MW) which may be 
expected as the size of a molecule will affect permeation and diffusion through 
membranes as demonstrated by Lipinski’s rule of 5 in pharmaceutical 
development [38]. These rules are used to ensure that pharmaceuticals will be 
bioavailable during oral dose administration. It has been demonstrated that dye 
pigments did not show bioaccumulation in fish as a result of their molecular size 
[39]. In another study, it suggested that there was a threshold diameter value of 
1.5 nm which governed bioconcentration in addition to hydrophobicity [40]. As 
molecular weight is a function of molecular size it is no surprise that MW was 
important to the model.  
The descriptors STN, Hnar, Ram, SPI and ICR are topological descriptors 
that relate to chemical graph theory. Chemical graph theory is used to represent 
a molecules structure where vertices correspond to atoms, edges correspond to 
chemical bonds and vertex degrees are the number of bonds associated with an 
atom [41]. The indices can be useful for differentiating between structural isomers 
(with the exception of optical isomerism) and have been used in many fields to 
determine and interpret relationships between different processes and activities. 
The descriptors STN (spanning tree number), Hnar (Narumi harmonic topoligcal 
index) and Ram (ramification index) were important to the model by varying 
degrees (error ratio 1.35 – 1.72). These descriptors are indices that are related 
to molecular branching (in acyclic and polycyclic graphs). The importance of 
these descriptors to the model could be explained by their reflection of molecular 
size, which is supported by the moderate collinearity of Ram and SPI with MW. 
ICR the radial centric information index is related to the molecular shape and thus 
could influence bioconcentration through steric effects including hindrance to 
diffusion and permeation through cellular membranes [42].  
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MAXDN and MAXDP are electrotopological descriptors that relate to the 
partial charges on atoms relative to their topological position in the molecule. 
Therefore the descriptors MAXDN and MAXDP relate to the nucleophilicity and 
electrophilicity of the molecule, respectively [43]. As mentioned previously, 
polarity of the molecule is important in accumulation due to the interaction with 
cellular membranes. In addition, it is also possible that these descriptors may also 
relate to accumulation through metabolism as metabolic processes of xenobiotics 
is often through nucleophilic attack of the substrate.  
Whilst assessing the importance of descriptors to developed models it is 
critical to evaluate any collinearity or multicollinearity. The collinearity of the 
descriptors showed that molecular weight was collinear with SPI (R=0.794) and 
Ram (R=0.696). The descriptor Ram was also collinear with SPI (R=0.787) and 
another topological index STN was collinear with HNar (R=0.748). The relation 
between these topological descriptors and molecular weight is that they all 
describe molecular size (shape, volume, weight) to some extent. Number of 
carbons was also collinear with the number of hydrogens which would be 
expected as these are organic compounds. As a small number of descriptors 
showed collinearity the rank importance of the descriptors should be approached 
with caution. Whilst the error ratio is higher for certain descriptors that are 
collinear, their removal from the network model may not correctly determine the 
ratio value as the remaining collinear descriptor will carry some redundant 
information.  
The invertebrate-based MLP used the same descriptors but the network 
was retrained. The new model generated was assessed for both descriptor 












As expected the relative importance of the descriptors have changed from 
the fish-based model. The most important descriptor was HNar (error ratio = 5.75) 
followed by nN (error ratio = 5.09) and logD (error ratio = 4.71). The increased 
importance of the number of nitrogen atoms will reflect the number of 
pharmaceutical compounds in the dataset which are often amine or amide 
containing molecules. In addition, logD has moved from the least important 
descriptor in the fish-based model to the top three descriptors in the invertebrate 
model. The increased sensitivity of the model to logD will also relate to the training 
of the model with pharmaceuticals. As this class of compounds contain multiple 
ionisation sites it would be expected that fraction of ionised and neutral species 
would affect bioconcentration. The lesser importance of logD in the fish-based 
model is that the dataset contained a majority of neutral compounds. Thus, 
stresses the importance of the inclusion of ionisation for current BCF models as 

















































Figure 6.13: Sensitivity analysis of the 14 descriptors in 
the invertebrate-based MLP 
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Table 6.3: Collinearity assessment of the 14 descriptors in the invertebrate-based MLP using Pearsons’ correlation. 
MW Me nH nC nN ICR MAXDN MAXDP Hnar Ram SPI STN TPSA logD
Me -0.287
nH 0.619 -0.825
nC 0.734 -0.681 0.819
nN 0.266 -0.239 0.339 0.271
ICR 0.609 -0.736 0.888 0.741 0.471
MAXDN 0.216 0.026 0.087 0.023 0.008 0.176
MAXDP 0.304 -0.254 0.301 0.431 0.042 0.411 0.34
Hnar 0.498 -0.537 0.524 0.795 0.425 0.582 -0.161 0.328
Ram 0.772 -0.169 0.417 0.715 0.251 0.326 0.139 0.371 0.462
SPI 0.799 -0.34 0.673 0.596 0.296 0.608 0.388 0.359 0.171 0.733
STN 0.504 -0.352 0.361 0.788 0.315 0.364 -0.171 0.31 0.904 0.67 0.173
TPSA 0.387 -0.204 0.424 0.187 0.503 0.468 0.369 0.325 -0.042 0.344 0.679 -0.105
logD 0.368 0.077 -0.072 0.066 -0.245 -0.147 -0.062 -0.247 0.115 0.169 0.032 0.148 -0.31
logBCF 0.088 0.227 -0.201 -0.088 -0.432 -0.199 0.298 -0.231 -0.099 -0.07 -0.113 -0.049 -0.423 0.627
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The difference of logD between the fish-based and invertebrate-based 
model can also be observed through regression of logD and logBCF (Figure 
6.14). The regressions demonstrated that logD in the G. pulex dataset had a 
higher R2 of 0.3927 compared with an R2 of 0.2069 for the fish dataset.  
From the observed fish-based plot a general increase in logBCF as logD 
increases. However, compounds exceeding a logD of 6 the logBCF no longer 
increases. This observation has been demonstrated in previous investigations 
concerned with hydrophobic organic contaminants [27]. The threshold value 
reflects that highly hydrophobic compounds cannot diffuse across cellular 





























Figure 6.14: Relationship between logD and measured logBCF 
for the invertebrate dataset (top) and the fish dataset (bottom).  
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compound have reduced bioavailability due to adsorption onto particulate and 
dissolved organic matter [44] Whilst hydrophobicity is the principal component 
attributed to bioconcentration prediction, it is possible that carrier-mediated 
transport may also play an important role. Both models presented demonstrated 
that other variables also strongly influence BCF prediction. Thus, QSAR models 
that rely solely on logP or logD are limited in their application. As a final point, it 
is important to consider that descriptors not used in this work may also have a 
potential for BCF modelling. For example, pigment solubility was suggested to 
influence BCF and therefore logS may be a useful descriptor. Furthermore, as 
the major mechanism of transport across epithelia tissue is passive diffusion it is 




 The application of ANNs to predict BCFs showed a good potential with 
>70 % of the variance in measured values described by the developed models. 
The models presented showed an improvement or similar accuracy to currently 
available QSAR models. Prediction accuracy may potentially be improved by the 
use of more reliable experimental data and larger datasets to represent the 
diversity of xenobiotics which are found as environmental contaminants. 
However, the improvement to prediction accuracy may also be limited by varying 
biological, physiological and environmental factors. Cross-species prediction of 
BCF between fish and invertebrates was also limited in application. The model 
did not perform well for predicting BCFs in G. pulex which may also be explained 
by differing biological and physiological traits. A new ANN model was developed 
and represents the first model to successfully predict invertebrate BCFs. 
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However, the type of model tested here is only single class of machine learning 
models. The applicability of other in silico methods such as support vector 
machines and tree-based learning should be investigated. A comparative study 
could reveal the most useful models for predicting accumulation in the 
environment. The model showed good accuracy in BCF prediction but a larger 
dataset would be required to fully assess the generalisability of the model to new 
compounds. Mechanistic interpretation of the models showed that in addition to 
hydrophobicity, molecular size, polarity, and ionisation of a compounds were 
important factors related to bioconcentration. Overall, the application of non-
linear modelling methods to predict BCF holds promise and can be used to 
screen or prioritise compounds for environmental risk assessment such as PBT 
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Chapter 7. Concluding Remarks  
 
7.1 Conclusions 
In summary, the work presented has included; (a) an analytical method 
using LC-MS/MS was developed to determine pharmaceuticals in G. pulex, (b) 
the assessment of the validity of BCF models for pharmaceutical uptake in 
invertebrates was critically assessed, (c) ANNs were successfully used to predict 
uptake onto POCIS devices, (d) Phase I and Phase II pharmaceutical metabolites 
were determined in G. pulex and (e) ANNs were successfully used to predict 
BCFs in fish and invertebrates (G. pulex).  
Bioconcentration factors in G. pulex, have successfully been modelled 
using ANNs which has not been previously achieved. The occurrence of several 
selected pharmaceuticals around the Greater London catchment area in G. pulex 
determined by LC-MS/MS was low. The method developed was relatively simple 
and overcame the analytical challenges associated with complex biological 
samples. However, the method was suitable for only 10 compounds that was 
extended to include several other metabolites. This is a relatively small space 
occupied when compared to the total number of pharmaceuticals available and 
their associated physico-chemical properties. Further testing of different sample 
preparation steps such as pressurised liquid extraction and different SPE 
sorbents may have improved the method diversity for a larger suite of PhACs.  
From the spatial study across London, pharmaceuticals most frequently 
detected and those reaching higher concentrations were collected from a site that 
was situated in close proximity to a WWTP. Thus, wild populations of animals 
most likely at risk are those areas which receive and are close to effluent outfalls 
from WWTPs. In addition, the study revealed that concentrations of 
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pharmaceuticals in surface waters did not translate well into animal body burden 
concentrations, due to factors such as temporal and spatial fluctuations in surface 
water contaminant levels. Therefore, to characterise risk it is proposed that 
monitoring campaigns should focus on the occurrence in biota, in addition to 
surface water. To avoid temporal flow limitations, passive sampling can be used 
to give a time-weighted average which may be more useful in monitoring 
campaigns. Furthermore, the available data for occurrence of pharmaceuticals in 
invertebrates is lacking and internalised concentrations are key to understanding 
the potential for risk in the environment. Thus future research efforts should focus 
on the use of biomonitoring for environmental risk assessment. To the authors 
knowledge the data presented herein was the first monitoring study for PhACs in 
invertebrates or fish in the UK (with the exception of endocrine disrupting 
compounds which have had much greater focus).  
 G. pulex were exposed in vivo to determine the toxicokinetics and further 
understand the potential of pharmaceuticals to bioconcentrate in invertebrates. 
The radiolabelled exposure of selected pharmaceuticals revealed that this group 
of compounds demonstrated a low potential to bioconcentrate and did not trigger 
any regulatory thresholds (BCF ≥ 2000). BCFs ranged from 12, for the β2 
adrenergic receptor agonist terbutaline, to 212 for the tricyclic antidepressant 
imipramine. However, the models were further examined and it was observed 
that assumptions of the first order kinetic model concerning the constancy of the 
k1 rate constant did not hold true for several of the compounds that were exposed. 
The deviation from constancy was further examined through meta-analysis of 
literature available data for organic micropollutants and further supported that 
selected compounds did not have a stable k1 rate constant during the uptake 
phase. The deviations in the k1 rate constant were potentially a compound 
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specific phenomenon that could be related to some specific physio-chemical 
property such as the sorption potential of the compound to the cuticle of the 
animals. As the model assumptions were demonstrated to be incorrect in 
particular cases it indicates that the currently used first order one compartment 
model may not be suitable to characterise the uptake and elimination of 
pharmaceuticals. Modification to the models, such as incorporating ionised and 
neutral speciation rate constants, could further improve the modelling 
approaches for estimation of accumulation. Alternatively, multi-compartment 
models may also give more reliable toxicokinetic data, thus future work should 
aim to develop kinetic models that can be used for pharmaceuticals in fish and 
invertebrates.  However, the authors recommend that at present toxicokinetic 
data should be checked for lack-of-fit and to determine whether the uptake rate 
constant is consistent.  
Further toxicokinetic exposures were performed using the developed LC-
MS method presented in Chapter 2. The use of LC-MS was cross-validated with 
two compounds which demonstrated that the method can be used to determine 
uptake and elimination kinetics. In addition the analytical method was also used 
to study the biotransformation products of some of the selected pharmaceuticals 
including propranolol, carbamazepine and diazepam. The LC-MS determination 
revealed that G. pulex are capable of Phase I and Phase II metabolism of 
pharmaceuticals. The first pharmaceutical sulphate conjugate to be detected in 
G. pulex was presented in Chapter 4, indicating that propranolol was extensively 
biotransformed to hydroxypropranolol sulphate. Thus, may explain the reason 
that the selected pharmaceuticals were demonstrated to show low 
bioconcentration potentials. Metabolism is relatively understudied within 
environmental toxicology and could be important for determining 
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bioconcentration and the fate of PhACs once they are internalised within an 
organism. The advantage for pharmaceuticals here is that pre-clinical and clinical 
data could be used to inform studies about possible biotransformation products 
and whether they are pharmacologically active. With the advent of high mass 
accuracy instruments (i.e. Orbitrap) it is also possible that even without available 
reference materials tentative identification could be based on measured m/z and 
also retention time modelling. The ANNs used to model bioconcentration in this 
work have also been used to model retention time for unknowns in surface waters 
and wastewaters. Finally, the identification of biotransformed products would also 
be useful in assessing exposure-effect relationships. In addition, the use of LC-
MS methodologies offer more accurate estimations of individual parameters 
(k1/k2) for parent and biotransformed compounds. However, the limitation of this 
approach was that LC-MS methods that do not determine metabolites may 
underestimate the total body burden of a compound (precursor + metabolite).  
Modelling approaches were investigated for both uptake on passive 
sampling devices and in biota. Models were developed using ANNs and 
demonstrated reliable prediction of uptake onto POCIS devices. As PSDs can 
determine a time weighted average concentration, demonstrating that modelling 
uptake onto POCIS devices is valuable in the field for biomonitoring studies. The 
work presented in Chapter 5, showed a strong potential to reduce the need for 
labour and resource intensive experimental measurements. Furthermore, PSDs 
could have biomimetic properties that would be useful for bioconcentration tests. 
The correlation of Rs with BCFs showed a poor linear correlation. As PSDs do 




The ANN modelling was extended to a fish (Cyprinus carpio) database of 
bioconcentration factors as invertebrate datasets do not exist. Overall, the 
modelling approach showed relatively good predictive accuracy in fish and was 
related to molecular descriptors that would be expected to influence uptake and 
elimination. The developed fish model was applied to the invertebrate BCFs 
determined in Chapters 3 and 4. However, the model was not applicable to the 
invertebrate data. Thus, this indicated that either cross-species prediction, the 
prediction of pharmaceutical compounds or a combination of both hindered the 
predictive ability of the model. Therefore, a new model was developed for the 
invertebrate pharmaceutical BCF data. This model again showed good predictive 
accuracy using the same molecular descriptors in the fish model but with a 
different order of importance. Thus, it suggested that pharmaceutical predictions 
may not be applicable from models developed with more traditional contaminant 
substances such as PAHs, PCBs, organochlorines, etc. The limitation to this is 
that the modelling approaches were limited in the number of training and test 
cases. Thus, to fully validate the developed models, more data points were 
required. Nonetheless, the models demonstrated that the potential for ANNs in 
prediction of bioconcentration is suitable and holds promise from a regulatory 
perspective for risk assessment of the environment. As a final consideration, and 
whilst this work assessed the use of ANNs for predictive ability, there are many 
different types of machine learning methods that are available. Thus, the use of 
alternative in silico approaches such as deep neural networks, support vector 






7.2 Future perspectives and challenges  
 Ecotoxicology remains an ever expanding field where future research 
needs have been highlighted in the current work presented. Perhaps the most 
essential focus should be on the use of invertebrates for environmental risk 
assessments. This phylum is of critical importance to ecosystem functioning and 
environmental services that are invaluable to anthropogenic activities. Thus, 
increased monitoring and vigilance concerning this group of organisms is 
required to further understand the risk of chemical pollutants in the environment. 
The extent of metabolism of chemical contaminants is also poorly understood as 
many studies overlook the role of biotransformation in occurrence, toxicokinetics 
and effect-based studies. Even with the predominance of fish studies, 
metabolism is still poorly characterised within this group of animals.  
A further challenge within the field is to delineate the variance associated 
from laboratory based studies to those data acquired in the field. The differences 
are likely to stem from the complex interactions between biotic and abiotic factors 
in the field. Without understanding the relevance of laboratory based studies to a 
realistic exposure scenario our risk assessments can be considered as relatively 
low quality. In addition, the challenge of also delineating the effect of complex 
chemical mixtures is a very challenging prospect. However, due to the complexity 
it is likely that machine learning algorithms may offer a viable solution to these 
challenges. Thus, the inclusion of intelligent computing is essential within the 
field. Whilst the ANN modelling here showed a good potential for predictive 
ecotoxicology it requires further work and there are several other types of 
algorithms including those used in deep learning which is becoming more 
popular. Predictive ecotoxicology is also perhaps the only feasible solution to 
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assess the sheer volume of chemicals that are manufactured and that will 
eventually enter either terrestrial or aquatic environments.  
 The data presented demonstrated that pharmaceuticals are likely to have 
a relatively low bioconcentration or bioaccumulation potential with the exception 
of specific cases. Thus, whilst further work is required to fully conclude this 
statement, future efforts should also focus on whether pharmaceuticals have the 
potential to cause adverse effects at their innately low level concentrations. 
However, studies often fail to fully link cause to effects. Thus, it is essential that 
cause and effect relationships are understood (e.g. adverse outcome pathway 
framework) where emerging fields such as environmental metabolomics will be 
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ABSTRACT: The computational generation of gradient
retention time data for retrospective detection of suspected
sports doping species in postanalysis human urine sample data
is presented herein. Retention data for a selection of 86
compounds included in the London 2012 Olympic and
Paralympic Games drug testing schedule were used to train,
verify, and test a range of computational models for this
purpose. Spiked urine samples were analyzed using solid phase
extraction followed by ultrahigh-pressure gradient liquid
chromatography coupled to electrospray ionization high-
resolution mass spectrometry. Most analyte retention times
varied ≤0.2 min over the relatively short runtime of 10 min.
Predicted retention times were within 0.5 min of experimental
values for 12 out of 15 blind test compounds (largest error: 0.97 min). Minimizing the variance in predictive ability across
replicate networks of identical architecture is presented for the ﬁrst time along with a quantitative discussion of the contribution
of each selected molecular descriptor toward the overall predicted value. The performance of neural computing predictions for
isobaric compound retention time is also discussed. This work presents the application of neural networks to the prediction of
gradient retention time in archived high-resolution urine analysis sample data for the ﬁrst time in the ﬁeld of anti-doping.
Drug testing in sport is becoming more and morechallenging because cheats rapidly switch to new or
designer drugs to avoid being caught by anti-doping tests.
Because of this, in 2011 the World Anti-Doping Agency
introduced a new section in the Prohibited List to specify that
any substance not approved for human therapeutic use is
prohibited.1 Unfortunately however, there is normally a delay
between new substances being used by cheats and the screening
methods being implemented to detect them.
New technologies in analytical chemistry now exist which oﬀer
a much more ﬂexible and universal approach compared to
targeted-type screening analyses. In particular, liquid chromatog-
raphy with full data capture high-resolution mass spectrometry
(LC-HRMS) is becoming very popular for drug screening
because it generally permits the addition of new analytes to a
screening method with little/no modiﬁcation to the method.
One of the most promising features is the possibility for
retrospective analysis of postacquisition data sets.2,3 The
ﬂexibility of the HRMS approach was exploited in our laboratory
during the London 2012 Olympic and Paralympic Games, where
an LC-HRMS screen was employed for the detection of nearly
200 analytes within a single assay.4 When permitted, in
accordance with the International Standard for Laboratories,5
all sample data acquired by this technique could be reprocessed
and re-evaluated (for example, where intelligence becomes
available about the potential use of new substances). However,
several challenges still exist for retrospective detection of drug
species in both new and archived samples. Analytical reference
standards are not always available, especially for new or
analogous compounds which may be synthesized relatively
easily and with suﬃcient eﬃcacy for practical use by athletes.
Moreover, the exact operating conditions of analytical equip-
ment may not be reproducible at a later date when a repeat
analysis is required. For example, chromatograms generated from
separate analyses even using the same columns may diﬀer due to
phase aging and loss of performance. Therefore, more eﬀort is
required to interpret the original data.
Predictive computing techniques, such as artiﬁcial neural
networks (ANNs), can interpret underlying trends in complex
data sets by learning from case examples. There are several types
of ANN, but the feed-forward multilayer type is commonly the
most used across a range of scientiﬁc applications such as
analytical chemistry, environmental science, and molecular
biology.6−10 By interconnecting a set of input data with a series
of hidden layer neurons, statistical weights and biases between
them are systematically optimized toward producing a
minimized error overall output. In the training phase, the ANN
requires a known true value as a comparator and once an
acceptable number of training cycles (or epochs) is determined,
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the optimized ANN can be used to predict the same output
where experimentally derived data is unavailable (i.e., a blind
test). In this case, information about a set of analytes or
chromatographic system (as inputs) and the experimentally
derived retention data for standards within spiked, matrix-
matched samples (as an output) could provide a useful body of
information for an ANN to predict retention time retrospectively
under the conditions observed at the time.
Research to characterize retention behavior has used linear
solvation energy relationships (LSERs). These use solute
descriptors and linear regression modeling to predict a retention
parameter for a particular set of compounds. Both algorithm-
based and predictive ANN approaches have incorporated the use
of LSERs as inputs to estimate retention (usually as retention
factor, k) across a number of chromatographic modes,11−14
column formats,15−17 for method optimization purposes,18−22 to
predict retention behavior across column formats, or to estimate
the retention of unknowns.23−25 Each LSER solute descriptor
must be calculated, and each coeﬃcient is usually obtained via
measured retention data for a set of representative compounds.
Thus, the time to produce an accurate LSER model can be
signiﬁcant (as well as especially challenging for ionizable
compounds in particular15,18). As LSER coeﬃcients for retention
modeling also depend on observed retention on a stationary
phase, factors such as the age of the phase may lead to observable
diﬀerences and lower accuracy over time. Furthermore, the exact
composition of a changing mobile phase under gradient
conditions is very diﬃcult to characterize and requires the
inclusion of extra variables such as purity and individual system
dwell time, for example. While the investigation of LSERs in
retention modeling advances, ANN-based predictive approaches
using alternative descriptors may therefore hold promise for
more immediate application.
The aim of this work was to investigate the use of ANNs for the
prediction of retention time in archived urine analysis data from
the London 2012 Olympic and Paralympic Games using a
method employing ultrahigh-pressure liquid chromatography
coupled to HRMS. In particular, the selection of alternative
molecular descriptor data to those used in LSERs is presented,
along with a study of the ANN dependency on these descriptors
and the variance across replicated ANNs. Lastly, this work aimed
to assess whether ANNs could be used to discriminate
structurally similar and/or isobaric species.
■ EXPERIMENTAL SECTION
Reagents. For a detailed account of all reagents used in the
experimental please see the accompanying Supporting Informa-
tion,26 Table S2. For those compounds where no certiﬁcate of
analysis was available, a solution of each compound was infused
separately into the HRMS, and full scan data were acquired
without any applied collisionally induced dissociation. The
internal calibrator was caﬀeine. Identity was considered
conﬁrmed where m/z values within 2 ppm of the theoretical
value were achieved along with a consistent fragmentation
pattern.
Urine Sample Preparation. Drug-free urine samples were
collected from 15 healthy volunteers, anonymized, divided into 1
mL aliquots, and stored at−10 °C until analysis. Each aliquot was
then spiked with all reference compounds. Following addition of
internal standards and glucuronide hydrolysis reagents (see SI, S
2.0), formic acid was added to the samples. This solution was
then extracted on Bond-Elut Plexa PCX (60 mg, 3 mL barrel)
solid phase extraction (SPE) cartridges (Agilent Technologies,
Lake Forest, CA). Cartridges were preconditioned with 0.5 mL
of methanol and 0.5 mL of 2% v/v formic acid. After loading,
cartridges were washed with 1 mL each of 2% formic acid, water,
and 20:80 v/v methanol/water. Elution was performed in 3 mL
of 3% (v/v) ammonium hydroxide in methanol/acetonitrile
(50:50, v/v). Extracts were dried under nitrogen at 60 °C and
then reconstituted to 100 μL of 0.3% v/v formic acid in 95:5 v/v
water/acetonitrile.
Instrumental Conditions. For all separations, a Waters
Acquity UPLC ultrahigh-pressure liquid chromatographic
system was used (Waters, Milford, MA, USA). Separations
were performed on aWaters Acquity BEH-C18 column (2.1× 50
mm, 1.7 μm). Gradient elution was performed as follows: 95:5
water/acetonitrile (both in 0.3% formic acid) for 0.5 min; then to
80:20 for 3.0 min; a linear ramp to 75:25 for 2.0 min; to 43:57 for
1.5 min; ﬁnally, to 10:90 for 1 min. Total time for the gradient
elution was 8 min, followed by 2 min for re-equilibration.
Separations were performed at 0.3 mL/min and at 30 °C
throughout. The injection volume was 10 μL. The syringe and
injector were washed sequentially with 0.2% formic acid in
acetonitrile/water (30:70, v/v) and methanol/acetonitrile
(90:10, v/v) up to 5 times each before every run to avoid
carryover.
Detection was performed using fast polarity switching high-
resolution mass spectrometry on an Exactive instrument
(Thermo Fisher Scientiﬁc, San Jose, CA) equipped with a
heated electrospray ionization (HESI-II) source. Enhanced-
resolutionmode was employed at 25 000 fwhm resolution. Three
events occurred during each acquisition cycle by performing a
full scan both in positive and negative ionization mode (both
with disabled CID) followed by a full scan in positive ionization
mode only with CID (HCD collision energy 30 eV). For a full
description of other HRMS conditions, see the SI.
Molecular Descriptors, Neural Network Prediction
Models and Architectures. Eighteen molecular descriptors
were generated for each compound in the optimized network. Of
these, 15 descriptors were computed using Parameter Client
freeware (Virtual Computational Chemistry Laboratory, Mu-
nich, Germany) using canonical simpliﬁed molecular-input line
entry system strings (SMILES, Table S1). Descriptors including
pKa, Ghose−Crippen and Moriguchi log P (AlogP or MlogP),
number of double bonds (nDB), number of four- to nine-
membered rings (nR04-nR09), and number of carbon or oxygen
atoms (nC or nO) were used for network optimization. A full list
of other descriptors is detailed in Table S1 and Figure 3. To
investigate the use of predicted pKa values, Percepta PhysChem
Proﬁler (ACD Laboratories, ON, Canada) software was used. All
predicted retention times (tr
P) were performed using licensed
ANN software (Trajan Software Ltd., Lincolnshire, U.K.) and
compared with experimentally determined retention time (tr
E). A
selection of ANN types and architectures were investigated
including linear, radial basis function (RBF), probabilistic neural
networks (PNN), and multilayer perceptrons (MLPs).
■ RESULTS AND DISCUSSION
Experimentally Determined Chromatographic Reten-
tion Time and Reproducibility. This screening method was
used during the 2012 Olympic Games for the detection of nearly
200 compounds in our ISO 17025 accredited laboratory. All of
these species were detectable at concentrations corresponding to
50% of the WADA minimum required performance level27 in
force at that time in spiked, drug-free urine. On average, peak
widths at baseline were of the order of ∼0.15 min with some
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notable exceptions. For example, peak widths for morphine and
etilefrine were 0.3 and 0.4 min, respectively, with some variability
between urine samples. In order to examine the potential
usefulness of computational tools for the retrospective
generation of retention times in archived data, the reliability of
generated chromatographic retention data was ﬁrst evaluated. An
in-depth evaluation of other method validation experiments
including selectivity, sensitivity, and limits of detection is given
elsewhere.4 The evaluation of retention time reproducibility was
performed using 15 diﬀerent urine samples analyzed in groups of
ﬁve with groups being analyzed on diﬀerent days. Rather than
expressing the reproducibility as a relative standard deviation, the
maximum variation in retention time was preferred, since the aim
was to establish a suitable detection window. The maximum
within-day tr
E variability was 0.22, 0.23, and 0.32min for the three
groups of ﬁve urine samples, respectively. Considering all 15
urine samples together (three groups, three diﬀerent days), the
maximum retention time variability was 0.35 min (i.e., ±0.175
min). Data analyses during screening were normally performed
by reviewing extracted ion chromatograms with an m/z window
of ±5 ppm and a retention time window of ±0.5 min. Athlete
urine samples were always run using a “bracketed” approach to
take into account phase aging and to ensure system performance
throughout the entire batch acquisition.
Selection of Molecular Descriptors, Network Type and
Architecture. By generating SMILES strings for each
compound, an initial set of >200 diverse molecular descriptors
were generated. While the instrumental screening method
incorporated a larger number of compounds in practice, the
number studied here was limited to those compounds with
literature reported, experimentally derived pKa values (as this
descriptor was not initially available within the Parameter Client
software). Given that the majority of these compounds were
fully/partly ionized in the mobile phase, this descriptor was
considered important for the potential prediction of retention
times. Multiple network types and architectures were examined.
On the whole, it was observed that use of a larger number of
inputs did not oﬀer advantages in terms of prediction accuracy,
and a much smaller set was ultimately more practical and yielded
better correlations. As a result, some descriptors were not
included in themodel whichmight have otherwise been expected
under reversed-phase chromatography conditions such as
analyte topological surface area, number of atoms containing
lone pairs of electrons (e.g., oxygen or nitrogen atoms), or
molecular weight.
Whether using a large or small input descriptor set, a linear-
type network oﬀered no detectable correlation (R2 and slope
both <0.1 in all cases) between tr
E and tr
P and irrespective of
whether inputs were used for training, veriﬁcation, or blind
testing. As such, this network type was removed from
consideration. Alternative network types, on the other hand,
oﬀered better performance and the best correlation coeﬃcients
achieved for each type ranged from R2 = 0.86 (RBF) to 0.98 (4-
layer MLP) with the slope (m) ranging from 0.97 (3-layer MLP)
to 1.03 (PNN), again for all 86 compounds. The best network
shown in Figure 1a was a feed-forward, back-propagation-type
MLP with two hidden layers of ﬁve and four nodes, respectively.
This 18:5:4:1 MLP architecture was trained using 18 molecular
descriptors using 61 compounds. Veriﬁcation was performed
with 10 compounds, and training of the network was ceased
when a minimum for residual error was observed (2000 epochs
here). The network was “blind” tested using 15 additional
compounds displaying structural variance and a spread of input
data and tr
E data across the 10 min runtime. Data for tr
E was not
used by the ANN for test compounds (see Table S2), and
performance was observed after training and veriﬁcation. When
the data set was divided into training, veriﬁcation, and blind
testing data, their respective m and R2 values remained
satisfactory and were also better than the corresponding plots
for PNN, RBF, and 3-layer MLP networks. By examining the
residual errors in the entire data set (Figure 1b), it was observed
that retention time could be predicted within 0.5 min of tr
E for 80
out of 86 compounds (∼93%). This windowwas initially selected
to cover the window employed during the experimental
screening outlined above. In particular, tr
P for 97%, 90%, and
80% of the training, veriﬁcation, and test compounds,
respectively, lay within this window. In fact, for the test set
alone, this level of accuracy was maintained even to ±0.3 min of
tr
E. Therefore, these results show that this type of network oﬀered
promising predictive ability for most compounds in a relatively
rapid gradient separation. The largest residual errors were
observed for MDA, clenbuterol, and p-methylamphetamine at
−0.947 min (used within the test set), −0.721 min (in
veriﬁcation set), and −0.704 min (in training set), respectively.
Therefore, all species could be predicted within 1 min of tr
E.
However, it should be noted that this ANN was speciﬁcally
tailored for this chromatographic system and method. If applied
to other separation systems and modes, it is likely that similar
descriptor and ANN optimization experiments would be
Figure 1. (a) Correlation between experimentally derived (tr
E) and
predicted (tr
P) retention times using the optimized 18:5:4:1 multilayer
perceptron (inset) trained for 2000 epochs; (b) residual errors in tr
P
using the optimized network for all analytes (n = 86). All raw data
represented in Table S2 in the SI.
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necessary. It is also important to note that the number of cases
used here is relatively small in comparison to some work using
several hundred training compounds for ANN modeling in both
GC and LC.28−30 Therefore, predicted retention times for
unknowns with partial overlap to the training structural feature
set may be limited. For example, larger molecules with markedly
diﬀerent logP or multiple pKa values may make prediction
problematic. Increasing the number of training cases may solve
this in the future and perhaps more immediately through
incorporation of non-WADA regulated compounds to expand
the training set further.
Consistency in tr
P Using Replicate Networks of
Identical Type and Architecture. One of the main issues
with ANNs is that training follows a random process toward
minimizing the overall error. However, at larger numbers of
training epochs, networks may become overtrained, and while
training set errors may be minimized, the veriﬁcation set error
can increase (as it is not used by the software itself during the
training process). The user oftenmanually deﬁnes where training
ceases by observing where the combined veriﬁcation set residual
error is at its lowest. In some cases, this veriﬁcation error is lowest
at lower numbers of training epochs but where training errors
may remain high. Therefore, the variability in network
connection weightings may be very diﬀerent from network to
network (even with identical architectures), and a balance is
required potentially toward achieving some consistency. In this
case, replicate networks (n = 10) using the optimized
architecture were built to examine consistency and the range of
tr
P values for the veriﬁcation, and test sets were plotted as Figure
2. Also, shown alongside each tr
P entry in Figure 2 is the tr
E
variance of the analytical method for comparison purposes. By
stopping training between 2000 and 3900 epochs in each case
(where veriﬁcation and training error combined were lowest), it
was found that relatively consistent input weightings were
achieved, and tr
P performance could be maintained. To our
knowledge, this has not been shown previously in predictive
chromatographic retention studies. However, and despite their
accuracies and consistencies, tr
E data for 6/15 blind test set
compounds still lay outside the range of tr
P values generated by all
10 networks. Of these, and of particular interest, were three
structurally related species: dimethylamphetamine, MDA, and
phentermine. As synthetic compounds of this general type often
only have slight variations in their molecular structure, this
approach could be very useful to predict retention time for an
array of related species where a reference standard is unavailable.
The average tr
P errors across all 10 networks for these three
compounds were +0.97, −0.62, and −0.24 min (trE = 2.76, 2.50,
and 2.91 min), respectively. The lowest respective errors in tr
P
achieved by any one network were +0.59, −0.57, and −0.07 min.
By comparison, and upon inspection of the average tr
P error for
other related species within the training set, compounds such as
MDMA, benzphetamine, fenﬂuramine, and methamphetamine
all performed reasonably well (average absolute error of 0.08−
0.18 min from tr
E for all 10 networks). However, and as noted
earlier, average tr
P error for p-methylamphetamine was the worst
case in the training set at an average of −0.44 min across all
networks. In the veriﬁcation set, only one related compound,
amphetamine, yielded 0.13 min error in tr
P (tr
E = 2.37 min).
Therefore, these ﬁgures suggest that dimethylamphetamine and
MDA may be unusual cases and that ANN predictive ability for
unknowns may not, on average, be poorer for these types of
compound.With regard to the general test set, all veriﬁcation and
test compound retention times could be predicted within 1 min
of tr
E (with average ± standard deviation of tr
P error for all 25
compounds = 0.3 ± 0.2 min for all 10 networks). In comparison
to the maximum measured experimental variance above (0.35
min), the potential for using multiple networks to predict
retention time shows promise. Therefore, the window for ANN
accuracy could be set at±0.5 min in total (again, also comparable
to the experimental retention time window used in practice
during the Olympic and Paralympic Games). Each network
required a few minutes to build, train, verify, and test. Therefore,
this in silico approach could represent a signiﬁcant saving in
terms of time, eﬀort, and cost when used in combination with a
semitargeted post-data-acquisition analysis of an athlete urine
sample. Samples from the Olympic Games are stored for a total
of 8 years in case reanalysis is required at a later date. However,
this is not the case for most other sporting events where negative
urine samples are discarded after 3 months unless probable cause
Figure 2. Paired comparisons of measured tr
E variability (left-hand box)
from n = 15 volunteer urine data versus tr
P variability for n = 10 replicate
18:5:4:1 MLP networks (right-hand box). Data is presented for the
veriﬁcation (marked V) and blind-test compounds (marked T) only.
Boxes represent 25−75th percentile, whiskers represent 10−90th
percentile, and dots are outliers. Thin lines represent the median, and
thick lines represent the mean. *Experimental variance was not
determined for benthiazide and polythiazide, and reported values
represent a single measurement. For all raw data (including for the
training set), please refer to Tables S3 and S4 in the SI.
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for prolonged storage is justiﬁed. As several isobaric compounds
can exist, HRMS data alone may be considered insuﬃcient for
this purpose. Therefore, the beneﬁts of ANN predictions could
aid in the investigation of doping before analysis, before the
reporting stage, and after the reporting stage. When used in
combination with HRMS, this gives added value, especially in
directing which analytical reference materials are to be
synthesized.
Molecular Descriptor Contribution toward tr
P and
Variance across Replicate Networks. Using the optimized
MLP network, the contribution of each descriptor toward the
generation of tr
P was calculated for a single compound, A, by
determining the absolute deviation, DA, arising from sequential
removal of one descriptor, i, at a time.31 Data were inputted into
eq 1 below to calculate the overall variance, VA, arising for that
compound. Values for VA for each compound (denoted A = 1−
61) were then used to determine the overall percentage change in
accuracy of predicted retention time for all compounds,ΔtrP(%),





















The contribution of each descriptor toward tr
P was diﬀerent.
Using the optimized network, the top ﬁve contributing molecular
descriptors (in decreasing order) to tr
P for all compounds using
the best network were nC (17.5% change in tr
P when removed),
nR09 (10.0% change), nO (9.9% change), nDB (8.8% change),
and ALogP (8.2% change). Overall, some of these ΔtrP values
were unsurprising given that silica-C18 was used as a stationary
phase. For experimentally derived descriptors, however, removal
of pKa only resulted in a change of 3.8%, but subsequent removal
of AlogD and MlogD resulted in ΔtrP of ≤3% each. As expected,
descriptors such as the number nR04 having little or no incidence
resulted in small ΔtrP when removed. Examination of the data
relative to tr
E revealed that predictions were on the whole worse
with the removal of selected descriptors.
To further understand the variability across replicate networks,
this experiment was repeated for nine additional replicate
networks. The contribution and variance of each descriptor is
shown as Figure 3. Taking the mean values, the top ﬁve
contributing molecular descriptors were the same as reported
above, albeit in a slightly diﬀerent order (from highest to lowest:
nC, nDB, nO, AlogP, and nR09). This indicated that ANNs
could be replicated with acceptable consistency in their
operation. Interestingly, the largest measured variance in tr
P
across replicate ANNs for removal of a single descriptor was also
observed as the most highly contributing descriptor, nC, at
∼11%. Removal of descriptors which resulted in the lowest % trP
variance were also those which were used least by ANNs during
prediction. However, for the rest of the descriptor set, no trend
was apparent to conclude that a more heavily used input would
result in a higher variance when omitted from replicate networks.
Furthermore, it was observed again that AlogP was repeatedly
used in preference to MlogP in tr predictions. MlogP has been
shown previously to be a less accurate descriptor in comparison
to other available computational models and in respect to
experimentally derived logP.32 Here, it was observed that MlogP
data oﬀered poorer discrimination between some species and
especially those of isobaric mass. It was also apparent that this
had a consequential eﬀect on the use of AlogD over MlogD as a
preferred input descriptor of the two. However, as a null %
change was not observed by removingMlogP from the data set in
any network, it was still used to some degree by ANNs.
Figure 3. Percentage change in tr
P relative to tr
E upon systematic removal of each molecular descriptor from 10 replicate 15:5:4:1 MLP networks. Boxes
include data from the 25th−75th percentile, the median (thin line), and the mean (thick line). Error bars include the 5th and 95th percentile, and dots
represent outliers. For all molecular descriptor deﬁnitions, please see the Experimental Section or Table S1 in the SI.
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Substitution of Experimentally Derived pKa with
Predicted pKa. In practice, retention on reversed-phase media
is likely to be heavily dependent on analyte logP and pKa (and
subsequently logD). The molecular description software used
here could generate predicted analyte logP but not pKa. The
initial use of experimentally derived pKa data from the literature
overcame this problem and resulted in satisfactory tr
P accuracy, as
shown earlier. However, the availability of (or indeed the ability
to generate) experimental pKa signiﬁcantly limits the usefulness
of this ANN approach if it is to be used in postacquisition data
mining. The use of a separate pKa prediction software package
was therefore investigated as a possible alternative. In an initial
Table 1. Performance of ANNs for Predictions of tr for Isobaric and Isomeric Compounds
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experiment, experimentally derived pKa data were removed from
the input data set and replaced directly with predicted values into
the pretrained ANN. With this substitution, a very slight
reduction in tr
P accuracy was observed, but it still remained
acceptable (not shown). The network in Figure 1a generated an
overall tr
P/tr
E correlation with a slope of 1.00 (R2 = 0.98)
compared with 0.95 (R2 = 0.98), in this case across all 86 analytes.
This obviously indicated some minor discrepancies between
numerical values in these data sets. To further understand the
importance of predicted versus experimentally derived pKa as
ANN inputs, a new network of identical architecture was
retrained using computationally derived pKa values to observe
whether prediction accuracy could be restored. From this, it was
seen that tr
P accuracy was marginally worse using computed pKa
(Figure S3), but it still remained acceptable overall (overall slope
= 0.94; R2 = 0.95). In previous work, Livingstone also showed
that predicted pKa data can display inaccuracies up to 1.5 log
units (using a larger compound set than here).32 Thus, in ANN
predictions of test compound retention time, experimentally
derived data should be used where possible, but predicted values
could potentially be substituted with awareness that accuracy
may be slightly aﬀected. The apparent pH of gradient LC eluent
composition and its eﬀect on analyte ionization (and hence
AlogD or MlogD) is another consideration when using pKa data
derived experimentally from, or predicted in, aqueous media
alone. The apparent pH of buﬀered aqueous−organic solutions
has been shown to increase in up to 60% acetonitrile content.
Similarly, a range of analyte pKa values have also been shown to
change in organic media.33 Despite this, the use of aqueous-
derived pKa and experimental tr data for training here resulted in
no discernible loss in predictive ability across the gradient.
Performance of ANNs for Isobaric and Isomeric
Compounds. If the ANN approach is to work in any realistic
scenario with HRMS detection, then tr
P accuracy should be high
for compounds which are both isobaric and which display high
degrees of structural similarity. From the list of compounds used
in this study, several such cases existed (Table 1). Nadolol and
metipranolol, both nonselective beta-blockers, display an
identical mass and molecular formula, but diﬀer slightly in their
molecular structure and logP. Experimentally, this translated to a
2-fold diﬀerence in their retention times on this C18 phase. In this
case, the optimized ANN performed well by predicting retention
within 0.4 min for both compounds despite their high structural
and pKa similarity. Diﬀerences in logP could have accounted for
this performance, as it was used here in the calculation of logD.
The hydrophilic factor was calculated on the basis of the number
of atoms in a molecule, the number of carbon atoms, and the
number of hydrophilic groups (such as −OH or −NH for
example). Unsaturation indices are calculated on the basis of the
number of atoms containing proton deﬁciencies (e.g., aromatic
rings or multiple bonds). Therefore, these latter two descriptors
could be considered loosely correlated with logP on a
fundamental level. Therefore, it might be somewhat unsurprising
that this resulted in higher accuracy in this case given the nature
of the separation mode.
In a second similar case involving the isobaric compounds,
phentermine and methamphetamine tr
P accuracy remained high
(±0.22 min from tr
E), but the order of elution was incorrectly
predicted. Furthermore, tr
P for a third isobaric compound, p-
methylamphetamine was predicted as similar to that of
phentermine and methamphetamine but was less accurate to
its tr
E at −0.7 min. All three of these compounds had identical
MlogP data but only slightly diﬀering AlogP and pKa values. For
the majority of the other 13 compounds eluting between
methamphetamine and p-methylamphetamine and where
descriptor diversity was more pronounced, this was less of a
problem and tr
P inaccuracy remained <0.5 min.
As a third case example, a set of diastereoisomers were chosen:
ephedrine and pseudoephedrine. With identical mass, molecular
formula, atomic connections, AlogP, and MlogP, it was
somewhat unsurprising that they remained experimentally
unresolved on this stationary phase. While their pKa values
were 0.3 units apart, and therefore a little further apart than of
those species in the previous example, this had little eﬀect on tr
P
(within 0.15 min of tr
E for both species). While further work on
the use of ANN using resolved diastereoisomers is required, it
should be noted that the SMILES strings used here employ a
string of characters that speciﬁed the structure of a selected
molecule including its spatial arrangements. Optical isomerism in
SMILES strings is designated by the ‘@’ symbol. Where a single
‘@’ is used, this represents the substituent groups giving rise to
the chirality being positioned anticlockwise around the chiral
atom, whereas two symbols (‘@@’) indicate clockwise
orientation of the groups around the chiral atom. Therefore, as
this may lead to a diﬀerence in molecular description, then this
could be used by the ANN to diﬀerentiate such species.
Naturally, this would also depend on the importance of the




This work showed that ANNs could be used to predict
chromatographic retention times for 93% of all selected
doping-related compounds to within 0.5 min of their true
value and to within 1 min for all other compounds. All
compounds were detected in a urine extract matrix and were
separated under gradient elution conditions.When applied to the
prediction of unknowns alone, the same level of accuracy was
maintained. Variance across replicate networks of identical
architecture revealed that descriptors were used to similar
degrees toward prediction of retention time. This approach could
be used with quantitative structure−activity relationships alone,
but it is recommended that analyte pKa should be experimentally
derived for ANN training. Ultimately, prediction of retention
times in archived screening data would simplify and aid data
reprocessing as a complementary tool to retrospective analysis
both in the identiﬁcation of unknowns and where reference
materials were not originally included in the analytical screen.
Therefore, the combination of full data capture HRMS and in
silico predictive approaches could improve the capability for




Tables containing the raw data relating to experimental and
predicted retention times for all compounds and experiments
herein; molecular descriptors and associated ANN input data; all
ANN models and architectures. This material is available free of
charge via the Internet at http://pubs.acs.org.
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OccurrenceThe development, characterisation and application of a new analytical method for multi-residue PPCP determination
in the freshwater amphipod, Gammarus pulex are presented. Analysis was performed using pulverised liquid extrac-
tion (PuLE), solid phase extraction (SPE) and liquid chromatography–tandemmass spectrometry (LC–MS/MS). Qual-
itative method performance offered excellent limits of detection at b20 ng g−1 for 18 out of 29 compounds. For
quantitative application, linearity and precision were considered acceptable for 10 compounds across the ng-μg g−1
range (R2 ≥ 0.99; ≤20% relative standard deviation respectively). The method was applied to the analysis of
G. pulex and river water sourced from six tributaries of the River Thames. Carbamazepine, diazepam, nimesulide, tri-
methoprim and warfarin were determined in G. pulex samples at low ng g−1 (dry weight) concentrations across
these sites. Temazepamand diclofenacwere also detected, butwere not quantiﬁable. Six pharmaceuticalswere quan-
tiﬁed in surface waters across the eight sites at concentrations ranging from 3 to 344 ng L−1. The possibility for con-
ﬁrmatory detection and subsequent quantiﬁcation of pharmaceutical residues in benthic organisms such as G. pulex
will enable further understanding on the susceptibility and ecological effects of PPCPs in the aquatic environment.
© 2014 Elsevier B.V. All rights reserved., Faringdon, Oxfordshire, SN7 7YR.
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ucts (PPCPs) into the aquatic environment via wastewater treatment
plant (WWTP) efﬂuent is driving research into the ﬁeld of ecotoxicology
due to a rising concern for the health of biota residing in contaminated
waters. Numerous monitoring studies have been carried out to assess
the extent of PPCP contamination in wastewater efﬂuent and impacted
surface waters such as rivers, lakes and seawater with PPCP residues
detected up to μg L−1 concentrations (Ashton et al., 2004; Behera
et al., 2011; Brown et al., 2006; Carmona et al., 2014; Kosma et al.,
2010; McEneff et al., 2014; Roberts and Thomas, 2006; Thomas and
Hilton, 2004; Vazquez-Roig et al., 2013). The release of pharmaceuticals
at low μg L−1 concentrations has been shown to impact on the quality of
the surrounding aquatic environment in Europe and America (Corcoran
et al., 2010; Huerta et al., 2012). However the paradigm of transient ex-
posure to temporal ﬂow makes the environmental risk assessment
complex. Internal concentrations are clearly the key to better under-
standing (and therefore prediction) of risk (Rand-Weaver et al., 2013).
The exposure of wild-caught and caged biota to contaminated surface
waters over extended periods of time have revealed the potential for
PPCP uptake and subsequent adverse chronic effects (Dodder et al.,
2014; Gatidou et al., 2010; Huerta et al., 2013; Subedi et al., 2012). It is
widely believed that bioaccumulation of contaminants occurs through
passive diffusion where the hydrophobicity of the compound (logP)
largely describes their permeability through membranes (Hamelink
and Spacie, 1977; McKim et al., 1985). However, due to their ability to
ionise and undergo various transformation processes, there ismounting
evidence to support carrier mediated transport of PPCPs through facili-
tated diffusion and active transport (Dobson and Kell, 2008; Schultz
et al., 2010). PPCP occurrence data in aquatic biota is of particular im-
portance as results may highlight highly bioaccumulative compounds
thatmay direct the attention of future risk assessment andmanagement
strategies for PPCPs. Furthermore, and given that several thousand
pharmaceutical compounds currently exist on the market, this repre-
sents a signiﬁcant challenge. It is of interest to enable discovery of
PPCPs in the environment, which might not otherwise be predicted
using simple logP-based approaches and analytical methods to detect
these are urgently required to aid in prioritisation efforts.
Aside from localisedmonitoring programmes, the only international
body in the EU to recognise PPCPs as an emerging environmental
concern was, until recently, the Oslo–Paris Convention for the Protec-
tion of the Marine Environment of the North-East Atlantic (OSPAR)
Commission. Pharmaceuticals remained outside the scope for regula-
tion and formal monitoring under the European Water Framework Di-
rective (WFD). However, following the results of numerous European
monitoring studies at a national level, the list of priority pollutants has
recently been revised with the addition of a ‘watch list’ of new
compounds. This list includes the anti-inﬂammatory, diclofenac and
the hormones, 17α-ethinylestradiol and 17β-estradiol, which are not
subject to regulation, but are instead closely monitored in EU surface
waters for possible future addition to the priority list (Commission,
2012).
Gammarus pulex has many attributes for use in biomonitoring
studies. It is a freshwater benthic dwelling detritivore which has an
important role in freshwater food chains as a food source for other
invertebrates, ﬁsh and birds (Friberg et al., 1994; Maltby et al., 2002).
G. pulex is widely distributed in freshwater rivers and tributaries across
Europe and can be collected in large numbers using simple kick
sampling techniques. More importantly G. pulex has already been used
as a model organism for assessing both the adverse effects (De Lange
et al., 2006, 2009) and uptake potential of PPCPs (Meredith-Williams
et al., 2012) as well as other common pollutants (Ashauer et al., 2012;
Nyman et al., 2012). Themain disadvantage of usingG. pulex in biomon-
itoring is their small size which poses a signiﬁcant analytical challenge
for multi-residue screening. A trade-off exists between achievingsuitable method sensitivity and using the minimum number of speci-
mens to make a single measurement. Very few methods exist for PPCP
residue analysis of such small species in the aquatic environment. It is
generally accepted that liquid or gas chromatography coupled to mass
spectrometry offers the sensitivity and selectivity required. It has been
successfully applied to the analysis of other smaller invertebrate species
such as Chironomus tentans and Hyallela azteca (Dussault et al., 2009;
Klosterhaus et al., 2013). However, robust analytical methods to deter-
mine PPCP residue occurrence in G. pulex are still lacking.
This paper presents, for the ﬁrst time, the occurrence and relative
distribution of PPCPs in surface waters and G. pulex collected from
several tributaries located in the greater London catchment area. The
aim of this study was to evaluate the extent of contamination in surface
waters ﬂowing into the River Thames and to investigate the potential
for the crustacean, G. pulex, to be utilised in future monitoring studies
as an indicator for PPCP pollution.
2. Materials and methods
2.1. Reagents, chemicals and consumables
HPLC grade methanol, acetonitrile, acetone, ethyl acetate, dichloro-
methane and dimethyldichlorosiloxane were purchased from Fischer
Scientiﬁc (Loughborough, UK). Analytical grade ammonium acetate was
sourced from Sigma-Aldrich (Dorset, UK). Propranolol hydrochloride,
ketoprofen, diclofenac sodium salt, bezaﬁbrate, warfarin, ﬂurbiprofen,
indomethacin, ibuprofen sodium salt, meclofenamic acid sodium salt,
gemﬁbrozil, atenolol, sulfamethoxazole, sulfamethazine sodium salt,
furosemide, carbamazepine, nimesulide, (±)-metoprolol (+)-tartrate
salt, triclocarban, cimetidine, ranitidine, antipyrin, temazepam, diazepam,
ﬂuoxetine, nifedipine andmefenamic acid were all obtained from Sigma-
Aldrich (Steinheim, Germany). Trimethoprim, caffeine, and naproxen
were ordered from Fluka (Buchs, Switzerland). Stable isotope-labelled
standards including carbamazepine-d10, propranolol-d7, temazepam-d5
and diazepam-d5 were ordered from Sigma-Aldrich. Trimethoprim-d3
and warfarin-d5 were ordered from QMX Laboratories (Essex, UK). All
pharmaceuticalswere of a purity of≥97%. Ultra-purewaterwas obtained
from a Millipore Milli-Q water puriﬁcation system with a speciﬁc
resistance of 18.3 M Ω cm or greater (Millipore, Bedford, MA, USA).
Stock solutions (1 mg mL−1) were prepared in methanol and stored in
silanised amber vials (40 mL). Working solutions were prepared daily
in ultra-pure water, as required. All solutions were stored at 4 °C and in
the dark for optimum stability.
2.2. Sample collection and preparation
G. pulex and surface waters were sourced from eight tributaries of
the River Thames, UK. These were spread across the greater London
catchment area and included the River Wandle (Sites 1 and 2), the
River Quaggy (Site 3), the River Ravenstone (Site 4), the River Cray
(Sites 5 and 6), the River Darent (Site 7) and Beverley Brook (Site 8).
The speciﬁc locations of the selected sites are shown in Fig. 1. Adult
specimens were collected in September 2012 via the kick sampling
netting method and weighed N5 mg (wet weight). Samples were
transported back to the laboratory in Nalgene™ ﬂasks containing
500 mL of freshwater obtained from each corresponding sampling
site. A bulk sample of G. pulex from Site 1 was used in all analytical
method optimisation experiments and was taken 6 months prior to
samples from the same site used for analyte reporting. G. pulex
were wiped free of debris, rinsed immediately with ultra-pure water
(n = 3) and gently blotted dry before freezing at−20 °C. A separate
1 L grab sample of surface water at each site was also collected and
transported back to the laboratory in 500 mL Nalgene™ ﬂasks. Water
samples were also frozen at−20 °C until analysis. All glassware was
washed in HPLC-grade solvents prior to use and on a monthly basis







Fig. 1. Locations fromwhich samples of G. pulex and surface waters were collected. Sites 1 and 2— RiverWandle, Site 3— River Quaggy, Site 4— River Ravensbourne, Sites 5 and 6— River
Cray, Site 7 — River Darent, and Site 8 — Beverley Brook. Map used with permission and contains Environment Agency information (© Environment Agency and database right).
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licate rinses with each of dichloromethane, methanol and ultrapure
water respectively.
2.3. Sample extraction and clean-up
Prior to extraction, frozenG. pulex sampleswere freeze-dried at−50 °C
under vacuum for 24 h and ground into a coarsematerial using a clean pes-
tle and mortar. Pulverised liquid extraction (PuLE) was performed on an
Ultra-Turrax® tube driver (IKA, Staufen, Germany). The tube driver was
used with an extraction vessel for sample homogenisation and extraction.
The contents of the extraction tube were agitated and pulverised at a set
rate by means of a rotor and glass beads located inside the tube. For each
analysis, freeze-dried composite sample material from each sampling site
(0.1 g)was transferred to a 20mL extraction tube (IKA)with any necessary
spiking carried out directly onto the solid matrix using a 100 μL volume of
an appropriate working solution followed by 5 mL of acetonitrile. Two
glass beads (diameter = 5 mm) were then added to the extraction tube
to enable further pulverisation of the sample and the tube agitated at
2500 rotations per minute (rpm) for 5 min (optimised). Following extrac-
tion and settling, an aliquot of the supernatant (4.5 mL) was diluted to
100 mL with 10 mM ammonium acetate in ultra-pure water (pH 6.5).
Solidphase extraction (SPE)was then carriedout as inpreviously published
work on a similar selection of compounds (Barron et al., 2008) on the dilut-
ed sample using Oasis HLB cartridges (6 mL, 200 mg, Waters Corp., Hert-
fordshire, UK). Before loading of the sample, SPE cartridges were ﬁrst
conditioned with 6 mL of methanol and 6 mL of ultra-pure water. After
sample extraction, cartridges were then washed with 1 mL ultra-pure
water and dried for ~30min under a vacuum. Sample extracts were eluted
with 10mLof 50:50 (v/v) ethyl acetate:acetone anddried under purenitro-
gen (1.0 bar) and heated at 30 °C using a TurboVap (Biotage, Uppsala,
Sweden). Extract residues were reconstituted in 0.5 mL 90:10 (v/v)
10 mM ammonium acetate in water:acetonitrile. Surface water samples
(100 mL) were adjusted to pH 6.5 with ammonium acetate (1 mL of a
1 M solution). Water samples then underwent SPE and reconstitution asdescribed above. Any necessary spiking or liquid volume measurements
were carried out using positive displacement pipettes (Gilson Microman,
Villiers-le-Bel, France).2.4. Instrumental conditions
A previously published chromatographic method for the analysis
of PPCPs in soil and sludge was adapted and applied to a biological
matrix (G. pulex) (Barron et al., 2008). Brieﬂy, liquid chromatogra-
phy (LC) was performed on an Agilent 1100 series LC system (Agilent
Technologies, Cheshire, UK) using a Waters SunFire C18 column
(3.5 μm, 2.1 mm × 150 mm, Waters Corp., Milford, MA, USA) with a
KrudKatcher™ Ultra guard column (0.1 mm ID, 0.5 μm ﬁlter,
Phenomenex, Macclesﬁeld, UK) at a ﬂow rate of 0.2 mL min−1 and
an injection volume of 20 μL. Mobile phases were 90:10 (v/v)
10 mM ammonium acetate in water:acetonitrile (A) and 20:80 (v/v)
10mMammoniumacetate inwater:acetonitrile (B). The proﬁle follow-
ed a linear ramp ofmobile phase Bwhich increased to 10% at 5min, 35%
at 28 min, 40% at 35 min, 50% at 40 min and 100% at 55 min and was
held for a further 7.5 min before returning to initial conditions.
Re-equilibration time was 12.5 min resulting in an overall run time
of 75 min. Detection and quantiﬁcation was carried out with a
Waters Quattro triple quadrupole mass spectrometer (Waters Corp.,
Milford, MA, USA) equipped with an atmospheric pressure interface–
electrospray ionisation (API–ESI) source. Mass spectrometric (MS)
analysis was carried out in selected reaction monitoring (SRM) mode
using positive–negative ionisation polarity switching. A scan rate of
0.03 min was utilised with a minimum of 15 points per peakmeasur-
ing ±0.5 mass units for all transitions monitored. Conﬁrmation of
the selected compounds was achieved using both retention time and
two transitions (MSn2 fragment ions where possible) with the most
intense fragment ion selected for analyte quantiﬁcation (Table 1). MS
conditions as well as all SRM transitions are summarised in Tables S1
and S2 of the supplementary information and were determined by
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alyte solution.2.5. Method performance characteristics and quality control
For this study,method performance characteristics are presented for
G. pulex only. Matrix-matched calibration curves were generated for
biota to assess method performance. Linearity was determined by
measuring the peak area at concentrations from 0.01 to 10 μg g−1 for
the G. pulex (n ≥ 5 for each compound). Limits of detection (LODs)
were determined as the lowest concentration of analyte which pro-
duced a signal-to-noise (S/N) ratio of 3:1. Limits of quantiﬁcation
(LOQs) were determined as that analyte concentration to give an S/N
ratio of 10:1. Both LOD and LOQ were calculated using the S/N ratios
of low concentration spiked samples and precision checked at this
level for n = 6 replicates to ensure satisfactory performance.
Instrumental retention time and method precision (intra-day) experi-
ments were performed for n = 6 replicate injections of a biotic sample
spiked at 1 μg g−1. Method accuracy (intra-day) was determined using
a biotic sample spiked at 20 ng g−1 for all compounds except for
sulfamethazine, metoprolol, propranolol, nimesulide and nifedipine,
where the biotic sample was spiked at 75 ng g−1 (n ≥ 3). Recovery
was determined by comparing spiked samples at 1 μg g−1 in G. pulex
(n= 6 andwhichwas also used to assess mid-rangemethod precision)
to sample extracts spiked post-extraction (n = 3) at the expected ﬁnal
concentration. Control samples were also analysed for background
correction purposes, where necessary. The measurement of ion
suppression or enhancement in ESI–MS involved the comparison of
sample extracts spiked post-extraction to a 100 ng g−1 working
solution mixture (n = 3). The target analytes in both surface waters
and biota were quantiﬁed based on their peak areas relative to that of
an isotopically-labelled internal standard or, where unavailable, by
external matrix-matched calibration. Relative recovery in G. pulex was
measured following the analysis of spiked biotic samples (analytesTable 1
Method performance characteristics for G. pulex analysis.





(min) (ng g−1) n ≥ 5 (ng
g−1)
n = 6 n = 6
Sulfamethazine 11.9 ± 0.1 (279→ 186) (+) 25–10,000 0.9987 4
(279→ 124)
Trimethoprim 16.8 ± 0.1 (291→ 230) (+) 10–10,000 0.9987 2
(291→ 123)
Metoprolol 19.7 ± 0.1 (268→ 116) (+) 10–10,000 0.9992 1
(268→ 159)
Propranolol 30.9 ± 0.5 (260→ 116) (+) 50–10,000 0.9952 13
(260→ 183)
Carbamazepine 31.3 ± 0.1 (237→ 194) (+) 25–10,000 0.9983 2
Warfarin 22.7 ± 0.1 (307→ 161) (−) 50–10,000 0.9973 2
(307→ 250)
Temazepam 40.2 ± 0.1 (301→ 255) (+) 10–10,000 0.993 2
(301→ 283)
Diazepam 46.8 ± 0.1 (285→ 153) (+) 10–10,000 0.9991 2
(285→ 193)
Nimesulide 44.0 ± 0.1 (307→ 229) (−) 25–10,000 0.9945 3
(307→ 79)
Nifedipine 44.4 ± 0.1 (347→ 315) (+) 10–10,000 0.9985 1
(347→ 271)
a SD= standard deviation.
b n N 5 concentration data points each performed in triplicate.
c Signal to noise ratio of 10:1 from 20 ng g−1 spiked matrix-matched sample.
d Signal to noise ratio of 10:1 from 75 ng g−1 spiked matrix-matched sample.
e Signal to noise ratio of 10:1 from 60 ng g−1 spiked matrix-matched sample.
f Using a 75 ng g−1 spiked sample (n = 3) and determined by matrix matched calibration (
g Using a 20 ng g−1 spiked sample (n = 4) and determined by the relevant isotopically-laband the internal standard at 100 ng g−1 each) by comparing the analyte
peak areas to that of the internal standard (n = 12).
Mobile phase Awas injected between samples from each site aswell
as between matrix-matched standards and controls to minimise the
possibility of carry over. Direct infusion of a propranolol standard
(1 μg mL−1) was carried out before each batch analysis to ensure that
the MS was operating satisfactorily. None of the targeted analytes
were detected in any solvents, reagents or ultra-pure water used in
this study.3. Results and discussion
3.1. Optimisation of analytical methods for G. pulex
The presence of pharmaceuticals in aquatic organisms, particularly
molluscs, has been previously investigated using extraction techniques
such as pressurised liquid extraction (PLE) or ultrasound-assisted
solvent extraction which involve the use of high temperatures,
pressures and/or relatively large volumes of organic solvent
(Cueva-Mestanza et al., 2008; McEneff et al., 2013). Other studies have
utilised PuLE as a simple and fast extraction method for the quantiﬁca-
tion of pharmaceuticals in solid dosage forms (Kok and Debets, 2001).
Due to the complexity of biological tissues (and especially here where
keratinousmaterial was present), PuLEwas used here to simultaneously
blend and extract all material before SPE. For this purpose, a specially
designed extraction vial was used and was equipped with a rotor for
agitation of the sample, liquid and two glass beads. The beads were
required for satisfactory agitation and pulverisation of the G. pulex
material, but also were considered valuable to potentially confer
ﬂexibility in the future for extraction of whole tissues/specimens where
necessary. Sorption to glass beads was brieﬂy investigated here by
performing the extraction procedure on a mixed 1 μg mL−1 standard
solution of all analytes prepared in the extraction solvent. The use of








(ng g−1) (%) (%) (%)
n = 6 n ≥ 3 n = 6 n = 6
15 ± 6d 95 ± 3f 41 ± 2 11 ± 2
5 ± 4c 126 ± 31g 65 ± 1 13 ± 6
4 ± 1d 100 ± 6f 71 ± 5 11 ± 2
61 ± 9e 81 ± 8f 52 ± 11 56 ± 4
6 ± 1c 124 ± 6g 69 ± 3 9 ± 2
5 ± 1c 102 ± 9g 71 ± 3 28 ± 4
6 ± 1c 100 ± 3g 85 ± 1 11 ± 3
5 ± 2c 176 ± 28g 89 ± 2 43 ± 3
13 ± 2c 97 ± 7f 87 ± 4 35 ± 3
4 ± 1d 104 ± 6f 70 ± 1 39 ± 4























































































































m/z transition: 307 → 229 
Gammarus pulex 
Site 1 
Fig. 2. Example extracted ion chromatograms of PPCPs detected in surface waters and
G. pulex sampled from each of the eight selected sites.
157T.H. Miller et al. / Science of the Total Environment 511 (2015) 153–160achieved using unsilanised glass beads. Therefore, glass bead silanisation
was not required (see Table S2).
The extraction of pharmaceuticals from aqueous samples is general-
ly performed by SPE and HLB-type SPE cartridges enable the extraction
of both polar and non-polar compounds from bothwater and biological
extracts (Baker and Kasprzyk-Hordern, 2011a; Barron et al., 2008;
Gomez et al., 2006; Weigel et al., 2004). The effect of the sample pH
prior to SPE was investigated at pH 2, 7 and 10 (n = 3). A sample pH
of 7 yielded the highest recoveries and lowest variability for the selected
analytes. Sample reconstitution volumes of 0.1mL and 0.5mLwere also
investigated. As shown in Table S4, analyte recovery using a reconstitu-
tion volume of 0.5 mL was higher overall than that of 0.1 mL. In partic-
ular, compounds such as diazepam, gemﬁbrozil, triclocarban, ibuprofen,
diclofenac and nimesulide showed moderately higher recoveries when
reconstituted to 0.5 mL. Solubility of a dried matrix residue may have
been a limiting factor at the reduced reconstitution solvent volume.
Furthermore, matrix suppression effects in ESI–MS are likely to increase
with a more concentrated sample extract (as was observed here).
Although a thorough sample clean-up method was developed, ﬁnal
extracts of the G. pulex contained an immiscible red-pigmented liquid.
A likely identity for this contaminant is astaxanthin, a relatively
non-polar carotenoid pigment found in crustaceans (Johnson and An,
1991), but further analysis would be required to conﬁrm this. Attempts
to remove this substance from the groundG. pulex sample via liquid–liq-
uid extraction (using a 50:50 (v/v) solution of acetonitrile with
hydrochloric acid at pH 2 and hexane) did not prove successful.
Additional approaches such as centrifugation and neutral alumina
addition were also investigated (the latter of which is often used to
remove pigments), but the substance remained in the sample extract
and analyte recoveries did not improve (data not shown). Therefore, a
0.5 mL reconstitution volume in 90:10 (v/v) 10mM ammonium acetate
in water:acetonitrile was considered optimised.
In line with many other studies, LC–MS/MS was the chosen analyti-
cal technique for the conﬁrmatory detection and subsequent determi-
nation of PPCPs in surface waters and G. pulex. A 10 mM ammonium
acetate solution in a mixture of acetonitrile and water was selected
again as a suitable mobile phase for reversed-phase separations in line
with previously published work (Barron et al., 2008). The mobile
phase gradients and column temperature (20, 30, 40 and 45 °C) were
further optimised to allow better separation of more PPCPs. A column
oven temperature of 45 °C offered the best separation of all compounds.
For mass spectrometry, direct infusion was carried out initially in full
scan mode to determine the most abundant precursor ion for each
analyte and to optimise MS parameters for the best signal response.
Compounds yielded [M + H]+, [M − H]− or [M-COOH]− precursor
ions in positive or negative polarity ESI–MS mode. Furthermore, SRM
performed under positive–negative switching mode yielded MS/MS
data for 29 analytes (Table S2). Secondary fragment ion transitions
were observed for 21 of these compounds.
3.2. Method performance characteristics
Few validated multi-residue methods exist for PPCP determination
in biota due to their complexity, variability, and potential to cause
analytical matrix effects. Therefore, a larger number of compounds
were included in the method development process originally as it was
expected that some would not meet acceptable method performance
criteria for quantitative analysis of small biotic samples. Those consid-
ered acceptable are presented in Table 1 (data from the full method
performance experiment are shown in Tables S4 and S5). Method
performance in surface waters is not presented here, but the method
was deemed suitable for semi-quantitative purposes as it was based
on previously published work (Lacey et al., 2012; Lacey et al., 2008).
Instrumental retention time precision in G. pulexmatrix was b0.5% for
all analytes except for propranolol whichwas 1.7% (n= 6). For method
linearity, correlation coefﬁcients of R2 N 0.98 (n ≥ 5 data points) wereachieved for triplicate experiments, again in G. pulex matrix, over the
calibration range for 18 compounds. Twelve compounds achieved
unacceptable correlation coefﬁcients and were included for qualitative
purposes only (Table S5). Following the assessment of linearity, limits
of quantitation (LOQs) of the method were determined for 23 analytes
and lay between 4 and 687 ng g−1. Intra-day method reproducibility
was b30% for 20 analytes at 1 μg/g. Mean absolute recoveries of 28
analytes ranged from4 to 89% (n=6)with eight compounds displaying
absolute recoveries N70%. Overall, it was observed that compounds
158 T.H. Miller et al. / Science of the Total Environment 511 (2015) 153–160determined in negative ESI–MS mode demonstrated lower recoveries
than compounds detected in positive ESI–MS mode. Signiﬁcant signal
suppression was observed in G. pulexmatrix as per Table S4 and signals
for 6 of 29 compoundswere suppressed greater than 50% in comparison
to a standard mixture. The precision and recovery of this method in
G. pulex correlates to data reported by Klosterhaus et al. (2013) for the
analysis of PPCPs in mussels from San Francisco Bay. Other similar
studies carried out on mussel and ﬁsh tissues, and other complex
matrices such as biosolids and sludge, have shown similar method
performance for PPCPs (Dodder et al., 2014; McEneff et al., 2013).
Overall, and of the 29 PPCPs initially included in method development
and performance characterisation, 10 compounds (carbamazepine,
trimethoprim,warfarin, diazepam, temazepam, propranolol, nifedipine,
nimesulide, sulfamethazine and metoprolol) showed acceptable
method performance for quantiﬁcation purposes. Precision was also
maintained for these compounds when measured near the LOQ across
n = 6 replicates.
3.3. Application to G. pulex and surface waters in tributaries of the River
Thames, UK
The developed methods were applied to the identiﬁcation of
pharmaceutical residues in water and biotic samples. Surface water
samples (500 mL) and G. pulex (n ≈ 60–100 specimens) were used
for replicate analysis across the selected sites. As the surface water and
biotic samples were collected by grab sampling, the results presented
represent pharmaceutical concentrations present at that point in time.
Example extracted ion chromatograms for compounds quantiﬁed in
surface waters and G. pulex, are shown in Fig. 2.
Of the 29 compounds included in the analyticalmethod for qualitative
screening of invertebrate tissues, a total of 6 compounds were quantiﬁed
in G. pulex (Table 2). Diclofenac was also detected at all sites but was not
quantiﬁable due to method performance limitations (Table S5). Due to
the lack of information regarding pharmaceutical uptake in G. pulex,
similar occurrence studies on other species were used for comparison.
Five compounds were quantiﬁed across the eight sites at concentrations
≤36 ng g−1 dry weight (Table 2). Carbamazepine was the most
frequently detected compound, which is perhaps unsurprising as this
compound has been reported in several solid and biological matrices
(Barron et al., 2008; Huerta et al., 2013). Site 7was themost contaminat-
ed of all sites. Diazepam was quantiﬁable across four sites at concentra-
tions ≤9 ng g−1 dry weight. Kwon and co-workers detected several
PPCP residues including carbamazepine and diazepam in ﬁsh livers and
the latterwas determined at concentrations up to 110 ng g−1wetweight
(Kwon et al., 2009). If hydrophobicity is to be considered a reliable
quantity for bioaccumulation of PPCPs, then this may be explained
given their moderate hydrophobicity relative to other PPCPs (logP =
2.45 and 2.86, respectively) (Barron et al., 2009). However, Meredith-
Williams et al. recently studied bioconcentration of diazepam and
carbamazepine in G. pulex, both of which were found to be minimal
with BCF values of 38 and 7, respectively. As these compounds have
relatively higher logP values in comparison to most other pharmaceuti-
cals, it suggests that uptake models based on hydrophobicity may notTable 2
Pharmaceutical residues (ng g−1) detected in Gammarus pulexmaterial sampled from eight sit
sites but was not quantiﬁable based on method performance limitations.
Compounds Site 1 n = 2 Site 2 n = 3 Site 3 n = 2 Site 4 n
Carbamazepine – bLOQ – ND–b L
Diazepam ND, 6 ND–8 – ND–6
Temazepam – – – –
Trimethoprim – – – –
Warfarin – – – –
Nimesulidea 13, 36 ND– b LOQ – ND– b
ND — not detected, all other compounds marked with ‘–’were also not detected.
a Quantiﬁed by three-point standard addition calibration.accurately represent the potential for a compound to bioconcentrate in
invertebrates. Tanoue et al. recently presented an analytical method for
the determination of 17 intermediate-polarity PPCPs (logP =
1.40–5.74) and its application to biological tissue from Japanese ﬁsh
and birds (Tanoue et al., 2014). Up to 13 PPCPs were determined across
ﬁsh plasma (0.03–22 ng mL−1), the brain and liver tissue (1–910 and
0.11–16 ng g−1 wet weight respectively) and all 17 were detected in
the surrounding aquatic environment (at 3–871 ng L−1). McEneff et al.
investigated pharmaceutical concentrations in marine bivalves residing
in efﬂuent-contaminated seawater. The antibiotic, trimethoprim,
measured highest at concentrations up to 9 ng g−1 dry weight and
carbamazepine was also detected, but below its LOQ (McEneff et al.,
2014). Here, trimethoprim was only quantiﬁable at Site 8 at 5 ng g−1
dry weight. Nimesulide was quantiﬁed at slightly higher concentrations
on average. This coincides with the results from surface water analysis
where nimesulide was detected in samples from Sites 1 to 4 and 7.
Nimesulide was banned in the Republic of Ireland in 2007 due to risks
associated with hepatic failure and it is not available on the UK market
as a pharmaceutical for human consumption. However, sources of input
into the environment still exist via veterinary routes and in addition
this compound has also been found in selected food supplements
(Lacey et al., 2012; MHRA, 2014).
Adverse effects such as increased oxidative stress and tissue lesions
have been observed following the exposure of species such as ﬁsh and
molluscs to environmentally relevant PPCP concentrations. A study
carried out by De Lange et al. (2006) investigated the behavioural
responses of G. pulex when exposed to environmentally relevant con-
centrations (from 0.1 ng L−1 up to 1 mg L−1) of the pharmaceuticals
carbamazepine, ﬂuoxetine and ibuprofen (De Lange et al., 2006). The
lowest observed effect concentration (LOEC) for ﬂuoxetine was report-
ed as 100 ng L−1 and the LOEC for ibuprofen and carbamazepine was
measured at even lower concentrations at 10 ng L−1. However, it was
noted that the reduced activity observed in G. pulex exposed to carba-
mazepine (≥10ng L−1)was not signiﬁcantly different to the control ex-
posure. Carbamazepine was measured at concentrations up to
344 ng L−1 in the surface waters from Site 8. Further work is still
required to establish reliable LOEC levels for pharmaceuticals both in
isolation and when present as a mixture (Arnold et al., 2014; Brooks,
2014). Indeed, with ongoing extensive debate in the literature
questioning the validity and reproducibility of experiments revealing
effects on bespoke endpoints (Sumpter et al., 2014), it is clearly
essential to have the tools available to measure both the exposure
concentrations (water) and internal concentrations in order to attribute
cause and effect.
With respect to surface waters, six PPCPs were detected at quantiﬁ-
able levels across all sites at concentrations ranging from 3 to
344 ng L−1 (Table 3). Carbamazepine and trimethoprim measured
highest at concentrations of 344 ng L−1 and 289 ng L−1, respectively.
From the eight sites, all of the selected analytes measured at their
highest concentration at Site 8, with the exception of propranolol
which measured at concentrations N250 ng L−1 at Site 5. An efﬂuent
outfall pipe lay in close proximity to Site 8, and potentially higher
concentrations of pharmaceutical contamination in river water werees located on the tributaries of the River Thames, UK. Note: diclofenac was detected at all
= 3 Site 5 n = 3 Site 6 n = 2 Site 7 n = 3 Site 8 n = 2
OQ bLOQ – ND– b LOQ 6
– – ND–9 –
– – bLOQ ND– b LOQ
– – ND– b LOQ 5
– – ND–7 –
LOQ ND–16
Table 3
Pharmaceutical residues (ng L−1) detected in surface water sampled from eight sites located on the tributaries of the River Thames, UK.
Compounds logP (Barron et al., 2009) Site 1 n = 3 Site 2 n = 3 Site 3 n = 3 Site 4 n = 3 Site 5 n = 3 Site 6 n = 3 Site 7 n = 3 Site 8 n = 3
Carbamazepine 2.45 12–27 10–62 13–17 20–156 6–149 8–9 6–53 320–344
Diazepam 2.86 ND ND–bLOQ ND–3 ND–bLOQ ND–bLOQ ND–bLOQ bLOQ 4
Propranolol 3.48 ND–bLOQ bLOQ–59 8–22 bLOQ–11 ND–253 21–52 5–23 98–119
Temazepam 2.19 ND–bLOQ bLOQ–2 bLOQ 5–6 ND–bLOQ ND ND–LOQ 60–67
Trimethoprim 0.91 bLOQ–8 ND–bLOQ 4–10 bLOQ–48 ND–41 6–16 bLOQ–9 263–289
Warfarin 2.60 ND–bLOQ ND–53 bLOQ–12 ND–bLOQ ND–9 11–14 ND–LOQ 15–29
ND — not detected.
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concentrations measured in G. pulex (highest internal concentrations
measured at Site 7). The Beverley Brook tributary was previously
classed as having ‘poor ecological status’ by the Environment Agency
in 2012 for failures in surrounding ecology, water chemistry and
morphology standards (Ehmann, 2013). River water samples from
Site 5 were also found to contain relatively high concentrations of
carbamazepine, propranolol and trimethoprim. Besides direct input
from WWTPs, other sources of pharmaceutical contamination include
sewage from the numerous combined sewer overﬂows serving this
river catchment area which overﬂow during periods of heavy rainfall
and interestingly, have been shown to intermittently discharge sewage
into surfacewaters evenwithout precipitation (Buerge et al., 2006). The
Environment Agency (England) has reported poor status for two
groundwater bodies which predominantly supply the river ﬂow
through Sites 5, 6 and 7 (Gorman, 2013). Although most of the PPCPs
were detected at all three of these sites, surface water samples from
the River Cray (Sites 6 and 7) were found to contain relatively low
residue concentrations overall. Diazepam was the least detected
compound in water and measured concentrations were 3 and
4 ng L−1 at Sites 3 and 8, respectively.
As expected from this ‘snapshot’ collection method, there was poor
correlation between water and G. pulex measured concentrations
(compare Tables 2 and 3). Temazepam and propranolol were both
measured in water (propranolol in 7 of the 8 sites), but neither were
detected within any G. pulex despite having higher LogP values than
trimethoprim which was measured in these organisms. This would
further support the hypothesis that for invertebrates, uptake is driven
by more than hydrophobicity alone. Intuitively one would predict a
constant state of ﬂux in the uptake and depuration of compounds as
the ﬂow of water and external exposure changes, and the poor correla-
tion could support that. Therefore, measuring concentrationswithin the
organism is likely to be more relevant (and important) for understand-
ing risk than external water alone.
Several monitoring studies have been carried out in freshwater
throughout the UK. A study carried out on the River Taff and the River
Ely in Wales consistently detected the presence of carbamazepine at
concentrations up to 684 ng L−1. Several recent monitoring studies
have detected the presence of propranolol and trimethoprim in surface
waters across the UK at concentrations up to 40 ng L−1 and 215 ng L−1,
respectively (Ashton et al., 2004; Baker and Kasprzyk-Hordern, 2011b;
Roberts and Thomas, 2006). The benzodiazepines, temazepam and
diazepam have also been reported in river water measuring at concen-
trations of 53 ng L-1 and 1 ng L−1, respectively (Baker and Kasprzyk-
Hordern, 2011a). All six selected pharmaceuticals detected here have
also been determined in riverwaters aroundEurope andAsia at concen-
trations measuring up to 1 μg L−1 in countries such as South Korea,
Spain and France (Feitosa-Felizzola and Chiron, 2009; Silva et al.,
2011; Yoon et al., 2010).
4. Conclusions
For the ﬁrst time, the occurrence of six pharmaceuticals was reported
from measured internal concentrations in the river shrimp, G. pulex,
and its surrounding waters. An analytical method involving PuLE, SPEand LC–MS/MS was optimised and applied to surface waters and
G. pulex samples collected from eight sites along several tributaries of
the River Thames. Five pharmaceuticals detected in the freshwater
samples were also found to occur in exposed G. pulex at concentrations
up to 36 ng g−1 dry weight, although direct correlation with water
concentrations at individual sites was not possible. Carbamazepine and
trimethoprim measured highest in river water at concentrations up to
344 ng L−1 and 289 ng L−1, respectively. These ﬁndings provide new
knowledge on the occurrence of pharmaceutical residues in a key aquatic
invertebrate, and tools to further investigate their potential effects via
internal concentration measurement.
Acknowledgements
This work was conducted with funding from the Biotechnology and
Biological Sciences Research Council (BBSRC) CASE industrial
scholarship scheme (Reference BB/K501177/1) and AstraZeneca Global
SHE research programme. AstraZeneca is a biopharmaceutical company
specialising in the discovery, development, manufacturing and market-
ing of prescription medicines, including some products measured here.
Funding bodies played no role in the design of the study or decision to
publish. The authors declare no ﬁnancial conﬂict of interest.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scitotenv.2014.12.034.
References
Arnold, K.E., Brown, A.R., Ankley, G.T., Sumpter, J.P., 2014. Medicating the environment:
assessing risks of pharmaceuticals to wildlife and ecosystems. Philos. Trans. R. Soc.
B Biol. Sci. 369.
Ashauer, R., Hintermeister, A., O'Connor, I., Elumelu, M., Hollender, J., Escher, B.I., 2012.
Signiﬁcance of xenobiotic metabolism for bioaccumulation kinetics of organic
chemicals in Gammarus pulex. Environ. Sci. Technol. 46, 3498–3508.
Ashton, D., Hilton, M., Thomas, K.V., 2004. Investigating the environmental transport of
human pharmaceuticals to streams in the United Kingdom. Sci. Total Environ. 333,
167–184.
Baker, D.R., Kasprzyk-Hordern, B., 2011a. Multi-residue analysis of drugs of abuse in
wastewater and surface water by solid-phase extraction and liquid chromatogra-
phy–positive electrospray ionisation tandem mass spectrometry. J. Chromatogr. A
1218, 1620–1631.
Baker, D.R., Kasprzyk-Hordern, B., 2011b. Multi-residue determination of the sorption of
illicit drugs and pharmaceuticals to wastewater suspended particulate matter using
pressurised liquid extraction, solid phase extraction and liquid chromatography
coupled with tandem mass spectrometry. J. Chromatogr. A 1218, 7901–7913.
Barron, L., Tobin, J., Paull, B., 2008. Multi-residue determination of pharmaceuticals in
sludge and sludge enriched soils using pressurized liquid extraction, solid phase
extraction and liquid chromatography with tandem mass spectrometry. J. Environ.
Monit. 10, 353–361.
Barron, L., Havel, J., Purcell, M., Szpak, M., Kelleher, B., Paull, B., 2009. Predicting sorption
of pharmaceuticals and personal care products onto soil and digested sludge using
artiﬁcial neural networks. Analyst 134, 663–670.
Behera, S.K., Kim, H.W., Oh, J.E., Park, H.S., 2011. Occurrence and removal of antibiotics,
hormones and several other pharmaceuticals in wastewater treatment plants of the
largest industrial city of Korea. Sci. Total Environ. 409, 4351–4360.
Brooks, B.W., 2014. Fish on Prozac (and Zoloft): ten years later. Aquat. Toxicol. 151,
61–67.
Brown, K.D., Kulis, J., Thomson, B., Chapman, T.H., Mawhinney, D.B., 2006. Occurrence of
antibiotics in hospital, residential, and dairy efﬂuent, municipal wastewater, and
the Rio Grande in New Mexico. Sci. Total Environ. 366, 772–783.
160 T.H. Miller et al. / Science of the Total Environment 511 (2015) 153–160Buerge, I.J., Poiger, T., Müller, M.D., Buser, H.-R., 2006. Combined sewer overﬂows to
surface waters detected by the anthropogenic marker caffeine. Environ. Sci. Technol.
40, 4096–4102.
Carmona, E., Andreu, V., Pico, Y., 2014. Occurrence of acidic pharmaceuticals and personal
care products in Tuna River Basin: from waste to drinking water. Sci. Total Environ.
484, 53–63.
Commission E, 2012. Commission Proposal on Priority Substances (COM(2011)876).
p. 2014.
Corcoran, J., Winter, M.J., Tyler, C.R., 2010. Pharmaceuticals in the aquatic environment: a
critical review of the evidence for health effects in ﬁsh. Crit. Rev. Toxicol. 40, 287–304.
Cueva-Mestanza, R., Torres-Padrón, M., Sosa-Ferrera, Z., Santana-Rodríguez, J., 2008.
Microwave‐assisted micellar extraction coupled with solid-phase extraction for
preconcentration of pharmaceuticals in molluscs prior to determination by HPLC.
Biomed. Chromatogr. 22, 1115–1122.
De Lange, H.J., Noordoven, W., Murk, A.J., Lürling, M., Peeters, E.T.H.M., 2006. Behavioural
responses of Gammarus pulex (Crustacea, Amphipoda) to low concentrations of
pharmaceuticals. Aquat. Toxicol. 78, 209–216.
De Lange, H.J., Peeters, E.T.H.M., Lürling, M., 2009. Changes in ventilation and locomotion
of Gammarus pulex (Crustacea, Amphipoda) in response to low concentrations of
pharmaceuticals. Human and Ecological Risk Assessment 15 (1), 111–120.
Dobson, P.D., Kell, D.B., 2008. Carrier-mediated cellular uptake of pharmaceutical drugs:
an exception or the rule? Nat. Rev. Drug Discov. 7, 205–220.
Dodder, N.G., Maruya, K.A., Lee Ferguson, P., Grace, R., Klosterhaus, S., La Guardia, M.J., et
al., 2014. Occurrence of contaminants of emerging concern in mussels (Mytilus spp.)
along the California coast and the inﬂuence of land use, storm water discharge, and
treated wastewater efﬂuent. Mar. Pollut. Bull. 81, 340–346.
Dussault, È.B., Balakrishnan, V.K., Solomon, K.R., Sibley, P.K., 2009. Matrix effects on mass
spectrometric determinations of four pharmaceuticals and personal care products in
water, sediments, and biota. Can. J. Chem. 87, 662–672.
Ehmann, P., 2013. Beverley Brook Information Pack 2014. Environment Agency.
Feitosa-Felizzola, J., Chiron, S., 2009. Occurrence and distribution of selected antibiotics in
a small Mediterranean stream (Arc River, Southern France). J. Hydrol. 364, 50–57.
Friberg, N., Andersen, T.H., Hansen, H.O., Iversen, T.M., Jacobsen, D., Krøjgaard, L., et al.,
1994. The effect of brown trout (Salmo Trutta L.) on stream invertebrate drift, with
special reference to Gammarus pulex L. Hydrobiologia 294, 105–110.
Gatidou, G., Vassalou, E., Thomaidis, N.S., 2010. Bioconcentration of selected endocrine
disrupting compounds in the Mediterranean mussel, Mytilus galloprovincialis. Mar.
Pollut. Bull. 60, 2111–2116.
Gomez, M.J., Petrovic, M., Fernandez-Alba, A.R., Barcelo, D., 2006. Determination of
pharmaceuticals of various therapeutic classes by solid-phase extraction and liquid
chromatography-tandem mass spectrometry analysis in hospital efﬂuent wastewa-
ters. J. Chromatogr. A 1114, 224–233.
Gorman, A., 2013. Water Body Action Plan 2014. Environment Agency.
Hamelink, J.L., Spacie, A., 1977. Fish and chemicals: the process of accumulation. Annu.
Rev. Pharmacol. Toxicol. 17, 167–177.
Huerta, B., Rodriguez-Mozaz, S., Barcelo, D., 2012. Pharmaceuticals in biota in the aquatic
environment: analytical methods and environmental implications. Anal. Bioanal.
Chem. 404, 2611–2624.
Huerta, B., Jakimska, A., Gros, M., Rodriguez-Mozaz, S., Barcelo, D., 2013. Analysis of
multi-class pharmaceuticals in ﬁsh tissues by ultra-high-performance liquid
chromatography tandem mass spectrometry. J. Chromatogr. A 1288, 63–72.
Johnson, E.A., An, G.-H., 1991. Astaxanthin from microbial sources. Crit. Rev. Biotechnol.
11, 297–326.
Klosterhaus, S.L., Grace, R., Hamilton, M.C., Yee, D., 2013. Method validation and
reconnaissance of pharmaceuticals, personal care products, and alkylphenols in
surface waters, sediments, and mussels in an urban estuary. Environ. Int. 54, 92–99.
Kok, S.J., Debets, A.J.J., 2001. Fast sample preparation for analysis of tablets and capsules:
the ball-mill extraction method. J. Pharm. Biomed. Anal. 26, 599–604.
Kosma, C.I., Lambropoulou, D.A., Albanis, T.A., 2010. Occurrence and removal of PPCPs in
municipal and hospital wastewaters in Greece. J. Hazard. Mater. 179, 804–817.
Kwon, J.-W., Armbrust, K.L., Vidal-Dorsch, D., Bay, S.M., Xia, K., 2009. Determination of 17
alpha-ethynylestradiol, carbamazepine, diazepam, simvastatin, and oxybenzone in
ﬁsh livers. J. AOAC Int. 92, 359–369.Lacey, C., McMahon, G., Bones, J., Barron, L., Morrissey, A., Tobin, J.M., 2008. An LC–MS
method for the determination of pharmaceutical compounds in wastewater
treatment plant inﬂuent and efﬂuent samples. Talanta 75, 1089–1097.
Lacey, C., Basha, S., Morrissey, A., Tobin, J., 2012. Occurrence of pharmaceutical
compounds in wastewater process streams in Dublin, Ireland. Environ. Monit. Assess.
184, 1049–1062.
Maltby, L., Clayton, S.A., Wood, R.M., McLoughlin, N., 2002. Evaluation of the Gammarus
pulex in situ feeding assay as a biomonitor of water quality: robustness, responsive-
ness, and relevance. Environ. Toxicol. Chem. 21, 361–368.
McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B., 2013. The determination of
pharmaceutical residues in cooked and uncooked marine bivalves using pressurised
liquid extraction, solid-phase extraction and liquid chromatography–tandem mass
spectrometry. Anal. Bioanal. Chem. 405, 9509–9521.
McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B., 2014. A year-long study of the
spatial occurrence and relative distribution of pharmaceutical residues in sewage
efﬂuent, receiving marine waters and marine bivalves. Sci. Total Environ. 476–477,
317–326.
McKim, J., Schmieder, P., Veith, G., 1985. Absorption dynamics of organic chemical
transport across trout gills as related to octanol–water partition coefﬁcient. Toxicol.
Appl. Pharmacol. 77, 1–10.
Meredith-Williams, M., Carter, L.J., Fussell, R., Raffaelli, D., Ashauer, R., Boxall, A.B.A., 2012.
Uptake and depuration of pharmaceuticals in aquatic invertebrates. Environ. Pollut.
165, 250–258.
MHRA, 2014. Medicines and Healthcare Products Regulatory Agency. p. 2014.
Nyman, A.-M., Schirmer, K., Ashauer, R., 2012. Toxicokinetic–toxicodynamic modelling of
survival of Gammarus pulex in multiple pulse exposures to propiconazole: model
assumptions, calibration data requirements and predictive power. Ecotoxicology 21,
1828–1840.
Rand-Weaver,M.,Margiotta-Casaluci, L., Patel, A., Panter, G.H., Owen, S.F., Sumpter, J.P., 2013.
The read-across hypothesis and environmental risk assessment of pharmaceuticals.
Environ. Sci. Technol. 47, 11384–11395.
Roberts, P.H., Thomas, K.V., 2006. The occurrence of selected pharmaceuticals in
wastewater efﬂuent and surface waters of the lower Tyne catchment. Sci. Total
Environ. 356, 143–153.
Schultz, M.M., Furlong, E.T., Kolpin, D.W., Werner, S.L., Schoenfuss, H.L., Barber, L.B., et al.,
2010. Antidepressant pharmaceuticals in two U.S. efﬂuent-impacted streams:
occurrence and fate in water and sediment, and selective uptake in ﬁsh neural tissue.
Environ. Sci. Technol. 44, 1918–1925.
Silva, B.F.d, Jelic, A., López-Serna, R., Mozeto, A.A., Petrovic, M., Barceló, D., 2011.
Occurrence and distribution of pharmaceuticals in surface water, suspended solids
and sediments of the Ebro river basin, Spain. Chemosphere 85, 1331–1339.
Subedi, B., Du, B., Chambliss, C.K., Koschorreck, J., Rudel, H., Quack, M., et al., 2012.
Occurrence of pharmaceuticals and personal care products in German ﬁsh tissue: a
national study. Environ. Sci. Technol. 46, 9047–9054.
Sumpter, J.P., Donnachie, R.L., Johnson, A.C., 2014. The apparently very variable potency of
the anti-depressant ﬂuoxetine. Aquat. Toxicol. 151, 57–60.
Tanoue, R., Nomiyama, K., Nakamura, H., Hayashi, T., Kim, J.-W., Isobe, T., et al., 2014.
Simultaneous determination of polar pharmaceuticals and personal care products
in biological organs and tissues. J. Chromatogr. A 1355, 193–205.
Thomas, K.V., Hilton, M.J., 2004. The occurrence of selected human pharmaceutical
compounds in UK estuaries. Mar. Pollut. Bull. 49, 436–444.
Vazquez-Roig, P., Blasco, C., Pico, Y., 2013. Advances in the analysis of legal and illegal
drugs in the aquatic environment. Trac-Trends Anal. Chem. 50, 65–77.
Weigel, S., Kallenborn, R., Hühnerfuss, H., 2004. Simultaneous solid-phase extraction of
acidic, neutral and basic pharmaceuticals from aqueous samples at ambient
(neutral) pH and their determination by gas chromatography–mass spectrometry.
J. Chromatogr. A 1023, 183–195.
Yoon, Y., Ryu, J., Oh, J., Choi, B.-G., Snyder, S.A., 2010. Occurrence of endocrine disrupting
compounds, pharmaceuticals, and personal care products in the Han River (Seoul,
































0Journal of Chromatography A, 1396 (2015) 34–44
Contents lists available at ScienceDirect
Journal  of  Chromatography  A
jo ur nal ho me pag e: www.elsev ier .com/ locate /chroma
rtiﬁcial  neural  network  modelling  of  pharmaceutical  residue
etention  times  in  wastewater  extracts  using  gradient  liquid
hromatography-high  resolution  mass  spectrometry  data
elly  Munroa, Thomas  H.  Millera,  Claudia  P.B.  Martinsb, Anthony  M.  Edgec,
avid  A.  Cowana,  Leon  P.  Barrona,∗
Analytical & Environmental Sciences Division, King’s College London, 150 Stamford Street, SE1 9NH London, United Kingdom
Thermo Fisher Scientiﬁc, 355 River Oaks Parkway, San Jose, CA 95134, USA
Thermo Fisher Scientiﬁc, Tudor Road, Runcorn, United Kingdom
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 10 November 2014
eceived in revised form 27 February 2015
ccepted 23 March 2015
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a  b  s  t  r  a  c  t
The  modelling  and  prediction  of  reversed-phase  chromatographic  retention  time  (tR)  under  gradient
elution  conditions  for 166  pharmaceuticals  in  wastewater  extracts  is  presented  using  artiﬁcial  neural
networks  for  the  ﬁrst  time. Radial  basis  function,  multilayer  perceptron  and  generalised  regression  neu-
ral networks  were  investigated  and a comparison  of their  predictive  ability  for  model  solutions  discussed.
For real  world  application,  the  effect  of  matrix complexity  on  tR measurements  is  presented.  Measured
tR for  some  compounds  in  inﬂuent  wastewater  varied  by  >1 min  in comparison  to  tR in model  solutions.
Similarly,  matrix  impact  on  artiﬁcial  neural  network  predictive  ability  was  addressed  towards  develop-
ing a  more  robust  approach  for routine  screening  applications.  Overall,  the  best  neural  network  had  a
predictive  accuracy  of  <1.3 min  at the  75th  percentile  of  all measured  tR data  in  wastewater  samples
(<10%  of  the total  runtime).  Coefﬁcients  of  determination  for 30 blind  test  compounds  in wastewater
matrices  lay  at  or above  R2 = 0.92.  Finally,  the model  was  evaluated  for application  to  the  semi-targeted
identiﬁcation  of  pharmaceutical  residues  during  a  weeklong  wastewater  sampling  campaign.  The  model
successfully  identiﬁed  native  compounds  at a rate  of 83  ±  4%  and  73  ±  5%  in  inﬂuent  and  efﬂuent  extracts,
respectively.  The  use  of an HRMS  database  and  the  optimised  ANN  model  was  also  applied  to shortlist-
ing  of  37  additional  compounds  in wastewater.  Ultimately,  this  research  will  potentially  enable  faster
identiﬁcation  of  emerging  contaminants  in  the  environment  through  more  efﬁcient  post-acquisition  data
mining.
©  2015  Elsevier  B.V.  All  rights  reserved.. Introduction
Characterising the breadth of occurrence of pharmaceuticals
nd personal care products (PPCPs) in the aquatic environment
as been on-going for the past two decades [1]. In most developed
ountries, wastewater treatment plant efﬂuents often act as identi-
able sources, and, given that they often serve large communities,
he potential exists for larger numbers of PPCPs to enter receiv-
ng waters via efﬂuent as a result. Several multi-residue analytical
ethods have been applied to PPCP determination in environmen-
al matrices [2–5] and mostly employ a targeted approach where
ompounds are pre-selected. Recent methods for larger numbers
∗ Corresponding author. Tel.: +44 20 7848 3842; fax: +44 20 7848 4980.
E-mail address: leon.barron@kcl.ac.uk (L.P. Barron).
ttp://dx.doi.org/10.1016/j.chroma.2015.03.063
021-9673/© 2015 Elsevier B.V. All rights reserved.of PPCPs have used online [6] or ofﬂine [7,8] solid phase extraction
(SPE) [9] for clean-up and concentration of wastewater samples
followed by analysis with gas chromatography (GC) [10,11] or
liquid chromatography (LC) coupled to various modes of mass spec-
trometry (MS) [8,12–15]. However, as >3000 licensed PPCPs exist,
targeted approaches only allow characterisation of a small portion
of PPCP occurrence. Methods for such large numbers of compounds
are often limited by unfeasibly long cycle times for tandem MS
experiments or full m/z  range scanning using lower resolution
instruments.
Relatively recent efforts have focused on hyphenation to high
resolution mass spectrometry (HRMS) for multi-residue screen-
ing [16–19]. The combination of full-scan m/z  data acquisition at
or below ppm m/z  accuracy and at high resolution has enabled
datasets to be interpreted in a non-targeted or semi-targeted man-
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etection, larger numbers of compounds can be screened in a sin-
le run and such methods have been applied to >400 compounds
n wastewater [23]. Full scan and tandem MS/all-ion fragmenta-
ion experiments may  also yield useful information to identify
ew compounds, but a number of chromatographic peaks and/or
otential candidates with matching m/z  may  still exist before con-
rmation becomes feasible. For this reason, there still exists a
equirement to conﬁrm compound identity using analyte retention
ime from the chromatographic separation. Conﬁrmation efforts
re further limited by the availability of PPCP reference materials,
ut also their metabolites and transformation products. Impor-
antly, this may  also require consideration of other isomeric and/or
sobaric compounds.
The use of in silico retention time modelling tools may  prove
seful in post-data acquisition analysis, at the very least, to
elp direct synthesis/acquisition of analytical reference materials
or more rapid compound conﬁrmation. Linear solvation-energy
elationships (LSERs) have been used for modelling solute reten-
ion behaviour in chromatography for some time [24–26]. As a
ore ﬂexible and practical alternative, researchers have also used
rtiﬁcial neural networks (ANNs) to model retention in several
hromatographic modes [27–29] and formats [30–32]; for method
ptimisation purposes [33–37]; or to estimate unknown compound
etention [38–40]. Fragkaki and colleagues recently compared the
se of linear regression, partial least squares and ANNs for the
rediction of relative retention time of 64 derivatised steroid com-
ounds in gradient GC-MS [41]. Recently, we developed and applied
NNs for the generation of sports doping compound retention time
n urine extracts, which were collected by LC-HRMS during the
ondon 2012 Olympic Games [42]. Using a short 8-min reversed-
hase gradient for 86 compounds, all predicted retention times (tPR)
ere within 1.0 min  of measured retention time (tMR ) and 12/15
lind test compounds were predicted to within 0.5 min  of the true
alue. However, the number of compounds used may  be limited
or use as the basis for broad-scope application to in silico wastew-
ter analysis given that a potentially larger diversity and number
f compounds are likely to exist simultaneously in samples of such
igh complexity.
The aim of this work was therefore to evaluate and conﬁrm ANN
odelling as a useful tool for semi-targeted screening of residues in
nﬂuent and efﬂuent wastewater extracts. In particular, the objec-
ives were to model a larger number of compound retention times
han included previously; to assess the effect of matrix on the relia-
ility of tMR data for ANN training; to assess ANN t
P
R performance and
o apply ANNs to the identiﬁcation of trace PPCPs in real samples
uring a week-long wastewater sampling campaign. This repre-
ents the ﬁrst study of its kind to use ANN modelling tools with
C-HRMS datasets for semi-targeted PPCP screening purposes.
. Experimental
.1. Reagents
All reagents were of analytical grade unless otherwise spec-
ﬁed. HPLC grade methanol, acetonitrile, dichloromethane and
imethyldichlorosiloxane were purchased from Fisher Scien-
iﬁc (Loughborough, UK). Ammonium acetate and 37% (w/v)
ydrochloric acid solution were sourced from Sigma-Aldrich
Gillingham, Dorset, UK). Ultrapure water was  obtained from a
illipore Synergy-UV water puriﬁcation system with a resistivity
f 18.2 M cm (Millipore, Bedford, USA). Analytical grade reference
ompounds were purchased from several different manufacturers
r donated by other laboratories. Stock standards were prepared
t concentrations of 1 mg/mL  in methanol and stored in silanised
mber vials at 4 ◦C in the dark when not in use. All 166 referencer. A 1396 (2015) 34–44 35
compounds used for retention time modelling are listed in the
supplementary information (SI).
2.2. Analytical instrumentation and conditions
Unless otherwise stated, all instrumentation, equipment and
associated software was procured from Thermo Fisher Scientiﬁc
(San Jose, CA, USA). An Accela ultra high performance liquid chro-
matography system was  used for all work presented herein. Sample
injection was  performed using a HTS-A5 autosampler with sample
storage compartment temperature control set at 10 ◦C. Separa-
tions were performed on a 150 × 2.1 mm,  2.6 m solid-core particle
Accucore C18 analytical column which was conﬁgured with a
matching 10 × 2.1 mm,  2.6 m particle size Accucore C18 guard.
Temperature was maintained at 24 ◦C. The ﬂow rate of mobile phase
was 0.4 mL/min and the injection volume was 20 L in order to
achieve acceptable sensitivity in wastewater extracts. A binary gra-
dient elution proﬁle of 90:10 to 20:80 10 mM ammonium acetate
in water:acetonitrile (mobile phase A and B, respectively; apparent
pH = 5.2) was  used over 27.5 min  as follows: 0% B for 2.5 min; a lin-
ear ramp to 30% B from 2.5 to 7.5 min; an isocratic stage of 30% B
from 7.5 to 12.5 min; a linear ramp to 40% B from 12.5 to 15 min; a
linear ramp to 100% B from 15.0 to 20.0 min; and then maintained
at 100% B from 20.0 to 27.5 min. Re-equilibration time was 7.5 min.
Detection was  performed using an Exactive HRMS instrument
ﬁtted with a heated electrospray ionisation source (HESI-II). Sepa-
rate chromatographic runs of all samples and model solutions were
performed in either positive or negative ionisation mode. Nitrogen
was used within the HESI-II source and the collision cell. Enhanced
resolution mode was  employed at 50,000 FWHM.  Two MS  experi-
ments occurred during each acquisition cycle by performing a full
scan without higher energy collisional dissociation (HCD) followed
by a full scan with HCD enabled (collision energy: 20 eV). The cycle
time was approximately 2 s, resulting in 1.2 scans per second due
to the switching between full scan and HCD fragmentation exper-
iments. The automatic gain control target was set to balanced,
meaning that ∼106 ions were collected in the C-trap before being
sent to the Orbitrap for acquisition. The sheath gas, auxiliary gas
and sweep gas ﬂow rate settings were 50, 10 and 0 arbitrary units,
respectively. The capillary temperature was  350 ◦C; the heater tem-
perature was  300 ◦C; and the positive/negative spray voltages were
+4.50 kV and −3.00 kV. The scan range was  m/z  100–1000 for all
MS experiments. All acquisition data was  processed using Xcalibur
v 2.0 software. The HRMS instrument was  calibrated prior to use
by infusion of a mixture of caffeine, MRFA (met-arg-phe-ala) and
UltraMark 1621® (a mixture of ﬂuorinated phosphazines) prepared
in a solvent of acetonitrile/methanol/acetic acid for positive mode
ESI-HRMS. For negative ESI-HRMS mode calibration infusion of a
solution containing sodium dodecyl sulfate (SDS), sodium tauro-
cholate and Ultramark 1621® was performed in the same solvent.
2.3. Sample preparation procedures
Samples of wastewater inﬂuent (taken immediately after
the ﬁne screen) and efﬂuent were obtained from a major
sewage treatment works in London (population equivalent = 3.4
million). Wastewater was  collected as seven consecutive, sep-
arate 24-h composite samples across a 1-week period from
11 to 17 March 2014 (using a set 60-min sampling interval).
Samples were refrigerated and transported to the labora-
tory in Nalgene bottles and adjusted to pH 2 using 37% (w/v)
hydrochloric acid solution and stored frozen at −20 ◦C until
analysis. Glassware was silanised to reduce analyte adsorp-
tion to glass surfaces. This included a rinse with 50:50 (v/v)
methanol:water before triplicate rinses with dichloromethane.
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olution was then used to silanise the container, followed by
riplicate sets of rinses with each of dichloromethane and 50:50
ethanol:water. Before extraction, samples were thawed and ﬁl-
ered under vacuum using Whatman GF/F 0.7 m glass microﬁbre
lters. For quantiﬁcation of mephedrone in inﬂuents, a pooled
astewater sample was used to generate a background-subtracted
atrix-matched calibration curve over 5–2500 ng/L. In addition to
his, n = 3 quality control 250 ng/L matrix-matched standards were
etermined to ensure method inaccuracy remained below 20%.
yperSep Retain Polar Enhanced Polymer (PEP) SPE cartridges
200 mg,  6 mL  barrel) were used for extraction of inﬂuent and
fﬂuent wastewater samples. Cartridges were conditioned with
 mL  methanol followed by 4 mL  ultrapure water. A 100 mL  sample
as loaded onto the cartridge followed by a wash step of 4 mL
:95 (v/v) methanol:water and dried under vacuum for 10 min.
ound solutes were subsequently eluted with 4 mL  methanol into
 pre-silanised tapered glass tube. Eluted extracts were evaporated
o dryness under N2 at 35 ◦C and reconstituted in 100 L of mobile
hase A. For retention modelling purposes only, and to generate
atrix-matched standards, dried extracts were reconstituted
n 100 L of a 250 g/L standard of all compounds prepared in
obile phase A. The reconstituted samples were sonicated for
0 min  before being transferred to pre-silanised and crimped
eptum-capped amber glass vials. Extracts were stored at 4 ◦C and
n the dark and analysed within 24 h.
.4. Molecular description, ANN models and architectures
In line with previously published works [42,43], canonical sim-
liﬁed molecular line entry system strings (SMILES) were created
or all 166 compounds using ChemSpider freeware (Royal Soci-
ty of Chemistry, UK). Using Parameter Client freeware (Virtual
omputational Chemistry Laboratory, Munich, Germany), ﬁfteen
olecular descriptors were generated as inputs to ANN models
hich included the number of double and triple bonds (nDB or
TB), the number of carbon and oxygen atoms (nC or nO), the
umber of 4–9 membered rings (nR04–nR09), unsaturation index
UI), hydrophilic factor [2], number of benzene rings (nBnz), and
origuchi and Ghose-Crippen log P (MlogP  and AlogP, respec-
ively). Data for two additional molecular descriptors (log D and
Ka) were generated using Percepta PhysChem Proﬁler (ACD Lab-
ratories, ON, Canada).
Prediction of retention times was performed using the Trajan 6.0
eural network simulator (Trajan Software Ltd., Lincolnshire, UK)
nd compared with measured retention time in matrix matched
tandards. Optimisation of each ANN type and architecture was
erformed in a number of stages. Firstly, all 17 input variables
isted were included in the design phase followed by a second stage
hich enabled subset selections to assess any improved correlation
r performance-limiting input variables. In these ﬁrst two  steps,
ase input variable data were randomised across training, veriﬁ-
ation and blind test experiments. When a suitable architecture
as identiﬁed, a third stage of optimisation involved randomising
ll but the blind test cases to identify the best model. For appli-
ation, all case datasets were subsequently ﬁxed. Networks were
et to balance their veriﬁcation set errors against network diver-
ity to cover as many architectures as possible across all model
ypes. For multilayer perceptrons (MLPs) in particular, and for
ach set of design parameters, ANN architectures were tested over
0 min  intervals and following this, the best 50 networks were
elected based on correlation and output error. Three- and four-
ayer MLPs were included and within each hidden layer the number
f nodes tested was ≤14 (software suggested value). For radial basis
unctions (RBFs), probabilistic neural networks (PNNs) and gener-
lised regression neural networks (GRNNs), 108 architectures were
nvestigated in each optimisation step. Fifty of the best RBF/GRNNr. A 1396 (2015) 34–44
networks were again ranked by correlation and output error. The
maximum number of nodes tested in RBF hidden layers was  42
(software suggested value). Pruning was  only applied to GRNNs
and fan-out weight thresholds for input variables and hidden layer
units were set to ≤0.05.
2.5. Post-acquisition data mining and peak selection
Post-acquisition automated peak selection was performed for
inﬂuent and efﬂuent sample data using TraceFinderTM version 3.1
software (Thermo); a separate peak selection process was  per-
formed for both the positive and negative ionisation mode runs
for each sample. Acquired HRMS data only was screened against
the commercially available ThermoFisher spectral library which
contained data for 1492 compounds comprising pesticides, her-
bicides, fungicides, pharmaceuticals, metabolites and illicit drugs
(and inclusive of all 166 compounds selected for retention mod-
elling herein). Neither empirical retention time nor peak width
were used for database searching to simulate a semi-targeted
approach. Identiﬁcation criteria were applied within the software
for automatic peak selection. With the exception of precursor ion
peak area, the same identiﬁcation criteria were applied in both the
positive and negative ESI-HRMS screening methods. A mass toler-
ance of 5 ppm was applied (i.e. precursors, fragments and isotope
ions). Where conﬁrmation was required, and in addition to the
accurate mass of the precursor ion, the most abundant matching
fragment ion (with the HCD cell enabled) was  used. Initial inten-
sity thresholds for automated screening of precursor ions were set
at 50:1 signal-noise ratio (S/N) and peak area ≥50,000 AU/peak
for positively ionised precursor ions and ≥10,000 AU/peak for neg-
atively ionised. Lastly, an 80% ﬁt threshold to theoretical isotope
proﬁle was set, with an acceptable intensity threshold deviation
for each isotope ion set at 25% of the theoretical value. The isotopic
ﬁt threshold represents the deviation allowed between the mea-
sured and theoretical isotopic patterns, based on the performed
pattern matching. The allowed intensity deviation considers the
intensity of the isotope ion relative to the monoisotopic ion. Follow-
ing the automated screen of wastewater data, manual inspection
of all shortlisted peaks was  performed to identify viable chro-
matographic peaks (see Section 3.4) for subsequent tR matching
with ANN and then conﬁrmation with its reference standard tMR
in the relevant matrix. Further criteria for acceptance included
peak proﬁle and deﬁnition (Gaussian-like proﬁle with n ≥ 10 dat-
apoints/peak). A second manual check of the S/N ratio (≥3:1) was
then applied to exclude erroneous peak identiﬁcations in the ﬁrst
automated screen.
3. Results and discussion
3.1. Modelling retention time in standard solutions using ANNs
Initial assessment of the comparative performance of ANN tR
predictions was performed without including the inﬂuence of
matrix. The choice of molecular descriptors was based on our pre-
vious work which showed that these input variables contributed
signiﬁcantly to retention time modelling under reversed-phase
conditions. It was  found that, for all ANN types, a 120:16:30 split
of cases across training, veriﬁcation and blind test experiments
yielded the best results for consistent comparison purposes. A com-
parison between three network types and architectures is shown in
Fig. 1. A MLP  network consists of a number of nodes housed within
discrete layers. Input nodes are fully interconnected to these layers
via non-linear activation functions. Inputs are mapped onto a set
of required output values (tMR ) and supervised learning is iterative
and based on back-propagation. RBFs employ real-value functions
which depend only on proximity from the origin or a single discrete
K. Munro et al. / J. Chromatogr. A 1396 (2015) 34–44 37
Fig. 1. The best correlation of predicted versus measured retention times achieved for MLPs, RBFs and GRNNs (left) and associated predicted retention time errors for each
(on  the right).
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oint. Lastly, GRNN-type ANNs combine an RBF layer with a linear
ctivation function layer [9]. This network yielded the best perfor-
ance overall (Fig. 1) and, along with RBFs, required a fraction of the
ime to optimise, train, verify and test (<10 s for 108 models) in com-
arison to MLPs. GRNNs also displayed excellent consistency across
ifferent architectures and case allocations. The optimised GRNN
isplayed correlation data of y = 0.8684x + 1.3313 (R2 = 0.9327) for
he training set; y = 0.7907x + 1.8897 (R2 = 0.8738) for the veriﬁca-
ion set; and y = 0.8075x + 1.8936 (R2 = 0.8858) for blind test cases.
n particular, the average absolute tPR error and standard deviation
or the blind test dataset was 1.39 ± 1.29 min. It was  clear that ANN
R accuracy thresholds were required by considering a portion of
he case data which lay within a reasonable percentile of tPR error
nd accepting that some false negatives would be encountered as a
esult. Moreover, as the GRNN-type network offered markedly bet-
er results than either the RBF or MLP-type networks at this stage
n the process, it was not likely, and indeed found, that this would
hange with inclusion of a matrix effect.
.2. Effect of wastewater matrix on measured retention time
Most retention modelling works have similarly focussed on
ata derived from standards prepared in puriﬁed solvents [30,44].
ertainly for targeted methods, it is reasonable to expect that
n optimised extraction procedure would eliminate or suitably
inimise matrix effects. However, the value of semi-targeted
ata screening lies in characterisation of extra matrix compo-
ents, which may  later become analytes. Therefore, co-extraction
f a matrix component could be considered advantageous in
ome respects. The SPE sorbent used here consisted of a
ydrophilic–lipophilic balanced (HLB) type chemistry which has
een widely adopted along with a similar protocol for this appli-
ation [45,46]. However, a disparity exists in SPE concentration
actors across the literature, which range from 100 to 2500-fold
o achieve acceptable sensitivity and mostly for target analytes
47–53]. Several studies also used rapid gradient separations prior
o mass spectrometry and reported signiﬁcant MS  signal sup-
ression (often >50%) showing that matrix exists at high enough
oncentrations, even after application of SPE clean-up, to inter-
ere with validated analytical methods [47,48,50]. Matrix effects on
easured retention time are rarely reported, but can be overcome
y using matrix-matched standards instead. Herein, an intermedi-
te concentration factor of 1000-fold followed by a moderately long
eparation of 27.5 min  was used in an attempt to balance this matrix
ffect with adequate sensitivity for broad, semi-targeted qualitative
creening at the ng/L concentration level.
Seven individual 24-h composite samples of both inﬂuent and
fﬂuent wastewaters across a week were used to prepare matrix-
atched standards in order to compile average tMR data in each
atrix type separately. This was preferred over replicate data from
 single composite sample of any one wastewater type (or combi-
ation thereof) to show how daily composition may  affect tMR . As
an be observed in Fig. 2(a), a mean tMR shift for all compounds in
astewater extracts was evident in comparison to model solutions.
s a result, several important considerations for tR predictions
ecame apparent. Firstly, under these conditions, the majority of
ompounds displayed an overall increase in tMR irrespective of sam-
le type meaning that use of non-matrix matched standards was
enerally considered inappropriate for comparison with wastew-
ter data for conﬁrmation purposes. Secondly, compounds eluting
n the ﬁrst 7 min  of the gradient separation suffered the largest
hange in tMR in comparison to model solutions. More pronounced
atrix effects over this window were observed for compounds
n inﬂuent wastewater in particular with examples of the worst
etention shifts being +0.99, +1.00 and +1.03 min  for pindolol,
henmetrazine and MDMA,  respectively, which all elutedFig. 2. The effect of matrix on (a) relative retention time in wastewater to a standard
in  ultra-pure water and (b) tMR standard deviation for standard solutions and spiked
wastewater samples taken across a 1-week period.
consecutively. Past this initial 7-min elution window, the differ-
ences between inﬂuent and efﬂuent matrix effects on tMR were less
obvious. Thirdly, it was observed that inter-day tMR measurement
variance on the whole was again largest for inﬂuent, followed by
treated efﬂuent and then model solutions over the same 7-min elu-
tion window (Fig. 2(b)). However, this variance was  still well within
acceptable method reproducibility limits (average tMR ± 15 s [54]).
Examination of total ion chromatograms revealed a broad matrix
elution proﬁle over this timeframe (maximum intensity = 4 × 108),
which may  have accounted for retention shifts and inter-sample
variance. Even after SPE, inﬂuent and efﬂuent wastewater extracts
were coloured showing that such a matrix effect with such a widely
adopted methodology was  still possible. Most tMR variance after this
initial 7-min window for all sample types was <1% relative standard
deviation (RSD). The largest standard deviation of mean retention
time was  10 s for MDMA  in inﬂuent wastewater (tMR = 5.12 min).
The mean of the measured tMR standard deviations for all com-
pounds was 2.5 ± 1.9 s and 2.1 ± 1.2 s for inﬂuent and efﬂuent,
respectively. The range of peak widths (at baseline) measured for
all compounds lay within the range of ∼0.2–0.5 min.
3.3. Performance of GRNNs for spiked wastewater extractsDirect replacement of tMR data in the GRNN for those measured in
either matrix resulted in a poorer correlation overall. In an attempt
to understand the robustness of GRNN networks, n = 6 identical
model architectures were created for each sample type and trained
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F astewaters using the optimised 17-120-16-30 GRNN. The predicted retention time error


























Fig. 4. Replicate network sensitivity to removal of individual molecular descrip-
tor  input variables. The error ratio represents the additional error in tP where thatig. 3. Predicted versus measured retention times in (a) inﬂuent and (b) efﬂuent w
or  each compound across the gradient run-time is shown as (c) for inﬂuent and as
b initio using the mean of tMR for each compound in each matrix.
he predictive ability of the GRNN model recovered and corre-
ation coefﬁcients even slightly improved. For the best network
pplied to inﬂuent wastewater (Fig. 3(a) and (c)), the average and
tandard deviation of absolute tPR error for the entire 166 cases
nd the 30 blind test cases in isolation were 0.98 ± 1.16 min  and
.79 ± 1.26 min, respectively. All but one of the absolute blind test
ase tPR errors lay within a window of 1.81 min. Mean and standard
eviation of tPR errors for the full dataset and blind test cases for
fﬂuent (Fig. 3(b) and (d)) were 0.99 ± 1.17 min  and 1.06 ± 1.15 min,
espectively and three of the absolute blind test case tPR errors lay
utside 1.81 min  by comparison.
Examination of replicate GRNN models showed that each input
ariable was used to similar degrees across matrices (Fig. 4). Error
atios >1 represented a worsening of network performance with
emoval of that descriptor. The top ﬁve molecular descriptors for
R prediction in both wastewater matrix types were nDB, logD,
O, pKa and nBnz in descending order. The consistency of input
ariable dependency across all 18 networks tested showed that
his GRNN model could potentially be used robustly in bracketed-
ype analyses where matrix-matched standards could be analysed
efore and after each batch of wastewater samples (a) for rela-
ive comparison purposes to rule out within-batch column fouling
vents and (b) for better application to retention modelling by
ccounting for the operational conditions at the time of analy-
is.
R
variable was  omitted from the network to that of tPR error where all network vari-
ables were included. Error bars represent standard deviation of the results from n = 6
replicate networks for each of standards in ultrapure water and spiked wastewater
extracts.

































iig. 5. Plots of absolute tPR error versus percentile of each training, veriﬁcation and
lind test dataset for (a) inﬂuent wastewater and (b) efﬂuent wastewater.
As can be seen in Fig. 5, plots of absolute tPR error in either matrix
elative to the percentile of data from each of the training, veriﬁca-
ion and blind test datasets revealed a moderate increase in error up
o ∼75–85% of the data population where it subsequently increased
arkedly due to the contribution of outliers. Therefore, taking the
5th percentile of all datasets across both sample types, this corre-
ponded to a tPR error of 1.30 min  (i.e. an elution window of 2.60 min
n total and <10% of total runtime). Whilst this threshold repre-
ented a potential 25% false negative rate, extension or reduction
f this threshold resulted in either an impractically wide or narrow
etention window relative to peak width for this chromatographic
ystem. As discussed later, the false negative rate was  shown to be
ample dependent in practice. Therefore, this limit enabled prac-
ical and rapid shortlisting of larger numbers of viable suspect
ompounds in a poorly understood sample. Obviously, thresholds
ay  be adjusted to extend the scope of the semi-targeted approach
n the future if needed by including more compounds during ANN
raining or by using a different set of chromatographic conditions.
he application of ANNs to semi-targeted screening, however, is not
ntended for conﬁrmatory identiﬁcation and should only be used to
educe the time required to source appropriate standard reference
aterials for this purpose.
.4. Trace screening of wastewater samples and evaluation of
RNN retention time predictions
Unspiked aliquots of the same 24-h composite samples of
astewater were analysed to characterise target PPCP occurrence
cross the week. Peak selection was performed using a much
arger database than the 166 target compounds used to simulate
 more realistic data mining exercise. In several cases, matching
/z  data existed within this wider database along with target
ompound data. Automated peak selection yielded between 2500
nd 3000 peaks for inﬂuent and between 1200 and 1900 peaks
n efﬂuent samples depending on the day (irrespective of the ESIr. A 1396 (2015) 34–44
mode). Despite the application of ﬁlters (as in Section 2.5), some
shortlisted peaks were not deemed satisfactory and were easily
excluded (e.g. they were not discrete/obvious chromatographic
peaks, or were integrated regions of noise). Manual inspection
reduced this number to ∼700 viable peaks in both inﬂuent and
efﬂuent positive ionisation data, with a lower number observed
for negative ionisation (∼500 inﬂuent/∼300 efﬂuent). As multiple
peaks often existed for each suspect compound, this correlated to
∼350 positively ionised compounds in both inﬂuent and efﬂuent,
again with a lower number observed for negative ionisation (∼250
inﬂuent/∼200 efﬂuent).
In the ﬁrst instance, data for the 166 target compounds were
extracted for conﬁrmation and ANN tPR evaluation. Retention time
conﬁrmation was  based on US EPA Method 1694 guidelines for
PPCP identiﬁcation whereby chromatographic peaks must elute
within ±15 s of the matrix-matched standard tMR [54]. Here, this
was taken as the average of all seven spiked inﬂuent or efﬂuent
retention times recorded across the week (inter-day tMR ). For ANN
tPR matching, the window was set as before at ±1.30 min. Out of
the full 166 compounds used in this work, post-acquisition LC-
HRMS data-mining yielded matching m/z  and isotope proﬁles for
between 70 and 82 compounds per day in wastewater (positive
mode ESI-HRMS), with a lower number (19–67) observed using
negative mode ESI-HRMS (Table 1 and SI). Individual compound
occurrence across all samples, as well as comparison of ANN sus-
pect shortlisting and matrix-matched standard conﬁrmation are
shown in the SI. On average, similar numbers of positively ionised
compounds were conﬁrmed using a matrix-matched standard in
inﬂuent and efﬂuent wastewaters (30–36 compounds/day). When
comparing to tPR data, this corresponded to an overall mean % ANN
success rate of 83 ± 4% and 73 ± 5% for PPCPs at trace concentra-
tions in inﬂuent and efﬂuent samples, respectively (p = 0.007). The
ANN correctly excluded the presence of between 32 and 44% of
TraceFinder-shortlisted compounds in wastewater each day.
Mephedrone represented an interesting example of an illicit
compound which occurred in both inﬂuent and efﬂuent wastew-
ater on all days. Taking inﬂuent on its own, it also represented a
blind test compound which could be used to reliably evaluate the
semi-targeted approach using LC-HRMS data and ANN together. As
can be observed from Fig. 6(a), an excellent retention time pre-
diction match was  achieved with the optimised GRNN at realistic
concentration levels. Retention time was  then conﬁrmed using a
matrix-matched standard along with matching isotopic m/z pro-
ﬁles (Fig. 6(b)). Following this, the concentration of this compound
was estimated in inﬂuent wastewater across the week at con-
centrations ranging between 42 and 160 ng/L with the highest
concentration measured on a Saturday (R2 = 0.9980; method per-
formance given in the SI).
For the majority of ions with m/z  within the ±5 ppm match win-
dow, more than one viable chromatographic peak was detected
(two to four viable peaks were often identiﬁed across the run-
time). These mostly constituted a number of well separated peaks
(e.g. codeine, betaxolol, efaproxiral, cathinone, mephedrone and
bunolol) or, in some cases, a number of closely eluting/unresolved
peaks (e.g. isometheptene and metipranolol). In a few cases, larger
numbers of viable peaks were detected even when using such a
narrow m/z  match window. Table 2 shows that up to 15 viable
chromatographic peaks were identiﬁed for suspected tramadol
occurrence (included as a blind test case) in wastewater. Prelim-
inary identiﬁcation of this compound without a reference standard
would be very challenging due to the presence of other isobaric
species. Application of the ANN reduced this number to three
suspect peaks in both inﬂuent and efﬂuent data on all days. Exam-
ination of CID data yielded no identiﬁable ion signatures within
this m/z  scan range, making this an especially difﬁcult case for
occurrence conﬁrmation. For this application using this type of
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Table  1
Application of LC-HRMS and ANN prediction models to determine the occurrence of 166 selected PPCPs in unspiked inﬂuent and efﬂuent wastewaters over a week long
sampling campaign at a London-based WWTP  (11th–17th March, 2014). See SI for individual compound occurrence and matching tMR data.
Inﬂuent wastewater Efﬂuent wastewater
Sampling Day 1 2 3 4 5 6 7 1 2 3 4 5 6 7
Number of targeted compounds shortlisted
by  TraceFinder software
130 134 89 134 137 140 137 116 120 121 119 121 122 112
Number of shortlisted compounds
excluded
59 61 42 69 67 62 64 49 53 60 56 58 56 53
Number of conﬁrmed compounds using
ANN + matrix-matched standard
39 37 28 36 41 36 38 28 29 31 29 35 34 31
Number of extra conﬁrmed compounds
using a matrix-matched standard only
(i.e. ANN false negative)
6 10 6 6 7 11 7 13 17 9 12 11 10 10
Number of extra suspected compounds
using ANN only (i.e. ANN false positive)
26 26 13 24 22 31 28 26 21 21 22 17 21 18
Total  number compounds conﬁrmed (with
standard only)
45 47 34 42 48 47 45 41 46 40 41 46 44 41
Success rate for ANN (%) 87 79 82 86 85 77 84 68 63 78 71 76 77 76
Mean  % ANN success rate ± standard
deviation (n = 7)
83 ± 4 73 ± 5
Fig. 6. Extracted ion chromatograms conﬁrming the presence of mephedrone in (a) an unspiked inﬂuent wastewater sample and (b) a 250 g/L matrix matched standard.
The  left panel in (a) and (b) both show the [M + H]+ ion of mephedrone (acquired in full scan mode) and its corresponding product ion (m/z 145.0886). Values listed for the
[M  + H]+ and product ion represent the calculated m/z. The right panel shows the isotopic proﬁle comparison between the measured [M + H]+ ion in wastewater relevant to
a  software-generated theoretical isotopic proﬁle.
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Table 2
Shortlist of viable chromatographic peak retention times recorded using LC-HRMS for suspected tramadol occurrence in unspiked inﬂuent and efﬂuent wastewaters. Retention
times  given in bold italics shading represent conﬁrmatory identiﬁcation of tramadol using HRMS data as well as ANN and from a matrix-matched standard. Retention data
given  in italics shading represent only those additional peaks suspected to be tramadol using HRMS and ANN data alone.
Calculated tramadol [M+H]+ m/z: 264.1958
Inﬂuent wastewater
Analyte in inﬂuent: 7.44 min  (Range: 7.19–7.69 min)a
Analyte ANN in inﬂuent: 7.56 min  (Range: 6.26–8.86 min)b
Viable peak (min)
Sampling day tR1 tR2 tR3 tR4 tR5 tR6 tR7 tR8 tR9 tR10 tR11 tR12 tR13 tR14 tR15
Day  1 2.57 5.78 6.54 7.41 8.53 11.74 16.30
Day  2 2.58 5.75 6.55 7.42 8.53 11.76 16.31
Day 3 2.57 5.73 6.52 7.39 8.52 11.77 16.30
Day  4 2.45 5.75 6.50 7.39 8.54 9.31 10.04 15.95 16.71 18.43 19.05 19.92
Day  5 2.46 5.73 6.48 7.35 8.49 9.20 11.74 15.93 16.28
Day  6 2.56 5.77 6.57 7.47 8.58 16.33
Day  7 2.59 5.76 6.56 7.43 8.54 16.30
Efﬂuent wastewater
Analyte in efﬂuent: 7.38 min  (Range: 7.13–7.63 min)a
Analyte ANN in efﬂuent: 7.49 min  (Range: 6.19–8.79 min)b
Viable peak (min)
Sampling day tR1 tR2 tR3 tR4 tR5 tR6 tR7 tR8 tR9 tR10 tR11 tR12 tR13 tR14
Day  1 2.27 4.33 5.66 6.39 7.31 8.45 8.83 11.73 15.91 16.24 18.39 19.03 19.88
Day  2 2.28 4.36 5.69 6.41 7.31 8.46 8.83 11.74 15.94 16.27 18.39 19.03 19.88
Day  3 2.29 4.37 5.70 6.44 7.35 8.50 8.85 11.75 15.95 16.30 18.43 19.05 19.92
Day  4 2.29 4.40 5.70 6.44 7.35 8.48 8.86 9.31 11.79 15.98 16.32 18.42 19.05 19.92
Day  5 2.29 4.42 5.72 6.44 7.35 8.48 11.75 16.28 18.41 19.89
Day  6 2.30 4.42 5.71 6.44 7.34 8.48 8.83 11.78 15.96 16.28 18.42 19.04 19.89











ga Range for conﬁrmation of tramadol occurrence deﬁned as ±15 s of in a spiked s
b Range deﬁned as ±1.30 min.
C-HRMS instrumentation, it reinforces the requirement for good
hromatographic separation of compounds during screening. After
omparison with a matrix-matched standard, tramadol was iden-
iﬁed chromatographically as one of the ANN-shortlisted peaks in
ll samples across the week. Pethidine, as another example, was
dentiﬁed in much the same manner (Table 3). Inﬂuent samples
able 3
hortlist of viable chromatographic peak retention times recorded using LC-HRMS for suspe
ata  given in bold italics shading represent conﬁrmatory identiﬁcation of pethidine usin
iven  in italics shading represent only those additional peaks suspected to be pethidine u
Calculated pethidine td:paraenter [M+H]+ m/z: 248.1645
Inﬂuent wastewater
Analyte in inﬂuent: 8.80 min  (Range: 8.55–9.05 min)a
Analyte ANN in inﬂuent: 7.86 min  (Range: 6.56-9.16 min)b
Sampling day tR1 tR2 tR3 tR4 
Day  1 – 2.29 – 3.40 
Day  2 – 2.28 – 3.36 
Day  3 – 2.28 – – 
Day  4 2.18 3.17 – 
Day  5 2.18 3.13 – 
Day  6 – 2.28 – – 
Day  7 – 2.32 – – 
Efﬂuent wastewater
Analyte in efﬂuent: 8.78 min  (Range: 8.53-9.03 min)a
Analyte ANN in efﬂuent: 7.79 min  (Range: 6.49-9.09 min)b
Sampling day tR1 tR2 tR3 tR4 
Day  1 – 2.90 – – 
Day  2 1.43 2.95 3.93 – 
Day  3 1.45 2.98 – – 
Day  4 – 2.96 – – 
Day  5 1.44 2.98 – 6.30 
Day  6 1.44 3.02 – – 
Day  7 1.46 3.06 – – 
a Range for conﬁrmation of pethidine occurrence deﬁned as ±15 s of in a spiked sampl
b Range deﬁned as ±1.30 min. extract.
yielded multiple chromatographic peaks with matching m/z. How-
ever, whilst perhaps more regular occurrence was observed for
other peaks, one peak at ∼8.90 min  was found to be a match with
ANN (which was subsequently conﬁrmed with a matrix-matched
standard at 8.80 min). In contrast, efﬂuent samples yielded signiﬁ-
cantly more viable peaks with matching m/z. Some of these peaks
cted pethidine occurrence in unspiked inﬂuent and efﬂuent wastewaters. Retention
g HRMS data as well as ANN and from a matrix-matched standard. Retention data











tR5 tR6 tR7 tR8 tR9 tR10
6.48 – 8.87 17.82 – –
6.53 8.55 8.88 17.44 17.82 –
– 8.57 8.90 17.84 – –
6.54 – 8.91 17.48 17.86 18.28
6.52 – 8.89 17.84 – –
6.53 – 8.90 17.48 17.83 18.25
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ccurred on most/all days. The ANN narrowed a total of ten viable
eaks to three in this case and conﬁrmation was then achieved with
he matrix-matched standard. Obviously, and where the informa-
ion exists, HCD fragments may  be used to eliminate more of these
eaks, but these would not necessarily be known in a semi-targeted
pplication however.
Lastly, this semi-targeted approach was applied to additional
harmaceutical residue matches occurring in an inﬂuent wastew-
ter sample. Following HRMS data screening, 95 compounds were
hortlisted, again with many showing multiple chromatographic
eaks at isobaric m/z. Molecular descriptors were generated and
ollowing the GRNN prediction, 37 compounds were found to
atch measured sample retention times. All shortlisted com-
ounds, along with their HRMS and tMR data are detailed in the SI.
nterestingly, whilst none of these compounds were used in the
evelopment of ANN models, many have been previously detected
n wastewater systems. Such examples included clozapine, feno-
rofen, ibuprofen, naproxen, sertraline and salbutamol [55–57]. It
s important to note however, such SPE methods may  not recover
ll compound types and coupled with a relatively small database
n comparison to the number of pharmaceuticals available, in real-
ty this is still likely to represent an under-estimation of total PPCP
ccurrence. Moreover, it must be re-stated here that, despite appli-
ation of ANNs and an HRMS database, conﬁrmatory identiﬁcation
f these compounds is still required using a reference standard, and
referably one prepared in matrix.
. Conclusion
Modelling of PPCP retention times from gradient reversed-
hase chromatography of inﬂuent and efﬂuent wastewater extracts
as been successfully demonstrated for the ﬁrst time. By selecting
 range of molecular descriptors, predictions at the 75th percentile
f all compound data were within 1.30 min  of tMR . Discrimina-
ion of structurally similar/isobaric compounds was also possible
n most cases and demonstrated acceptable tPR accuracy. Appli-
ation to real wastewater from a week-long sampling campaign
howed that ANNs could be used successfully for trace detection
ith similar performance. Furthermore, the application of ANNs
or retention time prediction markedly reduced the number of
iable chromatographic peaks for each compound and also accu-
ately excluded compounds from wastewater data. Ultimately, this
pproach will allow more rapid characterisation of PPCP occur-
ence in wastewaters by directing the synthesis of likely candidate
eference materials.
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The primary ﬁsh gill cell culture system (FIGCS) is an in vitro technique which has the potential to replace
animals in whole efﬂuent toxicity tests. In the current study FIGCS were transported into the ﬁeld and
exposed to ﬁltered (0.2 μm) river water for 24 h from 4 sites, on 2 different sampling dates. Sites 1 and
2 are situated in an urban catchment (River Wandle, London, UK) with site 1 downstream of a sewage
treatment work; site 3 is located in a suburban park (River Cray, Kent, UK), and site 4 is more rural (River
Darent, Kent, UK). The change in transepithelial electrical resistance (TER), the expression of the metal
responsive genes metallothionein A (mta) and B (mtb), cytochrome P450 1A1 (cyp1a1) and 3A27
(cyp3a27), involved in phase 1 metabolism, were assessed following exposure to sample water for 24 h.
TER was comparable between FIGCS exposed to 0.2 μm ﬁltered river water and those exposed to syn-
thetic moderately soft water for 24 h. During the ﬁrst sampling time, there was an increase in mta,
cyp1a1 and cyp3a27 gene expression in epithelium exposed to water from sites 1 and 2, and during the
second sampling period an increase in cyp3a27 gene expression at sites 1 and 4. Urban river water is a
complex mixture of contaminants (e.g., metals, pesticides, pharmaceuticals and polyaromatic hydro-
carbons) and the increase in the expression of genes encoding mta, cyp1a1 and cyp3a27 in FIGCS is
indicative of the presence of biologically active pollutants.
& 2015 Elsevier Inc. All rights reserved.1. Introduction
A large number of ﬁsh are used each year for waste efﬂuent
toxicity testing, with an estimated 3 million being used in the US
alone see Tanneberger et al. (2013). There is a desire worldwide to
reduce the number of ﬁsh used in toxicity testing and thus reliable
alternatives are being investigated. A number of studies have as-
sessed ﬁsh cell lines as alternative methodologies with success
(Davoren et al., 2005; Dayeh et al., 2009; Kinani et al., 2010;
Schnell et al., 2013). However, a drawback to using cell lines for
waterborne toxicity is that they are often unable to tolerate hy-
poosomotic water. To overcome this, water has to be modiﬁed by
the addition of osmolytes to ensure osmotic tonicity between the
external medium and the intracellular compartment. An alter-
native approach is the use of a primary FIsh Gill Cell cultureSystem (FIGCS; Walker et al., 2008; Minghetti et al., 2014, Bury
et al., 2014). This method uses a double seeding technique and
ensures that the epithelium contains the different cell types
characteristic of an intact gill (Fletcher et al., 2000; Walker et al.,
2007). When grown on permeable supports, the membrane forms
a polarised tight epithelium with transepithelial electrical re-
sistance (TER) measurements exceeding 10 KΩ. At this stage the
epithelium is able to tolerate the application of water on the apical
surface for up to 48 h. The property of tolerating freshwater has
led to the use of the system for physiological studies see Wood
et al. (2002), the assessment of pharmaceutical uptake (Stott et al.,
2015) and toxicity of pollutants within the aquatic environment
(Sandbacka et al., 1999, Bury et al., 2014).
A recent study also explored the potential for FIGCS to be used
for environmental monitoring of natural waters (Minghetti et al.,
2014). In this study the cells were transported 1000 km in a
temperature controlled container and were exposed in the ﬁeld to
metal-contaminated river water under non-sterile conditions. The
S. Schnell et al. / Ecotoxicology and Environmental Safety 120 (2015) 279–285280membrane maintained integrity, showing comparable changes in
TER after 24 h between those exposed to river water and those
exposed to reconstituted sterile water. The cells also showed no
signs of cell mortality, as measured by the Methylthiazol Tetra-
zolium (MTT) assay, but they did show an increase in expression of
the genes encoding for the metal binding proteins metallothionein
A and B (Minghetti et al., 2014), demonstrating the presence of
bioreactive metals.
The previous study (Minghetti et al., 2014) speciﬁcally targeted
rivers in Cornwall, South West England as they are known to have
elevated metals with very little other pollutant load and in the
laboratory the primary gill cells are known to respond to metals
with increased expression of mta and mtb genes (Walker et al.,
2007). The FIGCS output (gene expression) is an integrative re-
sponse that takes into account the over lying water chemistry,
which determines metal speciation, and the ability of the metal to
enter the cell and bind to intracellular receptors in sufﬁcient
quantities to cause an effect. If this system is to be used more
widely to detect the presence of compounds that may elicit a
biological effect, it is necessary to evaluate the response of the
cells to more complex aquatic matrices. Thus, the aims of the
current study are to expose the primary gill cell culture to a further
3 sites on urban rivers in London, UK, and one site on a more rural
river in Kent, UK, that potentially have a far complex mixture of
pollutants than the metal contaminated rivers in Cornwall (Min-
ghetti et al., 2014) and to measure the expression of genes en-
coding for mta and mtb, as well as cyp1a1 and cyp3a27, enzymes
which are involved in phase 1 organic compound metabolism
(Uno et al., 2012), as well as TER following 24 h of exposure to the
river water. An increased transcription of mta and mtb indicate
transactivation through metal-responsive transcription factor-1
(Mtf1) (Olsson et al., 1995; Samson and Gedamu, 1995), whilst
increased levels of mRNA for cyp1a1 and cyp3a27 are indicative of
increased activity of the aryl hydrocarbon receptor (Ahr) and the
pregnane-X-receptor /retinoic acid-X-receptor (Pxr/Rxr) hetero-
duplex, respectively (Uno et al., 2012).2. Materials and methods
2.1. Study sites and water chemistry
The 4 study sites were on the River Wandle at Colliers Wood (site
1, latitude 51.420368; longitude 0.181487) and Beddington (site 2,
51.370284; 0.125072), the river Cray at Sidcup (site 3, 51.428425;
0.132730), all in South East London, and the River Darent at Lul-
lingstone (site 4, 51.362372, 0.196315) in Kent, UK. Site 1 on the River
Wandle is highly urbanised and is approximately 4.5 km down-
stream of Beddington Sewage Treatment Works (STW) which re-
ceives wastewater from approximately 360,000 people. Site 2 is
above the input from Beddington STW, but is still within a heavily
urbanised catchment, receiving drainage from the Borough of Croy-
don. Site 3 is within a suburban park, whilst Site 4 is within a rural
setting; however the River Darent ﬂows through suburban area of
Sevenoaks, Kent. The ﬁrst sampling date was 2.12.2013 and the
second sampling on 11.12.2013.
Water pH, conductivity, temperature and suspended solids
were measured using a Hanna Hi991300 probe. For chemical
analysis water samples were collected in the ﬁeld in low density
polyethylene bottles and immediately frozen and stored at 20 °C
on returning to the laboratory. Total and Mg hardness and alkali-
nity were measured colourimetrically, and for Cu and Zn analysis
water samples were ﬁltered (0.2 μm ﬁlters) and acidiﬁed prior to
measurement via inductively coupled plasma mass spectrometer
(Aglient 7700x ICP-MS). For analysis of pharmaceuticals, sample
clean-up and pre-concentration was achieved by solid phaseextraction (SPE) on Waters Oasis mixed-mode hydrophilic lipo-
philic balanced (HLB) cartridges, 6 cc, 200 mg sorbent (Waters
Corporation, Milford, MA, USA), similarly to our previous works
(Lacey et al., 2008; Barron, et al., 2008, 2009; Miller et al., 2015).
Brieﬂy, 100 mL aliquots of surface water samples were adjusted to
pH 6.5 with ammonium acetate (1 mL of a 1 M solution). SPE
cartridges were conditioned with 6 mL of MeOH and ultra-pure
water followed by sample loading. Cartridges were then washed
with 1 mL ultra-pure water and dried for 30 min under a va-
cuum. Cartridges were eluted in 10 mL of 50:50 ethyl acetate:
acetone and dried under N2 and at 30 °C using a TurboVap (Bio-
tage, Uppsala, Sweden). The dried extract residues were recon-
stituted in 0.5 mL of 90:10 (v/v) 10 mM ammonium acetate in
water:acetonitrile and transferred to a septum capped vial. Ana-
lysis was performed on an Agilent 1100 high pressure liquid
chromatography system interfaced to Waters Quattro triple
quadrupole mass spectrometer according to the conditions listed
in Miller et al. (2015). Separations were performed on a C18 re-
versed-phase column (Waters Sunﬁre C18, 2.1150 mm, 2.5 μm).
Multiple reaction monitoring was used to detect characteristic
transitions of all targeted pharmaceutical compounds. Con-
centrations of all pharmaceuticals are expressed as single-shot
quantitation measurements based on comparison to a single ma-
trix matched calibrant at 200 ng L1 spiking level (in triplicate).
Therefore concentrations should be considered as semi-quanti-
tiative. These were extracted alongside unspiked samples (n¼3)
for background correction purposes.
2.2. Cell culture and ﬁeld exposures
Primary gill cell culture techniques and exposure methods
followed the methods described in Minghetti et al. (2014). Rain-
bow trout (Oncorhynchus mykiss) were obtained from a local trout
farm. Primary gill cell cultures were prepared from ﬁsh of 80–
100 g. All ﬁsh were housed at King's College London where they
were maintained in ﬁbreglass tanks (1000 L) with ﬂowing and
aerated de-chlorinated City of London tap water ([Naþ]¼
0.53 mM; [Ca2þ]¼0.92 mM; [Mg2þ]¼0.14 mM; [Kþ]¼0.066 mM;
[NH4þ]¼0.027 mM), which was passed through activated carbon,
mechanical and biological ﬁlters. Water temperature was main-
tained at 14 °C, while photoperiod was held constant (12 h light,
12 h dark). Fish were fed daily a one-percent (w/w) ration of trout
pellets. The primary gill cells were isolated and cultured as de-
scribed in Fletcher et al. (2000) and prepared using the double
seeding technique as described in Kelly et al. (2000) and Walker
et al. (2007). Sterile techniques were used throughout all cell
culture procedures. Brieﬂy, for each seeding, 2 ﬁsh were sacriﬁced
(following local UK Home Ofﬁce schedule 1), the gills were dis-
sected out and the gill ﬁlaments were subject to cleaning and
tryptic digestion (0.05% Trypsin-EDTA; Invitrogen). Isolated rain-
bow trout gill cells were seeded onto cyclopore polyethylene ter-
ephthalate membrane (cell, surface area 0.9 cm2, pore size 0.4 mm,
Falcon) at a cell density of 1.2106 per insert, in Leibovitz (L-15)
medium (Invitrogen) supplemented with antibiotics (5% foetal
bovine serum (FBS); Sigma, 2% penicillin and streptomycin (PEST);
Invitrogen and 2% gentamicin; GIBCO v/v). After 24 h incubation at
18 °C in an air atmosphere cool incubator (Sanyo Mir-253), the
cells were washed twice in phosphate-buffered saline (PBS) to
remove debris and another seeding of primary gill cells was added
at the same density per insert, and cultured in supplemented L-15
medium. After a further 24 h incubation another PBS wash fol-
lowed and supplemented L-15 was replaced at a volume of 1.5 mL
in the apical chamber of the insert and 2.0 mL in the basolateral
chamber. Cultures were grown at 18 °C. After 96 h the gill cell
system was cultured using L-15 medium þ5% FBS, but without
antibiotics with complete medium changes every 48 h. The
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through ‘blank’-corrected measurements of transepithelial elec-
trical resistance (TER) using a custom-modiﬁed epithelial tissue
voltohmeter (EVOMX; World Precision Instruments) ﬁtted with
chopstick electrodes (STX-2). Inserts with a TER410 KΩ (range
10–32.2 KΩ) were used for the study.
To avoid any potential alterations in water chemistry when
transporting samples from the ﬁeld to the laboratory for toxicity
testing we chose to transport the primary gill cell cultures to the
ﬁeld in a Labcold portable medical refrigerator (Model RPDF0012D)
at 18 °C and expose to water directly taken from the sites, before
being transported back to the laboratory. Two ﬁeld trips were
conducted in early December 2013 and inserts used in each trip had
been derived from 4 biological replicates. Prior to travelling into the
ﬁeld the TER was measured for each insert. In the ﬁeld, media was
removed and the cells washed with PBS. To the basolateral com-
partment fresh L15 media was added and to the apical compart-
ment either unﬁltered or ﬁltered (0.2 mm ﬁlters) river water or ﬁl-
tered medium-soft water (MSW: [Naþ]¼0.770 mM; [Cl]¼0.757;
[Ca2þ]¼0.340 mM; [Mg2þ]¼0.152 mM; [Kþ]¼0.077 mM;
[HCO3]¼0.771; [SO4]¼0.152). The inserts were transferred back to
the lab and remained in the Labcold portable medical refrigerator at
18 °C for 24 h.
2.3. QPCR
Total RNA was extracted from cells using TRIzol
s
Reagent
(Ambion, UK) and phase separation performed using Phase Lock
heavy tubes (5prime, USA). The puriﬁed total RNA was DNase
treated (TURBO DNase kit, Ambion, UK) and cDNA synthesis was
performed following the manufacturer’s instruction (Advantage RT
for PCR kit, Clontech) from 0.5 μg of total RNA. Primers for qPCR of
target genes metallothionein A (mta) and B (mtb) and cytochrome
P450 1A1 (cyp1a1) and 3A27 (cyp3a27), as well as the reference
gene elongation factor 1 beta (eef1b) were designed using Primer-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/), see Ta-
ble 1 for details. Only 1 reference gene (eef1b) was tested because
the invariability of its expression has previously been established
in the gill cell culture (Minghetti et al., 2014). All ampliﬁed cDNA
had been previously sequence veriﬁed (Minghetti et al., 2014;
Schnell et al. unpublished data). For each sample, qPCR was run in
triplicate on an ABI-prism 7900 HT qPCR thermocycler using
SYBR-green Premix Taq II (Takara, RR820A). QPCR conditions fol-
lowed those suggested by Takara, except for mta and mtb, where a
3 step programme was applied, 95 °C for 5 s, 55 °C for 30 s and
72 °C for 30 s. After 40 cycles, speciﬁcity of reactions was checked
by inspecting melting curve proﬁles. Gene expression of target
genes were normalised to eef1B and expressed as fold change re-
lative to those in the control MSW controls.
2.4. Statistics
All data are presented as meansþSEM. TER data (expressed as a
% of pre-exposed conditions) and gene expression, expressed as a
ratio of the expression measured in MSW controls. Differences
(po0.05) between the gene expression levels at each site and theTable 1
Primer details and GenBank (http://www.ncbi.nim.nih.gov/) accession number.





eef1b TTGGCGGCATAGGCTGCGATTCwater controls was assessed via a Student's t-test (SigmaPlot v
12.0) on log transformed data.3. Results
Site 1 is downstream of Beddington STW discharge and re-
ceives input from a catchment that has a greater proportion of
impervious cover compared to the other sites. At this site the
highest measured pH, conductivity, total dissolved solids (TDS),
hardness alkalinity, metal content and pharmaceutical con-
centrations were recorded (Tables 2 and 3), with the pH reaching
8.77, conductivity 801 μS/cm, total hardness 233 mg CaCO3 L1
and alkalinity 170 mg CaCO3 L1. Dissolved copper levels exceeded
the United Kingdom Environmental Quality Standards (EQS) for
waters with a hardness of between 200–250 mg CaCO3 L1 [dis-
solved Cu EQS 10 μg L1] at both sample points with concentra-
tions of 26 and 14.1 μg L1, the EQSs were not exceed at the other
sites. Dissolved zinc concentrations were also highest at site 1, but
these did not exceed the EQS (Table 2 – for waters of 200–250 mg
CaCO3 L1 Zn EQS 300 μg L1). Pharmaceuticals were detected at
each site on both of the sampling times with the highest con-
centrations determined at site 1. The highest of these was carba-
mazepine at 552 and 298 ng L1, followed by ranitidine at 359 and
179 ng L1, propranolol at 207 and 212 ng L1, and trimethroprim
at 156 and 162 ng L1. Of the other compounds, atentolol, cime-
tidine and bezaﬁbrate were also detected at site 1 at both sam-
pling points. At sites 2, 3 and 4 caffeine was also present along
with carbamazepine and propranolol. Of the other drugs measured
at sites 2, 3 and 4 atenolol, ranitidine, metoprolol, temazepam and
diazepam were occasionally detected (see Table 3 for full details).
The pharmaceutical concentrations were generally lower at the
second sampling point (Table 3).
On both sampling days the TER of FIGCS exposed to ﬁltered
(0.2 μm) river water following 24 h exposures were comparable to
the TER of FIGCS exposed to MSW (Fig. 1). FIGCS exposed to un-
ﬁltered urban river water showed a drop in TER of between 75%
and 90% (data not shown).
Gene expression levels were only performed on those cell
cultures exposed to the ﬁltered river water, because the large drop
in TER on exposure to unﬁltered water was presumed to be due to
a loss of membrane integrity and potentially cell death. The gene
expression levels of mta were signiﬁcantly elevated at site 1 and
2 on the ﬁrst sampling date. At all other sites and on the second
sampling date mta was not induced compared to the controls. mtb
did not differ from the MSW treatment during either of the two
ﬁeld trips (Fig. 2a and b). Expression of cyp1a1was also elevated at
sites 1 and 2 on the ﬁrst sampling, but not at the other sites and
not on the second sampling date. Cyp3a27 expression was elevated
also at sites 1 and 2 during the ﬁrst trip and during the second
exposure at sites 1 and site 4 during the second trip. Expression of
cyp3a27 was unaffected at the other sites at the other sampling







Water chemistry and metal concentrations at the 4 study sites.
Site 1 Site 2 Site 3 Site 4
2/12/13 11/12/13 2/12/13 11/12/13 2/12/13 11/12/13 2/12/13 11/12/13
pH 8.77 8.49 7.33 7.26 7.6 7.92 7.63 7.61
Conductivity (μS/cm) 790 801 709 609 626 645 555 556
TDS (ppm) 403 403 308 310 316 325 284 286
Total hardness 203 233 162 166 149 141 152 158
Calcium hardness 195 206 145 141 139 121 138 135
Alkalinity 170.2 165.2 130.1 115.1 120.1 120.1 110.1 95.1
Cu (μg L1) 26 14.1 2.45 1.55 1.11 3.71 2.3 1.74
Zn (μg L1) 36.3 15.5 6.38 4.81 0.6 3.25 1.51 2.61
Hardness and alkalinity expressed as (mg CaCO3 L1)
Fig. 1. Transepithelial electrical resistance (TER) of inserts exposed to ﬁltered
(0.2 μm) river water from the 4 sites from the ﬁrst (white bars, 2.12.13) and second
(black bars, 11.12.13) sampling period and medium soft water (MSW). Values re-
present an average of 4–6 inserts7SEM and are expressed as a % of the starting
TER prior to changing the media for water after 24 h exposure.
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The present study showed that the primary ﬁsh gill cell culture
system (FIGCS) can be transported to the ﬁeld to sample urban
rivers, withstands ﬁltered urban river water for 24 h and exhibits
altered expression of genes encoding the metal binding protein
metallothionein A and two phase 1 enzymes cytochrome P4501A1
and 3A27. Previous work had demonstrated the ability of the
primary gill cells to be transported to the ﬁeld for environmental
monitoring of rivers contaminated with metals in the South-West
of England (Minghetti et al., 2014). The current work corroborates
the ﬁndings that these cells show increased mta expression when
exposed to natural waters with elevated Cu and also extends this
observation to show that the cells can also detect chemicals cap-
able of inducing cyp1a1 and cyp3a27 expression. This supports the
use of the primary gill cells as a potential tool for detecting bio-
logically active chemicals in natural waters.
The transepithelial electrical resistance (TER) is a measure of
membrane integrity and the gill cultures form exceedingly tight
epithelia with TERs 410 KΩ (Fletcher et al., 2000; Bury et al.,
2014). In the laboratory the application of water to inserts where
the TER is still rising causes a further rapid rise in the TER before
dropping to around or below the starting TER (Schnell personal
observation): this can be maintained for 24–48 h (Walker et al.,
2007; Stott et al., 2015). Previously, the application of natural water
from metal contaminated rivers in the ﬁeld, whether unﬁltered or
ﬁltered (0.2 μm ﬁlter), had no signiﬁcant effect on the TER after
24 h if compared to inserts that received synthetic water or media
change in the ﬁeld (Minghetti et al., 2014). Similarly, FIGCS trans-
ported into the ﬁeld and exposed to (0.2 μm) ﬁltered urban river
waters for 24 h show a comparable TER to FIGCS exposed to MSW
under the same conditions (Fig. 1). However, exposure of the cells to
unﬁltered urban river water caused a rapid decline in TER (data not
shown). Urban streams receive a considerable amount of particulate
matter, including bacteria from faecal contamination and the as-
sumption is that this is toxic to the cells.
The most prominent molecular response measured in the cul-
tured cells was an induction of cypa3a27 at sites 1 and 2 during the
ﬁrst sampling trip (Fig. 2). The rainbow trout cyp3a27 belongs to
the CYP3A subfamily of cytochrome p450 monooxygenases in-
volved in xenobiotic phase 1 metabolism (Uno et al., 2012); the
trout sequence is similar to the human CYP3A4 (Lee et al., 1998).
Cyp3a27 is associated with steroid and other xenobiotic metabo-
lism in hepatocytes (Buhler et al., 2000), but it is also highly
expressed, 42 fold higher than the liver, in the pyloric caeca and
anterior intestine of rainbow trout, suggesting an important role in
ﬁrst phase metabolism of xenobiotics present in the diet (Lee et al.,
2001). Cyp3A27 is also expressed in rainbow trout gills and in-
creases during a salinity challenge and facilitates the metabolism
of the pesticide fenthion (Lavado et al., 2009).It is estimated that the hCYP3A4 gene is induced by an estimated
50% of all therapeutic drugs, primarily via the pregnane-X-receptor
signalling, and potentially other pathways (Luo et al., 2002; Luo
et al., 2004). Consequently, the study chose to analyse for the pre-
sence of pharmaceuticals using previously established methods
(Lacey et al., 2008; Barron, et al., 2008, 2009; Miller et al., 2015). Of
the pharmaceuticals measured in the river, carbamazepine was the
highest at Site 1 on both sampling times (Table 3) and this drug is
known to induce CYP3A gene expression in humans (Oscarson et al.,
2006) and rats (Tateishi et al., 1999). However, the concentrations of
carbamazepine often used in the mammalian studies (e.g. Usui
et al., 2003; Kamiguchi et al., 2010) are around the known clinical
plasma concentrations of 25.39 μmol L1 (reported in Usui et al.,
2003) which is equivalent to 5992 μg/L, a value in excess of an order
of magnitude higher than that measured at site during the ﬁrst
sampling time point ([carbamazepine]¼552 ng/L). It is difﬁcult to
associate an elevation in cyp3a27 expression solely with carbama-
zepine, as the expression of this gene was also seen at site 2 (ﬁrst
sampling period) and site 4 (second sampling period), where there
were signiﬁcantly lower pharmaceutical concentrations (Table 3). In
addition, within the mixture of pharmaceuticals measured at site
1 there are compounds such as cimetidine and ranitidine (Table 3),
which are inhibitors of CYP3A4 gene expression (Martínez et al.,
1999). The CYP3 family of enzymes are known for their oxidative
transformation of xenobiotics including, in addition to pharma-
ceuticals, pesticides (Lavado et al., 2009) and polyaromatic hydro-
carbons (Zanette et al., 2013). For example, in the bivalve Mytilus
edulis, cyp3-like 1 and cyp3-like 2 genes were induced by beta-
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current results would suggest that, besides pharmaceuticals, there
are other compounds present in these urban rivers that are inducers
of cyp3a27 gene expression in the primary gill cell cultures.
The induction of CYP1A1 gene occurs via the arhyl-hydrocarbonFig. 2. Fold induction of primary gill cell culture (A) metallothioenin a and (B) b, as we
water from the 4 sites from the ﬁrst (white bars, 2.12.13) and second (black bars, 11.12
exposed to moderately soft water (MSW). Values represent an average of 4–5 inserts7SE
Table 3
Semi-quantitative results for pharmaceutical concentrations measured in surface water
Site 1 Site 2
2/12/13 11/12/13 2/12/13 11
Atenolol 143 (6) 81 (71) ND ND
Caffeine 251 (47) 111 (22) 247(100) 32
Cimetidine 103 (12) 44 (13) ND ND
Rantidine 359 (51) 179 (152) ND ND
Sulfamehtazine 1.6 (2.8) 6.3 (10.9) ND ND
Antipyrin ND 21 (35) ND ND
Trimethoprim 156 (3) 162 (6) ND ND
Metoprolol 22 (0.6) 9.7 (5) 0.7 (1.2) ND
Ketaprofen 27 (5) 43 (35) ND ND
Bezaﬁbrate 108 (32) 102 (7) ND ND
Propranolol 207 (40) 212 (54) 71 (35) 18
Carbamazepine 552 (22) 298 (136) 7.9 (3) 8.3
Indometacin 50 (12) ND ND ND
Naproxen 561 (9) 339 (144) ND ND
Warfarin 9.1 (16) 59 (63) ND ND
Gemﬁbrozil ND ND ND ND
Nimesulide ND ND ND ND
Temazepan 69 (5) 55 (3.6) 2 (0.3) ND
Diazepam 3.9 (4.5) ND 28 (19) ND
Nifedipine ND ND ND ND
Values in ng/L. Values represent averageþSD in parentheses of triplicate measurement f
detected.receptor (AHR) and is associated with the detoxiﬁcation of poly-
aromatic hydrocarbons (Billard et al., 2006). The catchment of the
river Wandle (sites 1 and 2) is heavily urbanised and the induction
cyp1a1 in the primary gill cell at sites 1 and 2 during the ﬁrst
sampling period may reﬂect the presence of PAHs (Fig. 2), which,ll as (C) cytochrome p4501a1 and (D) 3a27 genes exposed to ﬁltered (0.2 μm) river
.13) sampling period. Values are expressed as fold induction of expression in cells
M and asterisks indicates signiﬁcance difference to MSW (Student's t-test, Po0.05).
s across 4 study sites.
Site 3 Site 4
/12/13 2/12/13 11/12/13 2/12/13 11/12/13
ND 2.6 (0.5) ND ND
1 (70) 463(119) 127 (23) 89 (36) 87 (9)
ND ND ND ND
16.7 (29) ND ND 16 (23)
ND ND ND ND
ND ND ND ND
ND ND ND ND
5.3 (0.7) 1.4 (1.2) ND ND
ND ND ND ND
ND ND ND ND
1 (108) 105 (29) 72 (14) 63 (46) 105 (10)
(0.2) 4.8 (0.1) 9.1 (5.1) 3.7 (3) 2.7 (0.2)
ND ND ND ND
ND ND ND ND
ND ND ND ND
ND ND ND ND
ND ND ND ND
ND ND ND ND
9.4 (12) 7.4 (7.1) ND ND
ND ND ND ND
rom a single water sample. NB The same water was used for the exposure. ND: not
S. Schnell et al. / Ecotoxicology and Environmental Safety 120 (2015) 279–285284also may inﬂuence cyp3a expression levels (Zanette et al., 2013).
However, again the situation may be more complicated because
caged rainbow trout exposed to a complex mixture of compounds
from STW efﬂuent, including pharmaceuticals, in Uppsala, Sweden
show a large increase in the expression of various isoforms of cyp1
(cyp1c3, 1c2, 1c1, 1a3 1a1) (Jonsson et al., 2010), and in the gills of
stickleback exposed to pharmaceutical production waste efﬂuent
also show an increase in cyp1a1 expression (Beijer et al., 2013). In
contrast, carbamazepine has been shown to inhibit Cyp1a1 en-
zyme activity in ﬁsh hepatocytes (Laville et al., 2004). Thus, this
increase in cyp1a1 and cyp3a27 expression is better described as
the detection of CYP1a and CYP3a-active pollutants, than speciﬁc
classes of compounds.
The induction of mta was only observed at sites 1 and 2 during
the ﬁrst sample period (Fig. 2). The lack of induction of mtb may
reﬂect the fewer number of metal response elements (MREs)
present in the promoter region of this gene (Olsson et al., 1995;
Samson and Gedamu, 1995). At site 1 at this time there is elevated
Cu concentrations above the EQS and high Zn, although this does
not exceed the EQS (Table 2). The concentrations of Cu are similar
to those measured at Relubbus (30.5 μg/L) and St Erth (20.2 μg/L)
on the river Hayle that induced mta expression in FIGCS (Min-
ghetti et al., 2014). However, at site 2 the Cu and Zn levels are less
than at site 1 and are similar to those at the other two sites, and
the concentrations of Cu (2.45 μg/L) and Zn (6.38 μg/L) are not
expected to induce mta expression in the primary gill cells, based
on previous work with natural waters and addition of metals to
synthetic waters in the laboratory (Walker et al., 2007; Minghetti
et al., 2014). Consequently, either other metals that have not been
measured or other inducers of mta gene expression are present in
these water samples. MT may also act as a free radical scavenger
(Kling and Olsson, 2000). Some pharmaceuticals and personal care
products have been shown to affect reactive oxygen species(ROS)
production in rainbow trout gonad cell line (RTG-2) (Ferandez
et al., 2013) and PAHs are known to induce free radical production
(e.g. Wells and Winn, 1996; Zhu et al., 2014). The distal region of
the rainbow trout mta promoter possess both activator protein 1
(AP1) and a nuclear factor interleukin-6 (NF-IL6) elements that
have been shown to play a direct role in mta induction in response
to paraquat, an herbicide that induces ROS (Kling et al., 2013). In
addition, FIGCS treated with H2O2, that produces ROS, show an
increase in mta and b gene expression, as well as other antioxidant
genes (Chung et al., 2005). The antioxidant gene expression is
attenuated by the zinc chelator N,N,N′,N′-tetrakis(2-pyridylmethyl)
ethylenediamine (TPEN), suggesting that the response to ROS in
FIGCS is in part mediated by an increase in intracellular zinc
concentrations (Chung et al., 2005).
The study further demonstrates the potential for the primary
ﬁsh gill cell culture system (FIGCS) to be used for environmental
monitoring and shows that that genes associated with metal ex-
posure and biotransformation of organic compounds are present
in FIGCS and are induced on exposure to ﬁltered (0.2 μm) urban
river water. Natural waters contain a mixture of pollutants, for
example at site 1 elevations in dissolved Cu and Zn, along with the
identiﬁcation of the presence of 16 pharmaceuticals were made
(Tables 2 and 3), but, this is only likely to be a fraction of the
chemicals present with urban rivers likely to possess PAHs from
road run-off as well as pesticides and herbicides. The primary gill
cell mta, cyp1a1 and 3a27 gene expression is thus an integrated
measure of the bioactive compounds, whether they are inducers
or inhibitors of gene expression, present in a complex natural river
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Time-of-ﬂight high resolution mass
spectrometry
Screening of emerging contaminantsThe recent development of broad-scope high resolution mass spectrometry (HRMS) screening methods has re-
sulted in amuch improved capability for new compound identiﬁcation in environmental samples. However, pos-
itive identiﬁcations at the ng/L concentration level rely on analytical reference standards for chromatographic
retention time (tR) and mass spectral comparisons. Chromatographic tR prediction can play a role in increasing
conﬁdence in suspect screening efforts for new compounds in the environment, especially when standards are
not available, but reliable methods are lacking. The current work focuses on the development of artiﬁcial neural
networks (ANNs) for tR prediction in gradient reversed-phase liquid chromatography and applied along with
HRMS data to suspect screening of wastewater and environmental surface water samples. Based on a compound
tR dataset of N500 compounds, an optimized 4-layer back-propagation multi-layer perceptron model enabled
predictions for 85% of all compounds to within 2min of theirmeasured tR for training (n= 344) and veriﬁcation
(n = 100) datasets. To evaluate the ANN ability for generalization to new data, the model was further tested
using 100 randomly selected compounds and revealed 95% prediction accuracy within the 2-minute elution in-
terval. Given the increasing concern on thepresence of drugmetabolites and other transformation products (TPs)
in the aquatic environment, the model was applied along with HRMS data for preliminary identiﬁcation of.
935R. Bade et al. / Science of the Total Environment 538 (2015) 934–941pharmaceutically-related compounds in real samples. Examples of compounds where reference standards were
subsequently acquired and later conﬁrmed are also presented. To our knowledge, this work presents for the ﬁrst
time, the successful application of an accurate retention time predictor and HRMS data-mining using the largest
number of compounds to preliminarily identify new or emerging contaminants in wastewater and surface
waters.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The number of emerging contaminants in the aquatic environment
is increasing, due to urbanization and subsequent societal and industrial
needs (Pal et al., 2014). The development of liquid chromatography–
high resolution mass spectrometry (LC–HRMS) technologies has revo-
lutionized the analysis of emerging contaminants in environmental wa-
ters, and especially for screening of large numbers of compounds
(Agüera et al., 2013; Gómez et al., 2010; Hernández et al., 2011;
Hogenboom et al., 2009). HRMS instruments allow the recording of
full-scan spectra with high mass accuracy and resolution, thus making
it possible to search for any given compound based on its exact mass.
There has been much interest in improving the conﬁdence in the
identiﬁcation of small molecules with HRMS; from potential positives
through to detection and ﬁnally conﬁrmation (Hernández et al.,
2015a; Schymanski et al., 2014). The main distinguishing factor be-
tween these levels is the (non-) availability of reference standards. Sus-
pect screening refers to compounds tentatively identiﬁed based solely
on HRMS data and comparable spectral libraries. Conﬁrmation requires
reference standards. An additional tool to increase the conﬁdence in the
tentative identiﬁcation of compounds for which standards are unavail-
able is reliable and accurate tR prediction. This is of particular relevance
in the case of degradation/transformation products (TPs), which can
reach the aquatic environment in high concentrations, but commonly
for which reference standards are less accessible. Chemical risk assess-
ment is therefore signiﬁcantly challenging for such compounds.
Prediction of tR plays an important role in the qualitative identiﬁcation
of emerging contaminants. Many different approaches to tR prediction
exist and range from the simple (Kern et al., 2009; Nurmi et al., 2012)
to the complex (Goryński et al., 2013; Ji et al., 2009; Kaliszan et al.,
2003; Ukić et al., 2014a). For example, logKow models can be derived
using freely accessible data from chemical databases such as ChemSpider
and PubChem, aswell as freeware prediction sources such as VCCLABS. Its
use in tR prediction is extremely simple to implement. It is frequently used
in environmental studies for the description of the fate of various pollut-
ants and as a simple tR predictor for TPs (Kern et al., 2009) and emerging
contaminants (Bade et al., 2015; Nurmi et al., 2012). Alongside simple al-
gorithms, other and more complex in silico approaches now exist which
are basedonquantitative structure–retention relationship (QSRR)model-
ing, including artiﬁcial neural networks, support vector machines and
random forests (Giaginis and Tsantili-Kakoulidou, 2012; Héberger,
2007). The principal aimof QSRR is to predict retention data from themo-
lecular structure and its physicochemical properties, using a range of
input descriptors andmeasured tR data. One QSRRmethod gaining recent
attention for broad screening using high resolution techniques is the use
of artiﬁcial neural networks (ANNs), a predictive computing technique
that has shown itself as a promising tR predictor with potentially higher
accuracy than classical models (Miller et al., 2013; Ukić et al., 2014b).
The design of ANNs were inspired by the human brain and differ from
classical computer programs in that they generally employ non-linear
learning techniques using a set of case examples (i.e. a training dataset)
(Kaliszan et al., 2003). In the training phase, the ANN requires a range of
suitable molecular descriptors as well as the true output value (in this
case, measured tR) to use for comparison with predicted values. At the
same time, a second dataset of case examples is often used for veriﬁcation
and to assess overall ANN predictive error. The true output values in the
veriﬁcation set are generally not employed for learning, but the number
of training cycles can be stopped by the user or the software when theoverall measured error across all cases is at its minimum. Therefore,
ANN learning is generally an iterative process and once an acceptable
number of training cycles is reached, the optimized ANN can be applied
to predict the output where experimentally derived data are unavailable
(Miller et al., 2013). In some cases, a third dataset can be used after the
model has been ﬁnalized to ‘blind test’ the predictive power of the net-
work. Its use is even more pertinent for analyses where large number of
new analytes are expected to occur and with potentially high variance
from sample to sample, such as in environmental and municipal water
samples. Therefore, since information from the sample includes chro-
matographic tR as well as HRMS data, it makes this interpretation of sus-
pect occurrence more accessible in the ﬁrst instance.
The aim of this work was to develop and evaluate ANN for predic-
tions of unknown chromatographic tR in suspect screening of environ-
mental waters. To the best of our knowledge, this method includes the
largest range of physicochemically diverse compounds for this purpose
(n = 544 in total) and includes both neutral and charged compounds
eluted under gradient reversed-phase LC conditions. Lastly, this work
aimed to improve upon a recent logKow-based tR prediction approach
(Bade et al., 2015) using the ANNs as an alternative. This work, for the
ﬁrst time, presents the use of ANN for identiﬁcation of additional sus-
pect compounds (including metabolites and TPs) in wastewater and
surface water samples both with and without reference standards.
2. Experimental
2.1. Reagents and chemicals
A total of 544 analytical grade referencematerials were used for prep-
aration ofmodel solutions at 25 μg/L or 50 μg/L (diluted frommixed stan-
dard solutions in methanol or acetonitrile with water) for ANNmodeling
of tR. These included pesticides, drugs of abuse, human/veterinary phar-
maceuticals and mycotoxins (See Supplementary Information (SI)
Table S1 for all compounds used in this study). These covered a large
range ofmolecular hydrophobicity (logKow−3 to 9). Information relating
to 595 standards was available (Bade et al., 2015), however after
transforming the compounds using SMILES codes, some errors were ob-
served, leading to incomplete data, and a further 42 were removed from
the initial ANNmethod development (Section 3.1) to use in a subsequent
blind test (Section 3.2). Further details relating to these compounds can
be found elsewhere (Bade et al., 2015; Hernández et al., 2015b).
2.2. Water samples for suspect identiﬁcation
A total of 44 composite (24-h) inﬂuent and efﬂuent wastewater
(IWW and EWW) samples and grab surface water (SW) samples
were used to demonstrate the application of the developed ANN
model. All these samples were previously used in different studies
performed at our lab using the same analytical instrumentation for
analysis (Hernández et al., 2015a). All measured tR data herein
were generated using ultra-high pressure liquid chromatography
coupled to quadrupole-time of ﬂight mass spectrometry (UHPLC–
QTOF-MS).
2.3. UHPLC-QTOF MS
A Waters Acquity UPLC system (Waters, Milford, MA, USA) was
interfaced to a hybrid quadrupole-orthogonal acceleration-TOF mass
936 R. Bade et al. / Science of the Total Environment 538 (2015) 934–941spectrometer (XEVO G2 QTOF, Waters Micromass, Manchester, UK),
using a electrospray ionization (ESI) Z-Spray interface operating in pos-
itive mode. The chromatographic separation was performed using an
Acquity UPLC BEH C18 100 × 2.1 mm, 1.7 μm particle size column
(Waters) at a ﬂow rate of 300 μl/min. Gradient elution was performed
using mobile phases of A = H2O and B = MeOH, both containing
0.01% HCOOH. The initial percentage of B was 10%, which was linearly
increased to 90% in 14 min, followed by a 2 min isocratic period and,
then, returned to initial conditions during 2 min. The total run time
was 18 min. Nitrogen was used as the drying gas and nebulizing gas.
MSdatawere acquired over anm/z range of 50–1000. A capillary volt-
age of 0.7 kV and cone voltage of 20 Vwere used. Collision gas was argon
99.995% (Praxair, Valencia, Spain). The desolvation temperature was set
to 600 °C, and the source temperature to 135 °C. The column temperature
was set to 40 °C. MS data was acquired inMSE mode, selecting a collision
energy of 4 eV for low energy (LE) and a ramp of 15–40 eV for high ener-
gy (HE). The LE and HE functions settings were for both a scan time of
0.4 s (Hernández et al., 2011; Ibáñez et al., 2013).
Processing of MS data was made using ChromaLynx XS application
manager (withinMassLynx v 4.1;Waters Corporation). The following pa-
rameters were used: mass window 0.020 Da (for positive ID ≤ 0.010 Da),
peak width at 5% height: 6 s, peak-to-peak baseline noise: 1000 and
threshold absolute area 500. When manually searching the data for all
peaks in an eXtracted Ion Chromatogram (XIC), a chromatographic
peak was thought viable when above an intensity threshold of 3000
counts.
2.4. Molecular description and neural network optimization procedures
Compound logD data (for a mobile phase of pH= 3.2) were gener-
ated using Percepta PhysChem Proﬁler (ACD Laboratories, ON, Canada)
and for all other descriptors, Parameter Client freewarewas used (Virtu-
al Computational Chemistry Laboratory, Munich, Germany). Canonical
simpliﬁed molecular line entry system strings (SMILES) were created
using ChemSpider freeware (Royal Society of Chemistry, UK) for 544
compounds and from these 16 molecular descriptors (as ANN inputs)
were generated including the number of double and triple bonds
(nDB or nTB), the number of carbon and oxygen atoms (nC or nO),
the number of 4–9 membered rings (nR04-nR09), unsaturation index
(UI), hydrophilic factor (Hy), Moriguchi and Ghose–Crippen logP
(MlogP and AlogP respectively) as well as with software predicted
logKow data (Tetko et al., 2005). Prediction of tR (as the designated single
output) via neural networks was performed using Trajan version 6.0
neural network simulator (Trajan Software Ltd., Lincolnshire, U.K.)
and compared with experimentally determined tR via correlation
graphs as well as assessment of residual errors. Table S1 has all com-
pounds and their respective predicted and experimental tR and ANN
subset.
3. Results and discussion
In a previous study, we developed a simple tR prediction model
based on logKow of nearly 600 compounds, predicted using freeware
(Bade et al., 2015). This resulted in approximately 70% of all compounds
being predictedwithin 2min of themeasured tR, and 95%within 4min.
This technique was simple to implement and facilitated the removal of
several false positives. However, when investigating unknowns and
compounds for which reference standardswere unavailable, it was con-
cluded that a more robust, accurate and precise methodology was still
needed. In this vein, ANNs were considered as an alternative. Recent
work successfully used ANN for a similar purpose, albeit using a much
smaller set of compounds of 86 and 166 compounds in either study
and focused only on pharmaceuticals (Miller et al., 2013; Munro et al.,
2015). It is unlikely that this fully represents the breadth of alternative
compound classes and chemistries potentially occurring simultaneously
in environmental waters. However, thesemodels successfully predictedtR for a range of blind test drug compounds in wastewater and urine to
warrant further investigation here using a much larger case dataset.
3.1. Prediction of tR using Artiﬁcial Neural Networks (ANNs)
The molecular descriptors chosen were based on the previous work
wherein more than 200 descriptors were evaluated (Miller et al., 2013).
As the same type of reversed-phase column and LC system were used in
both studies, the same descriptors were hoped to provide similar results.
These descriptors were used again to also assess the possibility for trans-
ferring the model to another laboratory and to extend the prediction to a
much larger set of chemically diverse compounds. Collinearity data for all
molecular descriptors and retention time are given in the SI. Higher Pear-
son correlations were observed for hydrophobicity-based descriptors
with retention time as was perhaps expected (maximum R = 0.823
with logKow). Similarly, these descriptors also showed some collinearity
with each other (R ≤ 0.889) which prevented strong conclusions to be
drawn regarding their relative importance to anANNmodel. Asmolecular
descriptors selected were from previous investigations, there is also the
possibility that additional descriptors may have had more importance to
retention prediction on this system. For example, retention on reversed-
phase media is not only dependent on hydrophobic interactions, but
also steric and shape effects. Large molecules may not interact with the
stationary phase well and thus show reduced retention (Wilson et al.,
2002). A simple Pearson correlation was examined for a selection of po-
tentially relevant additional descriptors covering charge states, geometri-
cal, topological and physicochemical properties. Overall, most of these
descriptors showed weak relationships b0.5 except for the descriptor
BTLA96 which showed a negative Pearson coefﬁcient of−0.649.
Over 100,000 network architectures for each model type were ini-
tially investigated for their predictive ability across ﬁve different ANN
model types including 3- and 4-layer multi-layer perceptrons (MLPs),
generalized regression neural networks (GRNNs), radial basis functions
(RBFs), linear neural networks and probabilistic neural networks
(PNN). For training, 344 cases were used along with 100 cases for
both veriﬁcation and blind testing of network performance. Cases
were randomly assigned at the beginning of each network test to pre-
vent any bias from pre-selection. Upon selection of the ‘best’model sta-
tistics (minimum/maximum values, interquartile ranges, standard
deviations, medians and means) were generated to ensure that a fair
representation of cases and descriptors were present in each dataset
subset (see SI). The diversity of ANN types and architectures tested
was balanced against the error generated. For network design and test-
ing the omission of input descriptors was included as an option. One
hundred of the best networks (software selected)were retained for fur-
ther investigation which mainly comprised of MLPs, GRNNs and RBFs.
Overall for this separation system, the best correlations of predicted ver-
sus experimentally measured tR were observed usingMLPs in compari-
son to all other types and these correlations were in agreement with
previous works despite different compounds being used for training,
veriﬁcation and blind testing (Barron et al., 2009; Miller et al., 2013;
Munro et al., 2015). The ﬁnalized network was found to be a 4-layer
16-19-9-1 MLP using all 16 molecular descriptors as inputs (Fig. 1).
The source code (in C) for this ANN has been attached in the SI. Reduc-
ing the number of descriptors further worsened predictive accuracy of
the blind test set in general. This ANN type and architecture was chosen
based on the lowest absolute errors (i.e. predicted tR-measured tR) in
the training, veriﬁcation and blind test sets across all networks. There-
fore, ANN architecture was based on performance and the software de-
signer tool was used to optimize the number and composition of hidden
layers. The coefﬁcients of determination (R2) were between 0.86 and
0.90 between the three sets, whichwas already amarked improvement
on that obtained fromour previous study at R2=0.67. Furthermore, the
root-mean-squared error (RMSE) of the blind set of compounds
(1.03 min) is less than half that of our previous work (2.19 min)
(Bade et al., 2015).
Fig. 1. TOP: Correlation ofmeasured andpredicted tR for all compounds. Theworst outliers
in each set are also shown:A=atenolol (training set, error of−6.21min); B= levamisole
(veriﬁcation set, +5.19min); C =metosulam (blind set, +3.56min). BOTTOM: Residual
errors for all compounds in each dataset. For training, veriﬁcation and blind test sets, n =
344, 100 and 100 compounds respectively.
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16.50 min (narasin; an antibiotic) and the lowest was 0.86 min
(methamidophos; an organophosphate insecticide). For all compounds
within this retention window of 15.64min, themean error in tR predic-
tion was b6% using this ANN approach for all compounds. Overall, the
mean absolute errors and standard deviations were recorded as
0.97 ± 0.95 min (training set); 0.79 ± 0.85 min (veriﬁcation set);
0.79 ± 0.69 min (blind test set); and 0.91 ± 0.89 min (all sets com-
bined). When focussing speciﬁcally on the blind test set which was
used to simulate a true application of the approach, 95% of compounds
had predicted tR values within 2.00 min of the measured value and
the maximum error was 3.56 min for metosulam (Fig. 2). However,
across the other datasets some larger errors were recorded in isolated
cases. Table 1 shows that for all datasets, 90% of all 544 compounds
could be predicted to within 2.00 min of the measured tr value. Upon
sub-division of the datasets, 85% of the compounds in the training and
veriﬁcation sets and 95% of compounds in the blind test set were pre-
dicted to within two minutes of the measured value. The maximum
error recorded within the training set was +6.25 min (for the beta
blocker atenolol; measured tr = 2.49 min); within the veriﬁcation setwas +5.19 min (for the anti-helminthic drug levamisole; measured
tr= 3.02min) andwithin the blind test setwas+3.56min (for the pes-
ticide, metosulam; measured tr = 7.54 min).
Prediction errors for all cases were investigated again with respect
to any apparent trends and it was found that a very slight over-
estimation existed for poorly retained compounds, as well as the con-
verse for strongly retained compounds. Recent work focussing on
modeling a smaller number of compounds in wastewater also revealed
a similarly slight bias, but used a different network type (a GRNN)
(Munro et al., 2015). When examining those compounds with absolute
errors N2.00 min (54 compounds in total across all sets), these were
spread across the entire compound retention range (mean measured
tR = 7.81 ± 3.93). However, a slight over-estimation was again appar-
ent for 29 compounds with tR from 1.34–5.38 min (mean measured
tR = 2.97 min). Reduced under-estimation was observed for the re-
maining 25 compounds eluting between 5.38–16.30 min (mean mea-
sured tR = 10.67 min for these compounds). Seventeen compounds
eluting b5.38 min were over-estimated and tR for eleven were under-
estimated when eluting N10.00 min.
The contribution of each descriptor towards the ﬁnal prediction out-
put was investigated using the ANN software sensitivity analysis tool. In
this test, each molecular descriptor is removed and treated as missing
by the ANN. A new predicted tR is generated and a ratio calculated be-
tween the network error with a given input omitted to the error of
the network with a complete input dataset. Ratios N1 indicated higher
importance in the prediction. Perhaps not surprisingly for a reversed-
phase chromatography system, the most important molecular descrip-
tors and their measured error ratioswere: logD (1.443), logKow (1.182),
AlogP (1.114), nO (1.096), UI (1.006) MlogP (1.023), Hy (1.017), nDB
(1.012), nR04-nR09 (all 1.000–1.063), nTB (1.004) and nC (1.002)
Hydrophobicity-based descriptors are likely to show importance as re-
tention on reversed-phasemedia is primarily by van derWaals interac-
tions. Again, while these descriptors together show their combined
importance to the network, moderate collinearity between them
means relative error ratios should be treated with caution for these de-
scriptors (Table SI). However, such collinearity should not adversely af-
fect predictive ability of the model. The lowest ratio was observed for
nR04 with a ratio of 1.000 meaning no change in network performance
was measured for its removal. Within the dataset, only 14 compounds
had 4-membered rings (amoxicillin, ampicillin, cefaclor, cefadroxil,
cefalexin, cefotaxime, cefquinome, cefuroxime, cloxacillin, dicloxacillin,
heptenophos, oxacillin, oxasulfuron, and penicillin G). Inclusion of nR04
still resulted in better performance in comparison to any other type or
architecture investigated during the network optimization stage and
so was retained as a descriptor in the ﬁnal ANN model. Error ratios
discussed above represent that of the entire dataset (training, veriﬁca-
tion and blind test). Sensitivity analysis (see SI) of each set separately
revealed excellent consistency across all sets, showing that predictive
accuracywas likely to be the dominant contributors to error ratios rath-
er than over-ﬁtting of the training set alone.
3.2. Use of ANN as a tR predictor in environmental water samples
In wide-scope screening methods, where thousands of compounds
are searched, it is of great importance to have secondary techniques
for aid in the identiﬁcation process. While reference standards can un-
equivocally conﬁrm the identiﬁcation of a compound, purchasing and
maintaining standards for all compounds is prohibitively expensive.
Data acquired from MS fragmentation of suspect compounds may also
direct investigations. Furthermore, for many TPs, reference standards
are not available and therefore alternatemeans for conﬁdence in detec-
tion/identiﬁcation are necessary. Although it is not comparatively infor-
mative as mass spectra, tR prediction models can be very helpful in
gaining more conﬁdence in the obtained data and reducing time-
consuming data processing. Most importantly, the application of tR
prediction is not to replace the use of reference standards, but to help
Fig. 2. LEFT: eXtracted Ion Chromatograms (XICs) of losartan in an EWW sample, together with ANN tR prediction (9.95 min) and associated ±2 minute window (dotted lines; center
dashed line is the ANN-predicted value). RIGHT: Mass spectra from LE (bottom) and HE (top), showing fragment ions (423.158, 377.156, 207.092).
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the usual manner. Prediction of tR is best used at the beginning of this
process and is especially useful when at a certain exact mass (i.e.
(de)protonatedmolecule of a suspect compound), more than one chro-
matographic peak appears in the corresponding XIC.
Along these lines, and to test the “blind” skills of theANN in a real en-
vironmental application, the 100 blind compounds as well as an addi-
tional set of compounds from our previous study not initially used
into the ANN method (a total of 142 compounds), including primarily
metabolites and TPs were searched. None of these compounds were in
the training or veriﬁcation sets used for ANN development. From this
list of 142 compounds, 46 were ﬁnally selected and searched in 44
water samples (EWW, IWW and SW) using ChromaLynx and the ANN
predicted tR, based on their possible occurrence in the environment
(Table S2) (Gracia-Lor et al., 2010, 2011; Hernández et al., 2015a;
Zuccato et al., 2006). For further conﬁdence, and to see how many
false positive chromatographic peaks (above the intensity threshold)
could be disregarded, fragment ionswere also included in the detection
process (Table S3).When a compoundwas identiﬁed on the basis of the
accuratemass of the (de)protonatedmolecule and at least one fragment
ion in at least one sample it was included in this test, leaving 26 com-
pounds of various chemical classes and including nine metabolites, for
only some of which standards were available in our laboratory
(Table 2). A tR window of 2 min was used in this section, as 95% of all
compounds in the ANN blind set were within this window, thereby giv-
ing high conﬁdence that almost all compounds should be found. The
only compound found to have a tR outside that of the ANN predicted 2Table 1
Summary of predicted tR errors for all ANN test sets. Numbers given in italics are those which
Percentile of compounds 50 55 60 65
Predicted tR error/min
All sets (n = 544) 0.66 0.75 0.85 0.97
Training set (n = 344) 0.70 0.81 0.89 1.02
Veriﬁcation set (n = 100) 0.51 0.59 0.64 0.76
Blind test set (n = 100) 0.70 0.78 0.84 0.89minute window was codeine. The incorporation of the ANN predicted
tR allowed almost half (49%) of all chromatographic peaks to be ignored,
and even after removing codeine from the calculation, 48% could be
disregarded. Furthermore, all but three compounds had a reduction in
the median number of potential positive peaks, while 11 compounds
had a median value of only one chromatographic peak remaining after
the introduction of the ANN predicted window.
In this section, examples are shown in the identiﬁcation of losartan
(originally tentatively identiﬁed with tR prediction before a reference
standard was purchased) and the tentative identiﬁcation of the metab-
olites 10,11-dihydroxy carbamazepine and O-desmethyl venlafaxine
(no reference standard available).
3.2.1. Assignment with reference standards
Losartan is a pharmaceutical used to treat hypertension that has been
both predicted (Howard andMuir, 2013; Oosterhuis et al., 2013) and de-
tected in environmental waters (Hernández et al., 2015a; Matsuo et al.,
2011). Its presence in a suspect list is thus warranted, and its exact mass
was incorporated into our HRMS database. When screening WW and
SW samples, XICs at the exact mass of losartan (m/z 423.1700) resulted
in two chromatographic peaks (4.63 and 10.13 min) (Fig. 2, bottom
left). The ANN tR predictor was used and calculated a tR of 9.95 min.
This is almost exactly the tR of one of the peaks, but it is worth noting
than even after incorporating a ±2 minute window only one peak
warranted further investigation. Nevertheless, both peaks could have
conceivably corresponded to losartan, therefore further research was
conducted.fall below the proposed 2-min window limit.
70 75 80 85 90 95
1.05 1.19 1.39 1.56 1.96 2.80
1.13 1.24 1.45 1.70 2.21 2.87
0.89 0.99 1.35 1.44 1.60 2.43
1.01 1.08 1.16 1.34 1.63 1.99
Table 2
All compounds used for testing ANN predicted tR, togetherwith the number of samples each compoundwas detected, average number of peaks in the XIC and the±2minutewindow and
the predicted and sample tR.
Compound Detection rate out
of 44 samples
Median peaks per XIC
(range)
Median peaks inside ±
2 min tR window (range)
Predicted tR (min) Sample tR (min) Inaccuracy in predicted
tR (min)
10,11-Dihydroxy carbamazepinea 30 2 (1–4) 1 (1–3) 6.29 6.66 0.37
2-Hydroxy-terbuthylazineb 6 6 (4–8) 2 (1–3) 4.24 5.50 1.26
4-Desmethoxy omeprazolea 33 1 (1–2) 1 (1–2) 8.15 6.29 −1.86
4-Formylamino-antipyrineb,c 37 2 (1–8) 2 (1–4) 3.53 3.70 0.17
a-Hydroxy metoprolola 17 5 (2–10) 3 (2–4) 2.73 3.30 0.57
Benzoylecgonineb 40 3 (1–6) 2 (1–5) 4.11 4.65 0.54
Bezaﬁbrateb 2 6 (4–7) 1 (1–1) 10.80 10.78 −0.02
Caffeinea 40 3 (1–6) 1 (1–3) 3.17 3.83 0.66
Carbamazepineb 40 3 (1–10) 3 (1–5) 7.73 8.82 1.09
Carboxy losartana 35 2 (1–3) 1 (1–1) 10.75 10.44 −0.31
Codeineb 25 5 (1–7) 1 (0–3) 4.85 2.46 −2.39
Cotininea 32 10 (4–14) 5 (3–7) 2.00 1.81 −0.19
Diazinonb,c 4 3 (2–5) 2 (1–2) 11.64 12.50 0.86
Diclofenacb 13 1 (1–2) 1 (1–1) 11.71 12.17 0.46
Gemﬁbrozilb 13 4 (3–7) 2 (1–4) 12.29 13.34 1.05
Lidocainea 40 5 (1–11) 2 (1–4) 5.21 4.24 −0.97
Lincomycinb,c 14 4 (2–8) 2 (1–4) 4.28 3.73 −0.55
Losartanb 42 2 (1–4) 2 (1–3) 9.95 10.13 −0.18
Metoprolola 24 3 (1–9) 1 (1–3) 4.07 5.44 1.37
Naproxenb 32 7 (4–11) 2 (1–4) 10.06 10.54 0.48
O-desmethylvenlafaxinea 29 3 (2–5) 3 (1–5) 5.76 4.68 −1.08
Paraxanthinea 39 7 (2–12) 3 (2–4) 2.03 2.97 0.94
Ranitidinea 23 4 (2–6) 1 (1–1) 3.03 2.10 −0.93
Terbuthylazineb,c 4 1 (1–3) 1 (1–2) 9.60 10.78 1.18
Trimethoprimb 32 7 (2–10) 4 (1–6) 3.11 3.52 0.41
Valsartanb 39 2 (1–7) 1 (1–3) 10.90 11.24 0.34
a Standard not available in laboratory Sample tR was based on HRMS data and the incorporation of fragment ions.
b Standard available in laboratory.
c Compound in blind set of ANN.
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gated for fragment ions:m/z 207.0917 (C14H11N2,−2.4 ppm), 377.1552
(C22H22N4Cl, +5 ppm) and 405.1590 (C22H22N4Cl,−2.3 ppm) (Fig. 2,
right). Literature (Hernández et al., 2015a) and the mass spectral data-
baseMassBank (Horai et al., 2010) were also searched to aid in the con-
ﬁdence of these fragment ions. It was found that these three fragment
ions did indeed correspond to losartan. As seen in the ﬁgure, all associ-
ated fragments corresponded to the peak at 10.13min, following the as-
sertion of the tR predictor. Furthermore, it is clearly seen that none of the
fragment ions correspond with that of the other peak in the LE
(4.63min). A standard was later purchased and injected, unequivocally
conﬁrming that the peak at 10.13 min did correspond to losartan.
3.2.2. Tentative identiﬁcation of metabolites without standard reference
materials
The elimination of false positives in suspect analysis is challenging,
especially the environmental matrices investigated herein (SW and
WW) as thousands of compounds may be present. Suspect screening,
by deﬁnition, does not rely on reference standards (Krauss et al.,
2010). While the exact mass capability of HRMS has gone some way
to avoid false positives, even at narrow mass window chromatograms,
matrix inferences can be present, thereby hindering conﬁdent identiﬁ-
cation (Bade et al., 2015; Croley et al., 2012). A precise tR predictor can
therefore be a great additional means of identiﬁcation.
Most research of emerging contaminants in the environment has fo-
cused on parent compounds, however many compounds can be at least
partially metabolized or degraded in natural conditions (Jakimska et al.,
2014). In this respect, the tentative identiﬁcation of two major metabo-
lites of carbamazepine and venlafaxine were explored: 10,11-dihydroxy
carbamazepine and O-desmethyl venlafaxine (Fig. 3a). More than one
chromatographic peak was observed at the exact mass of each protonat-
edmolecule. The ANN tR predictor was then used to try to helpminimize
the number of peaks to be analyzed,with the predicted tR calculated to be
6.29 and 5.76 min for 10,11-dihydroxy carbamazepine and O-desmethyl
venlafaxine, respectively.Two large (~4.00 and 6.66 min) and one small (~4.90 min) peaks are
seen in the LE XIC of 10,11-dihydroxy carbamazepine (m/z=271.1080).
The predicted tR was calculated to be 6.29 min and by including a ±2
minute window as in Section 3.2.1, the large peak at ~4.00 min could
be disregarded, leaving the peaks at 6.66 and ~4.90 min. The ability to
focus on fewer peaks is the primary aim and beneﬁt of tR prediction in en-
vironmental screening applications for unknowns.While having only one
(correct) peak remaining is ideal, being able to disregard some peaks
gives credence to the use of tR prediction in the identiﬁcation process.
To aid in the differentiation of these peaks, fragment ions were sought
in literature, whereby one group performed an MS/MS experiment with
a QTOF instrument to ﬁnd the fragment ions of 10,11-dihydroxy carba-
mazepine (271.1080, 236.0706, 210.0913 and 180.0808) (Ferrer and
Thurman, 2012). As the XICs in the ﬁgure show, all fragment ions have
the peak at 6.65 min in common. This provides great conﬁdence
that this peak is indeed from 10,11-dihydroxy carbamazepine, how-
ever for unequivocal identiﬁcation, a standard would still have to be
purchased.
The example of O-desmethyl venlafaxine represented the worst case
scenario, where no peaks could be removed after application of the ±2
minute limit window. However, it must be noted that this was a rare
case and only occurred for three of 26 compounds. In the LE XIC, two
large (4.69 and 5.00 min) and two small peaks (~4.20 and 6.50 min)
are seen. Even after incorporating the ANN predicted tR and associated
window (5.76 ± 2 min), all four peaks are still of interest. With the
peaks being so close together, even using a±1.3minute window (corre-
sponding to ~80% of compounds being successfully inside this window)
would result in the correct elimination of only one small peak. In this sit-
uation, fragment ions have to be used to gain further information on the
identity. Fragment ions were thus searched in literature (Herrera-Lopez
et al., 2014) and investigated in theHE. Fig. 3b shows all ions correspond-
ing to the peak at 4.69 min. While the ANN predicted tR and associated
window did include O-desmethyl venlafaxine, all other peaks in the LE
XICwere also inside, meaning that no further conﬁdence could be gained
by tR prediction, rather through the investigation of fragment ions.
Fig. 3. Tentative identiﬁcation of 10,11-dihydroxy carbamazepine (a) and O-desmethyl venlafaxine (b) in an IWW and EWW sample respectively, together with ANN prediction and±2
minute window.
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to the tentative identiﬁcation of this compound.
While the examples explained here show the successful assignment
of chromatographic peaks, it is impossible to have total conﬁdencewith
tR prediction. In cases where there is more than one peak in the XIC, and
the predicted peak is found to be incorrect, the peaks slightly outside
the prediction window will also have to be investigated. Nevertheless,
with data processing nowadays being the most time consuming part
of environmental screening methods, the time saved by incorporating
tR prediction outweighs the possibility of false negatives (and positives).
These examples clearly show the utility of ANN as a tR predictor, not
just for its ability to disregard some false positive peaks, but also for its
accuracy and subsequent conﬁdence for tentatively identiﬁed com-
pounds. It is therefore recommended when performing large scope
(e.g. N1000 compounds) screening of environmental samples to include
accurate tR prediction in the strategy used for identiﬁcation. This is par-
ticularly useful in the investigation of metabolites and TPs, for which
standards can be very costly or unavailable.
4. Conclusions
This work showed the development and use of a tR predictor based
on artiﬁcial neural networks. In particular, a four layer multilayer
perceptron successfully modeled retention of 544 compounds under
these separation conditions. Overall, 90% of all compounds eluted with-
in 2.00 min of the predicted value and for 100 blind test compounds,
95% were predicted within this window. The network was applied to
additional suspect compound occurrence in wide-scope screening
based on the use of LC-HRMS, demonstrating that it can reduce the
number of false negatives or positives. This saves time and effort in
the tentative identiﬁcation of the compounds detected, as only those
chromatographic peaks that ﬁt the predicted tR need to be focused on.
Several representative examples are given to illustrate the usefulness
of the complementary use of precise tR prediction in large suspect
screening of emerging contaminants. It is recommended to include
this prediction for the identiﬁcation of suspect compounds, particularlyin the investigation of metabolites and TPs of organic contaminants, for
which reference standards are commonly less accessible.
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The pseudo-persistent nature of pharmaceuticals and personal care
products (PPCPs) has beenhighlighted in recent years as an environmen-
tal concern and has led to the introduction of a watch list under the EU
Water Framework Directive which includes an anti-inﬂammatory,
diclofenac, and two hormones, the synthetic ethinyl-estradiol (EE2)
and natural estradiol (2013/39/EU, 2013). Several thousand PPCPs are
currently available worldwide and whilst measured environmental con-
centrations typically range from low ng L−1 to high μg L−1, their poten-
tial to effect an ecotoxicological response and/or bioaccumulate in a
range of biota still remains understudied (De Lange et al., 2006;
Contardo-Jara et al., 2011).
Ecotoxicological studies have shown thatmeasured PPCP concentra-
tions in surface waters would be highly unlikely to cause acute effects
on exposed organisms (Crane et al., 2006). However, chronic exposure
has been linked to behavioural activity changes, increased oxidative
stress and alterations to the function of several vital organs in ﬁsh and
invertebrates (Heckmann et al., 2007; Fernández et al., 2013). Aquatic
invertebrates such as molluscs and smaller crustacean species have
been previously utilised for monitoring PPCPs in the natural aquatic en-
vironment. Most recently, the freshwater amphipod, Gammarus pulex,
was found to contain residues of carbamazepine, diazepam, nimesulide,
trimethoprim and warfarin measuring at low ng g−1 concentrations in
UK streams (Miller et al., 2015). PPCP uptake has also been previously
observed at lowngg−1 concentrations inwild and cagedmussel species
collected from the coast of Ireland, the Bohai Sea in China, the Mediter-
ranean Sea and San Francisco Bay, highlighting the extent of PPCP con-
tamination worldwide (McEneff et al., 2014; Li et al., 2012; Bueno et al.,
2013; Klosterhaus et al., 2013). EU Directive 93/39/EEC requires an en-
vironmental risk assessment to be carried out prior to drug licencing in
order to determine any signiﬁcant toxicological risks associated with a
xenobiotic (Straub, 2002). Under the regulatory guidelines, environ-
mental toxicity testing of pharmaceuticals requires standard acute tox-
icity tests, such as LC50 testing, to be carried out unless the predicted
environmental concentration (PEC)/predicted no effect concentration
(PNEC) ratio is b1, whereby no further toxicity testing is required.
Standardised toxicity tests on aquatic organisms are generally limited
to algae (Desmodesmus subspicatus or Pseudokirchneriella subcapitata),
Daphnia magna and/or ﬁsh (e.g. Danio rerio) considered as good
model species from freshwater environments. Furthermore, a lack of
published research generally exists on the uptake and depuration kinet-
ics of PPCPs both in target and non-target aquatic species to help eluci-
date potential acute versus chronic effects.
Toxicokinetic studies identify whether a compound will accumulate
to potentially toxic levels in/on the organism itself over time or
potentially act as a source of toxicity in higher trophic organisms
(Ashauer & Escher, 2010). In aquatic species, this can involve the
study of either accumulation of compounds via water exposure only
(i.e. bioconcentration), or via exposure through both water and diet
(i.e. bioaccumulation or biomagniﬁcation) (Oliver & Niimi, 1983;
Meador et al., 1995). Fish exposure studies often allow a time period
for the compound of interest to reach steady-state within the organism,
where the rate of uptake is equal to the rate of depuration. However,
this time can vary considerably and has led to the application of kinetic
modelling where uptake and elimination rates are estimated and used
to derive a bioconcentration factor (BCF) (Veith et al., 1979). This factor
can be determined in two ways: (a) as a ratio of either the compound
concentrations in the organism and the water phase at steady-state, or(b) as the ratio of the uptake (k1) and elimination (k2) rate constants
(Kenaga, 1972). This approach has been widely evaluated in the litera-
ture. Earlier models, such as those for methylmercury in ﬁsh
(Norstrom et al., 1976) considered several variables including volume
of water passing the gills, assimilation across the gills and body weight
of the organism. More recent models have been developed to also ac-
count for water-phase and lipid-phase resistance, ﬁsh lipid content
and compound logKow (Veith et al., 1979; Gobas & MacKay, 1987;
Hendriks & Heikens, 2001). A widely known and accepted model used
to calculate the bioaccumulation of a compound in ﬁsh via aqueous
and dietary exposure is outlined in the Organisation for Economic Co-
Operation and Development (OECD) 305 guidelines (OECD, Test No.
305). These guidelines present two methods for estimation of k1 and
k2. The sequential method can be performed in one of two ways, a k2
value can be estimated by linear regression and then curve ﬁtting
methods are applied to ﬁnd k1. Alternatively, curve ﬁtting methods
can be used to estimate k2 ﬁrst which is then used to estimate k1. The si-
multaneous model calculates both k1 and k2 together and is considered
a potentially more reliable and realistic model for concurrent uptake
and elimination processes occurring in biological systems. Considering
the number of PPCPs available on the market that may require testing
under EU REACH legislation (European Commission, 2006), the time
scales (2 week acclimatisation followed by 28 days for the uptake
phase alone unless steady-state is achieved sooner) and number of or-
ganisms required for each test (n=4 per time-point for each exposure)
the testing regime to apply to all chemicals under REACHwould appear
unfeasible. Furthermore, current policy aims to reduce the number of
ﬁsh used for scientiﬁc research, thus current methods proposed such
as the OECD guidelines should account for this more ethical approach
(Carter et al., 2014; Browne, 2013). Several recent studies assessing
BCF have utilised shorter exposure times with experiments lasting
only 4–7 days using aquatic invertebrates as a means to assess the po-
tential for substance to bioaccumulate in aquatic organisms (Ashauer
et al., 2006; Meredith-Williams et al., 2012). These ecotoxicological
studies are important to direct future risk assessment and essential
when considering contaminant monitoring in water, sediment and
biota.
In the present study, an in vivo experiment was carried out to deter-
mine the uptake and depuration kinetics of environmentally relevant
(low μg·L−1) concentrations of several selected PPCPs in the common
freshwater invertebrate, G. pulex, using radioactive labels and liquid
scintillation analysis. Lastly, the OECD 305 guidelines currently used
for modelling of uptake and elimination kinetics in aquatic species are
critically evaluated for the ﬁrst time based on the results obtained
both in this study and other published works on micropollutants.
2. Materials and methods
2.1. Reagents, chemicals and consumables
Radio-labelled pharmaceuticals including 3H-propranolol hydro-
chloride (29.0 Ci mmol−1) were acquired from Amersham Biosciences.
3H-metoprolol (29.7 Ci mmol−1), 3H-formoterol (18.5 Ci mmol−1) and
3H-terbutaline (29.0 Ci mmol−1) were obtained from Vitrax. 14C-
ibuprofen (2.03 Cimmol−1) was obtained fromAmerican Radiolabelled
Chemicals Inc. (St Louis, US). 3H-ranitidine (2.5 Cimmol−1) was obtain-
ed from Moravek Biochemicals, 14C-diclofenac (0.063 Ci mmol−1) and
3H-imipramine hydrochloride (48.5 Ci mmol−1) from Perkin-Elmer.
All stock solutions were stored in ethanol. Hydrogen peroxide solution
398 T.H. Miller et al. / Science of the Total Environment 547 (2016) 396–404(30% w/w) and analytical grade salts (N99%) including sodium hydro-
gen carbonate, magnesium sulphate, calcium sulphate, potassium chlo-
ride were purchased from Sigma (Dorset, UK). Tissue solubiliser
(Solvable™) and liquid scintillation cocktail (Hionic Fluor™) were pur-
chased from Fischer Scientiﬁc Ltd. (Loughborough, UK). Ultra-pure
water was obtained from a Millipore Milli-Q water puriﬁcation system
with a speciﬁc resistance of 18.2 MΩ·cm or greater (Millipore, Bedford,
MA, USA). 6-Well culture plates were obtained from VWR (Leicester-
shire, UK).
2.2. Sample collection and culture maintenance
G. pulexwere collected by kick-sampling from the River Cray, South-
East London, UK, 51°23′09.5″N 0°06′32.4″E. This site was previously
shown to have low pharmaceutical contamination in both collected sur-
face water and animal samples (Miller et al., 2015). The populations
were transported to the laboratory in 500 mL Nalgene™ ﬂasks ﬁlled
with surface water from the sample collection site. Populations were
rinsedwith artiﬁcial freshwater (AFW) and then acclimatised to labora-
tory conditions (as speciﬁed below) for aminimumof 7 days before any
exposure experiments were performed. AFW was prepared from
1.15 mM of NaHCO3, 0.50 mM MgSO4, 0.44 mM CaSO4 and 0.05 mM
of KCl dissolved in 20 L of ultra-pure water. This water was subsequent-
ly aerated for several hours to remove dissolved carbonic acid andmax-
imise the dissolved oxygen concentrations. Each culture tank (n = 8)
was ﬁlled with 2.5 L of AFW and animals were fed with alder leaves
that were previously collected from the sampling site and conditioned
by submersion in surface water for two days prior to use.
2.3. Toxicokinetic exposure and conditions
Toxicokinetic experiments were performed separately for each
pharmaceutical for a total of 96 h which included a 48 h uptake phase
followed by a 48 h depuration period. Individual adult organisms,
both male and female and each N5 mg wet weight, were placed in
each well of 6-well culture plates. G. pulex were carefully transferred
to well plates using blunt forceps to avoid any harm to the organisms
before exposure. A single well contained one organism in 10 mL of ex-
posuremedia (AFWand test compound) and only non-parasitised indi-
viduals were used (absence of Pomphorhynchus laevis indicated by the
lack of an orange dot on the dorsal side of the animal).G. pulexwere ex-
posed to individual PPCPs at a concentration of 1 μg·L−1, except for
diclofenac and ibuprofen which were present at 10 μg·L−1. The higher
exposure of these two compounds was due to the low activity of the ra-
diolabel. All exposure media contained b0.05% of solvent (ethanol). A
total of 33 organisms were used per exposure and were sampled
(n= 3/time-point) at 2, 5, 18, 24 and 48 h in the uptake phase followed
by the same time-points in the depuration phase. Along with G. pulex,
50 μL water was also sampled from each well for analysis of radioactiv-
ity. Each sampled organismwaswashed in 10mL of ultra-purewater for
10 s (n = 6) and gently blotted dry to remove any excess exposure
media and unbound compound to the cuticle of the animal. Organisms
were weighed after sampling to determine body mass and then trans-
ferred to scintillation tubes for tissue solubilisation. Three individual or-
ganisms were also exposed to unspiked AFW in culture plates and
sampled after 96 h in a control experiment to account for any back-
ground radiation. Additionally, for each experiment, threewellswithout
G. pulex were ﬁlled with exposure media to account for losses of the
compound by sorption to the walls of culture plates. Culture plates
were stored in sealedplastic containerswithwet tissue to prevent evap-
orative losses during the static exposure. The light cycle followed
12:12 h light:dark without a dusk/dawn transition period. All experi-
ments were performed in a temperature controlled room at 15 °C
(±2 °C) and water pH was also measured across each experiment at
8.2 ± 0.1.2.4. Sample preparation and liquid scintillation counting
Water samples (50 μL) collected from each exposure well were
added to 2 mL of Hionic Fluor liquid scintillation cocktail and counted
for radioactivity on a Beckman LS6500 instrument (Beckman Coulter,
Inc.). Sampled G. pulex individuals were placed in a scintillation tube
with 2 mL of tissue solubiliser and maintained at room temperature
(approx. 20 °C) for 96 h. Samples were shaken vigorously and then a
50 μL aliquot of the solubilised biotic extract was added to 2 mL of
Hionic Fluor to be counted. To account for any difference in counts
caused by colour quenching, hydrogen peroxide (200 μL) was added
to a previously counted biotic extract and re-analysed. No difference
in counts was observed with or without the presence of hydrogen per-
oxide, therefore, all other biotic samples were counted without the ad-
dition of hydrogen peroxide. In addition, chemiluminescence accounted
for b0.01% of the overall counts, and was therefore ignored.
2.5. Modelling bioconcentration factors
Parameter estimation of uptake rate constant (k1) and depuration
rate constant (k2) was performed using a curve ﬁtting algorithm via
Minitab statistical software (Minitab Ltd., Coventry, UK) and as outlined
in the OECD 305 Fish Bioconcentration Guidelines (OECD, Test No. 305).
The concentration of compound in the organism is assumed to follow
ﬁrst order kinetics and is expressed in Eq. (1),
dCorganism
dt
¼ k1  Cwater½ −k2  Corganism
  ð1Þ
where, dCorganism/dt is the rate of change in the concentration of a com-
pound within/on G. pulex (mg kg−1 day−1), k1 is the uptake rate con-
stant (L kg−1 day−1), k2 is the elimination rate constant (day−1),
Cwater is the concentration in the water (mg L−1) and Corganism is the
concentration in the organism (mg kg−1). Eq. (1) was integrated into
Eqs. (2) and (3) for ﬁtting of curves to the uptake and depuration
data. This method, known as the Levenberg–Marquardt algorithm,
uses an iterative formula to minimise the residual errors between the
observed and predicted data points and simultaneously estimates k1
and k2 values from the ﬁtted curve i.e.
Corganism





  ¼ Cwater½   k1k2  1−e
−k2 t−teð Þ−e−k2t
 
; when tNte ð3Þ
where, t is the time (days) and te is the end time of the uptake phase
(days). At steady-state, the rate of uptake should be equal to the rate
of depuration and there should be no overall change in analyte concen-
tration within G. pulex, as expressed by Eq. (4),






Cwater½  ¼ BCF ð4Þ
where, BCF is the bioconcentration factor (L kg−1). BCF can also be esti-
mated using a sequential method where a simple linear regression
model is developed based on the depuration data only. With the as-
sumption of ﬁrst order kinetics, the model should ﬁt a straight line
and its slope represents the elimination rate constant as shown in
Eq. (5), i.e.
ln Corganism
  ¼−k2  t þ c ð5Þ
where, ln[Corganism] is thenatural log of the analyte concentrationwithin
G. pulex and c is the intercept, which here equals the natural log of the
analyte concentration in the G. pulex at the start of the depuration























































































































































































































































































































































































































































































































































































































































399T.H. Miller et al. / Science of the Total Environment 547 (2016) 396–404curve ﬁtting algorithm to estimate k1. The rearrangement of Eq. (2) al-
lows the value for k1 to be calculated over the time interval speciﬁed,
as shown in Eq. (6) (Crookes & Brooke, 2011). The assumptions of the
equation are that analyte concentration in thewater and k2 remain con-
stant. The k2 used in Eq. (6) was directly estimated by using linear re-
gression of the depuration data to obtain the slope (k2). The value of




Cwater½   1−e−k2t
  ð6Þ
For this study, initial parameters for k1 and k2 were arbitrarily set at
0.1 in the software with Cwater set in μg L−1, t set at 48 h and the maxi-
mum number of iterations was set at 200 upon which optimised k1 and
k2 values were subsequently derived. Conﬁdence intervals (95%) were
plotted for curves and the overall model ﬁts were assessed. The lack-
of-ﬁt test was calculated in theMinitab software andwas used to assess
the ﬁt of the line by comparing the variation in response of the replicate
data. Lack-of-ﬁt was assessed at a signiﬁcance level of 0.05. Correlation
coefﬁcients (r2) were evaluated when the sequential method was used
to estimate k2. The distribution coefﬁcient (logD) was generated using
ACD Labs Percepta software for the interpretation of estimated BCF
values. All compound information is displayed in Table S2 of the SI.
3. Results and discussion
3.1. Uptake and elimination kinetics for selected PPCPs within G. pulex
The exposure concentration of each PPCP was selected to approxi-
mate the higher ranges of trace pharmaceutical occurrence in the aquat-
ic environment to maintain practically quantiﬁable limits for reliable
analysis (Miller et al., 2015; Hilton & Thomas, 2003; Thomas & Hilton,
2004). Considering that natural uptake and depuration are not separate
processes, the BCF values for the selected compounds were determined
using the simultaneous model described above (Table 1). Uptake of
each pharmaceutical was observed in G. pulex as early as 2 h from the
point of exposure. The highest residue concentrations measured in
G. pulex at the 48h timepointwere ibuprofen and diclofenac, potentially
corresponding to the elevated exposure concentrations of 10 μg L−1. All
other compounds exposed at 1 μg L−1 measured b80 ng g−1 ww after
48 h uptake (Fig. 1). The rate of PPCP uptake measured in the exposed
G. pulex corresponds to the decreases in PPCP concentration measured
in the spiked AFW. The largest decrease in PPCP concentration was ob-
served for imipramine, where analyte concentrations in the water de-
creased to an average of 0.478 μg L−1 corresponding to a 52.2% loss.
After 48 h, formoterol concentration also decreased in water by 15% to
an average of 0.85 μg L−1. The exposure concentrations of the remaining
compounds did not decrease by ≥10% (Fig. 2 and Table S1). Additional
sources of potential PPCP loss in the aqueous phase should be men-
tioned and include photolysis, volatilisation, metabolism by microor-
ganisms and sorption to the walls of the exposure well. Of these
processes sorption was accounted for by control wells with exposure
media only andwas shown to account for negligible losses inwater con-
centration except in the case of imipramine (Table S1).Within 2 h, there
was a 27% loss of imipramine and within 48 h the loss increased to 39%.
As quantiﬁcation was performed by LSC, any degradation products
resulting from transformation or photolysis would contribute towards
the total radioactivity and counted as the precursor compound. Howev-
er, it should be considered that these formed products may potentially
have different accumulation potentials and hence latent uptake and
elimination kinetics.
Following removal from the contaminated source, relatively high
elimination rates were measured for most of the selected compounds.
However, imipramine showed increased uptake (k1 =
1.408 L kg−1 day−1), but lower elimination (k2 = 0.007 day−1),
resulting in the highest BCF value measured at 212. Diclofenac has the
Fig. 1. Uptake and elimination data for PPCPs in G. pulex. Dashed lines indicate 95% conﬁdence limits.
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Fig. 2. Relationship of uptake rate constants (k1) over time for eight PPCPs (black circles) and the respective water concentrations (Cw) over time (crosses).
401T.H. Miller et al. / Science of the Total Environment 547 (2016) 396–404same logP value as imipramine at 4.4 (logD8.2 =−1.1) but attained a
signiﬁcantly lower BCF value of 14 due to its high rate of elimination.
Ibuprofen, another acidic drug with a logP of 3.5 (calculated
logD8.2 =−0.1), also had a low BCF value determined at 27. The BCF
values for the four compoundswith logP b 2. (i.e. metoprolol, ranitidine,terbutaline and formoterol) were determined between 12 and 17. Hy-
drophobicity is generally considered a major factor when determining
the bioaccumulation potential of a compound. However, uptake studies
related to pharmaceuticals in several species of plants, for example,
showed poor correlations between logDow and logBCF and especially
402 T.H. Miller et al. / Science of the Total Environment 547 (2016) 396–404so for ionised molecules (Wu et al., 2013). Low bioconcentration of the
selected PPCPs was in agreement with a study by Meredith-Williams
et al., in which toxicokinetic data for six pharmaceuticals within
G. pulexwas shown with the exception of ﬂuoxetine, a selective seroto-
nin reuptake inhibitor (BCF = 185,900) (Meredith-Williams et al.,
2012). In the cases of diclofenac, ibuprofen, imipramine and proprano-
lol, logP is similar (3.3–4.7). Therefore, using an uptake model based
on hydrophobicity, it would be logical to assume similar uptake rates.
A potential reason for their difference could be physicochemical in na-
ture, e.g. due to their anionic or cationic nature as well as the degree
of ionisation and logDow value (Erickson et al., 2006). It could also be
due to biological factors such as gill surface charge or the boundary
layer between the bulk water and the gill surface (Tao et al., 2001). Up-
take across the gill may also occur bymore than simple passive diffusion
for these ionic compounds and thus carriermediated transportmay also
have inﬂuence on the different ionic species (Sugano et al., 2010; Kell &
Oliver, 2014). The increased uptake constants of imipramine, proprano-
lol and formoterol are in agreement with reported gill cell permeabil-
ities to these compounds in the same order of
imipramine N propranolol N formoterol (Stott et al., 2015). The low con-
centrations of PPCP residues measured in the G. pulex and unspiked
AFW post-exposure highlights the ability for G. pulex to readily
metabolise and eliminate xenobiotics, as previously shown by Nyman
et al. (2014) and Ashauer et al. (2012). This evidence suggests there is
conservation of cytochrome P450 enzymes, similarly observed in
other aquatic invertebrate species (Solé & Livingstone, 2005).
3.2. Comparison of simultaneous versus sequential uptake and depuration
process models
Methods used for the calculation of BCF values in G. pulex are
summarised in Table 1 and also include uptake and elimination con-
stants (±standard error). Many of the toxicokinetic plots in Fig. 1 are
shown to have some lack-of-ﬁt. The p-value generated from a lack-of-
ﬁt test shows that in the simultaneous method there are 5 models
that have a statistically signiﬁcant lack-of-ﬁt indicating potentially inac-
curate and unreliable BCF values. It is possible that several large outliers
could inﬂuence the lack-of-ﬁt test, thus resulting in a statistical signiﬁ-
cance when potentially none exists. When using the simultaneous
method, if a poor ﬁt exists, then the sequential method should be inves-
tigated as a potential alternative. The linear regression of the depuration
phase data points gives a direct estimate of k2. The goodness-of-ﬁt is
interpreted by visual inspection of the linearity and the r2 (Fig. S1). Con-
sideration of the sequential method showed an over-estimation of BCF
values when compared to the simultaneousmodel. Deviations from lin-
earity can indicate higher order kinetics. Simple plots of 1/[Corganism]Table 2
Toxicokinetic parameters and standard errors (SE) for 14 organic micropollutants with biocon






4-Nitrobenzyl chloride 185 666 665.740 4.540 4.540 0.000
2,4-Dichloroaniline 56 140 20.073 2.830 0.465 0.000
2,4-Dichlorophenol 4466 600 34.196 0.066 0.024 0.000
4,6-Dinitro-o-cresol 37 39 2.610 1.146 0.124 0.070
1,2,3-Trichlorobenzene 191 1142 403.773 10.648 3.781 0.513
2,4,5-Trichlorophenol 2635 941 79.280 0.252 0.064 0.001
Aldicarb 2 16 1.421 10.419 0.938 0.000
Carbofuran 65 10 0.355 0.146 0.019 0.026
Diazinon 82 276 24.271 3.569 0.3264 0.005
Ethylacrylate 87 110 12.139 1.594 0.2446 0.000
Hexachlorobenzene 2915 553 36.8714 0.221 0.046 0.000
Imidacloprid 7 2 0.093 0.265 0.038 0.000
Malathion 114 86 6.782 0.721 0.113 0.000
Sea nine 1732 755 57.821 0.303 0.065 0.000
a Reported from Ashauer et al. (2010).here did not indicate second order kinetics and therefore k2 values
from plots of ln[Corganism] were accepted. Low r2 values for some com-
pounds were likely due to the scatter in measured internal concentra-
tions. Comparison of derived k2 values showed that imipramine,
formoterol, ranitidine, diclofenac and terbutaline had signiﬁcantly
lower elimination constants in comparison to the simultaneous model
approach (Table 1). Markedly reduced estimations in k2 for imipramine
and ranitidine corresponded to a large increase in BCF for ranitidine, in-
creasing 4-fold, and imipramine, increasing N10-fold to ~4200 on aver-
age between curve ﬁtting and linear regression approaches. Given the
inherent non-standard method we have applied, further work would
be necessary to better understand this apparently high BCF and we
would caution reliance on this value from such a limited study. When
using a curve ﬁtting method to calculate an elimination constant in
the sequential method there was good agreement between the linear
regression estimates of k2, indicating the estimate of k2 was correct.
The p-values for the curve ﬁts indicated that there was only one statis-
tical lack-of-ﬁt for the k2 value generated for ibuprofen. Uptake curves
displayed a poor ﬁt (as shown for imipramine concentration in
G. pulex, which was consistently under-estimated). In addition, uptake
constants in Table 1 speciﬁcally showed signiﬁcant lack-of-ﬁt for all
compounds except propranolol and formoterol (p-value N 0.05). In
ﬁtting the depuration data using the sequential approach, a zero to
mildly increasing slope was observed overall for metoprolol due to a
wider scatter of data. A k2 value could not therefore be calculated for
metoprolol. The potential for model uncertainty highlighted in this
study is signiﬁcant from a regulatory perspective, especially for com-
pounds such as imipramine that was determined to be accumulative
using the sequential method and non-accumulative using the simulta-
neous method (European Commission, 2006).
3.3. Assessment of k1, k2 and Cw constancy
The OECD 305 model makes several assumptions that Cw, k1 and k2
do not change over time. To assess the potential validity of the k1 con-
stancy assumption in the ﬁrst instance, k1 was derived at each time
point accordingly (Crookes & Brooke, 2011). It should be noted that a
potential limitation to this approach was that the equation to calculate
k1 uses the k2 estimate from the depuration phase, but this was deemed
sufﬁcient to identify any trends in any variation observed. As the lack-
of-ﬁt tests of the simultaneous method showed signiﬁcant lacks-of-ﬁt
a direct estimation of k2 from linear regression is used in Eq. (6) for sim-
plicity and increased reliability. When plotted against time (Fig. 2), a
clear reduction in k1 over the exposure period was observed (especially
for imipramine and diclofenac). Some random variance was also ob-







147 259 28.324 0.00 1.212 0.149 0.230 214
50 70 4.689 0.03 0.392 0.092 0.868 179
9050 750 48.646 0.00 0.010 0.018 0.400 72,728
34 37 1.595 1.00 0.729 0.077 0.033 51
107 167 32.257 0.06 0.475 0.300 0.986 351
3729 1091 109.906 0.21 0.131 0.039 0.001 8327
2 3 0.245 0.00 0.936 0.140 0.003 3
68 10 0.570 0.11 0.140 0.019 0.025 72
77 161 10.418 0.00 1.590 0.287 0.259 101
69 67 5.122 0.00 0.204 0.033 0.000 331
2505 631 56.518 0.00 0.152 0.031 0.637 4160
7 2 0.117 0.02 0.175 0.022 0.000 13
120 80 5.059 0.02 0.378 0.072 0.001 212
2491 950 69.141 0.05 0.123 0.020 0.084 7696
403T.H. Miller et al. / Science of the Total Environment 547 (2016) 396–404average k1 value of 0.58 (±0.23), as would be expected. The simulta-
neous and sequential models estimated its k1 value to be 0.54 and
0.62 L kg−1 day−1, respectively and therefore showed reasonable
agreement. This observation is signiﬁcant as propranolol showed no
lack-of-ﬁt in the uptake curve; therefore, the agreement indicates that
a lack-of-ﬁt arises from variable k1 values over time.
This suggests that a decreasing k1 trend is the cause of the poor
model ﬁts although it is possible that this may also be caused by a
changing k2 value (giving an apparent decrease in k1) or variable expo-
sure concentrations in the water. However, water was monitored dur-
ing the course of the experiments to account for any losses (Fig. 2 &
Table S1) and the only compound that showed any signiﬁcant loss
was imipramine (N20% nominal concentration). The k1 and k2 values
should also be independent of pharmaceutical concentrations in the
aqueous phase thus the trend observed is not in response to this vari-
able (van Leeuwen & Vermeire, 2007). A change in k2 is likely to be rep-
resented as a decrease over time (unless the compound induces its own
metabolism) assuming growth has a negligible effect and therefore
would not account for decreases in k1. The elimination curves also
showed no lack-of-ﬁt for 6 compounds and the linear regression
showed no trends of changing k2 values. The trend observed therefore
is not in response to the parameters Cw or k2 and we therefore suggest
the variability in uptake (decreasing k1) trend is the cause of the poor
model ﬁt.
3.4. Performance of OECD models using other micro-pollutant studies in
G. pulex
G. pulex has been shown tometabolise organic compounds with low
bioaccumulation factors previously observed (b1500) (Ashauer et al.,
2012). As deﬁned by Annex XIII of the REACH criteria, for a compound
to be considered bioaccumulative the BCF/BAF should be N2000
(European Commission, 2006). Other work by Ashauer et al. investigat-
ed the toxicokinetics of 14 micro-pollutants in G. pulex and presented
higher BCFs for three polychlorophenols in particular (Ashauer et al.,
2010). As discussed by the authors, correlations showed an observable
lack-of-ﬁt in some cases. A slightly different model to the OECD 305
model was used in this work, where changes in Cw were accounted
for as well as inclusion of an extra statistical algorithm to select the
best parameter combinations of k1 and k2. However, when applying
the OECD 305 models to BAF prediction, it is important to understand
whether this is likely to be inaccurate and, amongst other reasons, po-
tentially due to variation in k1, k2 or Cw. To determine if any similar
trends could be identiﬁed in other published G. pulex toxicokinetics
studies, raw data from Ashauer et al., was re-examined using the
OECD 305 modelling approach and presented in Table 2 (Ashauer
et al., 2010). Although the authors' experiments were originally de-
signed for determination of bioaccumulation, the report showed this
to account for a small percentage of accumulation. Therefore, feeding
was not included in any calculations. Similar to ourﬁndings for pharma-
ceuticals, both models displayed a statistically signiﬁcant lack-of-ﬁt for
these organic micro-pollutant compounds. When the sequential meth-
od was applied, better ﬁts were obtained for the depuration phase in
comparison to the uptake phase. However, despite models used herein
not performing as well overall, there was good agreement between the
predicted BCF values and those generated byAshauer et al. The datawas
then used to plot k1 versus time (Fig. S2), and again an obvious system-
atic decrease was observed for 9 out of 14 compounds. Statistical lack-
of-ﬁts (p b 0.05) were observed in the sequential uptake model espe-
cially for 4-nitrobenzylchloride, ethylacrylate, diazinon, aldicarb and
hexachlorobenzene (p b 0.001). The latter two compounds were nota-
ble cases where the spread of replicate k1 data at each time-point was
especially narrow and so the trend in k1 reduction over timewas appar-
ent. Of the remaining ﬁve compounds, trends in k1 were less evident
and were coupled with p N 0.05 for lack-of-ﬁt for four compounds
using the sequential uptake model. The remaining compound, 2,4-dichlorophenol, showed no obvious trends in k1 variance as the major
reason for the observed lack-of-ﬁt in the uptake phase. In summary, k1
data could be considered reliable for only 5 of 14 compounds using
the OECD 305 sequential model. In addition to the data of these 14 dif-
ferent organic pollutants, we also reassessed data from an exposure
study of chlorpyrifos across 15 different invertebrate species to assess
the issue more broadly (Rubach et al., 2010). Decreases in k1 were ob-
served in several species and the trend was somewhat similar, albeit
with larger scatter of the data (Fig. S3). This also identiﬁes a further lim-
itation thatmetabolism is likely to affect k1 and k2 values thus the differ-
ences in k1 constancy between organisms may be as a result of
biotransformation. The study showed considerable differences between
species in uptake and elimination rates showing that species type may
affect the constancy of k1 in particular and further studies are required
using more compounds between different species to fully assess this
possibility. If the assumption of k1 constancy varies on a compound-
by-compound basis, curve ﬁtting methods to predict BCF are likely to
be inherently inaccurate for environmental risk assessment purposes
for G. pulex. Therefore, it is suggested that the approach taken herein
(Crookes & Brooke, 2011) could be used to check the reliability of BCF
data where a statistical lack-of-ﬁt exists for this species.
Decreasing k1 could be explained by several possible mechanisms.
The ﬁrst is that growth dilution could cause an apparent decrease in
k1 due to the mass of the organism increasing while the concentration
of substance remains the same. However, this situation is unlikely
given the short timescales of this work and that of Ashauer et al.
(Ashauer et al., 2010). Therefore, growth of G. pulex is assumed to be
negligible, particularly as this is regulated in line with their moulting
cycle. However, further investigationwould be required to fully support
this. A second possibility is that G. pulex have been shown to alter respi-
ration rates in the presence of a poor diet (Graça et al., 1993). As the an-
imals were not fed during these experiments, it is possible that this
slowed uptake. However, the toxicokinetic experiments by Ashauer
et al. involved feeding organisms over their uptake period suggesting
the uptake trend is not in response to diet induced factors (Ashauer
et al., 2010). As these compounds are exposed to non-target animals,
it is also possible that toxicodynamic effects could affect uptake, which
is more easily interpreted using the dataset by Ashauer et al., where
the exposure concentration was between 2 and 88 fold below the 24 h
LC50 value. However for our dataset, mortality was not signiﬁcantly
higher than in controls for pharmaceuticals at the exposure concentra-
tions used. Another consideration is that instantaneous sorption to the
animal cuticle could account for the initially high k1 constants. However,
an examination of the decrease in uptake rate against logD and logP re-
vealed no correlation and compounds displayed independent k1 de-
creases (Fig. S4). However, logD only governs sorption to a certain
extent and other physicochemical properties including polar/topologi-
cal surface area, ionic state, amongst others, could inﬂuence sorption
onto the exoskeleton. Where animals shed their exoskeleton during
the exposure period, these were collected, weighedwet and radioactiv-
itymeasured in a brief experiment. It was found that themaximumcon-
centration of ﬁve of the eight pharmaceuticals on the exoskeleton
material recovered did not exceed 24% of total compound mass in the
animal in these cases (Table S3). Therefore, reduction in k1 via this
mechanism is indeed plausible, but extended measurements across
more compounds, conditions and replicates are recommended for full
characterisation of this process. The potential for sorption as the reason
for changes in k1 is not based on physiology, but rather on the physico-
chemical properties of the xenobiotic itself, suggesting that rate con-
stant stability may be compound speciﬁc.
4. Conclusions
This work demonstrates the importance of data interpretation using
multiple modelling methods to estimate BCFs. Speciﬁcally, the compar-
ative assessment of model lack-of-ﬁts for both simultaneous and
404 T.H. Miller et al. / Science of the Total Environment 547 (2016) 396–404sequential models (where k2 remains constant) is recommended to re-
liably estimate and to ensure the accuracy of xenobiotic risk assess-
ments. A decreasing trend in the uptake rate constant over time was
apparent which disrupted the validity of the standard model assump-
tions tested, and suggests that more complex models are needed to de-
scribe accumulation of xenobiotics in invertebrates,more particularly in
G. pulex. Kinetic BCF/BAF are an estimate of steady-state values, but it is
possible that these models are adequate enough to indicate whether a
compound may have a potential to accumulate or not. It is now impor-
tant to identify whether such trends are also observed more generally
across different species as well as a fuller investigation into the roles
sorption and metabolism have in these standard models.
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Editor: D. BarceloThe effects of pharmaceuticals and personal care products (PPCPs) on aquatic organisms represent a signiﬁcant cur-
rent concern. Herein, a targeted metabolomics approach using liquid chromatography-high resolution mass spec-
trometry (LC-HRMS) is presented to characterise concentration changes in 29 selected metabolites following
exposures of aquatic invertebrates, Gammarus pulex, to pharmaceuticals. Method performance revealed excellent
linearity (R2 N 0.99), precision (0.1–19%) and lower instrumental limits of detection (0.002–0.20 ng) for all metab-
olites studied. Three pharmaceuticalswere selected representing the low,middle andhigh range ofmeasured acute
measured toxicities (of a total of 26 compounds). Gammarids were exposed to both the no-observed-adverse-
effect-level (NOAEL) and the lowest-observed-adverse-effect-level (LOAEL) of triclosan (0.1 and 0.3 mg L−1),
nimesulide (0.5 and1.4mgL−1) andpropranolol (100 and153mg L−1) over 24h.Quantitativemetabolite proﬁling
was then performed. Signiﬁcant changes inmetabolite concentrations relative to controls are presented anddisplay
distinct clustered trends for each pharmaceutical. Approximately 37% (triclosan), 33% (nimesulide) and 46%
(propranolol) of metabolites showed statistically signiﬁcant time-related effects. Observed changes are also
discussed with respect to internal concentrations of the three pharmaceuticals measured using a method based
on pulverised liquid extraction, solid phase extraction and LC-MS/MS. Potentialmetabolic pathways thatmay be af-
fected by such exposures are also discussed. This represents theﬁrst study focussing onquantitative, targetedmeta-
bolomics of this lower trophic level benthic invertebrate that may elucidate biomarkers for future risk assessment.
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emerging class of environmental contaminants and their fate, occur-
rence and physicochemical behaviour in the aquatic environment
have been extensively studied and reviewed (Daughton and Ternes,
1999; Evgenidou et al., 2015; Monteiro and Boxall, 2010). The ecotoxi-
cological consequences of incomplete removal of pharmaceuticals
or their metabolites in wastewater or drinking water treatment
plants (WWTP/DWTP) are a matter of current environmental concern
which still requires further research (Gómez-Canela et al., 2013). Fur-
thermore, pharmaceuticals designed for hospital use are suspected to
have more adverse effects than other pharmaceuticals regarding their
effect on the aquatic environment (Gómez-Canela et al., 2014;
Franquet-Griell et al., 2015). As such, in the last decade, much research
has focused on understanding the occurrence and effects (Heberer,
2002) of these contaminants in exposed organisms. Recently, we devel-
oped a multi-residue analytical method and determined occurrence of
pharmaceuticals in tributaries of the River Thames and in Gammarus
pulex (G. pulex) at ng L−1 and ng g−1 concentrations respectively across
eight sites (Miller et al., 2015). G. pulex is a small, low trophic level spe-
cies of amphipod crustacean found in freshwaters across Europe and is
very common throughout the United Kingdom (UK). G. pulex has many
attributes for use in biomonitoring studies including its important role
in freshwater food chains where they serve as a food source for other
invertebrates, ﬁsh and birds (Maltby et al., 2002). This organism has
also been extensively used in contaminant monitoring including
toxicity assays for various pollutants such as metals, pharmaceuticals,
PAHs/PCBs and natural stressors which has shown the importance of
this species in environmental risk assessment (Bourgeault et al., 2013;
Coulaud et al., 2011; De Lange et al., 2006, 2009; Lebrun et al., 2012;
Maltby et al., 2002; Pellet et al., 2014; Schaller et al., 2011; Vellinger
et al., 2012).
Studies of the effects of pharmaceuticals on low trophic level inver-
tebrate organisms such as G. pulex using high resolution conﬁrmatory
chemical analysis techniques are lacking. In particular, metabolomics
may reduce this knowledge gap by directing effect-based studies that
reveal alternative markers or end-points to assess potential toxicity of
contaminants. Advances in mass spectrometry (MS) over the last de-
cade have enabled better characterization of the links between the me-
tabolome and phenotype (Dettmer et al., 2007; Villas-Bôas et al., 2005).
Targeted liquid chromatography coupled to mass spectrometry (LC-
MS) is the technique of choice for the reliable quantitation of known,
pre-selected metabolites. It is an approach that will increasingly be
used to apply knowledge discovered by non-targeted metabolomics;
i.e. the eventual targeted measurement of a metabolic biomarker signa-
ture that can predict exposure to a speciﬁc environmental stress (Viant,
2008; Viant and Sommer, 2013). Metabolomics studies have made use
of high resolution, conﬁrmatory analytical techniques such as nuclear
magnetic resonance (NMR) or hyphenated MS technologies to charac-
terise large numbers of compounds for metabolic proﬁling (targeted)
(Zhang et al., 2012). With the development of high resolution mass
spectrometry (HRMS), non-targeted screening of several thousand
compounds has become possible for studying larger portions of theme-
tabolome in contrast to NMR, which is often limited by low sensitivity
(Dunn et al., 2005; Zhang et al., 2012). Early investigations focused on
human, plant and microbial metabolomes (Frisvad and Filtenborg,
1983; Horning and Horning, 1971; Taylor et al., 2002; Tweeddale
et al., 1998). Other studies have identiﬁed changes in metabolomic
proﬁles in mussels resulting from hypoxic conditions; biomarkers asso-
ciated with withering syndrome in abalone sea snails; and responses to
ethinylestradiol (EE2) by rainbow trout (Hines et al., 2007; Samuelsson
et al., 2006; Viant et al., 2003). Approaches to characterise the metabo-
lome can involve non-targeted or targeted strategies where for quanti-
tative purposes, targeted analysis offers greater accuracy and precision
(Grifﬁths et al., 2010; Lei et al., 2011).The aimof thepresent studywas to develop a targetedmulti-residue
method for the determination of 29 metabolites pertaining to different
biochemical classes (amino acids, organic acids, nucleosides, nucleo-
tides, and sugars) using LC-HRMS. As a full scan method also suitable
for non-target analysis, the analytical performance of the method was
evaluated quantitatively in terms of comprehensive mass spectral
characterization, selectivity, sensitivity, intra- and inter-day precision,
range and linearity. Acute toxicity of 26 pharmaceuticals in G. pulex
was also assessed as an initial screen for compound selection for
metabolomics. Three pharmaceuticals showing low, median and
high measured LC50 values were then selected for exposures at no-
observed-adverse-effect-level (NOAEL) and lowest-observed-adverse-
effect-level (LOAEL) concentrations to evaluate alterations in the me-
tabolite proﬁle at 2, 6 and 24 h. This represents the ﬁrst environmental
metabolomics-based investigation of G. pulex by determining changes
in endogenous metabolites in response to pharmaceutical residue
exposure.
2. Materials and methods
2.1. Reagents, chemicals and consumables
All pharmaceuticals were purchased from Sigma-Aldrich
(Steinheim, Germany) and Fluka (Buchs, Switzerland) with a purity of
≥97%. HPLC grade acetone, dimethylsulfoxide (DMSO), ethanol (EtOH)
and methanol (MeOH) were purchased from Fischer Scientiﬁc (Lough-
borough, UK). Ultra-pure water was sourced from a Millipore Milli-Q
water puriﬁcation system with a speciﬁc resistance of 18.2 MΩ cm or
greater (Millipore, Bedford, MA, USA). Stock solutions (40 mg mL−1)
were prepared in ultrapure water, acetone, MeOH, EtOH or DMSO,
respectively. All stock solutions were stored in silanised amber vials
(40 mL) and at−20 °C in the dark for optimum stability. Organic sol-
vent concentration (acetone, MeOH, EtOH and DMSO) in aqueous solu-
tions used for toxicity testing was negligible. Metabolite standards
(organic acids, nucleosides, nucleotides, sugars and amino acids) were
supplied by Sigma Aldrich (Steinheim, Germany) and Fluka (Buchs,
Switzerland). In addition, the isotopically-labelled algal amino acidmix-
ture (98 atom% as 13C, 98 atom% as 15N) was provided from Sigma
Aldrich. The targeted metabolome studied was comprised of 15 amino
acids (AAs), 4 nucleosides, 2 nucleotides, 1 sugar, 3 organic acids and
4 compounds related to other families. Full details of the target metab-
olites and the labelled compounds are shown in Table 1. Finally, the 26
pharmaceutical compounds belonging to 12 different therapeutic
classes are listed in Table S1.
2.2. Sample collection and preparation
Adult G. pulex were collected several times between September
2014 and April 2015 from the River Cray, UK, a tributary of the River
Darent that feeds into the River Thames (51°23′10.5″N 0°06′34.8″E).
Adult specimens were collected via the kick sampling netting method.
Samples were transported back to the laboratory in Nalgene™ ﬂasks
containing a 500 mL grab sample of freshwater obtained from the
River Cray. This site has previously been demonstrated to have low
pharmaceutical contamination (bLOQ) (Miller et al., 2015). After collec-
tion, G. pulexwere stored in different artiﬁcial freshwater tanks and ac-
climatized for a minimum of 2–3 days at 15 ± 2 °C under a 12 h:12 h
light:dark cycle to allow depuration of any residual contamination.
The freshwater crustaceans were fed ad libitum with a minimum of
three horse-chestnut leaf discs (Ashauer et al., 2011). Artiﬁcial freshwa-
ter (AFW)was prepared following United States Environmental Protec-
tion Agency (USEPA) regulation (USEPA, 2002). Brieﬂy, 1.20 g MgSO4,
1.92 g NaHCO3 and 0.080 g KCl were added to 19 L of ultra-pure water
that was aerated overnight. In parallel, 1.20 g of CaSO4·2H2O was
added to 1 L of Milli-Q water and mixed with the previous salt solution
Table 1
Target analytes formetabolic proﬁling. Kegg number, molecular formula, molecular weight (Mw) andmass spectral characterization (ordered bymetabolic group) by LC-HRMS. Instrumental method performance. F: slope; R2: regression coefﬁcient;



















L-2-Amino-n-butyric acid (AABA) C00334 C4H9NO2 103.06 103.0633 102.0560 0.05–15 External 1e6 0.993 0.06 9 2 107 ± 14 13.9
L-Alanine C00041 C3H7NO2 89.05 89.0477 88.0404 0.05–15 External 1e6 0.998 0.03 8 8 92 ± 9 0.99
L-Aspartic acid C00049 C4H7NO4 133.04 133.0375 132.0302 0.05–15 External 4e5 0.995 0.20 4 14 87 ± 11 22.7
L-Citrulline C00327 C6H13N3O3 175.09 175.0957 174.0884 0.1–15 External 1e6 0.999 0.15 2 6 87 ± 1 23.9
L-Isoleucine C00407 C6H13NO2 131.09 131.0946 130.0873 0.1–15 Internal 4.5 0.998 0.03 12 6 42 ± 8 0.28
L-Leucine C00123 C6H13NO2 131.09 131.0946 130.0873 0.1–15 Internal 1.6 0.994 0.02 13 9 99 ± 1 0.47
L-Methionine C00073 C5H11NO2S 149.05 149.0510 148.0437 0.05–15 Internal 21 0.997 0.02 5 6 67 ± 14 2.66
L-Ornithine hydrochloride C00077 C5H12N2O2 132.10 132.0899 131.0826 0.05–15 Internal 0.83 0.994 0.01 4 8 109 ± 6 3.51
L-Phenylalanine C00079 C9H11NO2 165.08 165.0790 164.0717 0.1–15 Internal 1.6 0.996 0.02 14 14 97 ± 4 0.42
L-(−)-Proline C00148 C5H9NO2 115.06 115.0633 114.0560 0.05–15 Internal 1.2 0.997 0.01 5 11 87 ± 8 1.13
L-Serine C00065 C3H7NO3 105.04 105.0426 104.0353 0.05–15 Internal 1.1 0.996 0.01 13 13 88 ± 14 9.50
L-Threonine C00188 C4H9NO3 119.05 119.0582 118.0509 0.1–15 Internal 2.0 0.999 0.2 13 7 103 ± 11 3.59
L-Tryptophan C00078 C11H12N2O2 204.09 204.0899 203.0826 0.1–15 External 7e6 0.998 0.02 8 6 102 ± 5 1.35
L-Tyrosine C00082 C9H11NO3 181.07 181.0739 180.0666 0.1–15 External 2.1 0.996 0.03 7 12 80 ± 8 0.35
L-Valine C00183 C5H11NO2 117.08 117.0790 116.0717 0.05–15 Internal 1.3 0.991 0.05 12 13 91 ± 6 0.80
Cytidine C00475 C9H13N3O5 243.08 243.0855 242.0777 0.05–15 External 3e6 0.999 0.01 8 1 110 ± 9 1.94
Inosine C00294 C10H12N4O5 268.09 268.0808 267.0734 0.01–15 Internal 1.01 0.995 0.002 1 14 108 ± 8 0.04
Thymidine C00214 C10H14N2O5 242.20 242.0903 241.0829 0.05–15 Internal 0.7 0.991 0.01 7 5 99 ± 7 0.50
Uridine C00299 C9H12N2O6 244.07 244.0695 243.0622 0.05–15 External 2e6 0.997 0.03 7 5 138 ± 2 0.33
ADP C00008 C10H15N5O10P2 427.03 427.0294 426.0221 3–15 External 7e5 0.993 0.15 9 11 25 ± 11 162
NADH C00004 C21H27N7O14P2 663.07 663.1091 662.1018 0.1–15 External 1e6 0.990 0.06 2 19 162 ± 10 7.80
Trehalose C01083 C12H22O11 342.12 342.1162 341.1089 0.05–15 External 2e6 0.996 0.01 10 0.2 81 ± 7 1.03
Creatine C00300 C4H9N3O2 131.07 131.0695 130.0622 0.1–15 External 3e5 0.991 0.11 3 0.5 107 ± 2 37.3
Phthalic acid C01606 C8H6O4 166.14 166.0266 165.0193 0.1–15 External 1e6 0.997 0.01 6 7 102 ± 2 13.6
Taurine C00245 C2H7NO3S 125.01 125.0147 124.0073 0.05–15 Internal 2.03 0.992 0.03 8 14 92 ± 20 0.23
1,7-Dimethylxanthine C13747 C7H8N4O2 180.20 180.0647 179.0574 0.05–15 Internal 1.19 0.997 0.01 10 13 72 ± 4 2.33
Hypoxanthine C00262 C5H4N4O 136.04 136.0385 135.0312 0.01–15 External 8e6 0.991 0.004 4 9 102 ± 7 0.47
Pyridoxine C00314 C8H11NO3 169.20 169.0739 168.0666 0.05–15 External 3e6 0.94 0.07 6 0.1 105 ± 10 21.6
(−)-Riboﬂavin C00255 C17H20N4O6 376.37 376.1383 375.1310 0.1–15 Internal 0.9 0.996 0.04 12 9 89 ± 7 6.50
13C,15N-Isoleucinea – C6H13NO2 138.12 138.1115 137.1041 – – – – – – – – –
13C,15N-Leucinea – C6H13NO2 138.12 138.1115 137.1041 – – – – – – – – –
13C,15N-Methioninea – C5H11NO2S 155.17 155.0646 154.0573 – – – – – – – – –
13C,15N-Phenylalaninea – C9H11NO2 175.12 175.1057 174.0984 – – – – – – – – –
13C,15N-Prolinea – C5H9NO2 121.09 121.0769 120.0695 – – – – – – – – –
13C,15N-Serinea – C3H7NO3 109.08 109.0495 108.0422 – – – – – – – – –
13C,15N-Threoninea – C4H9NO3 124.08 124.0685 123.0611 – – – – – – – – –
13C,15N-Valinea – C5H11NO2 123.10 123.0925 122.0852 – – – – – – – – –
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2.3. Pharmaceutical exposures
To select speciﬁc pharmaceuticals, the concentrations for exposures
and subsequentmetabolite proﬁling, a series of acute toxicity tests to 26
pharmaceuticals were initially performed following the Organization
for Economic Co-operation and Development (OECD) 1488/94 guide-
line (European Communities Commission, 1996). Lethal median con-
centration effects and its 95% conﬁdence interval (CI), were estimated
by ﬁtting immobility concentration responses to the Hill regression
model (Eq. 1).




Where, I(Ci) is the proportion of immobile animals at concentration
Ci; Ci is the concentration of the respective compound (i); LC50 is the
median lethal concentration to the 50% of population and Hill is the
shape constant, which depends on the parameters adjusted in the re-
gression model. From these toxicity proﬁles the NOAEL and the LOAEL
were determined. Exposure experiments were performed in Pyrex®
beakers, each containing 200 mL of AFW at 15 °C and ten adult animals
(N5mgwet weight, ww). Live/dead animals were counted after 24 h by
gently prodding and observingmovement of appendages. The pharma-
ceutical concentrations tested were in the range of 0.01 to 250 mg L−1.
Control (AFW only) and solvent controls showed no measurable toxic-
ity. Concentrations where 100, 50 and 0% of the animals died were re-
peated in duplicate or triplicate.
From the initial toxicity tests on 26 pharmaceuticals, 3 were chosen
for metabolomics studies representing the high (triclosan), medium
(nimesulide) and low (propranolol) range of measured acute toxicity.
Each exposure consisted of G. pulex exposed at the NOAEL (C1) and a
second higher concentration at the LOAEL (C2) as follows: triclosan,
C1 = 0.1 mg L−1/C2 = 0.3 mg L−1; nimesulide, C1 = 0.5 mg L−1/
C2 = 1.4 mg L−1; and propranolol, C1 = 100 mg L−1/C2 =
153 mg L−1. Approximately 100 specimens were introduced in a tank
containing 1 L of AFW (control), 1 L of AFW spiked with C1 and 1 L of
AFW with C2. At three different times (2, 6 and 24 h), 4 replicates of
live G. pulex (a pool of 6–7 animals for each replicate) were collected,
frozen on dry ice and then stored at−80 °C before metabolite proﬁling
was performed. A preliminary extraction protocol with 1, 3, 6 and 10
animals showed that a pool of 6–7 G. pulex provided the best method
recoveries.
Quantiﬁcation of pharmaceutical concentrations in G. pulex at the
24 h exposure interval was performed. Separate exposures were set
up in triplicate in beakers containing 200 mL of exposure solution
(AFWspikedwith the respective C1 pharmaceutical dose) and 20organ-
isms. At 24 h, animals were immediately rinsed with ultra-pure water
and then frozen at−20 °C for 24h. Full analyticalmethod details are de-
scribed in Miller et al., 2015. Prior to extraction, frozen G. pulex samples
were lyophilised at −50 °C under vacuum for 48 h and milled in an
agate mortar to a ﬁne powder. For each analysis, 20 mg of a lyophilised
composite sample were transferred to 2 mL polypropylene tubes
(Eppendorf®, Hamburg, Germany), for solid-liquid extraction (SLE).
After the addition of 80 μL of stable isotope-labelled internal standards
at concentrations between 3.29 and 43.11 ng μL−1 (ﬁnal concentration
dependent on the AA concentration in the stock referencematerialmix-
ture), 800 μL of MeOH:HPLC water (90:10) mixture was added and the
samples were thoroughly mixed using a Vortex mixer. Then, samples
were shaken for 25 min on a vibration plate (IKA® KS 260 basic) and
centrifuged at 14,000 rpm for 25 min at 0 °C. Finally, the supernatant
was transferred to a chromatographic vial by using a 0.20 μM syringeﬁlter (Whatman, GE Healthcare Life Sciences, Buckinghamshire, UK).
All samples were stored at−80 °C until LC-HRMS analysis.
2.4. Internal pharmaceutical residue determination and metabolite
proﬁling
Internal concentrations of pharmaceuticals in G. pulex were deter-
mined using a previously describedmethod (Miller et al., 2015). Brieﬂy,
50 mg of lyophilised G. pulexwere extracted in 5 mL of acetonitrile and
pre-concentrated on Oasis HLB SPE cartridges (6 mL, 200 mg sorbent).
The extractwas eluted, dried-down and reconstituted in starting LCmo-
bile phase. The chromatographic separation followed a 75 min gradient
(including 12.5 min re-equilibration) using water and acetonitrile with
10 mM ammonium acetate salt. Separation was achieved using a
Waters Sunﬁre C18 reversed-phase column (2.1 × 150 mm, 2.5 μM
particle size) and detection was performed by a Waters Quattro triple
quadrupole mass analyser using positive and negative electrospray
ionization polarity switching (Waters Corporation, Milford, MA, USA).
Organic acids, nucleosides, nucleotides, sugars and AAs were measured
using LC–HRMS. An Exactive™mass spectrometer equipped with heat-
ed electrospray ionization (H-ESI) source was used (Thermo Fisher Sci-
entiﬁc, Bremen, Germany). The system was equipped with a HTC PAL
autosampler and a SurveyorMS Plus pump. A TSKGel-Amide 80 column
(2 × 250 mm, 5 μm) for analyte separation was purchased from Sigma
Aldrich. Mobile phases were binary mixtures of acetonitrile (A) and
5 mM ammonium acetate (pH 5) in HPLC-grade water (B). Gradient
elution started at 75% A and 25% B, which was increased linearly to
30% B in 8 min, increased linearly to 60% B to 12 min and then held
for a further 5 min. Initial conditions were returned in 3 min and the
system was stabilized after a total equilibration time of 10 min (total
run time = 30 min). The ﬂow rate was set at 150 μL min−1 and the
injection volume was 5 μL. Metabolites were analysed under positive/
negative ESI mode, but better resolution was obtained in negative ioni-
zation mode and so this was used for all experiments. Full scan acquisi-
tion over amass range of 80–800 Dawas performed at 70,000 full width
at half maximum (FWHM) and spray voltage at 3.00 kV, capillary volt-
age at 30 V, skimmer voltage at 28 V and tube lens voltage at 130 V
were used. A sheath gas ﬂow rate of 45 arbitrary units (au), an auxiliary
gas ﬂow rate of 10 au and a capillary temperature at 300 °C were
selected.
2.5. Method performance and quantiﬁcation
Methodperformance for internal pharmaceutical residue concentra-
tions in G. pulex are described elsewhere (Miller et al., 2015). Here,
pharmaceutical residue quantiﬁcation in exposed G. pulex was per-
formed by a 3-point matrix-matched calibration curve. For nimesulide,
spiking concentrations were 2.5, 5 and 10 μg g−1; for triclosan, these
were 1, 2.5 and 5 μg g−1; and for propranolol these were 1, 2.5 and
5 mg g−1. The calibration range for endogenous metabolites was from
0.01 to 15 ng μL−1, using 9 calibration points. The algal amino acid
mixture-13C,15N (see Table 1) was used as internal standard (IS) for
extraction and analytical control. L-ornithine hydrochloride, inosine,
thymidine, taurine, 1.7-dimethylxanthine and (−)-riboﬂavin were
quantiﬁed using either 13C,15N-proline or 13C,15N-tyrosine as the inter-
nal standard. The remaining 15 compounds were quantiﬁed using
external calibration and the target compound itself was used as external
standard. The instrumental detection limit (IDL) was initially calculated
as that concentration giving a signal intensity of 1 × 103, and afterwards
measured experimentally by injecting a standard concentration that
gave this signal intensity. Themethod detection limit (MDL) was calcu-
lated following the same procedure, using spiked lyophilised G. pulex
samples at a concentration of 1 μg g−1. Intra-assay variation was
assessed using ﬁve consecutive injections of 5 ng μL−1 standard solu-
tion, and inter-assay variation was determined by measuring the same
standard solution on four different days. Solvent blanks did not contain
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HRMS runs. Recovery studies were performed in triplicate, using
lyophilised G. pulex samples spiked at 1 μg g−1 with the metabolites
mixture and the algal amino acid mixture-13C, 15N. Five replicates of
a pool with 6–7 G. pulex were analysed ﬁrst and the traces of target
compounds were subtracted.
2.6. Statistical analysis
Two-way ANOVA considering signiﬁcant p values ≤ 0.05was used as
a ﬁrst step to select metabolites with signiﬁcant changes and to further
explore their concentration and time trends. Thus, p values were de-
rived and examined to determine any differences between exposed
and control specimens, and to evaluate the effect of the exposure
time. All data satisﬁed the assumptions of normality and homoscedas-
ticity. In addition, all calculations were performed in MATLAB software
version R2013b.
3. Results and discussion
3.1. Analytical method performance
Good correlation coefﬁcients (R2 ≥ 0.99) were obtained for 29 me-
tabolites (Table 1). Responses for ﬁfteen metabolites were linear from
0.05 to 15 ng μL−1; and for 11 other metabolites, linearity ranged
from0.1 to 15ng μL−1. Signals for inosine andhypoxanthinewere linear
over the range of 0.01 to 15 ng μL−1; and ADP in the range 3 to
15 ng μL−1. Therefore, given that this represents a lower concentration
range of 10 to 1500 ng g−1, these were considered ﬁt for purpose for
this study. IDL ranged from 0.002 to 0.20 ng, and intra and inter-day
precision ranges were from 1 to 14% and from 0.1 to 19%, respectively
at the 5 ng μL−1 concentration level. Twenty seven compounds showed
recoveries within the range of 42 ± 8% to 138 ± 2% (Table 1). Overall,
recoveries were acceptable and showed excellent precision. However,
the two nucleotides ADP and NADH displayed poorer recoveries of
25 ± 11% and 162 ± 10%, respectively. Finally, the MDL ranged from
0.04 (inosine) to 37.3 ng g−1 (creatine), with the exception of ADP,
for which sensitivity was low aswould be expected due to the lower re-
covery observed (MDL: 162 ng g−1). The extracted ion chromatograms
of a target metabolite mixed solution at 5 ng μL−1 using the TSK Gel-
Amide 80HILIC column is shown in Fig. 1. In summary, themethod per-
formance of this analytical method indicated that reliable quantitative
measurements could be made for most metabolites and with minimal
variance contribution from the matrix. Moreover, as this method incor-
porated HRMS in full-scan mode, post hoc untargeted data analysis of
the metabolome remains possible if required.
3.2. Acute toxicity, 24-h pharmaceutical exposures and observed changes in
target metabolite concentrations
Acute toxicity tests revealed LC50 at themg L−1 level for most of the
26 tested pharmaceuticals. Similar values have been obtained in other
freshwater crustaceans (see Table S3). Kim et al. (2009) studied
the acute toxicity of pharmaceuticals and personal care products in
the freshwater crustacean, Thamnocephalus platyurus (T. platyurus).
They reported a similar LC50 value to the present study for triclosan
(0.57 mg L−1), but not for propranolol which lay at 10.31 mg L−1
(Kim et al., 2009). These values provide a means of ranking the toxic
risk, but such values are not environmentally relevant as pharmaceuti-
cals are generally found at concentrations approximately one to two or-
ders of magnitude less (Miller et al., 2015). Therefore, it is unlikely that
the majority of these compounds will display any signiﬁcant acute tox-
icity. Nonetheless, as a starting point and based on these data, exposures
were performed at NOAEL and LOAEL concentrations for triclosan,
nimesulide and propranolol to represent compounds at the high, medi-
an and low range of measured LC50 (Figs. S1–S3).3.2.1. Triclosan
Triclosan, the most toxic of the selected pharmaceuticals (LC50
0.57mg L−1) measured here, caused changes in themetabolite concen-
trations inG. pulex at 0.1mg L−1 (C1) and 0.3mg L−1 (C2), andwas dose
responsive. Exposure to triclosan produced signiﬁcant changes (Two-
way ANOVA, p b 0.05) in 19 metabolites: 13 amino acids (L-alanine,
cytidine, L-citrulline, L-isoleucine, L-leucine, L-methionine, L-phenylala-
nine, L-proline, taurine, L-threonine, L-tryptophan, L-tyrosine and
L-valine), inosine and uridine (nucleosides) and others like trehalose,
hypoxanthine, riboﬂavin and thymidine (Table 2 and Figure S4). How-
ever, only the concentration of 37% of metabolites changed signiﬁcantly
(up or down) across the exposure time. L-isoleucine, L-phenylalanine, L-
(−)-proline, taurine, L-threonine, L-tyrosine, L-valine, inosine and thy-
midine concentrations varied signiﬁcantly (p b 0.05) with exposure du-
ration (Table 2). A 2-way ANOVA was used to evaluate the interaction
between dose and time factors. Cytidine, L-methionine, L-phenylalanine
and L-(−)-proline were the only metabolites that had signiﬁcant inter-
actions (Table 2). As shown in Figure S4, all metabolites except L-citrul-
line changed in their mean concentrations at C1 relative to the controls.
Somemetabolites increasedmore than two to three-fold in comparison
to controls such as L-tryptophan, hypoxanthine, L-alanine, L-isoleucine,
L-threonine, L-valine and L-thymidine. In other cases, measured concen-
trations between the exposed and control samples decreased over time
(ADP and L-proline). Similar trends occurred at C2 where the 75% of the
metabolites increased in their concentration, with the remaining me-
tabolites showing no signiﬁcant changes (also see Table S1). Table S2
shows the metabolite concentrations determined from all conditions
studied. To more conveniently highlight trends, Fig. 2 represents the
fold change values at each exposure concentration with respect to con-
trols and plotted in a heat map and hierarchical analysis revealed two
distinct clusters (A & B). In general, and for each metabolite in Cluster
A of Fig. 2, the fold changes in gammarid metabolites exposed at C1 de-
creased across the 24-h period. On the contrary, Cluster B generally
showed the opposite trend where concentrations of metabolites mostly
increased. In the case of samples exposed at C2, eight metabolites of
Cluster A (L-aspartic acid, L-leucine, L-valine, L-methionine, inosine, tau-
rine, L-tyrosine and thymidine) had a fold increase and the remainder
showed a slight decrease in concentration. The metabolites of Cluster
B also showed fold decreases along the 24-h period and the opposite
effect to those exposed at C1.3.2.2. Nimesulide
Exposure to nimesulide produced signiﬁcant changes (Two-way
ANOVA, P b 0.05) for 83% of the metabolites analysed, including most
amino acids (except L-alanine), such as inosine, uridine and other me-
tabolites including hypoxanthine, riboﬂavin and thymidine (Table 2
and Fig. S5). L-2-amino-n-butyric (AABA), L-alanine, L-aspartic acid,
cytidine, L-citrulline, L-leucine, L-(−)-proline, L-serine, trehalose and
thymidine showed a time-related effect (Table 2), affecting 42% of the
metabolites studied. On the other hand, considering the interaction
between time and dose factor, signiﬁcant differences (p b 0.05) in all
metabolites except for L-tyrosine and NADH were detected (Table 2).
Nimesulide exposures induced changes in the metabolome of G. pulex
in comparison to controls (Fig. S5). A heat map of nimesulide was pre-
pared as before and hierarchical analysis again revealed two clusters
(Fig. 3). In this case, at C1, all the metabolites except trehalose had fold
increases along the 24-h period (Cluster A, Fig. 3). Speciﬁcally, L-alanine,
(−)-riboﬂavin, cytidine, hypoxanthine, L-tryptophan, inosine, taurine,
L-tyrosine and NADH suffered the more important changes (garnet
colour). On the other hand, trehalose (Cluster B, Fig. 3) showed the
opposite trend and, at 24-h exposure time, the fold change had de-
creased (blue). In the samples exposed at C2, the metabolites in Cluster
A began with positive fold changes (red/orange) at 2-h exposure time
and decreased (blue) at 24-h exposure time, with the exception of
NADH, ADP and trehalose (Cluster B, Fig. 3).
Fig. 1. LC–HRMS extracted ion chromatogram of 29 target compounds from a full scan LC-Orbitrap-MS spectrum using a 5 ppm extraction window.
782 C. Gómez-Canela et al. / Science of the Total Environment 562 (2016) 777–788
Fig. 1 (continued).
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Table 2





















AABA 0.49 0.23 0.91 – 3e−4 0.003 – 0.24 0.32
L-Alanine – 0.19 0.15 0.53 – 6e−4 – 0.001 0.03
L-Aspartic acid 0.17 0.37 0.25 2e−4 0.005 0.004 0.28 0.04 0.44
Cytidine 0.001 0.08 0.02 – 0.02 – 5e−6 1e−5 1e−6
L-Citrulline 0.01 0.81 0.95 4e−6 2e−5 8e−6 0.53 0.29 0.07
L-Isoleucine – 9e−4 0.12 – 0.29 – 0.06 3e−4 0.003
L-Leucine 0.01 0.47 0.73 – 0.003 – 0.25 – –
L-Methionine – 0.18 0.003 – 0.15 1e−4 0.003 0.005 0.007
L-Ornithine hydrochloride Not detected in Gammarus pulex organism
L-Phenylalanine – 0.001 0.001 – 0.53 0.0001 0.69 – 0.001
L-(−)-Proline – 0.001 0.01 4e−7 6e−13 8e−9 – – 2e−4
L-Serine 0.21 0.05 0.23 0.04 0.02 0.03 – 0.73 0.01
Taurine – 0.002 0.10 – 0.58 0.002 0.03 0.05 0.75
L-Threonine – 0.03 0.07 – 0.07 0.001 0.34 – 0.001
L-Tryptophan – 0.28 0.53 – 0.08 – 0.0012 – –
L-Tyrosine – 0.01 0.40 0.003 0.97 0.12 0.70 0.01 0.27
L-Valine – 0.01 0.05 – 0.42 – 5e−4 2e−4 –
Inosine – 0.01 0.11 – 0.17 0.03 0.12 0.002 0.27
Uridine 8e−4 0.45 0.26 – 0.98 – 0.002 6e−4 0.009
ADP 0.21 0.25 0.74 0.04 0.14 0.01 0.02 0.87 0.64
NADH 0.05 0.41 0.31 0.49 0.72 0.12 0.52 0.58 0.83
Trehalose 0.03 0.11 0.08 0.07 – – 0.21 – –
Creatine Not detected in Gammarus pulex organism
1,7-dimethylxanthine Not detected in Gammarus pulex organism
Hypoxanthine – 0.08 0.07 – 0.14 – 1e−6 4e−5 8e−7
Phtalic acid Not detected in Gammarus pulex organism
Pyridoxine (vitamin B6) Not detected in Gammarus pulex organism
(−)-Riboﬂavin 0.01 0.49 0.36 – 0.46 0.002 3e−4 0.69 0.008
Thymidine – 0.01 0.12 – 7e−4 – 4e−4 0.009 2e−4
a Dose factor corresponds at the two different concentrations used for each pharmaceutical.
b Time factor corresponds at the different times studied (2, 6 and 24 h).
Fig. 2.Heatmapof triclosan exposure representing the fold change of targetedmetabolites in each exposure subgroup (C1, C2) relative to controls. All data have been auto scaled by column
and dendrograms represent hierarchical analysis for clustering (A & B) of metabolite responses.
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Fig. 3. Heat map of nimesulide exposure representing the fold change of targeted metabolites in each exposure subgroup (C1, C2) relative to controls. All data have been auto scaled by
column and dendrograms represent hierarchical analysis for clustering (A & B) of metabolite responses.
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Exposure to propranolol produced signiﬁcant changes (based on
two-way ANOVA, p b 0.05 analysis) in 8 out of 15 AAs (AABA, cytidine,
L-methionine, L-proline, L-serine, taurine, L-tryptophan and L-valine),
uridine (nucleoside), ADP (nucleotide) and others like hypoxanthine,
riboﬂavin and thymidine (Table 2 and Fig. S6). Moreover, the exposure
time affected 71% of the metabolites studied. L-alanine, L-aspartic acid,
cytidine, L-isoleucine, L-leucine, L-methionine, L-phenylalanine, L-(−)-
proline, L-threonine, L-tryptophan, L-tyrosine, L-valine, inosine, uridine,
trehalose, hypoxanthine and thymidine displayed signiﬁcant changes
(p values b 0.05) across the 24 h experiments, see Table 2. Exposures
at C1, a concentration below LC10, showed signiﬁcant changes in the
concentrations of themetabolites with respect to controls. For example,
AABA increased its concentration by more than two-fold (Fig. S6). In
other metabolites, decreasing metabolite concentrations were observed
such as taurine, an essential amino acid for cardiovascular function and
the central nervous system, or inosine, a nucleoside formed when hypo-
xanthine is attached to a ribose ring. Table S2 shows the concentrations
of themetabolites determined from all exposures. At the higher exposure
concentration, 153mgL−1 (C2), similarmetabolite concentration changes
occurred for AABA, taurine and inosine. Additionally, hypoxanthine and
thymidine concentrations were different compared to controls (Fig. S6).
In the samples exposed at C1, all the metabolites in Cluster A (Fig. 4)
had fold decreases along the 24-h exposure time. However, L-citrulline
and L-tyrosine (Cluster B, Fig. 4) andADP had fold increases at 24-h. Final-
ly, in the samples at C2, the general trend in Cluster A plus ADP is that the
metabolites had fold increases along 24-h, with the exception of NADH
and taurine. Moreover, the metabolites in Cluster B of the Fig. 4 (L-citrul-
line and L-tyrosine) also decreased their fold changes at 24-h exposure
time.3.3. Metabolic pathways potentially affected by selected single
pharmaceutical exposures
Little or no reported metabolomics or pathway-based analysis
data exists for G. pulex in the literature to our knowledge. However,changes in its metabolic proﬁle following exposure to pharmaceuticals
may result in processes that are suggestive of either metabolic
(i.e. detoxiﬁcation) or toxic responses. Firstly, and to support this, the
internal concentrations were determined for the two compounds
nimesulide and propranolol at the C1 concentration at 24-h time inter-
val. Triclosan was detected, but was unfortunately not quantiﬁable
due to poor standard addition linearity (and similarly poormethod per-
formance as a whole). The C1 propranolol dose resulted in measured
concentrations up to 4.9 ± 0.3 mg g−1 (dry weight) and nimesulide
reached a mean concentration of 12.2 ± 4.1 μg g−1 which are both sig-
niﬁcantly higher concentrations than the estimated dose required for
therapeutic effects in humans. When comparing to environmental oc-
currence concentrations, these compounds did not exceed 36 ng g−1
inG. pulex (Miller et al., 2015) and other studies in aquatic invertebrates
often report concentrations of b200 ng g−1 (Dodder et al., 2014; Huerta
et al., 2015). However, and although the concentrations determined
here are unlikely to be seen in the environment, measurement using
such analytical methods enables interpretation of metabolic responses
and potentially metabolic pathways indicative of adverse effects in
the future for risk assessment purposes. The different responses
may be elicited through numerous complex biochemical pathways
such as nucleic acid expression, protein synthesis, enzymatic processes
and signaling cascades. Thus, identifying and quantifying metabolite
change is a useful starting point perhaps to direct metabolomics and
extended pathway-based research in the future. The advantage of
operating HRMS mass analysers in full-scan mode (as in the present
study) is that such further qualitative meta-analysis of the data is still
possible using untargeted and/or chemometric approaches at a later
time (Farrés et al., 2014). The unbiased nature of non-target metabolo-
micswould also allow the interpretation of metabolic responses in rela-
tion to known mode-of-action pathways for pharmaceuticals.
Nonetheless, this was beyond the scope of this work and future work
will be pursued in this direction. A general observation was that control
levels of metabolites showed relatively large scatter in speciﬁc cases.
During the study the organisms were collected from the same site and
were of similar size, but the variances in metabolite proﬁles of the con-
trols are likely to have resulted from differences between individuals
Fig. 4. Heat map of propranolol exposure representing the fold change of targeted metabolites in each exposure subgroup (C1, C2) relative to controls. All data have been auto scaled by
column and dendrograms represent hierarchical analysis for clustering (A & B) of metabolite responses.
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sation of mussel populations in laboratory conditions has also been
demonstrated to lead to increased metabolic variability (Hines et al.,
2007).3.3.1. Protein synthesis
Exposure to all three pharmaceuticals resulted in an increase in
thymidine and inosine concentrations when compared to controls.
Amongst other potential reasons, their increase in concentration could
be related to increases in protein synthesis as they are associated with
tRNA. Cytidine concentrations varied between exposure concentrations
and time points for all compounds. Triclosan had elevated cytidine con-
centrations at both 2 and 6-h time intervals relative to controls in the C1
exposure. The same effect was not observed in C2, often remaining close
to the control levels except at the 6-h time interval. Cytidine in the
nimesulide exposurewas upregulated relative to controls atC1,whereas
C2 showed a steady increase in cytidine concentrations over the 24-h
exposure period. For propranolol, cytidine concentrations remained
below controls at C2 andwere initially upregulated at C1 before decreas-
ing below control levels at 24 h. Uridine showed no obvious differences
between controls for either exposure concentration in propranolol. Uri-
dinewas upregulated in the nimesulide C2 exposure by 24-hwhereas in
the C1 remained higher than controls at all time points. Triclosan
showed increased uridine concentrations in both exposures at the 2
and 6-h intervals when compared with control levels, the C2 uridine
concentrations returned to the control level at 24-h. As uridine is absent
from DNA and only present in RNA, it is plausible that together these
four nucleosides are generally indicative of upregulation of protein syn-
thesiswhich is potentially induced by all three pharmaceuticals. The up-
regulation could be considered as a general metabolic response to such
xenobiotic exposure, for example, via the production of P450 enzymes
(Marionnet et al., 1997; Ortiz-Delgado et al., 2008). Triclosan has also
been shown to increase the P450 content of rat liver microsomes
(Kanetoshi et al., 1992; Liang et al., 2013).3.3.2. Xenometabolic pathways
The internal concentrations reached in G. pulex exceed the human
therapeutic doses and thus are likely to induce xenometabolism by
means of enzymes associatedwithphase I and IImetabolism. It is possible
that the increased content of uridine is also related to phase II metabolic
processes. Uridine, when converted to a triphosphate nucleotide (UTP),
is involved in the biosynthesis of uridine diphosphate glucose (UDPG)
which serves as a precursor of uridine glucuronic acid, the primary sub-
strate for phase II glucuronidation reactions catalysed by uridine 5′-
diphospho-glucuronosyltransferase (UGT). Major metabolites associated
with these three pharmaceuticals are glucuronide conjugates, which sup-
port this argument (Macpherson et al., 2013;Walle et al., 1985;Wu et al.,
2010). Riboﬂavin also showed statistically signiﬁcant 2–3 fold increases in
concentration relative to control concentrations. Thismetabolite is essen-
tial for xenometabolic processes as it forms part of ﬂavin adenine nucleo-
tide (FAD) and ﬂavin mononucleotide (FMN), which are essential
cofactors for redox reactions involving P450 enzymes and ﬂavin-
containing monooxygenases (FMOs). These cofactors are also required
for regeneration of reduced glutathione (GSH) from its oxidized formglu-
tathione disulﬁde (GSSG).
At C1 and C2 nimesulide exposures, AABA showed a signiﬁcant re-
duction in concentration and also decreased over the course of the ex-
periment. This metabolite is a precursor to ophthalmic acid, which is
associated with oxidative stress and the induction of ophthalmic acid
pathways is shown when glutathione levels are reduced (Soga et al.,
2006). As nimesulide has been shown to reduceGSH levels aswell as in-
duce oxidative stress, it is suggestive that the low levels of AABA are a
result of its conversion to ophthalmic acid, but this requires conﬁrma-
tion (Chatterjee et al., 2006; Mingatto et al., 2002; Singh et al., 2010).
It has been suggested that the physiological signiﬁcance in the produc-
tion of AABA is that it is a cofactor in the transport of glucuronidemetab-
olites in the multi-drug resistance protein 1 (MRP-1) and thus required
for elimination of xenobiotics (Soga et al., 2006). Lastly, perturbations in
methionine concentrations may also be indicative of xenometabolic
pathways. The concentrations of methionine in all exposures were
787C. Gómez-Canela et al. / Science of the Total Environment 562 (2016) 777–788elevated relative to control with the exception of the 2 h C2 sampling
point in the propranolol exposure. Methionine acts as a precursor to
S-adenosyl methionine (SAM) that is involved in methylation reactions
for xenobiotic metabolism. Triclosan, for example, undergoes methyla-
tion during metabolism to methyltriclosan and therefore may explain
its elevated concentrations in both triclosan exposures (Wu et al.,
2010). Finally, this compound also serves as a precursor to GSH biosyn-
thesis and therefore may be elevated even when xenobiotics are not
methylated during detoxiﬁcation.
3.3.3. Signaling cascade
Tryptophan was signiﬁcantly expressed at increased concentrations
in all three pharmaceutical exposures at both C1 and C2. This AA acts as a
precursor to serotonin that is often released as a stress response. It is
possible that the exposure to these pharmaceuticals induced a stress
response. Indeed, C2 is set at the LOAELwithmortality as the adverse ef-
fect, which upregulated the synthesis of tryptophan forwhich serotonin
synthesis is dependent (Joseph and Kennett, 1983). Xenobiotics have
been previously shown to induce the release of serotonin in rats
(Yokogoshi, 1989). However, it is also possible that tryptophan is pro-
duced in response to reactive oxygen and nitrogen species (ROS/RNS)
produced by the metabolism of the pharmaceuticals (Peyrot and
Ducrocq, 2008). Triclosan displayed the highest concentrations of
tryptophan reaching up to 142 μg g−1 when exposed at C2. The higher
toxicity of this compound may lead to added stress in comparison to
propranolol and nimesulide. The amino acid proline also showed statis-
tically signiﬁcant changes during the three exposures. In particular, the
C1 exposures showed a decrease in proline over time until they approx-
imately reached control levels at the 24-h time interval. The same trend
is not observed in the C2 exposures and is more variable when com-
pared to the controls. Proline has been shown in previous studies to
be important during stress responses as this amino acid has roles in
preventing oxidative stress, maintenance of osmoregulation, energy
production, and many other biological functions in plants and amphi-
pods (Maity et al., 2012; Choudhary et al., 2007).
4. Conclusions
A comprehensive optimisation of a targetedmulti-residuemethod for
the quantitative determination of 29metabolites fromdifferent biochem-
ical classes using LC-HRMS was performed. The acute toxicity (LC50) was
also estimated for 26 pharmaceuticals and revealed that triclosanwas the
most toxic compound to G. pulex. However, the reliance on acute toxicity
data such as LC50 for pharmaceutical risk assessment may ultimately not
be realistic as these were at least one–two orders of magnitudes higher
than concentrations typically found in the aquatic environment. Expo-
sures performed at the NOAEL and LOAEL with three pharmaceuticals
across the range of measured toxicity resulted in quantiﬁable changes
in the metabolome in G. pulex. Measured internal concentrations of
nimesulide and propranololwere far higher than the daily recommended
doses for therapeutic effects in humans. Alterations inmetabolite concen-
trationswere observed,which could be involved in several different path-
ways relating to protein synthesis, oxidative stress and signaling
cascades. However, further efforts are required to fully characterise and
understand the effects these contaminants have on any speciﬁc pathway.
In greater knowledge using such analytical methods for quantitative de-
terminations of endogenous metabolites in aquatic organisms can now
be acquired. In addition, the use of full-scan HRMS detection enables
non-targetmeta-analysis to be performed in the future using chemomet-
ric tools that could identify biomarkers of exposure and effect for use in
the environmental risk assessment of pharmaceuticals.
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ABSTRACT: Modeling and prediction of polar organic chemical integrative
sampler (POCIS) sampling rates (Rs) for 73 compounds using artiﬁcial
neural networks (ANNs) is presented for the ﬁrst time. Two models were
constructed: the ﬁrst was developed ab initio using a genetic algorithm
(GSD-model) to shortlist 24 descriptors covering constitutional, topological,
geometrical and physicochemical properties and the second model was
adapted for Rs prediction from a previous chromatographic retention model
(RTD-model). Mechanistic evaluation of descriptors showed that models did
not require comprehensive a priori information to predict Rs. Average
predicted errors for the veriﬁcation and blind test sets were 0.03 ± 0.02 L d−1
(RTD-model) and 0.03 ± 0.03 L d−1 (GSD-model) relative to
experimentally determined Rs. Prediction variability in replicated models
was the same or less than for measured Rs. Networks were externally
validated using a measured Rs data set of six benzodiazepines. The RTD-model performed best in comparison to the GSD-model
for these compounds (average absolute errors of 0.0145 ± 0.008 L d−1 and 0.0437 ± 0.02 L d−1, respectively). Improvements to
generalizability of modeling approaches will be reliant on the need for standardized guidelines for Rs measurement. The use of in
silico tools for Rs determination represents a more economical approach than laboratory calibrations.
■ INTRODUCTION
Contamination of the aquatic environment with herbicides,
pesticides, pharmaceuticals, and personal care products
(PPCPs), among other contaminants, has been the focus of
environmental monitoring campaigns over the last two decades.
Reported concentrations and associated adverse eﬀects of these
contaminants has led to the introduction of legislative
procedures to monitor and assess risk associated with
pollutants, such as the EU water framework directive and the
EU registration, evaluation, authorization, and restriction of
chemicals (REACH).1,2
High frequency sampling campaigns often involve the use of
grab or composite sampling, but are practically diﬃcult and
costly to manage for monitoring longer-term ﬂuctuations in
contaminant concentrations in the aquatic environment. These
methods are also often labor intensive with respect to sampling
and can lead to considerable cost during instrumental analysis.
More recently, however, the development and use of passive
sampling devices (PSDs) is increasing due to their capability for
a time-integrated approach to averaging contaminant concen-
trations in surface waters as well as inﬂuent and eﬄuent
wastewater over extended periods.3 PSDs minimize sample
preparation and allow in situ enrichment of analytes which may
potentially reduce limits of quantiﬁcation in comparison to
those achieved by point sampling.4 Passive sampling devices in
some ﬁelds are well-established, such as use of semipermeable
membrane devices (SPMD) for organochlorines5 and other
similarly hydrophobic compounds.6−8 However, one type of
PSD which is emerging currently is the polar organic chemical
integrative sampler (POCIS). These samplers have been used
to determine the occurrence of a range of chemically diverse,
and comparatively polar to moderately nonpolar com-
pounds.9−13 However, for quantitative studies, POCIS suﬀer
from some limitations, mainly relating to the reliability of
derived estimations of the sampling rates (Rs) from
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experimental measurements, as well the lack of a well-
developed performance reference compound (PRC) exposure
correction method.14−16 One further hindrance is that reported
sampling rate data are few and methods for their estimation
vary which leads to limited transferability across other locations
or studies.17
Given the time-intensive nature of determining Rs exper-
imentally, it is possible that computational modeling
approaches could oﬀer a solution that would enable prediction
of sampling rate data for compounds without the need for
experimental determination. A previous investigation by
Stephens et al.18 evaluated the use of an empirical method
(Sherwoods correlation) to determine PSD kinetic parameters
for a limited number of compounds showing maximum errors
of +40 and −20% for the estimation of the aqueous boundary
layer mass transfer coeﬃcient (kf). In contrast to empirical
methods for estimating speciﬁc parameters, quantitative
structure−property relationship (QSPR) models are becoming
more frequently used in ecotoxicology where a set of x variables
are used to predict a response, y.19 The variables are often
molecular descriptors that cover constitutional, topological,
geometrical, and physicochemical properties which can then be
used to model a desired output. Models can vary from simple
linear regression approaches to complex nonlinear functions
where such models are often designed by machine learning
methods. Two well-known machine learning methods are
support vector machines (SVMs) and artiﬁcial neural networks
(ANNs) and have been used successfully in related areas such
as the prediction of bioconcentration factors (BCFs), octanol−
water partition coeﬃcients (logP) and biosolid/water partition
coeﬃcients (Kd), as well as for suspect compound screening via
prediction of chromatographic retention time.20−27 The use of
SVMs for environmental applications is still in its infancy and
substantial programming capability is required for routine
application. On the other hand, ANNs are well-known and
more user-friendly software has been available for many years.
ANNs comprise a layered structure (normally three), each with
a diﬀerent purpose. The input layer contains the molecular
descriptor data for each compound for training, veriﬁcation and
blind testing and the output layer is the response. The hidden
layer sits in between and contains several nodes, and often
multiple sublayers of such nodes, where linear or nonlinear
functions are used to relate the descriptors to the output layer.
The residual errors are monitored and reduced by using
iterative algorithms which adjust weights associated with the
nodes in the hidden layer. Thus, such modeling approaches
could greatly increase the applicability of POCIS in environ-
mental monitoring studies through bypassing the need for
laboratory and in situ calibrations.
The aim of this work was to investigate the potential of
ANNs to model and predict Rs for POCIS devices for a range of
pharmaceuticals, endocrine disrupting chemicals, pesticides,
herbicides and drugs of abuse. The objectives were to identify
suitable analyte molecular descriptors to build, train and test a
range of suitable model types and architectures and then ﬁnally
to externally validate the approach for predicting Rs for several
compounds which were, for comparison, determined in parallel
by laboratory calibration. To the authors’ knowledge, this
represents the ﬁrst study to draw together, harmonize and
predict the published Rs data for ionizable pharmaceutical
compounds on POCIS. Ultimately, where such tools can
provide adequate predictions using new data generated in the
future, this approach could reduce the analytical burden of
laboratory estimations of Rs.
■ MATERIALS AND METHODS
Selection of Data Sets, Molecular Descriptors and
ANN Models. A working data set derived from the literature
(2007-present) was used to build, train and optimize models
for Rs prediction on POCIS. A total of n = 73 compound Rs
data were derived from Fauvelle et al.28 and Morin et al.,24
which were generated using similar experimental conditions to
give the largest combined data set of all studies. Compounds
included herbicides, pesticides, endocrine disrupting com-
pounds and pharmaceuticals. Where duplicate compound Rs
data existed, both values were removed entirely from the data
set (six compounds). Generally, in these cases Rs diﬀered and it
was uncertain which value was correct or whether an average
was appropriate for modeling. Simpliﬁed molecular input line
entry system (SMILES) strings were generated from
Chemspider (Royal Society of Chemistry, UK). Using these,
n = 185 molecular descriptors were generated from Parameter
Client freeware (Virtual Computational Chemistry Laboratory,
Munich, Germany) and an additional n = 16 descriptors were
from ACD laboratories Percepta software (Advanced Chem-
istry Development Laboratories, ON, Canada).
Two models were generated using two separate sets of
descriptors covering constitutional, topological, geometrical and
physicochemical properties that were investigated for their
comparative prediction performance. The ﬁrst subset of 24
descriptors (see Supporting Information (SI), Table S1) was
generated using a genetic feature selection algorithm to
produce the genetically selected descriptor model (GSD-
model). Genetic feature selection algorithms follow evolu-
tionary concepts to convert input descriptors into binary
strings, in this case to prioritise descriptors for Rs prediction.
Using a process similar to natural selection, prioritised strings
are crossed to form a new population of strings. The
generational “breeding” of strings produced an optimized
selection of input variables for application to prediction. The
parameters for the GA were as follows; population = 100,
generation = 100, mutation rate = 0.1 and crossover rate = 1. In
an alternative approach, a much simpler descriptor data set
previously used to model elution from reversed-phase liquid
chromatography (RPLC) stationary phases was investigated to
assess any improvement (see SI Table S2).23,25 This model is
referred to as the retention time descriptor model (RTD-
model). POCIS devices contain a divinylbenzene and N-
vinylpyrrolidone copolymer, which enabled dual polar and
nonpolar interactions for retention. As retention on reversed-
phase chromatographic columns is governed predominantly by
hydrophobic interactions too, it is possible that these same
descriptors will also be important in passive sampling. No
retention data was available for the studies by Fauvelle et al.28
and Morin et al.24,29 However, correlation between Rs and 21
corresponding retention times (tR) gathered on a C18 stationary
phase in a study by Bade et al.30 showed a weak relationship (R
= 0.472).
For both descriptor subsets, several network types were
tested for predictive ability using Trajan 6.0 neural network
software (Trajan Software Ltd., Lincolnshire, UK) and these
included radial basis function (RBF), generalized regression
neural networks (GRNNs) and multilayer perceptrons (MLPs).
Following training and optimization using both data sets, the
GSD- and RTD-models were produced. The GSD-model
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architecture was a four-layer MLP with 24 descriptors in the
input layer (independent variables); two hidden layers
containing 17 and 14 nodes and the dependent variable output
layer (Rs). Training involved two types of algorithms, the ﬁrst
was back-propagation (BP) and the second was conjugate
gradient descent (CGD). The data set was split into 45:14:14
cases for the training, veriﬁcation and test subsets (optimized).
The RTD-model architecture was also a four-layer MLP using
both BP and CGD. The ﬁrst and fourth layers were the inputs
(using the set of descriptors previously used for chromato-
graphic retention modeling) and outputs (Rs), respectively, and
the second and third layers (hidden layers) contained 14 and 9
nodes, respectively. The division of cases included 51
compounds for training, 11 compounds for veriﬁcation and
11 compounds for blind testing (optimized).27 All cases were
randomly selected to avoid bias. The veriﬁcation data set was
used to characterize network predictive performance during
training and also to allow regularisation to prevent overﬁtting.
The test set was then used to validate the model to ensure that
the model generalized well to new cases. The optimized models
were selected based on the lowest errors and consistency across
the training, veriﬁcation and test subsets.
Laboratory Calibration of Sampling Rates to Test
Model Generalizability. Sampling rates (L d−1) were
determined using a static renewal method over a 14 day
exposure period and in a similar manner to data in the literature
which were used for modeling here.28 Brieﬂy, 3 L of high-
density polyethylene vessels were ﬁlled with ultrapure water,
the pH adjusted to 7.6 with 20 mg L−1 NaHCO3 and spiked
with the mixture of respective compounds to expose the
POCIS. Each vessel contained three POCIS devices for
exposure to an aqueous-based standard mixture of 200 ng
L−1 of each target compound (solvent <0.001%). This standard
solution was prepared and replaced daily in 3 L volumetric
ﬂasks to maintain the nominal concentration. Following this, all
three POCIS were removed from each vessel at day 4, 7, and
14, rinsed with ultrapure water and frozen at −20 °C.
Extraction of POCIS sorbents was performed using a wash
phase of 5 mL of ultrapure water and then elution using 5 mL
of MeOH. Eluate was dried under nitrogen at 35 °C for 40 min.
The dried residue was then reconstituted in 0.5 mL of starting
mobile phase. The analysis of the benzodiazepines was
performed on an Acquity UPLC system coupled to a Xevo
G2 S QTOF mass analyzer (Milford, MA) with an online Oasis
HLB Direct Connect HP loading column. Analyte separation
was performed on an Acquity UPLC BEH C18 column (1.7 μm,
50 × 2.1 mm) from Waters (Milford, MA) at 50 °C. Gradient
elution (0.6 mL min−1) for analyte separation was with 0.1%
(v/v) formic acid in water (phase A) and 0.1% formic acid in
methanol (phase B). Full method details for the laboratory
calibration experiments and analysis are given in the SI.
■ RESULTS AND DISCUSSION
Rs Prediction Using a GSD-Model. Following genetic
feature selection, a 24−17−14−1 MLP yielded the best
performance using 24 input descriptors with R2 = 0.8800,
0.8694, and 0.8050 for training, veriﬁcation and blind test sets
respectively (sum of squared residual errors were 0.084, 0.062,
and 0.116, respectively). Therefore, this model initially seemed
quite promising for application to prediction of Rs for new
compounds (Figure 1a). Many shortlisted descriptors were
derived from topological indices, but some others were
expected to have more importance for this application, such
as those that describe molecular hydrophobicity. These include
the octanol−water partition coeﬃcient (logP) and the
distribution ratio between octanol and water (logDow). The
latter takes into account the ionised proportion of a compound
at a particular pH and is dependent on the logP and the pKa of
all ionizable functional groups in a molecule. An investigation
by Booij et al.,31 demonstrated that uptake rates in SPMDs
correlated well with logP where Rs ≈ P−0.044. Correlations
between logP and Rs has also been observed for POCIS
devices.32−34 Assessment of the collinearity with Rs (SI Table
S7) showed rather unsurprisingly for so many ionizable
compounds that logDow had, by far, the highest correlation
(R = 0.59), but was insuﬃcient by itself to describe sorption to
POCIS sorbents. To the authors knowledge, no previous
investigations have used logDow to model Rs, although it has
been weakly correlated with Rs.
35 Furthermore, interinput
descriptor collinearity also existed and especially for constitu-
tional descriptors such as the number of non-H bonds (nBO)
and the sum of conventional bond orders (SCBO); as well as
topological descriptors such as log Narumi simple topological
Figure 1. Measured Rs against predicted Rs for (a) the GSD-model and (b) the RTD-model. Crosses, circles and triangles are the training,
veriﬁcation and test subsets, respectively. Open circles and triangles indicate predicted inaccuracies of >30% of the measured value.
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index (Snar), second Zagreb index (ZM2). Pearson’s
coeﬃcients were ≥0.8 for these descriptors with at least eight
other descriptors. Therefore, though genetic algorithms short-
listed useful descriptors for potential Rs modeling here, back-
interpretation of model sensitivity to descriptor data for
derivation of mechanistic understanding of physicochemical
POCIS uptake mechanisms would be limited. However, as a
tool to predict Rs, the training set overall displayed good
accuracy within 22% of the measured value on average. In
comparison, the veriﬁcation and test subsets were predicted on
average within 19% of their measured values showing
consistency across all subsets (SI, Figure S1). For particular
blind test cases, however, some notably large inaccuracies were
observed such as for sotalol (80% inaccuracy) where the lower
hydrophobicity of this molecule may explain poorer correlation
with Rs.
31 Larger errors were also recorded for acetochlor
ethanesulfonic acid (40%), diclofenac (39%) and sulcotrione
(38%). The veriﬁcation subset contained two largely inaccurate
predictions (2,4-dichlorophenoxyacetic acid at 59% and timolol
at 31%), but all remaining compounds were within 20% of
measured Rs. Larger inaccuracies may be related to poor
learning from selected training data. For example, mesotrione
had a 59% inaccuracy to the measured value in the training set
which may explain the poor prediction of another structurally
similar compound, sulcotrione, in the test set. Overall,
inaccuracy was most prevalent for sulfonate-containing
compounds where genetic selection did not suﬃciently
prioritise descriptors for this portion of cases for reliable Rs
prediction. As the number of available cases expands, genetic
selection of descriptors may improve for such compounds in
the future. It is also unclear whether sulfonate bearing
molecules are subject to steric and/or repulsive forces arising
from the PES membrane. Furthermore, larger inaccuracies
(>30%) in the full data set generally corresponded to
compounds with Rs < 0.1 such as 2,4-dichlorophenoxyacetic
acid, sotalol, sulcotrione and nicosulfuron. However, when
predictive accuracy was plotted against Rs for all compounds,
no correlation was observed for other compounds with Rs < 0.1
(SI, Figures S2 and S3).
Rs Prediction Using a RTD-Model. The correlation of
predicted versus measured Rs for the RTD-model is shown in
Figure 1b. The error (sum squared) for the subsets were 0.092,
0.062, and 0.121 for the training, veriﬁcation and test sets,
respectively. The model was, again, a four-layered MLP with a
16:14:9:1 architecture. Generally, acceptable correlations were
achieved for the training, veriﬁcation and blind test sets (R2 =
0.8511, 0.9085, and 0.6425, respectively) though this model
performed slightly worse (training and test) than the GSD-
model. The training subset showed several larger errors which
corresponded to the compounds t-butylphenol (149%), 2,4-
dichlorphenol (41%), and simazine (41%). The compound
sulfamethoxazole showed an 81% overestimation of its
experimentally determined Rs. As discussed earlier, this large
inaccuracy was also reﬂected in the GSD-model which showed
an overestimation of 230% for sulfamethoxazole which also
bears a sulfonate group. Overall, however, the model showed
relatively good predictions of Rs (mean absolute error for
training set = 15%; and for both veriﬁcation and test subsets =
Figure 2. RTD-model residual plot of predicted Rs values for the veriﬁcation and test subset only, ordered in parentheses by their ascending
distribution ratio values between octanol and water (logDow). Circles and triangles represent the veriﬁcation and test subset, respectively. The
measured Rs values are displayed in parentheses on the x-axis. 2,4-D (2,4-dichlorophenoxyacetic acid), ESA (ethanesulfonic acid), OA (oxanilic acid),
and IPPMU (isoproturon-monodemethyl).
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22%). The average error ± standard deviation across the
veriﬁcation and blind test subsets was 0.03 ± 0.02 L day−1
showing acceptable overall predictive accuracy for Rs. Atenolol,
the compound with the lowest Rs, yielded poor prediction
accuracy (predicted Rs = 0.067, measured Rs = 0.025) which
was initially thought to be due its higher polarity in comparison
to others selected for this study. However, no correlation was
observed between predictive accuracy and logDow (Figure 2).
Average predictive mean error of the veriﬁcation and blind test
sets both reduced to ∼15% upon removal of the atenolol data-
point. Importantly, as very polar compounds are generally not
retained well by n-vinylpyrrolidone-co-divinylbenzene-based
polymer sorbents, inaccuracy in measured Rs may be
compound speciﬁc as a result, which in turn may contribute
to RTD-model prediction errors. This highlights the lack of
consistent measurements available for training of such models
for predictive purposes. Nonetheless, considering this perform-
ance alongside the potential for inaccuracy in Rs data from
diﬀerent laboratory calibrations, predictions using these models
were considered reasonable.
Model Interpretation and Descriptor Contribution to
Rs Prediction. Given the level of multicollinearity observed for
GSD-model descriptors, a sensitivity analysis could only be
performed to identify the relative contribution of each
descriptor to predictions in the RTD-model. This was
represented as the error ratio, i.e. the ratio between the
model error using all descriptors and the model error when one
descriptor was removed. However, like in the GSD-model, the
use of sensitivity analysis to further mechanistic understanding
of sorption processes should be approached with caution if
some individual descriptors display multicollinearity (please
refer to SI Tables S1−S3 for full descriptor details and data).
The logDow, the Moriguchi octanol−water partition coeﬃcient
(MlogP), the Ghose-Crippen octanol−water partition coef-
ﬁcient (AlogP) and the number of Benzene rings (nBnz) were
the top four descriptors used by the RTD-model (Figure 3).
This is in agreement with Baüerlein et al., who showed that
hydrophobicity and pi-pi interactions (e.g., via benzene rings)
were important for adsorption to HLB sorbents in batch
experiments36 and which can also aﬀect diﬀusion. Other
important descriptors were the number of triple bonds (nTB;
error ratio = 1.2165), number of ﬁve-membered rings (nR05;
error ratio = 1.2041) and number of nine-membered rings
(nR09; error ratio = 1.4544). The importance of the n-
membered ring descriptors could be attributed to molecular
size and ﬂexibility thus aﬀecting the diﬀusivity of molecules
through the water boundary layer (WBL), PES membrane
(pore = 0.1 μm) or pores of the HLB copolymer (80 Å).37−39 A
previous investigation showed that size descriptors were also
important for predicting soil sorption coeﬃcients for
pesticides.39 We also previously showed these descriptors
were important for ANN-based predictions of pharmaceutical
sorption to soils and sludge.40 In addition to those mentioned
above, the number of carbons (nC), number of oxygens (nO)
and hydrophilic factor (Hy) also showed that they were
important to the RTD-model. Hy relates to the number of
hydrophilic groups in the molecule such as hydroxyls, thiols and
sulfonates. As polar surface area has been previously shown to
inﬂuence interactions with HLB sorbents, it is logical that
hydrophilicity/polarity related descriptors would have some
importance.36 Several authors have suggested that diﬀusion is
the main factor governing uptake rates in PSDs.41 We have
attributed the importance of the descriptors mainly to sorbent
interactions so far, but it is also possible that these same
descriptors could relate to diﬀusion processes due to the
number of molecular properties that will aﬀect it including
dipole moments, polarizability, molecular size (including
hydration radius) and electrostatic charge.42 The genetic
feature selection algorithm did not select some recognized
diﬀusion-related descriptors, such as molecular weight as a
simple example. However, it did select other descriptors that
showed interdependencies on factors aﬀecting diﬀusion such as
number of atoms, number of rotatable bonds, and electro-
topological states. Rs has been attributed mainly in the past to
diﬀusion processes in partition samplers such as silicone
rubbers.41 The portion of Rs governed by diﬀusion in
adsorption samplers using HLB-type sorbents in POCIS
remains unclear especially whether sorption of analytes via
hydrogen bonding, dipole−dipole, dipole−induced dipole, van
der Waals and pi-pi interactions plays a more signiﬁcant role. It
is also possible that the models presented here for Rs prediction
could be developed and improved further with additional or
alternative descriptors, such as diﬀusion coeﬃcients. However,
adding such descriptors may introduce a greater uncertainty
into the model as estimates can be based on several diﬀerent
approaches.43−45 In addition, diﬀusion coeﬃcients will be
aﬀected by numerous environmental factors and hydrodynamic
conditions that would be diﬃcult to replicate or control in situ.
Inclusion of larger numbers of descriptors to cover all the
processes involved will likely inhibit model generalizability.
Indeed, ANNs learn more holistically, making predictions
possible without the need for such comprehensive a priori
information. However, such a holistic approach obviously limits
deeper understanding of the precise contribution of individual
mechanisms involved in POCIS.
By comparison, the GSD-model featured many more
topological and geometrical descriptors than in the RTD-
model. These descriptors showed multicollinearity and there-
fore the sensitivity analysis could not be performed reliably
(Table S7). Simply adding noncollinear descriptors to the
RTD-model is also disadvantageous at this point. As the
number of descriptors increases, overﬁtting of data is more
likely to occur and would require signiﬁcantly more case
examples for valid application.46 Model complexity will also
Figure 3. Sensitivity analysis of the optimized RTD-model. Acronyms:
nDB/nTB = number of double/triple bonds; nC/nO = number of
carbon/oxygen atoms; nR04-nR09= number of 4−9 membered rings;
Ui = unsaturation index; Hy = hydrophilic factor; nBnz = number of
benzene-like rings; MlogP/AlogP = Moriguchi/Ghose-Crippen
logarithm of octanol−water partition coeﬃcient; logD7.6 = logarithm
of distribution ratio between octanol and water at pH 7.6.
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limit the ability of the network to generalize when predicting
unknown compounds therefore a smaller number of descriptors
(and nodes in the hidden layer(s)) is ultimately more
beneﬁcial.
Reproducibility of Predicted and Experimentally
Determined Rs. Model performance and generalizability is
limited by the quality of input data. Measured Rs can diﬀer
considerably even within calibration studies performed in the
same laboratory. The largest variance in measured Rs used
corresponded to diclofop which had a 60% relative standard
deviation (RSD), n = 15.28 Many of the reported Rs values vary
by more than 2-fold depending on the methodology used for
their estimation.29 Although pH and temperature during
collection of both sets of data used herein were similar, the
type of calibration experiment applied was slightly diﬀerent
(ﬂow-through and static renewal) therefore the resulting
diﬀerences in the Rs estimates from each investigation could
have aﬀected the performance of a model. For the six
compounds common to both calibration methods that were
removed from the original data set used for model
optimization, the absolute diﬀerence in Rs was 0.088 ± 0.072
L day−1 between measurements.
The average % RSD of measured Rs data used herein was
11% (mean deviation was ±0.017 L day−1) (Figure 4). In 45%
of all cases, the % RSDs of predicted Rs across triplicate
network trained ab initio were better than the % RSDs of the
measured data. For several speciﬁc cases, such as DET, DIA,
diclofop and ioxynil, the experimental variation was relatively
large when compared to the variation in predicted Rs. Such
deviation in experimentally derived sampling rates can be
attributed to several similar factors to those already discussed
above (e.g., temperature, pH, ﬂow rate etc.). Figure 4 shows
that for cases which had poor predictive accuracy with respect
to the mean true value, such as for acetochlor ESA, the standard
deviation of the predicted Rs overlapped with the reported
experimental variance. A review by Harman et al., suggests that
literature reported Rs data should only be considered as an
approximation.47 However, in the absence of a standardized
method for POCIS calibration, either in the laboratory or in the
ﬁeld, it would seem that Rs modeling in this way oﬀers similar
accuracy and precision without being labor or resource
intensive. Calibration experiments for each compound can
take several weeks, requiring a large mass of reference material
for static renewal and ﬂow through experiments, or very
frequent and accurate water sampling for in situ experiments.
Furthermore, given that models developed herein are derived
from a very limited number of training cases, any new reported
Rs data generated by similar methods to those used herein will
likely enable better generalizability in the future, as was
observed with retention time predictions in reversed-phase
liquid chromatography.27
External Application to Rs Prediction. To further
support the application of the optimized modeling approach,
Rs data for several additional benzodiazepines were exper-
imentally determined in our laboratory using a similar
approach. In the previous sections, blind test compounds
Figure 4. Comparison of the measured and predicted Rs values and their respective variances against the variance in predicted Rs (n = 73) from
replicate RTD-models (n = 3). Inset: Optimized 16−14−9−1 model architecture. Compounds in bold represent the veriﬁcation and blind test cases.
All others were used for model training.
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were structurally diverse which is logical for testing model
accuracy.48 However, for this experiment, structural similarity
was deliberately chosen to externally test its discriminative
power. Despite this similarity, it was expected that measured Rs
could be diﬀerent on POCIS given their slight diﬀerences in
chromatographic retention on C18 phases. The retention order
of the benzodiazepines was as follows: oxazepam (3.26 min)
nitrazepam (3.26 min), clonazepam (3.29 min), lorazepam
(3.29 min), alprazolam (3.31 min), midazolam (3.32 min),
ﬂunitrazepam (3.37 min) and diazepam (3.58 min). As
discussed previously, measurement of Rs often suﬀers from
some imprecision. The calibration experiment performed here
was not exempt from this either. Two compounds, lorazepam
(Rs: 0.205 L d
−1) and oxazepam (Rs: 0.226 L d
−1), were
originally present in the training set and veriﬁcation set
respectively during model development. The Rs values for these
compounds were experimentally determined again here to
characterize the variance between the selected calibration
method used here and the method by Morin et al.24 The Rs
determined here varied by approximately 0.1 L d−1 for both
compounds (lorazepam: 0.302 L d−1 and oxazepam: 0.327 L
d−1). This observation showed again that the diﬀerence in
calibrations between ﬂow-through and static renewals is not
negligible and was an unavoidable limitation of the calibration
experiment used here. Standard deviations for the six
compounds ranged from ±0.024 to ±0.055 L day−1 (n = 9).
Overall, the average RSD for all compounds was 20 ± 6%
(ﬂunitrazepam: 19%; clonazepam: 13%; nitrazepam: 13%;
midazolam: 23%; diazepam: 23%; and alprazolam: 29%) and
this variance was consistent with other studies.29
As shown in Figure 5, both the GSD- and RTD-models
predicted Rs well to within the measured value for all six
compounds. The two largest errors in the RTD-model
corresponded to those substances with the highest Rs variance
(diazepam and alprazolam at 16 and 17%, respectively), but the
four remaining compounds showed little inaccuracy (≤5%). In
terms of absolute inaccuracy of the measured Rs however,
examination of the RTD-model residual errors showed that for
all compounds except nitrazepam, that predictions were slightly
overestimated. The GSD-model performed worse by compar-
ison (Figure 5). The two largest errors corresponded to
nitrazepam and midazolam that were 37% and 43% inaccurate,
respectively. The remaining compound inaccuracies were
alprazolam (28%), clonazepam (18%), diazepam (10%) and
ﬂunitrazepam (19%). The average absolute error for the GSD-
model predictions was 0.0437 L d−1 and all compounds were
predicted within ±0.075 L d−1. By contrast, the RTD-model
had an average absolute error of 0.0145 L d−1 for these
benzodiazepines (and Rs for all compounds were predicted
within 0.03 L day−1). These predictions again demonstrated
that predicted Rs were similar enough to those determined by
experimental determination to be practical.
Passive sampling for nonhydrophobic compounds is mainly
used for screening purposes and as a semiquantitative
technique. Furthermore, in situ exposures are diﬃcult to
quantify accurately as laboratory calibrations may not translate
well into ﬁeld Rs due to several factors such as biofouling and
other matrix- or environmentally related eﬀects on diﬀusion, for
example. In addition, for reliable quantiﬁcation the performance
reference compound approach has limited availability and
application for polar passive sampling due to the strong
retention of analytes on HLB sorbents.49 However, modeling
approaches could potentially overcome these limitations if
models were built from in situ calibration data. It is also
possible that estimation of Rs by in silico approaches may oﬀer
a viable alternative for compounds where Rs data cannot be
estimated by ﬁeld studies due to poor correlation of
concentrations in water to sample mass on the PSD.35 Lastly,
the two diﬀerent approaches to the molecular descriptor
selection presented show acceptable predictive accuracy for
polar compound passive sampling. However, the use of
descriptors derived for tR prediction in a model for Rs
prediction holds signiﬁcant potential for application to new
compounds based solely on their SMILES strings by
simultaneously allowing preliminary identiﬁcation (by tR and
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A B S T R A C T
The ability to estimate the age of the donor from recovered biological material at a crime scene can be of
substantial value in forensic investigations. Aging can be complex and is associated with various
molecular modiﬁcations in cells that accumulate over a person’s lifetime including epigenetic patterns.
The aim of this study was to use age-speciﬁc DNA methylation patterns to generate an accurate model for
the prediction of chronological age using data from whole blood. In total, 45 age-associated CpG sites
were selected based on their reported age coefﬁcients in a previous extensive study and investigated
using publicly available methylation data obtained from 1156 whole blood samples (aged 2–90 years)
analysed with Illumina’s genome-wide methylation platforms (27 K/450 K). Applying stepwise
regression for variable selection, 23 of these CpG sites were identiﬁed that could signiﬁcantly contribute
to age prediction modelling and multiple regression analysis carried out with these markers provided an
accurate prediction of age (R2 = 0.92, mean absolute error (MAE) = 4.6 years). However, applying machine
learning, and more speciﬁcally a generalised regression neural network model, the age prediction
signiﬁcantly improved (R2 = 0.96) with a MAE = 3.3 years for the training set and 4.4 years for a blind test
set of 231 cases. The machine learning approach used 16 CpG sites, located in 16 different genomic
regions, with the top 3 predictors of age belonged to the genes NHLRC1, SCGN and CSNK1D. The proposed
model was further tested using independent cohorts of 53 monozygotic twins (MAE = 7.1 years) and a
cohort of 1011 disease state individuals (MAE = 7.2 years). Furthermore, we highlighted the age markers’
potential applicability in samples other than blood by predicting age with similar accuracy in 265 saliva
samples (R2 = 0.96) with a MAE = 3.2 years (training set) and 4.0 years (blind test). In an attempt to create
a sensitive and accurate age prediction test, a next generation sequencing (NGS)-based method able to
quantify the methylation status of the selected 16 CpG sites was developed using the Illumina MiSeq1
platform. The method was validated using DNA standards of known methylation levels and the age
prediction accuracy has been initially assessed in a set of 46 whole blood samples. Although the resulted
prediction accuracy using the NGS data was lower compared to the original model (MAE = 7.5 years), it is
expected that future optimization of our strategy to account for technical variation as well as increasing
the sample size will improve both the prediction accuracy and reproducibility.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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proﬁling; nevertheless, extracting additional information regard-
ing the donor, such as chronological age, could provide signiﬁcant
investigative leads and prove very useful in police investigations.
For intelligence purposes, estimating the age of a recovered stain’s
donor could potentially narrow down the number of suspects,
especially in cases where an eyewitness is not available.
Over the last decades, research has shown that aging is a very
complex process inﬂuenced by various genetic, lifestyle and
environmental factors. It causes a variety of molecular modiﬁca-
tions and adjustments in tissues or organs that accumulate over anss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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expression alterations [2] and variations at the DNA level [3,4].
Although there have been various approaches to estimate age at
death in human remains or chronological age in living individuals
[5,6], most of these attempts show limitations including low
sensitivity and prediction accuracy as well as lack of stand-
ardisation, restraining their applicability in crime scene samples.
Undoubtedly, developing an age prediction test is a major
challenge for forensic scientists since they would need to be able
to apply and validate it using minute or degraded samples
consisting of a range of tissues and body ﬂuids. As a ﬁrst step, the
generation of reliable age prediction models is a necessity.
It is believed that epigenetic analysis could serve as an
alternative or supplementary method to existing approaches since
particularly DNA methylation is well-known to be one of the
mechanisms responsible for cell differentiation and the cellular
response to aging [7,8]. It is generally suggested that there is an
increase in global epigenetic drift with age [9] and various
genome-wide methylation analyses have revealed a substantial
decrease in global DNA methylation levels with advancing age [10].
Changes in DNA methylation patterns due to aging are quickly
observed during the ﬁrst months of an individual’s life and
throughout childhood [11,12]. Cumulative evidence points towards
the distinct contributions of genetic [13], environmental [14,15]
and stochastic factors to DNA methylation levels at single genomic
areas. In order to identify speciﬁc age-associated differentially
methylated CpG sites for a particular body ﬂuid, scientists have
chosen to perform genome-wide studies [7,16–20]. Interestingly,
>95% of the associated sites were located within 500 bp of the
transcriptional start site of the associated gene, implying a
connection with regulation of gene expression [16].
From an intelligence perspective, it would be very advantageous
to translate observed biological age-associated DNA methylation
differences in a way that the chronological age of an individual is
revealed through an age prediction model. Overall, current
methodologies for methylation analysis can be divided into
genome-wide or gene-speciﬁc depending on the number of CpG
sites being investigated. As an example, following analysis of >650
whole blood samples from individuals aged 19–101 years using a
genome-wide approach, Hannum et al. built a quantitative model
using 71 highly age-predictive markers with a correlation between
true and predicted age of 0.96 and an average error of 3.9 years [21].
However, it should be emphasised that each tissue or body ﬂuid
could show a different age-associated DNA methylation pattern;
therefore, predicting age across a broad spectrum of human tissues
and cell types could be a very challenging task. Testing 13 different
cell types, Kock and Wagner [22] proposed a set of 5 CpG sites,
however the precision of their model was slightly lower (mean error
of 9.3 years). While the genome-wide DNA methylation arrays are
considered as the best tool during the discovery phase of potential
age-associated CpG sites, targeted sequencing is also required to
validate any association. Replicating the detected methylation levels
is necessary to conﬁrm the utility of the selected CpG sites and assess
their performance in a different dataset. From a forensic perspective,
the main challenge to be faced is the low quality and quantity of
forensic specimens, making it impossible to implement such age
prediction models (based on hundreds of markers) in forensic
casework in their current form. Therefore, developing an accurate,
robust and sensitive method that can analyse the proposed CpG sites
in forensic-type samples is essential.
In an attempt to narrow down the number of markers needed
for accurate prediction, Weidner et al. [23] performed a
comprehensive analysis of blood methylation proﬁles and found
that the methylation levels of only 3 CpGs – located in the integrin,
alpha 2b (ITGA2B), aspartoacylase (ASPA) and phosphodiesterase
4C, cAMP speciﬁc (PDE4C) genes – were substantial to create anepigenetic-aging-signature with a mean absolute deviation (MAD)
from chronological age of 5.4 years (RMSE = 7.2 years). Within the
forensic ﬁeld, recent age prediction models based on a small
number of CpG sites have also been studied, mainly in blood [24–
30], but also in other tissues such as saliva [31], semen [32] and
teeth [33]. However, most of these models are based on a limited
number of individuals and some still lack validation in an
independent cohort of samples. The reported mean prediction
errors range between 4–8 years (especially in validation sets where
available), suggesting that current tools allow for the prediction of
an individual’s decade (for example, the blood belongs to someone
in their 30s) rather than an accurate prediction outcome. In this
study, in an attempt to minimise the prediction error and increase
model accuracy, the potential of artiﬁcial neural networks (ANN)
was explored together with regression analysis. ANNs are a group
of machine learning algorithms inspired by biological systems and
have previously been used successfully to ﬁnd underlying trends in
complex datasets. There are various types of ANNs and the best
type to be used depends on the application. Normally, ANNs
consist of discrete layers; the ﬁrst is the input layer, which contains
the dependent variables (i.e. methylation data from age-depen-
dent CpG sites). Each of these variables are connected to a middle
layer via an optimised number of ‘nodes’, which, in turn,
interconnect all inputs to each other and eventually to the third
layer containing the designated output variable (i.e. age in years).
During the learning process, ANNs generally aim to minimise the
error in output estimations by systematically optimising the
connective weights between the nodes within the network. Given
their ability to learn holistically and often in a non-linear fashion,
ANNs have been extensively studied and applied in a range of other
applications [34,35].
Also, while most of these studies are based on targeted
methylation detection via pyrosequencing, qPCR [36], melting
curve analysis [37] and the EpiTYPER system [38,39] have also
been used. Although pyrosequencing has been the gold standard
for such analysis since its introduction [40,41] and shows various
advantages over other methylation techniques [42], it is mainly
performed as single reactions because multiplex pyrosequencing
can be complex [43]. In this study we also address the question of
whether a methylation assay based on benchtop next-generation
sequencing (NGS) of a small number of CpG sites could not only
provide focused 5-methylcytosine quantiﬁcation with base reso-
lution, but also allow for a sensitive and less costly age prediction
approach with similar accuracy to genome-wide DNA methylation
proﬁling approaches that could be applied in a forensic setting.
Towards achieving this aim, we pooled publicly available DNA
methylation proﬁles derived from whole blood samples to
investigate a subset of 45 previously reported age-associated
CpGs, which belong to 45 different genomic locations/genes, in an
attempt to identify those displaying the highest correlation with
age. Following multivariate, linear regression and ANN analysis, we
identiﬁed an epigenetic aging signature based on the methylation
status of a total of 16 CpG sites. To allow for reliable age predictions,
a next-generation sequencing protocol based on Illumina’s MiSeq1
platform was developed and optimised using commercially
available DNA methylation standards. To the best of our
knowledge, this is the ﬁrst study that uses machine learning, via
ANNs, together with an NGS-based DNA methylation detection
method for forensic age prediction.
2. Materials and methods
2.1. Description of genome-wide DNA methylation data sets
Genome-wide proﬁling has led to a more comprehensive
understanding of gene regulation epigenetic mechanisms.
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most commonly used genome-wide methylation platforms that
allows for simultaneous measurement of the methylation status of
27,578 (27 K chip) or 482,421 (450 K chip) CpG sites in the genome
at single nucleotide resolution. Thousands of samples have been
assayed using this platform in the literature and researchers have
made some of these genome-wide methylation data available in
online databases such as the National Center for Biotechnology
Information Gene Expression Omnibus (GEO).
In order to build the age prediction model, data from a total of
1156 whole blood samples were collected from individuals aged
between 2 and 90 years old and from various ethnic backgrounds
(mean age = 44) from seven genome-wide DNA methylation
studies summarised in Table S1 [12,16,17,19,21,44]. Methylation
data gathered from individual blood cell types such as peripheral
blood mononuclear cells (PBMCs) or CD4+ cells were avoided since
the ultimate aim of this research was to predict age from whole
blood stains. Samples were carefully collected so that there was an
equal representation of samples for all age groups, aiming for
100–150 samples per decade (see Fig. S1). The gathered samples
were either healthy control volunteers in studies investigating
DNA methylation changes of various diseases (usually above 40
years old) or were part of studies investigating epigenetic effects of
aging (usually either very young or very old), hence collecting
sufﬁcient samples of ‘middle’ age (particularly 30–40 years old)
was quite challenging. Additionally, even though the dataset
included roughly equal numbers of both females and males (597
and 559 respectively), there was an uneven gender distribution
within speciﬁc age groups due to the selected studies’ design
(Fig. S1). However, it was concluded that this should not affect age
prediction since none of the sex-speciﬁc differentially methylated
CpG sites previously reported in the literature, following analysis
with Illumina’s 27 K platform, were included in the group of
selected markers in this study [44].
Following the development of age prediction models, environ-
mental inﬂuences on age prediction were further investigated
using an independent cohort of healthy blood samples comprising
of 53 female monozygotic twin pairs collected from two genome-
wide studies [7,45] (Table S1). Secondly, to test the robustness of
the selected age-associated CpG sites when applied to body ﬂuids
other than blood, methylation data from 265 saliva samples was
collected from two different studies [46,47] (Table S1). One key
limitation when building a model for body ﬂuids other than blood
is the scarcity of non-blood based genome-wide studies that are
both run on one of the Illumina platforms and include information
regarding the volunteers’ age. Finally, according to Horvath [48]
the correlation between the observed and expected age in cancer/
diseased tissues was generally weak as there was evidence of
signiﬁcant biological age acceleration in most patients included in
his study (n = 5826). However, since there is usually no information
regarding possible disease status in a forensic blood sample of
unknown origin, it is important that the proposed age prediction
model can be universally applied. To assess potential variability in
age prediction, a data set including blood samples from a total of
1011 (577 females and 434 males) individuals aged 17–91 years
suffering from various diseases and cancers analysed on Illumina’s
27 K or 450 K platforms was analysed [8,17,19,49–52] (Table S2).
In each dataset, the DNA methylation value of each CpG site is
calculated as a beta (b) value, which is interpreted as the average
methylation for a particular site taking into account all cells
forming a body ﬂuid sample. Beta values can range from 0,
representing the unmethylated sites to 1, corresponding to those
completely methylated. Prior to analysis, genome-wide DNA
methylation datasets underwent a quality control analysis to
account for common experimental biases, such as batch effects
using the IBM SPSS v.22 software. Therefore, we used overall meandetected methylation levels to normalise the methylation levels
between different datasets, but without removing the occurring
DNA methylation variation, partly explained by age. We used the
normalised methylation values for age prediction analysis.
2.2. Selection of potential age-associated CpG sites
The ability to accurately predict age regardless of the tissue type
would be very advantageous in criminal investigations where the
identiﬁcation of the tissue source of a sample is often challenging.
Even if the purpose of this study was to identify age-associated CpG
sites in blood, the ability to apply a potential model in other tissues
with similar accuracy would save both time and resources. In an
attempt to select more robust age-associated differentially-
methylated markers across tissues, the study by Horvath [48]
was chosen as the most appropriate. The author built an age
prediction model applicable in various tissues using a total of 353
markers, which were categorised by a coefﬁcient value (ranging
from 1.719 to 3.067) that relates the CpG sites to a transformed
version of age. In order to cover all potential correlations with age
and maximise the chance of selecting suitable markers, 45 CpG
sites from the 353 marker pool included in Hovarth’s model were
selected, speciﬁcally this included those displaying the highest
(positive/negative) coefﬁcients (Table S3). Their chromosomal
location was conﬁrmed using the Ensembl genome browser; most
are located within or near a gene. While it has previously been
demonstrated that the ELOVL2 marker can be a good predictor of
chronological age in blood [24], there is an absence of genome-
wide data for the relevant CpG sites, hence these sites could not be
included in this study.
2.3. Statistical analysis
Statistical analysis was performed using STATISTICA software
v.13.1 (StatSoft Inc., 2014, Oklahome, United States). To assess data
distribution, the minimum, maximum, mean and standard
deviation (SD) were calculated. Hypothesis testing was evaluated
by calculating p-values with a signiﬁcance cut-off of 0.05.
Multivariate analysis was used to assess if other deﬁned factors
in the datasets (such as sex) were signiﬁcantly associated with age.
The degree of linear association between methylation levels and
chronological age was measured by calculating the correlation
coefﬁcient (r), while a general regression model, implemented
using a forward stepwise approach, was used to assess the
accuracy of age prediction with the selected marker candidates.
The ﬁtted regression line explains a proportion of the variability in
the dependent variable (y) and the residuals indicate the amount of
unexplained variability. The proportion of the total variation
explained by the model was also assessed by the goodness-of-ﬁt of
the line (R2 value). In some cases, regression lines were linear but
there were cases where the relationship between two variables
was curved revealing non-linear relationships. For example, in
methylation quantiﬁcation by bisulﬁte PCR the polynomial
regression was often observed either as quadratic curves (y = ax2 +
bx + c) or cubic curves (y = ax3 + bx2 + cx + d).
2.4. Artiﬁcial neural network (ANN) modelling
The age-speciﬁc CpG site methylation data was used to build,
train and test a suitable ANN for chronological age prediction. In
this study, several ANN types including 2- and 3-layer multi-layer
perceptrons (MLPs), radial basis functions (RBFs), probabilistic
neural networks (PNNs) and generalised regression neural net-
works (GRNNs) were built and their performance critically
evaluated using Trajan v6 software (Trajan Software Ltd.,
Lincolnshire, UK). Brieﬂy, optimisation of each ANN type and
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variables (45 selected age-associated CpG sites) were included in
the initial design phase to elucidate which ANN model type was
likely to be most applicable to age prediction. Following this, the
most promising network type (GRNN) was optimised further in a
series of stages. GRNNs are a type of ANN that use a combination of
a radial basis and linear functions to perform the output estimation
[53]. The ﬁrst optimisation stage was performed to ﬁnalise training
and veriﬁcation dataset proportions by assessing the performance
of the mean inaccuracy of the blind test sets. Depending on the
application, between 50% and 70% of the full 1156 cases were
assigned as training cases with equal splitting of the remaining
proportion between veriﬁcation and blind test cases. This was
repeated several times for each proportion value and with random
assignment of cases for training, veriﬁcation and testing every
time. The network designer tool was set to balance GRNN
veriﬁcation set errors against network diversity to cover as many
architectures as possible across all model types. In total, 108
architectures were investigated in each stage and 50 of the best
GRNN networks were ranked by correlation and output error
separately for the training, veriﬁcation and blind test datasets. In
Stage 2, advanced random sampling was applied whereby training
and veriﬁcation cases were assigned as per the best performing
GRNN architecture from Stage 1, but blind test cases were ﬁxed. In
Stage 3, the reproducibility of ten replicates of the model was
assessed by selecting the best GRNN from Stage 2 and ﬁxing all
training, veriﬁcation and blind test subsets and the best model
overall was then selected from this pool. The variability in age
estimations for all subsets across all replicate GRNN models was
then expressed as mean error  one standard deviation. Following
this, all ten networks were each subjected to a sensitivity analysis
to assess the relative contribution of each CpG site input to model
accuracy. The error ratio was calculated as the ratio of the observed
GRNN test error using all variables to the error obtained when eachTable 1
Designed bisulﬁte PCR assays.
CpG site Gene Primer Sequence (
cg19761273 CSNK1D F 
R 
cg27544190 C21orf63 F 
R 
cg03286783 CASC4 F 
R 
cg01511567 SSRP1 F 
R 
cg07158339 FXN F 
R 
cg05442902 P2RXL1 F 
R 
cg24450312 RASSF5 F 
R 
cg17274064 ERG F 
R 
cg02085507 TRIP10 F 
R 
cg20692569 FZD9 F 
R 
cg04528819 KLF14 F 
R 
cg08370996 NR2F2 F 
R 
cg04084157 VGF F 
R 
cg22736354 NHLRC1 F 
R 
cg06493994 SCGN F 
R 
cg02479575 C19orf30 F 
R variable was systematically removed. Larger error ratio values
represented more network dependency on that speciﬁc CpG site
variable. All input variables were also assessed for collinearity
using SPSS Statistics v23 (IBM Corporation, New York, USA).
2.5. Body ﬂuid samples and DNA preparation
A set of whole blood samples were collected to test the
developed ANN model with the proposed methodology. The
present study was carried out following full ethical approval by
King’s College London Biomedical Sciences, Dentistry, Medicine
and Natural & Mathematical Sciences Research Ethics Subcommit-
tee (BDM/13/14-30). Full informed consent was obtained from the
donors or their parents in case of under-aged individuals prior to
collection. Whole blood was collected from a total of 46 individuals
aged 11–76 years old coming from various ethnic backgrounds.
Genomic DNA was isolated from 200 ml of whole blood using the
BioRobot EZ1 DNA blood kit (QIAGEN, Hilden, Germany). Following
puriﬁcation, samples were quantiﬁed using the Quantiﬁler Human
DNA Quantiﬁcation kit (Applied Biosystems, Foster City, United
States). 500 ng of each DNA sample was used for bisulﬁte
conversion using the MethylEdge Bisulﬁte Conversion system
(Promega, Madison, United States) and bisulﬁte-treated DNA was
eluted in 20 ml of elution buffer. For control and linearity analysis, a
set of DNA standards of known methylation levels ranging from 0%
to 100% (EpigenDx, Hopkinton, United States) were used.
2.6. Bisulﬁte PCRs
In this study the online Ensembl genome browser (GRCh37/
hg19) genome was used to obtain the required genetic information
for assay design. Primers were designed to speciﬁcally amplify
bisulphite-treated DNA using the online-tool BiSearch [54] and
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to the T-richness of the bisulphite-treated DNA sequences. A total
of 16 singleplex assays were designed to investigate the selected
age-associated CpG sites; each bisulﬁte PCR assay includes a PCR
primer set (forward and reverse), none of which binds to areas
containing other CpG sites to avoid potential bias (Table 1).
Information on the obtained amplicons including their chromo-
somal location and number of included bisulﬁte-conversion
controls and CpG sites are presented in Table S4. Although the
assays were primarily designed to interrogate the 16 selected CpG
sites, sequencing of the entire PCR product on the MiSeq1 platform
(Illumina, San Diego, United States) allowed for the co-analysis of
all adjacent CpG sites included in the fragment. Brieﬂy, PCRs were
carried out in 13 ml reaction volumes containing a ﬁnal concen-
tration of 1X ZymoTaq premix (Zymo Research, Irvine, United
States), 3.2 mM MgCl2, 0.4 mM forward and reverse primers, with
the addition of 1 ml of bisulﬁte DNA template. The thermocycling
program used was: 95 C for 10 min, followed by 30 cycles of 94 C
for 30 s, Tm for 30 s, 72 C for 30 s, and a ﬁnal extension step of 72 C
for 7 min. The optimised Tm was as follows: 48 C for cg07158339,
cg17274064, cg02085507, cg20692569 and cg02479575, 50 C for
cg19761273, cg27544190, cg01511567, cg24450312 and
cg04528819 and 52 C for cg03286783, cg05442902,
cg08370996, cg04084157, cg22736354, cg06493994. Following
ampliﬁcation, the quality of PCR products was assessed on a 2%
agarose gel if necessary.
2.7. Next generation sequencing using illumina MiSeq1
Singleplex PCR products were pooled together and puriﬁed
using the MinElute PCR puriﬁcation kit (QIAGEN) in 16 ml of
DNase-free water. Prior to library preparation, all puriﬁed samples
were quantiﬁed using the Qubit dsDNA HS Assay kit (Invitrogen,
Carlsbad, United States) according to the manufacturer’s instruc-
tions and in combination with the Qubit 2.0 Fluorometer
instrument. Pooled PCR products were diluted appropriately to
provide 50 ng of ampliﬁed DNA within 25 ml. Library preparation
was performed using the KAPA Hyper Prep kit for Illumina (Kapa
Biosystems, Wilmington, United States) with half volume reac-
tions. Library ampliﬁcation proceeded with 8 cycles while the
clean-up steps were performed using the AMPure XP Beads
(Beckman Coulter Genomics, Danvers, United States) and the
Illumina Resuspension buffer (Illumina). To assess libraries’
quantity, puriﬁed libraries were diluted 1:4000 in DNase-free
water and quantiﬁed using the KAPA Library Quantiﬁcation Kit for
Illumina platforms (Kapa Biosystems). Indexed DNA libraries were
then normalised to 4 nM using Tris-HCL 10 mM/pH 8.5 with 0.1%
Tween and were pooled together to a ﬁnal volume of 240 ml. Using
freshly made 0.2N NaOH, 5 ml of pooled libraries were denatured
and, through dilution with pre-chilled Hybridisation buffer (HT1,
Illumina), a 10pM library was obtained. Finally, 13% diluted PhiX
control (80 ml) was added to the library and sequencing was
performed using the 300-cycle MiSeq1 reagent v2 cartridge
(Illumina). The preparation of the ﬂow cell and the set-up of the
instrument were performed per manufacturer’s instructions. It
should be noted that the instrument was set up to run a paired-end
read of 150 bp of DNA sequence from both ends of the library
products. Auto analysis was set up as a FASTQ-only method.
Following auto-analysis by the MiSeq1 Reporter Software,
which separated the millions of generated sequences into the
constituent samples on the basis of the ligated adaptor tags,
collated sequences were packaged in a text-based format (FASTQ
ﬁles). For alignment, we used a custom bisulﬁte-converted
reference genome containing all analysed DNA sequences, which
is quicker and more user-friendly compared to available align-
ments using the entire genome. Sequences within these FASTQﬁles were aligned using a Burrows-Wheeler alignment (BWA)
algorithm. This process was implemented in the BWA program [55]
using the maximum entropy method (mem) algorithm that
matched the sequences generated to the respective methylation
marker (i.e. a sequence obtained from the PCR product of any
speciﬁc marker would be most similar to the reference sequence
for that marker, and hence the software would align this sequence
with that marker). Therefore, the millions of sequences contained
within the FASTQ ﬁle can be associated with their respective
marker, giving potentially hundreds of thousands of individual
sequences all aligned in parallel to a speciﬁc reference sequence/
marker. At the conclusion of this alignment process, a sequence
alignment/map (SAM) ﬁle was produced, which was further
modiﬁed using SAMtools [56] to facilitate the conversion into a
BAM ﬁle. The Genome Analysis Toolkit (GATK) [57] was
subsequently used to interrogate this BAM ﬁle by targeting
speciﬁc positions in these aligned sequences (i.e. each CpG site)
and reporting the number of sequences containing a C and the
number of sequences containing a T at this position. In this way it
was possible to assess the methylation state at every studied CpG
site. The uniﬁed genotyper algorithm was employed within GATK
to produce these genotype data for each CpG site, which were
written into a variant call format (vcf) ﬁle that could subsequently
be manipulated in Excel. The Integrative Genomics Viewer
software (IGV) was used for visualisation and veriﬁcation of the
alignment. While in most cases the bisulﬁte conversion rates were
>99%, methylation values were ‘corrected’ by taking into account
the mean bisulﬁte conversion rates per fragment calculated by the
built-in conversion controls (non-CpG cytosines). The obtained
methylation values for each CpG site were further normalised
using the resulting equations of standard curves created from
known DNA methylation standards. Lastly, to account for potential
methodology-dependent differences, the NGS derived methylation
values were normalised to the genome-wide data, used to build the
prediction model, by applying the method previously described
when normalising the different genome-wide data sets.
3. Results and discussion
3.1. Age-associated DNA methylation changes in blood
Using publicly available DNA methylation databases, normal-
ised beta values for the selected 45 CpG sites were gathered for a
total of 1156 whole blood samples from individuals 2–90 years old.
Methylation fractions (zero to one) were compared against the
actual age of each individual in order to investigate potential
correlation between methylation levels and age (example graphs
for 16 out of 45 CpGs are presented in Fig. 1). As expected, some
CpG sites showed greater variation than others; for example,
cg07455279 (NDUFA3) demonstrated the largest methylation
range (difference between the lowest and highest detected
methylation value for each marker) (0.815) while cg05442902
(P2RXL1) usually showed low methylation levels (<0.387). In
general, the methylation of certain CpG sites such as cg19761273
(CSNK1D), cg01511567 (SSRP1), cg07158339 (FXN) and
cg05442902 (P2RXL1) was clearly decreasing with advancing
age, while others, cg20692569 (FZD9), cg04528819 (KLF14),
cg04084157 (VGF) and cg22736354 (NHLRC1) to name but a
few, were increasingly methylated over time. These observations
align with the age relationship that Horvath reported in his study
[48].
3.2. Identiﬁcation of the epigenetic aging signature
The observed age-associated methylation changes for all
markers were assessed for their statistical signiﬁcance in an
Fig. 1. Change of methylation levels over advancing age for the 16 CpG sites included in the eventual ANN model.
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epigenetic-aging-signature. Firstly, using multivariate analysis and
testing for the effect of gender and ethnicity on age-associated
methylation, no signiﬁcant correlation was determined (p = 0.77
and p = 0.09 respectively). Using linear regression analysis, a
signiﬁcant correlation between methylation levels and age (p
< 0.05) was conﬁrmed for 25 out of the 45 CpG sites (Table S5).
Applying stepwise multiple linear regression for variable selection,
we obtained similar results regarding the importance and order of
markers (Table S6). In order to perform this type of analysis, the
markers were added one by one into the age prediction model until
there was no statistical improvement. As a result, the use of 23 CpG
sites resulted in a value of R2 = 0.923, which was not further
improved with the addition of more markers. All 23 age-associated
CpG sites revealed following stepwise regression are included in
the set of markers identiﬁed after individual linear regressionanalysis. In both analyses cg22736354 (NHLRC1) was found to be
the most important. Interestingly, while cg07455279 (NDUFA3)
had demonstrated the higher methylation range, it did not
demonstrate a statistically signiﬁcant correlation with age, which
mirrors the complexity and high, inter-individually variable nature
of methylation patterns.
Applying multiple linear regression analysis on the methylation
values of all 1156 individuals for the 23 age-associated CpG sites,
the correlation between ﬁtted and true age was strong (linear
correlation, R2 = 0.923), while the mean absolute age modelling
error using all data was 4.61 years (standard deviation = 4.36 years)
(Fig. 2a). In a brief summary, 61% (700/1156) of individuals were
ﬁtted within a 5 year error range, while 89% (1029/1156) of
samples were ﬁtted within a 10 year error range. Multivariate
regression was mainly applied to explore the relationship between
DNA methylation patterns and age, but also revealed that none of
Fig. 2. Age prediction using multiple regression analysis (23 CpG sites) (a) Predicted vs. Chronological age (years) for all 1156 individuals used in this study (linear correlation
R2 = 0.923, mean absolute error = 4.61 years, standard deviation = 4.36 years), (b) Predicted error (years) over advancing age. As shown most individuals were predicted within
a 5 year error range (0.61), while 1029 out of 1156 samples were predicted within a 10 year error range (0.89).
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associated DNA methylation patterns in a statistically signiﬁcant
way. While there were individuals that seemed to age fast, there
were also others that were ﬁtted as much younger (Fig. 2b).
Notably, the error in older individuals (>60 years old) was higher
compared to younger ones, which is not only expected as older
individuals have been exposed to more environmental stress
throughout their lifetime that could have potentially caused
changes in DNA methylation patterns (epigenetic drift), but has
also been observed before in previous models [25,33].
3.3. Age predictions from blood using artiﬁcial neural networks
Neural network models showed that the prediction accuracy
could be signiﬁcantly improved over multiple linear regression
models. It is believed that ANN models have the ability to recognise
complex patterns, which are often observed in complex traits like
chronological age. The best model (Fig. 3a) was a 16-694-2-1
GRNN-type model, which was built on a 60:20:20 training,
veriﬁcation and blind test set dataset proportion (optimised).
The average absolute errors and standard deviations in each of
these subsets were 3.3  3.0, 4.6  3.5, and 4.4  3.6 years,
respectively (Fig. 3b). As a whole, a correlation between predicted
and true age of R2 > 0.96 was achieved across all subsets with an
average absolute error of 3.8  3.3 years. The correlation for the
blind test set (R2 = 0.95) was consistent with both the training and
veriﬁcation sets showing that the model could generalise very
well. For the blind test set in particular, the 75th percentile of all
231 case errors lay within 6.3 years. This performance is consistent
with other ANN-based applications from our research group which
revealed a 3–5% average inaccuracy across predictions [58] and
with a recent study reporting a percentage of prediction error of
6.3% [38].
This ANN model used data from 16 of the CpG sites, all 16 of
these sites having also been identiﬁed in the stepwise multiple
regression analysis: the methylation changes over time for these 16
markers are illustrated in Fig. 1. While a distinct methylation trend
is observed in all cases, there are occasional samples that
demonstrate an ‘unusual’ methylation status for a few CpG sites.
This can be explained either as natural inter-individual variation or
as a result of a ‘unique’/personalised environment that couldinﬂuence the methylation of these particular sites. Of course,
technical variation cannot be excluded, however efforts were made
to take this into account and normalise the data before analysis.
Information regarding the genes that the CpG sites lay near or
within was acquired to identify their function and potential
involvement in aging. The exact chromosomal locations of the CpG
sites as well as the involved genes are shown in Table 2.
As expected, all markers showing signiﬁcant correlation with
age belong to genes involved in age-related processes and
conditions; a few examples are presented here. cg19761273 is
associated with CSNK1D, which is a serine-threonine protein
kinase involved in essential cell pathways including circadian
rhythms and DNA repair. It is believed that CSNK1D has a role in
arranging the microtubule network during mitosis to prevent DNA
damage [59]. On the same theme, SSRP1 linked with cg01511567
seems to be crucial to anticancer mechanisms since it forms a
transcriptional factor that interacts speciﬁcally with histones and
prevents DNA damage [60]. Additionally, cg03286783 belongs to
the CASC4 gene, increased expression levels of which have been
found in breast and ovarian cancers [61]. Moreover, cg05442902 is
associated with the P2RXL1 gene known for its involvement in
inﬂammatory and immune processes, all affected by aging [62]. A
recent study has also linked TRIP10 gene (cg02085507) with the
regulation of cancer cell growth; in fact differential DNA
methylation of this gene has been suggested to promote cell
survival or death [63]. Additionally, cg04528819 belongs to
transcription factor KLF14, which is known as the ‘master
regulator’ of obesity and other metabolic traits [64]. Lastly, the
nerve growth factor VGF associated with cg04084157 has been
linked with altered expression levels in the age-associated
Alzheimer’s disease [65]. Even though some of the genes are
associated with age-related diseases, Fig. 1 demonstrates a gradual
and consistent methylation increase or decrease over time at these
particular CpG sites; therefore, their detected correlation with age
should not be linked with effects due to these individuals being
affected by age-related conditions.
The residual error obtained by the GRNN (Fig. 3b) displayed a
distinct, imbalanced pattern in comparison to that obtained from
multiple regression analysis (Fig. 2b), which was more randomly
distributed around the mean. Residual errors obtained by the
GRNN for old individuals (>60 years old) revealed a different
Fig. 3. Summary of ANN model for age prediction analysis. (a) Predicted vs. Chronological age for all 1156 individuals included in the study using the optimised 16–694-2-1
GRNN model, (b) Residual errors for the optimised model, (c) Prediction skewness for the blind test cases only using the optimised model, and (d) Sensitivity analysis and
marker input consistency to age predictions across training, veriﬁcation and blind test subsets. Error ratios are calculated as the ratio of the prediction inaccuracy by including
all inputs to the prediction accuracy following systematic removal of each CpG site from 10 replicated GRNN networks. Boxes include data from the 25th–75th percentile as
well as the median (thin line) and mean (thick line); error bars include the 5th and 95th percentile; numbers over boxes represent the rank order based on the mean.
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their age. These ﬁndings could indicate that there is a potential
ANN bias in age prediction within speciﬁc age groups, that could
perhaps be corrected in the future, or that there is a learning
artefact due to so many different study datasets being combined.
Lastly, the skewness of the blind test predictions alone showed that
there was a marginal bias towards under-prediction of age using
the GRNN model (Fig. 3c). In an attempt to further understand the
relative contribution and consistency of each CpG site variable for
age prediction, ten replicate GRNNs were generated. Sensitivity
analysis showed that all error ratios lay above 1.0 meaning that
they all contributed to the model positively (Fig. 3d). Most notably,
cg22736354 (NHLRC1) and cg06493994 (SCGN) contributed the
most to prediction, which was also true for the former in the
stepwise regression analysis. Some moderate collinearity existedbetween these two variables and so the relative ranking of either
should be considered carefully (variable inﬂation factors were
6.172 and 7.743 respectively, see Table S7 & S8), which has also
been observed in previous models [38]. Overall, it was decided not
to remove either variable from the network as predictions became
worse overall, even after re-training. From the third highest ranked
variable (cg19761273, CSNK1D) onwards, no severe collinearity
existed and therefore these rankings were more reliable. Despite
contributing to the prediction in a minor way (error ratio = 1.0127),
cg03286783 (CASC4) was the lowest ranked of all 16 variables
across all replicate GRNNs. Consistency of contribution across all
ten GRNNs was also acceptable and in general error ratios varied
<0.1 units for 25th–75th percentile of all data.
Considering that a similar prediction accuracy was observed
when using 353 CpG sites in Horvath’s study (age correlation of
Table 2
Epigenetic aging signature consisted of 16 CpG sites Information in this table includes the exact chromosomal location of the selected CpG sites (GRCh37/hg19) as well as the
involved genes.
CpG sites Chromosomal location Gene
cg19761273 17: 80,232,096 CSNK1D  casein kinase 1; delta isoform 1
cg27544190 21: 33,785,434 C21orf63  chromosome 21 open reading frame 63
cg03286783 15: 44,580,973 CASC4  cancer susceptibility candidate 4 isoform a
cg01511567 11: 57,103,631 SSRP1  structure speciﬁc recognition protein 1
cg07158339 9: 71,650,237 FXN frataxin, mitochondrial isoform 1 preproprotein
cg05442902 22: 21,369,010 P2RXL1  purinergic receptor P2X-like 1; orphan receptor
cg24450312 1: 206,681,158 RASSF5  Ras association domain family 5 isoform B
cg17274064 21: 40,033,892 ERG  v-ets erythroblastosis virus E26 oncogene like isoform 2
cg02085507 19: 6,739,192 TRIP10  thyroid hormone receptor interactor 10
cg20692569 7: 72,848,481 FZD9  frizzled 9
cg04528819 7: 130,418,315 KLF14  Kruppel-like factor 14
cg08370996 15: 96,874,031 NR2F2  nuclear receptor subfamily 2; group F; member 2
cg04084157 7: 100,809,049 VGF  nerve growth factor inducible precursor
cg22736354 6: 18,122,719 NHLRC1  malin
cg06493994 6: 25,652,602 SCGN  secretagogin precursor
cg02479575 19: 4,769,653 C19orf30  hypothetical protein LOC284424
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high accuracy using a smaller number of CpG sites (16 in our case)
was possible (mean absolute error of 4.4 years in the blind test set).
This is also supported by previous studies where researchers
obtained mean prediction errors of 4–8 years in their validation
tests, such as 5.1 years using 8 markers by Zubakov et al. [39], 6.9
years using 3 markers by Park et al. [30], 4.2 years using 7 markers
by Freire-Aradas et al. [38], 3.9 years using 5 markers by Zbiec-
Piekarska et al. [25], to name but a few. To the best of our
knowledge, only one of the proposed 16 age-associated genes in
our study has been used before in a forensic age model (more
speciﬁcally, KLF14 is included in the Zbiec-Piekarska model),
therefore contributing towards building a bank of potential
markers. As shown before, our model sensitivity analysis revealed
that there were markers contributing more to age prediction,
therefore, one could propose that by replacing or adding some of
the other ‘strong’, age-associated CpG sites reported in the
literature, such as the example of ELOVL2 locus [24], the resulting
prediction accuracy can be further improved. Also, for future
studies, one should also consider the combination of the best age-
associated CpG markers with other age-related molecules, like
mRNA, as this can also improve accuracy [39].
3.4. Validation through an independent cohort of monozygotic twins
Even though the model was applied to 231 blind test cases in
the model optimisation stage, it was important to externally test
model performance with an independent cohort of samples. For
this reason, we evaluated the optimised model using 106 blood
samples belonging to 53 monozygotic twin pairs aged 33–77 years.
Monozygotic twins were chosen since they begin life with nearly
identical genetic and epigenetic proﬁle and it is the effect of
various environmental factors that alters their genome-wide DNA
methylation proﬁle later in life. The methylation values of each
sample for all 16 CpG sites were imported into the model as a blind
test and the average mean absolute error was 7.07  5.78 years.
This higher prediction error could be partly explained by the fact
that most twins were old (mean age of 58 years in this dataset),
therefore the effect of environmental conditions and lifestyle
should be considered. Interestingly, between pairs there were
twins that were predicted to be either much older or much younger
than their actual age, but the prediction differences within twin
pairs (mean = 2.65  2.37 years) were not statistically signiﬁcant as
obtained by paired t-test analysis (p-value = 0.99). These results
can be interesting since they indicate some sort of systematic
inﬂuence of either the twins’ genetics or environment. According
to Horvath, while the heritability of age acceleration was found tobe 100% in new-borns, it was only 39% in older subjects suggesting
that non-genetic factors become more relevant later in life [48].
Also, although all twins were volunteered as healthy controls, it
would be beneﬁcial if information regarding disease status or
susceptibility was available, that could possibly partly explain
these results.
3.5. Effect of disease state on age predictions
It is important to bear in mind that, in contrast with a medical
setting, information regarding possible disease status is not
available when trying to predict chronological age from an
unknown bloodstain or sample during a criminal investigation.
Consequently, it is important to build a robust age prediction
model containing DNA methylation markers that would not show
differential methylation patterns due to disease states. However,
this might be extremely challenging to do. Therefore, although
Horvath has already reported that the predicted age from cancer
tissues correlated poorly with patient age in his study [48], we
aimed to investigate a set of diseased samples and the effect on age
prediction. For this purpose, seven datasets including diseased
samples were analysed in an attempt to further validate the
proposed age prediction model (Table S2). Fig. S2 shows the
predicted vs. chronological age for all 1011 samples; combining all
diseases together, a correlation of 0.74 and a mean absolute error of
7.18 years was obtained. However, when analysing separately
samples suffering from blood vs. non-blood related diseases it
becomes evident that the error is much higher for blood related
diseases (error = 12.74 years). This is of course expected since the
methylation data were gathered by analysing whole blood samples
and therefore the potential effect is direct. In more detail, the
obtained mean absolute errors for each disease were as follows:
type I diabetes – 8.63 years, anaemia – 14.38 years, bone marrow
disorders (including leukaemia) – 11.09 years, ovarian cancer –
7.45 years, breast cancer – 6.77 years and schizophrenia – 5.03
years.
Schizophrenia showed the lowest age prediction error, while
anaemia demonstrated the lower correlation with age. While
changes in expression of one of the markers included in the model
– cg04084157 (VGF) – have been detected in the cerebrospinal ﬂuid
of patients with different neurological and psychiatric conditions
such as schizophrenia [66], it did not seem to affect prediction in
blood. It should also be noted that schizophrenia patients
comprised the largest dataset; therefore a better prediction error
could also be due to the greater number of samples. On the other
hand, the results regarding anaemia (n = 28) come as no surprise
since anaemia is one of the most common blood disorders, which
Fig. 4. Age prediction in blood using the developed MiSeq method (n = 46).
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patterns, especially in blood. Interestingly, cg07158339 is located
near the FXN gene which has been associated with selectively and
non-covalently interacting with ferric ion Fe (III) to assemble the
iron-sulphur cluster [67]. Consequently, differential methylation
patterns due to the disease status in blood cannot be excluded.
Another example includes the ERG oncogene associated with
cg17274064, which is an erythroblast transformation-speciﬁc
transcription regulator typically mutated in myeloid leukaemia
[68]. As shown, the dataset comprised by various bone marrow
disorders including leukaemia demonstrated the second largest
mean error (11.09 years). Thus, by testing this limited range of
diseases, it seems that our model has the potential to perform quite
well in disease-stressed samples unless these are blood-related,
and the possibility of disease state should be taken into account
when attempting predictions.
3.6. Applying the age prediction model in saliva
In Horvath’s study, this set of 353 markers, which included our
16 CpG sites, were used to predict age in a wide range of other
tissues. However, individual marker capabilities should not be
overlooked, therefore to assess potential tissue-speciﬁc variations
in age prediction, the selected markers were also tested in a set of
saliva samples. Saliva is not only one of the most common types of
biological evidence found at crime scenes in the form of used
glasses, cigarette butts or stamps, but also was the only tissue
where sufﬁcient genome-wide methylation data was available for
robust analysis. One confounding factor when analysing saliva
methylation data is the variation derived from the collection
method used. Depending on the method applied to collect saliva
(for example by mouth wash, oral ﬂuid swab or by ‘touch’ samples),
the body ﬂuid stain might contain differing proportions of various
cell types (for example, buccal epithelial cells and white blood
cells), which can result in detecting variable DNA methylation
levels. Methylation values regarding the selected 16 CpG sites were
collected from a total of 265 samples of individuals aged 21–55
years; while 159 samples were used to train a GRNN model, 53
samples were used for each of the veriﬁcation and blind test sets.
As shown in Fig. S3, a good correlation of 0.73 was obtained
between predicted and true age, while the mean error was 3.18
years (training), 6.26 years (veriﬁcation) and 4 years (blind test).
The prediction accuracy was encouraging considering the size of
the dataset; however, the narrow age range (21–55 years) cannot
be ignored. Furthermore, saliva was collected and extracted
differently between the two studies used, which could introduce
further variation. The majority of saliva samples used here were
collected via the Oragene DNA collection kit, which can typically
result in DNA being extracted primarily from white blood cells,
rather than buccal epithelial cells; which, in this case, could
explain the high accuracy of obtained predictions. Again, as shown
in the graph representing the age residuals, age prediction seemed
to be more accurate in younger individuals, where underestimat-
ing age was not very common. Even though including more saliva-
speciﬁc age-associated CpG sites could signiﬁcantly improve the
obtained prediction error, these results highlight the potential
applicability of the proposed model in non-blood tissues.
3.7. Model validation by means of next generation sequencing
Our last goal in this study was to implement our age prediction
model by using an accurate, robust and sensitive method that can
analyse the proposed CpG sites in forensic-type samples.
Compared to previous analog methylation methods used for age
prediction analysis, we strongly believe that NGS can show great
potential, as not only it can be more sensitive and accurate, but canalso provide data of higher-resolution. Therefore, an NGS-based
protocol capable to detect DNA methylation differences in
bisulﬁte-converted DNA fragments was developed and adjusted
using a previously published method [69]. The overall perfor-
mance of the method was good including <0.05 standard deviation
in methylation detection for most markers, even though we
observed an imbalance between the average reads of the
investigated fragments; speciﬁcally, cg24450312 (RASSF5) and
cg17274064 (ERG) were the most challenging markers. This could
be due to different PCR efﬁciencies explained by DNA sequence
differences among markers, and can be improved in future
experiments. Nevertheless, to ensure accurate methylation quan-
tiﬁcation, a minimum of 1000 reads per marker was set. For
prediction analysis, a set of 46 blood samples from individuals aged
11–76 years old were analysed in triplicate using the proposed
method and their predicted age was calculated using the average as
a blind test in our age model. As a result, the age correlation taking
the ﬁnal normalised methylation data was 0.86 and we could
predict age with a mean absolute error of 7.45 years (Fig. 4).
These results are very encouraging, and even though the age
prediction accuracy is lower than that obtained in the model’s
blind test, for this sample set we are introducing an additional layer
of variation when normalising methylation values between totally
different detection systems (the NGS-derived methylation values
in the samples with the microarray-derived ones used to train the
model). As we aimed to investigate a representative population
sample, no information regarding the individuals’ health and
lifestyle were collected as this information would not be available
to a ‘standard’ forensic scenario. Since DNA methylation is known
to not only be age-speciﬁc but can also be inﬂuenced by diet [70],
lifestyle [71], smoking [14], ancestry [72] and other factors, we
cannot exclude that these factors could have affected the
methylation status of the selected sites in these individuals.
However, even if efforts were made to normalise the NGS data over
the genome-wide methylation data that the age prediction model
uses, we cannot also ignore other potential (PCR-introduced)
technical variation. Current experiments focus not only on
increasing the sample size to achieve a more representative
prediction accuracy, but also to analyse enough samples to re-train
the model with NGS data; the latter would eliminate any
methodological or technical variation. Furthermore, we are also
investigating the possibility of multiplexing the bisulﬁte PCRs to
allow for more sensitive analysis and validating the entire method
using forensically relevant criteria. We understand that both the
required high coverage (1000X) and triplicate analysis may be
impractical in routine forensic analysis, albeit less so for blood
traces where DNA is often, although not exclusively, found in
relatively high quantities. Future efforts should therefore also be
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ibility of the proposed NGS based method. We believe that
introducing an NGS-based solution for age prediction can provide
many advantages from a casework point of view, mainly due to its
high sensitivity, multiplexing capabilities and the potential for
merging with other DNA marker analysis. Nevertheless, all of the
factors mentioned above, including the biological variation that
may result from disease state and lifestyle, need to be established
before such methods can be applied routinely in forensic casework.
4. Conclusions
Forensic age prediction using DNA methylation-based
approaches is a fast-developing ﬁeld of forensic epigenetics that
has a great potential to provide accurate outcomes. Our study
contributes to a range of already published prediction models, not
only by providing potential age-associated markers but also by
introducing a novel methodology in prediction analysis, namely
machine learning by artiﬁcial neural network analysis. The
proposed age prediction model does not only exhibit good
prediction accuracy, but also has the potential to be applied in
individuals of a very wide age range including under-aged children,
individuals of various ethnic backgrounds as well as in non-blood
tissues. Nevertheless, it is believed that prediction can be improved
in the future by normalising for the different technologies of DNA
methylation analysis used. Also, the model worked signiﬁcantly
less accurately in a subset of unhealthy individuals, therefore
testing the markers’ ‘resistance’ to DNA methylation alterations in
disease state should be further tested. To the best of our
knowledge, this is the ﬁrst study that tests the ability of next
generation sequencing technology to detect DNA methylation
variation for age prediction in forensic samples. Following an
extensive validation in future experiments it could provide the
basis to an eventually combined analysis of DNA methylation and
DNA sequence variation in a single streamline using an NGS
platform.
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Bioconcentrationa b s t r a c t
Methods were developed to assess uptake and elimination kinetics in Gammarus pulex of nine phar-
maceuticals (sulfamethazine, carbamazepine, diazepam, temazepam, trimethoprim, warfarin, metopro-
lol, nifedipine and propranolol) using targeted LC-MS/MS to determine bioconcentration factors (BCFs)
using a 96 h toxicokinetic exposure and depuration period. The derived BCFs for these pharmaceuticals
did not trigger any regulatory thresholds and ranged from 0 to 73 L kg1 (sulfamethazine showed no
bioconcentration). Metabolism of chemicals can affect accurate BCF determination through parameter-
isation of the kinetic models. The added selectivity of LC-MS/MS allowed us to develop conﬁrmatory
methods to monitor the biotransformation of propranolol, carbamazepine and diazepam in G. pulex.
Varying concentrations of the biotransformed products; 4-hydroxypropranolol sulphate, carbamazepine-
10,11-epoxide, nordiazepam, oxazepam and temazepam were measured following exposure of the
precursor compounds. For diazepam, the biotransformation product nordiazepam was present at higher
concentrations than the parent compound at 94 ng g1 dw. Overall, the results indicate that pharma-
ceutical accumulation is low in these freshwater amphipods, which can potentially be explained by the
rapid biotransformation and excretion.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).).
r Ltd. This is an open access article1. Introduction
Extensive research into organic environmental micropollutants
has enabled the elucidation of the mechanisms for the uptake andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
T.H. Miller et al. / Chemosphere 183 (2017) 389e400390accumulation in biota (Barber et al., 1988, 1991; Mackay and Fraser,
2000). Uptake was mainly considered to occur by passive diffusion
across cellular membranes and traditional models relied heavily on
physico-chemical properties such as octanol-water partition co-
efﬁcients (logP) to describe and predict xenobiotic concentrations
in biota (Kanazawa, 1981; Neely et al., 1974; Veith et al., 1979). Such
earlier works often focussed on neutral compounds (Fu et al., 2009;
Klosterhaus et al., 2013; Wu et al., 2013), but more recently iden-
tiﬁed micropollutant classes, such as pharmaceuticals, are some-
what different in that they are often ionisable and have a wider
range of molecular polarity. Additional mechanisms such as ion
trapping, carrier mediated transport and partitioning to non-lipid
components (protein binding) could also inﬂuence the accumula-
tion of pharmaceutical residues in the environment (Fu et al., 2009;
Klosterhaus et al., 2013; Stott et al., 2015). As most of the reported
work has focussed on vertebrates such as ﬁsh (Gobas et al., 1986;
Kanazawa, 1981; Spacie and Hamelink, 1982; Veith et al., 1979),
the bioaccumulation of compounds in invertebrates is not well
understood.
The OECD 305 guidelines are widely used for estimating the
bioconcentration factor (BCF) or bioaccumulation factor (BAF) in
ﬁsh and have also been applied to invertebrates, such as bivalves
and amphipods (Ashauer et al., 2006, 2010; Meredith-Williams
et al., 2012; OECD; Sordet et al., 2016). Estimations using these
guidelines can be determined using steady-state or kinetic mea-
surements. Kinetic measurement estimates are based on non-linear
regression to generate uptake (k1) and elimination rate constants
(k2) and used together to estimate BCF/BAF. Models assume that
rate constants do not change. However, recent investigations in our
laboratory showed that the OECD model led to signiﬁcant lack-of-
ﬁts for measured data in invertebrates (Miller et al., 2016). The
lack-of-ﬁts were shown to arise from a potentially decreasing k1
trend over time for a proportion of compounds tested. This ﬁnding
was signiﬁcant as such models could lead to under/over estimation
of BCF/BAFs during risk assessment of chemicals in invertebrates.
Possible causes for the decreases in k1 could be related to several
factors such as growth, metabolism and sorption processes. Meta-
bolism in particular, is generally not considered in bioconcentration
studies. Many analytical methods rely on measurement of total
radioactivity of a labelled compound using liquid scintillation
counting (LSC) (Arnot and Gobas, 2006) as an alternative to
conﬁrmatory analytical tools based on liquid chromatography (LC)
or gas chromatography (GC) coupled to mass spectrometry (MS).
However for small freshwater invertebrates, only a few published
LC or GC-MS-based methods exist for parent compound determi-
nation (Grabicova et al., 2015; Inostroza et al., 2016; Miller et al.,
2015; Sordet et al., 2016). A reason for the small number of pub-
lished methods is that sensitivity at environmentally relevant
concentrations is often challenging due to their small size. Simi-
larly, simply increasing the sample mass to be extracted (via
pooling of individuals) is often undesirable due to extra MS signal
suppression or enhancement effects caused by the matrix. There-
fore, a delicate balance is required to ensure sufﬁcient MS sensi-
tivity and that reliable quantiﬁcations can be performed. In the
absence of conﬁrmatory analytical methods, biotransformation
during the exposure period could have a signiﬁcant effect on
invertebrate BCF/BAF estimation using scintillation counting
methods (de Wolf et al., 1992; Oliver and Niimi, 1985; Opperhuizen
and Sijm, 1990). Xenobiotics can also induce or inhibit their own
metabolism or the metabolism of other compounds that will affect
the clearance rate and hence the BCF/BAF (Golan et al., 2011).
Moreover, as standardised methods to measure metabolic products
and the kinetics of biotransformation currently do not exist, it is
difﬁcult to assess the inﬂuence of biotransformation in accumula-
tion (Cowan-Ellsberry et al., 2008). Several authors have appliedin vitro intrinsic clearance rates to extrapolate to whole body
biotransformation rates for predictive BCF modelling (Arnot et al.,
2008; Nichols et al., 2013). However, these extrapolations mea-
sure only the loss of parent compound to predict whole body
biotransformation. Thus, in vitro clearance rates may not reliably
reﬂect whole body metabolic rates (Nichols et al., 2006).
To date only three studies have measured biotransformation
products and their associated toxicokinetics in invertebrates
(Ashauer et al., 2012; Jeon et al., 2013b; R€osch et al., 2016). Two of
these works used LC coupled to high resolution MS (HRMS) or LC
with a radioactivity detector to model the uptake and elimination
proﬁles of organic micropollutants and their biotransformation
products in G. pulex (Ashauer et al., 2012; R€osch et al., 2016).
Ashauer et al. showed that the measurement of biotransformation
improved the accuracy of BCF estimates when compared to esti-
mates using total radioactivity counts (Ashauer et al., 2012). A
further constraint to the study of xenometabolism is that a priori
knowledge of biotransformation products in aquatic organisms is
lacking leading to difﬁculty when developing targeted analytical
methods (Celiz et al., 2009). Current methods have focussed on the
determination of organic pollutants in ﬁsh, with little attention
given to invertebrates or pharmaceutical biotransformation.
Therefore, it is essential that methods are developed that can
determine pharmaceutical biotransformation products to more
reliably assess the affect metabolism has on bioconcentration
models.
The aim of this work was to assess the bioconcentration of a
selection of nine pharmaceuticals in G. pulex using targeted LC-MS/
MS methods described in (Miller et al., 2015). In this regard, the
method developed for pharmaceutical occurrence was used for the
determination of selected known pharmaceutical biotransforma-
tion products of carbamazepine, diazepam and propranolol. The
method showed good performance in terms of linearity, recovery,
precision and robustness. In particular, BCFs were estimated using
the OECD 305 guidelines and kinetic parameters were checked for
constancy over time. Finally, the optimised LC-MS/MS method was
used for the identiﬁcation and determination of biotransformation
products of propranolol, carbamazepine and diazepam. As few
published works have studied pharmaceutical bioconcentration
and biotransformation, the work presented herein addresses the
knowledge gaps concerning their bioaccumulation and biotrans-
formation in invertebrates at environmentally relevant concentra-
tions using a minimised test design.
2. Materials and methods
2.1. Reagents, chemicals and consumables
HPLC grade methanol, acetonitrile, acetone, ethyl acetate,
dichloromethane and dimethyldichlorosiloxane were purchased
from Fischer Scientiﬁc (Loughborough, UK). Analytical grade
ammonium acetate was sourced from Sigma-Aldrich (Dorset, UK).
Propranolol hydrochloride, warfarin, sulfamethazine, carbamaze-
pine, nimesulide, (±)-metoprolol (þ)-tartrate salt, temazepam,
diazepam, nifedipine, oxazepam, nordiazepam, carbamazepine-
10,11-epoxide, and sulfamethazine were all obtained from Sigma-
Aldrich (Steinheim, Germany). Trimethoprim, was ordered from
Fluka (Buchs, Switzerland). Stable isotope-labelled standards
including carbamazepine-d10, propranolol-d7, temazepam-d5 and
diazepam-d5 were ordered from Sigma-Aldrich. Sulfamethazine-d4,
nifedipine-d4, metoprolol-d7, trimethoprim-d3 and warfarin-d5
were ordered from QMX Laboratories (Essex, UK). The propranolol
biotransformation products; 4-hydroxypropranolol, 4-
hydroxypropranolol sulphate and 4-hydroxypropranolol glucuro-
nide were sourced from Santa Cruz Biotechnology (Heidelberg,
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grade salts (>99%) including sodium hydrogen carbonate, magne-
sium sulphate, calcium sulphate, potassium chloride were pur-
chased from Sigma. Ultra-pure water was obtained from aMillipore
Milli-Q water puriﬁcation system with a speciﬁc resistance of
18.2 MU cm or greater (Millipore, Bedford, MA, USA).
2.2. Sample collection and culture maintenance
Gammarus pulexwere collected by kick-sampling from the River
Cray, South-East London, UK, 5123009.500N 006032.400E. This site
was previously shown to have low pharmaceutical contamination
in both collected surface water and animal samples (Miller et al.,
2015). The populations were transported to the laboratory in
500 mL Nalgene™ ﬂasks ﬁlled with surface water from the sample
collection site. Populations were rinsed with artiﬁcial freshwater
(AFW) and then acclimatised to laboratory conditions (as speciﬁed
below) for a minimum of 7 days before any exposure experiments
were performed. AFW was prepared from 1.15 mM of NaHCO3,
0.50 mM MgSO4, 0.44 mM CaSO4 and 0.05 mM of KCl dissolved in
20 L of ultra-pure water. This water was subsequently aerated for
several hours to remove dissolved carbonic acid and maximise the
dissolved oxygen concentrations. Each culture tank (n ¼ 8) was
ﬁlled with 2.5 L of AFW and animals were fed with either alder or
horse chestnut leaves obtained from the sampling site and condi-
tioned by submersion in surface water for two days prior to use.
2.3. Toxicokinetic exposure and conditions
Toxicokinetic experiments were performed separately for each
pharmaceutical for a total of 96 h which included a 48 h uptake
phase followed by a 48 h depuration period as per (Miller et al.,
2016). Individual adult organisms (n ¼ 25), both male and female
(>5 mg wet weight) were placed in Pyrex glass beakers. G. pulex
were carefully transferred to beakers using blunt forceps to avoid
any harm to the organisms before exposure. Each beaker contained
25 organisms in 200 mL of exposure media (AFW and test com-
pound). G. pulex were exposed to individual pharmaceuticals at a
concentration of 1 mg L1, except for propranolol and warfarin
which were exposed at 10 mg L1. All exposure media contained
<0.001% of organic solvent (methanol). A total of 300 organisms
were used per compound exposure and were sampled for n ¼ 3 per
time-point. Samples were taken at 6, 24, 48 and 96 h across the
toxicokinetic experiments. Negative control exposures were set up
and also sampled at the 96 h time interval. These were subse-
quently analysed for background contamination. The exposure
media was replaced daily and water samples (n ¼ 3) were analysed
at 0 and 24 h after exposure to ensure concentrations of the com-
pounds remained constant in the AFW. Each animal specimen was
rinsed with ultra-pure water and then frozen at 20 C. The light
cycle was 12 h light followed by 12 h dark without a dusk/dawn
transition period. All experiments were performed in a tempera-
ture controlled room at 15 C (±2 C) and water pH was also
monitored across each experiment and measured at an average of
8.19 ± 0.05.
2.4. Sample preparation
Water samples collected from exposure experiments were
ﬁltered using Whatman ﬁlters (0.2 mM) and directly injected onto
the LC-MS/MS for analysis. For G. pulex, A mass of 50 mg of
lyophilised and ground material was extracted by glass bead pul-
verisation in 5 mL of acetonitrile and diluted with 100 mL of
ammonium acetate buffer (10 mM) for loading onto Waters HLB
solid phase extraction (SPE) cartridges (6 cc, 200 mg sorbent). Afterloading, samples were eluted using a mixture of ethyl acetate:a-
cetone (50:50 v/v) which was subsequently evaporated under ni-
trogen (99% purity) and reconstituted in 250 mL of starting LC
mobile phase (90:10 v/v, 10 mM ammonium acetate buffer:
acetonitrile).
2.5. Instrumental analysis
Full instrumental conditions were used as per (Miller et al.,
2015). Brieﬂy, separations were performed on an Agilent HP1100
LC system conﬁgured with a Waters SunFire reversed-phase C18
column (150 mm  2.1 mm, 2.5 mM particle size). Following in-
jection (20 mL), elution followed a gradient proﬁle (totalling 75 min
including a 12.5-min re-equilibration time) using a mixture of
acetonitrile and ultra-pure water with 10 mM ammonium acetate.
Detectionwas performed using a Waters Quattro triple quadrupole
mass spectrometer with electrospray ionisation operated in posi-
tive and negative polarity switching mode. Quantiﬁcation of ana-
lytes was performed using 3-point internal standard matrix-
matched calibration using the peak area ratio of non-labelled an-
alyte (precursor range: 50e300 ng g1, biotransformation product
range: 50e150 ng g1) to the stable isotope labelled internal
standard (SIL-IS) (100 ng g1). The exception to this was in the
temazepam exposure where quantiﬁcation was performed against
a SIL-IS calibrant concentration (100 ng g1) by comparing the
response ratio of SIL-IS:unlabelled temazepam. The compounds (4-
hydroxypropranolol sulphate and carbamazepine-10,11-epoxide)
were quantiﬁed using 3-point external matrix-matched calibration
curves due to unavailability of SIL-IS standards.
2.6. Modelling bioconcentration factors
Parameter estimation of uptake rate constant (k1) and depu-
ration rate constant (k2) was performed using a curve ﬁtting algo-
rithm via Minitab statistical software (Minitab Ltd., Coventry UK)
and as outlined in the OECD 305 Fish Bioconcentration Guidelines
(OECD). Full details of parameter estimation can be found in (Miller
et al., 2016). Herein, the authors deﬁne BCFtotal as the summation of
the BCF of both parent/precursor and biotransformation products
(i.e. the total body burden). Whereas, BCFparent will be used to
describe the BCF determined for the parent compound alone.
3. Results and discussion
3.1. Analytical performance and minimised test design evaluation
The previously described analytical method required a sample
mass of 100 mg dw, which corresponded to approximately 40 an-
imals per measurement (Miller et al., 2015). This presented feasi-
bility issues for sampling, maintaining cultures and the scale of
exposure experiments. To mitigate this, 50 mg was used instead
and the reconstitution volume of solvent (post-SPE) was also scaled
down (to 250 mL) to maintain sensitivity. Analytical method per-
formancewas reassessed for 10 pharmaceuticals (See SI, Fig. S1 and
Table S1). In general, imprecision increased with decreasing sample
mass extracted. The use of SIL-IS has been shown to offer improved
precision during analytical method development (Stokvis et al.,
2005). The corresponding SIL-IS for each analyte here also resul-
ted in markedly improved precision for all compounds with % RSDs
ranging from 1 to 11%. Linearity also improved using SIL-IS in
comparison to matrix-matched calibration curves (R2 0.9897).
Therefore, for precise analysis of biota like G. pulex for trace phar-
maceutical residue determination, it is recommended that SIL-IS be
used with LC-MS/MS to overcome precision problems relating to
the limited sample mass available and to enable the number of
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In addition to the reduction in the number of organisms, a
reduction in the number of sampling time intervals was also
considered. Time points were selected at 6, 24, 48 and 96 h so that
the uptake phase had three time points and the elimination phase
contained two intervals. The additional time point in the uptake
phase was selected so that any losses in k1 constancy could be
highlighted as identiﬁed previously (Miller et al., 2016). The po-
tential limitation when using a small number of time intervals is
that the data may not reﬂect reliably the ability of a compound to
concentrate as modelling is limited to a few data points. The OECD
305 guidelines do propose a minimised test design with two time
intervals in the uptake and elimination phase, respectively (e.g. day
14, 28, 35 & 42). This minimised study design was evaluated
independently in the literature and it was concluded that the test
was valuable and offered reliable BCF estimation for regulatory
purposes (Carter et al., 2014). Springer et al. proposed a second
minimised test design involving only two sampling time intervals
in a 14 d depuration period (Springer et al., 2008). They also found
that minimised test designs were a viable alternative to a full study
design. Given that our experiments here focused on a non-standard
invertebrate species and much shorter uptake and depuration
phases, re-evaluation of the uptake and elimination data from
(Miller et al., 2016) was performed to assess the suitability of a
minimised test design for simultaneous and sequential methods of
BCF estimation in G. pulex (Table S3). An ANOVAwas performed for
each method of estimation and resulted in p-values of 0.95 for
comparison of simultaneous BCFtotal, 0.43 for sequential BCFtotal and
0.45 for sequential BCFtotal determined using linear regression in
the elimination phase data. All three p-values were >0.05 indi-
cating that there were no statistically signiﬁcant differences be-
tween the BCFs estimated by the full study design nor the
minimised design. Therefore, going forward all non-radiolabelled
exposures were performed using the minimised design.
3.2. Toxicokinetic modelling of eight selected pharmaceuticals
Aqueous pharmaceutical concentrations remained stable across
the exposure period for carbamazepine, diazepam, temazepam,
sulfamethazine, metoprolol and trimethoprim (Table 1). Propran-
olol showed stable aqueous concentrations over the ﬁrst 24 h, but
declined by 29% to an average of 6.41 mg L1 thereafter. Nifedipine
showed an average decrease of 39% across both days of the uptake
phase. It is possible that sorption was the cause in the reduction of
nifedipine in the exposure media or could also be attributed to
other transformation processes.
For pharmaceuticals in G. pulex, maximal concentrations after
the uptake phasewere observed for propranolol and likely due to itsTable 1
Pharmaceutical concentrations in exposure media during the uptake phase. 24 h and 48 h
1 or Day 2.
Compound Concentration (mg L1)
Day 1 (n ¼ 3) SD 24 h (n ¼ 3)
Carbamazepine 1.12 0.03 1.01
Diazepam 1.02 0.03 0.86
Temazepam 0.96 0.03 0.85
Nifedipine 0.94 0.09 0.59
Sulfamethazine 1.06 0.07 0.99
Trimethoprim 1.09 0.04 1.01
Metoprolol 0.77 0.18 0.72
Propranolol 9.22 0.5 8.92
Day 1- initial pharmaceutical concentration on day 1.
Day 2- initial pharmaceutical concentration on day 2.
a n ¼ 2higher exposure concentration at 10 mg L1 (due to a relatively high
LOQ value (61 ng g1 dw). In this exposure, internal concentrations
reached 519 ± 143 ng g1 with a mean value of 210 ± 9 ng g1 at the
end of the uptake period. Warfarin also showed relatively higher
concentrations in G. pulex which again was likely explained by the
higher exposure concentration. In contrast to the other studied
compounds, the data for warfarin suggested that it did not reach/
approach steady state in the uptake period as no plateau was
observed in the toxicokinetic proﬁle. The remaining pharmaceuti-
cals carbamazepine, diazepam, metoprolol, nifedipine, trimetho-
prim and temazepam exposed at 1 mg L1 showed internal
concentrations of 51 ng g1 at the end of the uptake phase. These
internal concentrations showed rapid elimination and were
reduced to  LOQ/LOD. The rapid turnover of all pharmaceuticals
suggested that bioaccumulation could be less relevant for these
types of ionisable compounds. BCFs were generated using both
simultaneous and sequential modelling presented in Table 2. The
BCFparent generated for each compound was in the order of
trimethoprim and nifedipine < metoprolol < warfarin
< carbamazepine < propranolol < temazepam < diazepam. The
highest BCFparent generated by the simultaneous method was
41 L kg1 for diazepam and the lowest estimation was 16 L kg1 for
both trimethoprim and nifedipine. These values remain signiﬁ-
cantly lower than any regulatory threshold to be considered bio-
accumulative or very bioaccumulative (European Commission,
2006). The BCFparent values for propranolol and metoprolol were
also compared with the BCFtotal generated previously (Miller et al.,
2016). Propranolol BCFtotal was estimated to be 32 L kg1 and
metoprolol BCFtotal was 16 L kg1, which showed very good agree-
ment with the BCFparent values of 28 and 17 determined by LC-MS/
MS here. Sulfamethazine was not detected in any sample and
therefore indicated that no accumulation in G. pulex had occurred.
Interestingly, exposure to nifedipine (logP ¼ 3.45) resulted in a low
BCF despite it being less polar and was similar to that of trimetho-
prim (logP¼ 1.12). This further suggested that logPwas not a reliable
indicator for BCF of pharmaceuticals and the degree of ionisation
may also play an important role in uptake and bioconcentration
mechanisms. Uptake models have usually been based on neutral
organic micropollutants and is the reason that logP can be a good
indicator of bioconcentration for these compounds especially when
logP is < 6. The logP, logD and predominant form of each pharma-
ceutical exposed to G. pulex is shown in Table S4. Temazepam,
diazepam and carbamazepine remain neutral, but their respective
BCFparent do not followany speciﬁc trendwhen directly compared to
their logP. However, the selection of pharmaceuticals here is limited
and therefore discernible trends may not be apparent. A plot of
logD/P versus estimated BCF showed that therewere no identiﬁable
trends (Fig. S2). Consideration of the complexity of biologicalrepresent the concentration after 24 h of exposure with solutions used on either Day
SD Day 2 (n ¼ 2) 48 h (n ¼ 3) SD
0.05 1.08 1.07 0.02
0.05 1.04 0.89 0.11
0.03 1.17 1.03 0
0.06 0.82 0.49 0.18
0.17 0.89 0.71 0.15
0.11 0.99 0.97 0.04
0.15 0.86 0.87 0.21












































































































































































































































































































































































































































































































































































































































T.H. Miller et al. / Chemosphere 183 (2017) 389e400 393systems and the unique characteristics of pharmaceuticals, it may
be expected that uptake and bioconcentration is a much more
complex process than can be predicted by a single or small number
of physicochemical properties. Many factors have been proposed
and reported to inﬂuence the bioconcentration of pharmaceuticals
including hydrophobicity, biotransformation, bioavailability, envi-
ronmental exposure scenarios, and carrier mediated uptake
(Barron, 1990). A particularly important factor is the environmental
exposure as the complexity of environmental matrices on BCFsmay
well increase or decrease predicted BCFs or measured BCFs from
in vivo laboratory exposures. Surface water temperature, pH, con-
centrations in sediment and the composition of other components
in the surface water (e.g. complex mixtures including other phar-
maceuticals, colloids, surfactants, organic chemicals etc.) may
directly or indirectly affect the accumulation potential of a com-
pound (Brown et al., 2007; Chen et al., 2017; Nichols et al., 2015).
Few data or reported studies exist on the uptake of pharma-
ceuticals in invertebrates. However, comparison of the BCFparent
estimated here showed good agreement with a study on G. pulex by
Meredith-Williams et al. for two compounds, carbamazepine and
diazepam, (Meredith-Williams et al., 2012). Sordet et al., reported
carbamazepine BCF of 5 L kg1 in Gammarus fossarum which was
~5-fold lower than the BCF determined here (Sordet et al., 2016).
Another study also reported a similar BCF of 51 L kg1 for diazepam
in a marine mussel,Mytilus galloprovincialis (E. Gomez et al., 2012).
In Daphnia magna, BCFs of between 18 and 83 L kg1 for propran-
olol were reported, but the estimated value varied with exposure
concentration (Ding et al., 2016). A review of ﬁsh data generally
revealed low level bioconcentration of the selected pharmaceuti-
cals herein. For example, diazepam BCF in ﬁsh (Ictalurus punctatus)
ranged from 2 to 146 L kg1 depending on the tissue type (Overturf
et al., 2016); sulfamethazine BCF in sturgeons was shown to be
1 L kg1 (Hou et al., 2003); carbamazepine BCF in two species of ﬁsh
(Pimephales notatus and I. punctatus) was <7 L kg1 depending on
tissue (Garcia et al., 2012); and propranolol was also estimated to
have a BCF of <1 L kg1 in Oncorhynchus mykiss and I. punctatus (C.
F. Gomez et al., 2010). These data further support the results herein
and indicate that the selected pharmaceuticals are likely to have a
low potential for bioconcentration in aquatic species.
The model ﬁts of simultaneous and sequential BCFparent esti-
mation showed a signiﬁcant lack-of-ﬁt for several pharmaceuticals
(Fig. 1). Lack-of-ﬁts may arise from a large scatter in the data.
However, the advantage of pooling organisms through LC-MS/MS
measurements is that it reduces scatter of measured internal con-
centrations from single organisms that arises from inter-individual
variability. The lack-of-ﬁt observed seemed to arise from the uptake
phase data and therefore the rate constant was estimated over each
time interval during the uptake period. This revealed that therewas
a decreasing trend in the k1 rate constant which again did not obey
the model's assumptions. Lack-of-ﬁts were observed in the simul-
taneous method of estimation for ﬁve compounds (carbamazepine,
propranolol, metoprolol, warfarin and diazepam) with two com-
pounds showing no signiﬁcant lack-of-ﬁts (temazepam and
trimethoprim). Lack-of-ﬁt for the ﬁnal compound nifedipine was
not possible to estimate due to line that was ﬁt (Fig.1(d)). As several
signiﬁcant lack-of-ﬁts were observed, the k1 rate constant was re-
calculated over the time intervals for the uptake phase data
(Fig. 2). Again, k1 was observed to decrease over time. These de-
creases again are potentially the cause of the lack-of-ﬁts, as sug-
gested previously (Miller et al., 2016). The reason for the decrease in
k1 over time could be attributed to either sorption on to the cuticle
of the animal during the uptake phase, toxicodynamic effects
where the pharmaceuticals are reducing the ability of the organism
to eliminate the compound or growth dilution of the animal.
However, preliminary evidence in (Miller et al., 2016) and the larger
Fig. 1. Toxicokinetic proﬁles of selected pharmaceuticals in G. pulex measured using LC-MS/MS. Solid line represents model ﬁt, dashed lines represent 95% conﬁdence interval. (a)
carbamazepine, (b) diazepam, (c) metoprolol, (d) nifedipine, (e) propranolol, (f) trimethoprim, (g) temazepam and (h) warfarin.
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Fig. 2. Plots of k1 over time for the selected eight pharmaceuticals.
T.H. Miller et al. / Chemosphere 183 (2017) 389e400 395decreases in k1 at the earlier time interval (this study) suggest that
sorption might be a signiﬁcant cause of the decreases in k1 over
time. In the cases of warfarin, carbamazepine, diazepam and
temazepam an apparent plateau had been reached indicating k1
constancy and it was possible to use this value to estimate the
BCFparent. The average of the k1 over the 48 h time interval for these
compounds resulted in a BCFparent of 20, 26, 40 and 48 L kg1 for
warfarin, carbamazepine, temazepam and diazepam, respectively.
These values showed good agreement between the BCFs generated
by the simultaneous method indicating this could provide analternative method for BCF estimation when k1 values are found to
decrease over time. However, it is also possible that steady-state
measurements are more appropriate over kinetic measurements
when estimating pharmaceutical BCFs. Behaviour of pharmaceuti-
cals is also different to more traditional organic pollutants (PAHs,
PCBs, etc.), it appears they often reach steady-state within a rela-
tively short timeframe (~2e3 days) (Meredith-Williams et al., 2012;
Miller et al., 2016). Thus, determination of BCFs using kinetic
parameterisation offers no advantage over the time requirements
for steady-state BCF estimates. Furthermore, steady-state
Fig. 3. SRM transitions for the detected biotransformed products during toxicokinetic
exposures.
T.H. Miller et al. / Chemosphere 183 (2017) 389e400396measurements would also be less resource intensive as they do not
require a depuration period. In addition, the inconsistencies of ki-
netic data as demonstrated here and in (Miller et al., 2016) might
not provide a reliable estimate of BCFs.
3.3. Biotransformation of carbamazepine, diazepam and
propranolol by G. pulex
In addition to their medium to low logP, pharmaceuticals are
designed to bemetabolised and excreted tominimise accumulation
(Kumar and Surapaneni, 2001). As the data suggests, factors other
than hydrophobicity may be important in accumulation, such as
biotransformation, which could also partly explain the variability in
BCFs. Authors have demonstrated that G. pulex are able to metab-
olise a range of organic micropollutants (Ashauer et al., 2012; Jeon
et al., 2013b; R€osch et al., 2016). Conservation of cytochrome P450
enzymes has also been observed in invertebrates (Snyder, 2000)
and pharmaceuticals have been shown to undergo oxidative and
conjugation reactions (Jeon et al., 2013b). As the targeted LC-MS/
MS method only determines the amount of parent compound,
the BCFparent values presented above (Table 2) do not take into
account the accumulation of any biotransformation products. The
biotransformation product half-lives in the body can be longer or
shorter than the parent compound as they are modiﬁed by
biotransformation processes and potentially may lead to increased
or decreased accumulation (Jeon et al., 2013a) and thus will not be
accounted for by estimations of BCFparent.
Selected pharmaceuticals with readily available biotransforma-
tion product reference standards (propranolol, carbamazepine and
diazepam) were used in biotransformation studies and several
transformation products were targeted in the analytical method
including 4-hydroxypropranolol, 4-hydroxypropranolol sulphate,
4-hydroxypropranolol glucuronide, carbamazepine-10,11-epoxide,
oxazepam and nordiazepam and temazepam, the latter of which
was already included in analytical method. A matrix effect and
recovery experiment was performed for these additional analytes
before exposures were performed (SI Table S5). Unfortunately, poor
stability in solution made the matrix effect or recovery assessment
for 4-hydroxypropranolol impossible. This has been reported pre-
viously (Pritchard et al., 1979) and samples required additives
(sodium metabisulﬁte and sodium bisulﬁte) to maintain stability.
Overall, matrix effects were relatively minor for most biotransfor-
mation products ranging from 4% suppression to 9% enhancement.
However the exceptionwas nordiazepamwhich showed 31% signal
suppression. biotransformation products showed acceptable abso-
lute recoveries ranging 82e103% (13% RSD) with the exception of
4-hydroxypropranolol sulphate (34% recovery and 20% RSD) and 4-
hydroxypropranolol glucuronide (no recovery). The lower re-
coveries and precision of these polar conjugates are likely to arise
from poor afﬁnity to the SPE sorbents (HLB) used during sample
preparation. The lower recoveries and precision of these polar
conjugates are likely to arise from poorer afﬁnity to these SPE
sorbents. The use of alternative chemistries including mixed-mode
ion exchangers or dipole bearing polymers may improve the
selectivity for such polar compounds.
Carbamazepine exposures resulted in the detection of carba-
mazepine-10,11-epoxide at 24 h and 48 h in G. pulex. Control or-
ganisms (exposed to AFW only) also showed no detectable peaks
for carbamazepine-10,11-epoxide. This was identiﬁed by a singlem/
z transition (253 / 235) and chromatographic retention time
(within 0.4%). Unfortunately, carbamazepine-10,11-epoxide was
not quantiﬁable as signals were below a signal to noise ratio of 10:1
(Fig. 3). Carbamazepine-10,11-epoxide was not detected at 96 h
suggesting that the biotransformation product may have been
eliminated from the organism by this point. Elimination may eitherbe via excretion or further biotransformation, e.g. carbamazepine-
10,11ediol is excreted in its free form or as a glucuronic acid con-
jugate in humans (Kudriakova et al., 1992). However, limited data is
available for biotransformation of xenobiotics in invertebrates. A
previous study identiﬁed that carbamazepine was converted to
carbamazepine-10,11-epoxide and was the main metabolic
T.H. Miller et al. / Chemosphere 183 (2017) 389e400 397pathway in themussel,Mytilus galloprovincialis (Boillot et al., 2015).
Fish exposed to carbamazepine have also shown the presence of
two carbamazepine biotransformation products, carbamazepine-
10,11-epoxide and 2-hydroxycarbamazepine (Boillot et al., 2015).
For propranolol exposures, 4-hydroxypropranolol sulphate was
conﬁrmed with a single peak transition (356.3 / 276.2) and
chromatographic retention time (within 0.25%) (Fig. 3). HP-SULPH
reached a mean concentration of 75 ± 17 ng g1 dw by the end of
the uptake phase (Fig. 4(a)). The elimination phase showed no
decreases in the concentration 4-hydroxypropranolol sulphate
which was measured at a mean concentration of 84 ± 4 ng g1 dw
at 96 h. Determination of the parent compound propranolol
showed a peak at the 24 h time interval which decreased by 48 h.
Decreases of internal concentrations during the uptake phase are
indicative of active metabolic pathways (Crookes and Brooke,
2011). To the authors’ knowledge, no propranolol biotransforma-
tion products have previously been speciﬁcally identiﬁed using LC-
MS/MS in either ﬁsh or invertebrates. However, from the induced
P450 activity of trout in vivo and in vitro propranolol was suggested
to likely induce its metabolism and it was hypothesised that
biotransformation products may be identiﬁed (Bartram et al.,
2012). More recently trout gill cells have been shown to be
capable of propranolol transport and biotransformation (Stott et al.,
2015), and in carp a range of biotransformation products were
tentatively identiﬁed in vivo using UV methods (Ding et al., 2015).
Furthermore, sulphate conjugates of pharmaceuticals have not
been previously detected in invertebrates. However, previous
works have detected sulphate and glucose conjugates of pyrene in
Daphnia magna (Ikenaka et al., 2006, 2007) and sulphateFig. 4. Determination of biotransformation products (a) Concentration-time proﬁle for
propranolol (solid circles) and 4-hydroxypropranolol sulphate (crosses) in G. pulex. (b)
Concentration-time proﬁle for diazepam (solid circles), nordiazepam (triangles),
oxazepam (squares) and temazepam (crosses) in G. pulex.conjugates of aldicarb, carbaryl and dichlorophenols in G. pulex
(Ashauer et al., 2012). For biocides (algicides), glutathione conju-
gates have been detected in G. pulex and D. magna (Jeon et al.,
2013b). Finally, G. pulex have also been shown to biotransform
azole fungicides into sulphate, glutathione and glucose-sulphate
conjugates (R€osch et al., 2016). Human trials show that the major
biotransformation products of propranolol were HP and napthox-
ylactic acid (Walle and Gaffney, 1972). The relative importance of
this sulphate conjugation pathway in G. pulex is not known as the
napthoxylactic acid and the glucuronide conjugate could not be
determined. However, some authors have suggested that sulphate
and glucoside conjugation is the major metabolic process in in-
vertebrates for the metabolism of aryl group containing com-
pounds such as propranolol (Ikenaka et al., 2007; Livingstone,
1998).
The ﬁnal exposure was performed with diazepam and all three
selected biotransformation products were detected and quantiﬁed
(Fig. 4(b)). Nordiazepam showed concentrations that reached a
mean concentration of 64 ± 27 ng g1 dw in contrast to temazepam
that reached a maximummean concentration of 6 ± 3 ng g1 dw at
48 h. The 10-fold difference in concentrations suggested that the
biotransformation of diazepam to nordiazepam is the major
metabolic pathway in contrast to the conversion of diazepam to
temazepam. This agrees with mammalian data that shows the
demethylation of diazepam to nordiazepam is the primary meta-
bolic pathway (Umezawa et al., 2008). Temazepam was not
detectable by the 96 h time interval, suggesting this compound had
been either excreted or further biotransformed to oxazepam. The k2
was determined at 0.0194 d1 which is 3-fold lower than the k2 of
diazepam. The estimated half-lives of diazepam and nordiazepam
were 12 h and 36 h, respectively. The difference observed is also in
agreement with the reported half-lives, as nordiazepam has a
longer half-life (50e120 h) than its parent compound diazepam
(44 h) (Umezawa et al., 2008). The k2 of temazepamwas estimated
at 0.016 d1, approximately 4-fold lower than the k2 of temazepam
when exposed to G. pulex as a parent compound. The lower k2 may
be explained by the apparent preferential metabolism of diazepam
to nordiazepam. Thus, enzymes involved in the temazepam
pathway may be less active.
The ﬁnal biotransformation product oxazepam was not detect-
able until 48 h reaching amean concentration of 50 ± 23 ng g1 dw.
The biotransformation of diazepam to either nordiazepam or
temazepam and further conversion to oxazepam would be rate
liming steps leading to the apparent lag phase in the detection of
oxazepam. The k2 estimated for oxazepam was 0.009 d1, with
mean internal concentrations reduced by 21 ng g1 dw over the
48 h depuration period. The half-life determined for oxazepamwas
70 h which is much greater than the reported single or multiple
dose half-life in humans (9e11.6 h) (Greenblatt, 1981). The differ-
ence in half-lives could be due to the continued conversion of
nordiazepam or temazepam to oxazepam after the uptake phase
ended giving an apparent longer half-life. Furthermore, oxazepam
is primarily excreted by conjugation with glucuronide moieties
indicating that G. pulex may not readily metabolise oxazepam as
well as in humans. The degree of accumulation of each biotrans-
formation product is in agreement with Overturf et al., whom
generally found higher concentrations of nordiazepam and oxaz-
epam in comparison to temazepam dependent on the tissue type
(Overturf et al., 2016).
Metabolite enrichment factors (MEFs) can be determined for
biotransformation products (Ashauer et al., 2012). The MEFs can be
likened to a ‘pseudo-BCF’ and further indicate that these
biotransformation products were not accumulative. However,
nordiazepam and oxazepam reached higher internal concentra-
tions relative to the parent compound diazepam. The BCF of
T.H. Miller et al. / Chemosphere 183 (2017) 389e400398oxazepam has been reported at 22 L kg1 in G. fossarum indicating
that this compound is not accumulative (Sordet et al., 2016).
Furthermore, the summation of the BCFparent and MEFs can give a
BCF that would be comparable to those determined by total
radioactivity counts (i.e. BCFtotal) (Ashauer et al., 2012). For
example, the BCFparent of diazepam ranged from 41 to 58 L kg1
whereas summation of the diazepam BCF and the MEFs would give
a BCFtotal estimate of 165 L kg1. However, it should be considered
that targeted methods will likely only show a small window of the
biotransformation pathways involved with xenobiotic detoxiﬁca-
tion (as in this work). Secondly, targeted methods may not focus on
the important biotransformation products in terms of accumula-
tion, toxicity and elimination. Therefore, untargeted analytical
techniques such as high resolution mass spectrometry (HRMS)
could potentially offer a much greater insight into biotransforma-
tion pathways involved with xenobiotic detoxiﬁcation or identiﬁ-
cation of new compounds (Ashauer et al., 2012; Munro et al., 2015).
However, the quantitative application of LC-HRMS to toxicokinetic
proﬁling needs to be considered carefully, especially where refer-
ence materials for biotransformation products are not available as
discussed previously (Jeon et al., 2013a; R€osch et al., 2016).
Furthermore, studies that only monitor the parent compound by
non-speciﬁc methods should be cautious when reporting BCFs,
especially if there is a high potential for biotransformation. Com-
parison of the total BCF (BCFparent þ MEF) to BCFs determined by
LSC was not possible here. However, Ashauer et al. (2012) reported
that comparison of total BAF and BAF by LSC gave values that were
within a single order of magnitude. However, the differentiation
between biotransformation products and their respective parents
gave better accuracy in parameter estimates (k1/k2) compared to
radioactivity measurements (Ashauer et al., 2012). The reason for
this is that radioactivity measurements can over or underestimate
elimination if biotransformation is not taken into account. As a ﬁnal
consideration, the data presented show that at environmentally
relevant exposure concentrations, pharmaceuticals remain at very
low level concentrations. Furthermore, for the selected compounds
herein, they do not show any signiﬁcant accumulation which has
also been evidenced in the literature by several authors (Boillot
et al., 2015; Meredith-Williams et al., 2012; Miller et al., 2016;
Paterson and Metcalfe, 2008; Sordet et al., 2016). Thus, biotrans-
formation studies will be key in highlighting the behaviour of these
contaminants inside the animal and reveal the role of metabolic
clearance for regulating accumulation. In addition, whilst the
accumulation potential of pharmaceuticals is low, it must now be
considered how these innately low level concentrations of pre-
cursor and biotransformed products will affect the organisms that
are exposed to them. Thus, future work should aim to link accu-
mulation data to effect data for more comprehensive understand-
ing of the potential for adverse outcomes of these emerging
contaminants.
4. Conclusions
As an alternative to traditional LSC approaches, LC-MS/MS was
shown as a suitable technique for the measurement of uptake and
elimination kinetics. The simultaneous BCF estimates ranged from
16 to 41 L kg1 for eight compounds (diazepam, temazepam,
nifedipine, propranolol, metoprolol, carbamazepine, warfarin and
trimethoprim) using the simultaneous model method. Sequential
parameterisation resulted in BCFs of 21e72 L kg1 showing over-
estimates compared to the simultaneous method. Sulfamethazine
showed no bioconcentration in the animals, as no peaks were
detected upon exposure. Models were shown to have signiﬁcant
lack-of-ﬁts for six of the eight pharmaceuticals. The lack-of-ﬁts also
coincided with decreases in the uptake rate constant over timesuggesting that poor model ﬁts may have resulted from this trend.
No trends in bioconcentration were observed with logD or logP,
suggesting factors other than compound hydrophobicity were
important in bioconcentration. The role of metabolism was inves-
tigated for three selected pharmaceuticals (carbamazepine, pro-
pranolol and diazepam). G. pulex were shown to metabolise all
three pharmaceuticals into several different biotransformation
products, indicating the conservation of cytochrome P450 enzymes
in this species. Furthermore, detection of 4-hydroxpropranolol
sulphate indicates the presence of transferases. The ability of
G. pulex to readily metabolise these xenobiotics may explain, in
part, the relatively low BCFs determined for pharmaceuticals in this
work and the literature. Biotransformation pathways and products
were found to be the same between vertebrate data. However,
differences between half-lives were observed for the benzodiaze-
pine compounds (diazepam ¼ 12 h, nordiazepam ¼ 36 h) sug-
gesting that rates of metabolism and elimination are different.
Whilst, kinetics may differ, the same metabolic pathways involved
in elimination mean that human pharmacokinetic data is valuable
for consideration of pharmaceuticals in environmental risk
assessment. Analytical methods that only target and determine the
parent compound in toxicokinetic studies do not measure a BCFtotal.
As MEFs for the diazepam biotransformation products, nordiaze-
pam and oxazepam, showed that some compounds may be more
accumulative than the parent and could potentially be more toxic.
Therefore, it is advisable that targeted MS methods account for
biotransformed products when estimating BCFs.
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